<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004028.pub4" GROUP_ID="SCHIZ" ID="881202072510043806" MERGED_FROM="" MODIFIED="2016-11-18 11:45:18 +0000" MODIFIED_BY="Claire Irving" REVIEW_NO="8765" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2016-11-18 11:45:15 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Valproate for schizophrenia</TITLE>
<CONTACT MODIFIED="2016-11-18 11:45:15 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Vice-chairman</POSITION><EMAIL_1>Stefan.Leucht@lrz.tum.de</EMAIL_1><MOBILE_PHONE>+49 151 270 42590</MOBILE_PHONE><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaninger Straße 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-11-18 11:45:15 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="z1303130939086112491133527493155" ROLE="AUTHOR"><FIRST_NAME>Yijun</FIRST_NAME><LAST_NAME>Wang</LAST_NAME><POSITION>Student</POSITION><EMAIL_1>yijun.wang895@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Neuro-Cognitive Psychology Master Program</DEPARTMENT><ORGANISATION>Ludwig-Maximilians-Universität München</ORGANISATION><ADDRESS_1>Thalkirchner Str. 9</ADDRESS_1><CITY>Munich</CITY><ZIP>D-80337</ZIP><REGION>Bavaria</REGION><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+4915779399868</PHONE_1></ADDRESS></PERSON><PERSON ID="258C268D82E26AA2000C5DBBFFD4E447" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Jun</FIRST_NAME><LAST_NAME>Xia</LAST_NAME><POSITION>Research Associate</POSITION><EMAIL_1>Jun.Xia@nottingham.ac.uk</EMAIL_1><EMAIL_2>jun-xia@review-solutions.cn</EMAIL_2><ADDRESS><DEPARTMENT>Cochrane Schizophrenia Group</DEPARTMENT><ORGANISATION>The University of Nottingham</ORGANISATION><ADDRESS_1>Institute of Mental Health</ADDRESS_1><ADDRESS_2>University of Nottingham Innovation Park, Triumph Road,</ADDRESS_2><CITY>Nottingham</CITY><ZIP>NG7 2TU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113 8550686</PHONE_1></ADDRESS></PERSON><PERSON ID="z1301311112022346974199538643931" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Bartosz</FIRST_NAME><LAST_NAME>Helfer</LAST_NAME><POSITION>Wissenschaftlicher Mitarbeiter (Researcher)</POSITION><EMAIL_1>bartosz.helfer@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaninger Straße 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 6415</PHONE_1><FAX_1>+49-89-4140-4987</FAX_1></ADDRESS></PERSON><PERSON ID="7E028C0382E26AA200C1C7C465D3B6B4" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Chunbo</FIRST_NAME><LAST_NAME>Li</LAST_NAME><POSITION>Vice President</POSITION><EMAIL_1>chunbo_li@163.com</EMAIL_1><EMAIL_2>chunbo_li@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Shanghai Key Laboratory of Psychotic Disorders</DEPARTMENT><ORGANISATION>Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine</ORGANISATION><ADDRESS_1>600 Wan Ping Nan Road</ADDRESS_1><CITY>Shanghai</CITY><ZIP>200030</ZIP><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 21 3477 3243</PHONE_1><FAX_1>+86 21 6438 7986</FAX_1></ADDRESS></PERSON><PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Stefan</FIRST_NAME><LAST_NAME>Leucht</LAST_NAME><POSITION>Vice-chairman</POSITION><EMAIL_1>Stefan.Leucht@lrz.tum.de</EMAIL_1><MOBILE_PHONE>+49 151 270 42590</MOBILE_PHONE><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaninger Straße 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49-89-4140 ext: 4249</PHONE_1><FAX_1>+49-89-4140-4888</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-07-20 16:00:08 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="4" MONTH="3" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="4" MONTH="3" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="3" YEAR="2019"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="11" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="9" YEAR="2016"/>
<DESCRIPTION>
<P>New trial data available but overall conclusions regarding effectiveness remain unclear. Large well-conducted randomised trials needed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="3" YEAR="2016"/>
<DESCRIPTION>
<P>Search updated, 81 new references added to 'Classification pending references' section of the review. Eight of these turned out to be additional publications of included studies and nine could be immediately excluded based on the title or abstract. The remaining references had to be classified as 'studies awaiting assessment'. Sixty-four references were added to those already in 'awaiting classification'. This section now contains 69 reports, 28 of these are unclear allocation, 35 are Chinese and awaiting translation, 6 need more detailed assessment.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-07-26 09:44:06 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>Results from July 2012 search added to review. 19 new studies, mostly Chinese, added to included studies table. The risk of bias tables and description of bias added; background information, results and discussion extended; structure of the review updated to meet new standards.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-09-29 15:32:05 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-09-29 15:31:50 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="4" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-14 14:41:13 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="9" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>With new Plain Language Summary added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-09-29 15:31:55 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Missing text in Discussion section amended
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-09-29 15:32:02 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>

Update search run Feb 2008</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-09-29 15:31:59 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>

Update search run Feb 2008</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-09-29 15:32:05 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="7" MONTH="3" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Freistaat Bayern</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>German Ministry of Health, Network of Competence Schizophrenia</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-11-18 11:43:17 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2016-08-04 11:15:48 +0100" MODIFIED_BY="[Empty name]">Valproate for schizophrenia</TITLE>
<SUMMARY_BODY MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Review question </B>
</P>
<P>To review the effects of adding valproate to an anitpyschotic for the treatment of schizophrenia and schizophrenia-like illnesses.</P>
<P>
<B>Background</B>
</P>
<P>The main treatment for schizophrenia is antipsychotic medication. Despite this treatment, about 30% of people will continue to experience some signs of illness. Other drugs are sometimes added to antipsychotic medication to attempt to reduce the symptoms that people experience. Valproate is one such drug and is typically used to treat epilepsy, to stabilise mood in people who have bipolar disorder and for people who have both schizophrenia and mood disorder (schizoaffective disorder).</P>
<P>
<B>Study characteristics</B>
</P>
<P>The review includes 26 studies, found through electronic searching of relevant databases, with a total of 2184 participants. All trials examined the effectiveness of valproate as an add on to antipsychotics. With the exception of two studies, the studies were small, and most of them were short-term and poorly reported.</P>
<P>
<B>Key results</B>
</P>
<P>Data from the included trials showed that participants receiving valproate plus an antipsychotic had better clinical response, compared to those taking an antipsychotic with a placebo. However, this advantage was lost when lower-quality trials were taken out of the analysis. Valproate was also indicated to be effective in controlling excitement and aggression. Acceptability and overall tolerability of the combined treatment was similar between treatment groups and did not cause more weight gain, however, adding valproate did cause greater sedation and dizziness. No trial reported effect on quality of life.</P>
<P>
<B>Quality of the evidence </B>
</P>
<P>Evidence is limited and firm conclusions cannot be made. For the main outcomes of interest, the review authors judged the quality of evidence to be low or very low quality<I>, </I>due to methodological issues in the reviewed studies. Most of them were small, short-term and did not blind the participants or personnel. Large, double-blind and long-term randomised trials should be undertaken to properly determine the clinical effects of adding valproate to antipsychotic treatment for people with schizophrenia.</P>
<P>This summary was written by Ben Gray, Senior Peer Researcher, McPin Foundation. <A HREF="http://mcpin.org/">mcpin.org/</A>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-10-25 04:05:13 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2016-10-24 10:08:21 +0100" MODIFIED_BY="[Empty name]">
<P>Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment. In these cases, various add-on medications are used, and valproate is one of these.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-10-05 10:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>To examine whether:</P>
<P>1. valproate alone is an effective treatment for schizophrenia and schizoaffective psychoses; and</P>
<P>2. valproate augmentation of antipsychotic medication is an effective treatment for the same illnesses.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-03-18 14:54:41 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Schizophrenia Group&#8217;s Study-Based Register of Trials (July 2002; February 2007; July 2012; March 04, 2016). We also contacted pharmaceutical companies and authors of relevant studies in order to identify further trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-02-29 14:44:46 +0000" MODIFIED_BY="[Empty name]">
<P>We included all randomised controlled trials comparing valproate to antipsychotics or to placebo (or no intervention), whether as the sole agent or as an adjunct to antipsychotic medication for the treatment of people with schizophrenia or schizophrenia-like psychoses.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>We independently inspected citations and, where possible, abstracts, ordered papers, and re-inspected and quality-assessed these. At least two review authors independently extracted data. We analysed dichotomous data using risk ratio (RR) and its 95% confidence intervals (CI). We analysed continuous data using mean differences (MD) and their 95% CI. We assessed risk of bias for included studies and used GRADE (Grading of Recommendations Assessment, Development and Evaluation) to create a 'Summary of findings' table.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-10-25 04:05:13 +0100" MODIFIED_BY="[Empty name]">
<P>The 2012 update search identified 19 further relevant studies, most of which were from China. Thus the review currently includes 26 studies with a total of 2184 participants. All trials examined the effectiveness of valproate as an adjunct to antipsychotics. With the exception of two studies, the studies were small, the participants and personnel were not blinded (neither was outcome assessment), and most were short-term and incompletely reported.</P>
<P>For this update we prespecified seven main outcomes of interest: clinical response (clinically significant response, aggression/agitation), leaving the study early (acceptability of treatment, overall tolerability), adverse events (sedation, weight gain) and quality of life.</P>
<P>Adding valproate to antipsychotic treatment resulted in more clinically significant response than adding placebo to antipsychotic drugs (14 RCTs, n = 1049, RR 1.31, 95% CI 1.16 to 1.47, I<SUP>2 </SUP>= 12%, low-quality evidence). However, this effect was removed after excluding open RCTs in a sensitivity analysis. In terms of acceptability of treatment (measured by the number of participants leaving the study early due to any reason) valproate was just as acceptable as placebo (11 RCTs, n = 951, RR 0.76, 95% CI 0.47 to 1.24, I<SUP>2 </SUP>= 55%). Also overall tolerability (measured by the number of participants leaving the study early for adverse events) between valproate and placebo was similar (6 RCTs, n = 974, RR 1.33, 95% CI 0.90 to 1.97, I<SUP>2</SUP> = 0).</P>
<P>Participants in the valproate group were found to be less aggressive than the control group based on the Modified Overt Aggression Scale (3 RCTs, n = 186, MD -2.55, 95% CI -3.92 to -1.19, I<SUP>2 </SUP>= 82%, very low-quality evidence). Participants receiving valproate more frequently experienced sedation (8 RCTs, n = 770, RR 1.38, 95% CI 1.07 to 1.79, I<SUP>2 </SUP>= 0, low-quality evidence) but were no more likely to gain weight than those receiving placebo (4 RCTs, n = 427, RR 1.17, 95% CI 0.76 to 1.82, I<SUP>2 </SUP>= 0, low-quality evidence). No study reported on the important outcome of quality of life.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>There is limited evidence, based on a number of trials, that the augmentation of antipsychotics with valproate may be effective for overall clinical response, and also for specific symptoms, especially in terms of excitement and aggression. However, this evidence was entirely based on open RCTs. Moreover, valproate was associated with a number of adverse events among which sedation and dizziness appeared significantly more frequently than in the control groups. Further randomised studies which are blinded are necessary before any clear recommendation can be made. Ideally these would focus on people with schizophrenia and aggression, on those with treatment-resistant forms of the illness and on those with schizoaffective disorders.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-10-26 10:23:41 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>Despite the introduction of antipsychotic (neuroleptic) medications in the 1950s, there is still a sizeable minority (at least 30% of people with schizophrenia and related conditions), who do not achieve remission of symptoms (<LINK REF="REF-Schooler-1993" TYPE="REFERENCE">Schooler 1993</LINK>). Over the last 40 years a variety of adjunctive treatments have been used to treat schizophrenia (<LINK REF="REF-Christison-1991" TYPE="REFERENCE">Christison 1991</LINK>). These are often used in addition to antipsychotics, in an attempt to alleviate the symptoms of schizophrenia such as hallucinations and delusional beliefs, although they have been used instead of antipsychotics. Treatments such as lithium (<LINK REF="REF-Leucht-2007b" TYPE="REFERENCE">Leucht 2007b</LINK>, indicated for bipolar affective disorder), carbamazepine (<LINK REF="REF-Leucht-2007c" TYPE="REFERENCE">Leucht 2007c</LINK>), valproate (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>), benzodiazepine (<LINK REF="REF-Dold-2012" TYPE="REFERENCE">Dold 2012</LINK>), beta-blockers (<LINK REF="REF-Cheine-2003" TYPE="REFERENCE">Cheine 2003</LINK>) and electroconvulsive therapy (<LINK REF="REF-Tharyan-2005" TYPE="REFERENCE">Tharyan 2005</LINK>) have all been used for people whose psychosis did not respond to traditional therapy. The situation has improved somewhat in recent years, with the re-introduction of clozapine, which has proven efficacy for those that have not responded to traditional antipsychotic medications (<LINK REF="REF-Essali-2010" TYPE="REFERENCE">Essali 2010</LINK>). Whether the other second-generation ('atypical') antipsychotics are more effective for the treatment of those with treatment-resistant schizophrenia is unclear (<LINK REF="REF-Bagnall-2000" TYPE="REFERENCE">Bagnall 2000</LINK>, <LINK REF="REF-Gilbody-2000" TYPE="REFERENCE">Gilbody 2000</LINK>, <LINK REF="REF-Srisurapanont-2004" TYPE="REFERENCE">Srisurapanont 2004</LINK>).</P>
<CONDITION MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>Schizophrenia is often a chronic and disabling psychiatric disorder. It afflicts approximately one per cent of the population world-wide with few gender differences. Its typical manifestations are 'positive' symptoms such as fixed, false beliefs (delusions) and perceptions without stimuli (hallucinations), and 'negative' symptoms such as apathy and lack of drive, disorganisation of behaviour and thought, and catatonic symptoms such as mannerisms and bizarre posturing (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). The degree of suffering and disability is considerable with 80% to 90% unemployed (<LINK REF="REF-Marvaha-2004" TYPE="REFERENCE">Marvaha 2004</LINK>) and 10% going on to commit suicide (<LINK REF="REF-Tsuang-1978" TYPE="REFERENCE">Tsuang 1978</LINK>, <LINK REF="REF-Palmer-2005" TYPE="REFERENCE">Palmer 2005</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-06-30 10:22:35 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate (valproic acid) is traditionally used as an anticonvulsant drug and is also used for affective disorders, especially for the treatment of acute mania. Furthermore it is thought to have anti-aggressive effects and it may reduce impulsive behaviour, which might be useful for some people with schizophrenia (<LINK REF="REF-Citrome-2000" TYPE="REFERENCE">Citrome 2000</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-05-29 15:22:33 +0100" MODIFIED_BY="[Empty name]">
<P>It is assumed that GABA-ergic drugs such as valproate have a potential role in the treatment of schizophrenia as they down-regulate dopamine (<LINK REF="STD-Wassef-2000" TYPE="STUDY">Wassef 2000</LINK>). Mesolimbic dopamine hyperactivity is considered one of the main reasons for the development of positive symptoms in schizophrenia.</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>In this review we examined the role of valproate in the treatment of schizophrenia and schizophrenia-like psychoses. The importance of performing such a review is emphasised by the fact that valproate is already frequently used for schizophrenia. For example, between 1994 and 1998 the use of valproate almost tripled among inpatients in the New York State psychiatric hospital system, with 43.4% of 4922 participants with a diagnosis of schizophrenia receiving valproate (<LINK REF="REF-Citrome-2000" TYPE="REFERENCE">Citrome 2000</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-10-05 10:10:07 +0100" MODIFIED_BY="[Empty name]">
<P>To examine whether:</P>
<P>1. valproate alone is an effective treatment for schizophrenia and schizoaffective psychoses; and</P>
<P>2. valproate augmentation of antipsychotic medication is an effective treatment for the same illnesses.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-10-26 10:23:41 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>All relevant randomised controlled trials (RCT). If a trial was described as 'double-blind' but implies randomisation, we included such trials in a sensitivity analysis (see <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>). If their inclusion did not result in a substantive difference, they remained in the analyses. If their inclusion did result in statistically significant differences, we did not add the data from these lower-quality studies to the results of the better trials, but presented such data within a subcategory. We excluded quasi-randomised studies, such as those allocating by alternate days of the week. Where people were given additional treatments within valproate, we only included data if the adjunct treatment was evenly distributed between groups and it was only the valproate that was randomised.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-02-29 14:55:49 +0000" MODIFIED_BY="[Empty name]">
<P>Adults, however defined, with schizophrenia or related disorders including schizophreniform disorder, schizoaffective disorder and delusional disorder, again, by any means of diagnosis.</P>
<P>We are interested in making sure that information is as relevant to the current care of people with schizophrenia as possible and planned to clearly highlight the current clinical state (acute, early post-acute, partial remission, remission) as well as the stage (prodromal, first episode, early illness, persistent) and as to whether the studies primarily focused on people with particular problems (for example, negative symptoms, treatment-resistant illnesses etc.).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Valproate alone</HEADING>
<P>Any dose; versus</P>
<SUBSECTION>
<HEADING LEVEL="5">i. Placebo</HEADING>
<P>Includes no intervention</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Valproate combination</HEADING>
<P>In combination with any antipsychotic treatment: any dose; versus</P>
<SUBSECTION>
<HEADING LEVEL="5">i. Placebo</HEADING>
<P>Includes no intervention in combination with any antipsychotic treatment, or</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ii. Antipsychotics alone</HEADING>
<P>Any dose</P>
</SUBSECTION>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>We aimed to group outcomes by time: short-term (up to 12 weeks), medium-term (13 to 26 weeks) and long-term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-08-04 15:34:05 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Clincally significant response: important change - as defined by each of the studies</HEADING>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Leaving the study early: acceptability/tolerability of treatment</HEADING>
<P>1.1 Acceptability - leaving the study early for any reason<BR/>1.2 Overall tolerability - leaving the study early due to adverse events<BR/>1.3 Leaving the study early due to poor clinical effect</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Service utilisation</HEADING>
<P>2.1 Hospital admission<BR/>2.2 Days in hospital<BR/>2.3 Change in hospital status</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Clinical response</HEADING>
<P>3.1 Any change global state - as defined by each of the studies<BR/>3.2 Average endpoint/change score on global state scale<BR/>3.3 Relapse - as defined by each of the studies<BR/>3.4 Clinically important change mental state - as defined by each of the studies<BR/>3.5 Average endpoint/change score on mental state scale<BR/>3.6 Clinically important change in positive symptoms - as defined by each of the studies<BR/>3.7 Average endpoint/change score on positive symptoms scale<BR/>3.8 Clinically important change in negative symptoms - as defined by each of the studies<BR/>3.9 Average endpoint/change score on negative symptoms scale<BR/>3.10 Clinically important change in depressive symptoms - as defined by each of the studies<BR/>3.11 Average endpoint/change score on depressive symptoms scale<BR/>3.12 Clinically important change in manic symptoms - as defined by each of the studies<BR/>3.13 Average endpoint/change score on manic symptoms scale<BR/>3.14 Clinically important change in aggressive symptoms/agitation - as defined by each of the studies<BR/>3.15 Average endpoint/change score on aggression/agitation symptoms scale</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Behaviour</HEADING>
<P>4.1 Clincally important change general behaviour - as defined by each of the studies<BR/>4.2 Specific behaviour change - as defined by each of the studies<BR/>4.2.1 Clinically important change social functioning - as defined by each of the studies<BR/>4.2.2 Employment status during trial (employed/unemployed)<BR/>4.2.3 Occurrence of violent incidents (to self, others, or property)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Adverse events</HEADING>
<P>5.1 General adverse events<BR/>5.2 Specific adverse events<BR/>5.2.1 Allergic reactions<BR/>5.2.2 Reversible thrombocytopenia<BR/>5.2.3 Central nervous system (ataxia, nystagmus, drowsiness, fits, diplopia, tremor)<BR/>5.2.4 Gastrointestinal (nausea, vomiting, diarrhoea)<BR/>5.2.5 Pancreatitis<BR/>5.2.6 Weight gain</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Use of additional medication</HEADING>
<P>6.1 Antipsychotics<BR/>6.2 Benzodiazepines</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Economic (cost of care)</HEADING>
<P>7.1 Direct cost of care<BR/>7.2 Indirect cost of care</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">8. Quality of life</HEADING>
<P>8.1 Clincically important change in quality of life - as defined by individual studies<BR/>8.2 Any change in quality of life - as defined by individual studies<BR/>8.3 Average endpoint/change score on quality of life scale</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">'Summary of findings' table</HEADING>
<P>We used the GRADE approach to interpret findings (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>) and used GRADE profiler (<A HREF="http://www.tech.cochrane.org/gradepro">GRADEPRO</A>) to import data from RevMan 5 (<A HREF="http://www.tech.cochrane.org/revman">Review Manager</A>) to create a 'Summary of findings' table. These tables provided outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to participant care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table.</P>
<OL>
<LI>Clinically significant response: important change - as defined by each of the studies</LI>
<LI>Leaving the study early: acceptability of treatment - leaving the study early for any reason</LI>
<LI>Leaving the study early: overall tolerability - leaving the study early due to adverse events</LI>
<LI>Clinical response: aggression/agitation</LI>
<LI>Adverse events: sedation</LI>
<LI>Adverse events: weight gain</LI>
<LI>Quality of life: clincially important change in quality of life - as defined by each of the studies</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cochrane Schizophrenia Group&#8217;s Study-Based Register of Trials</HEADING>
<P>On 4 March 2016, the Information Specialist searched the register using the following search strategy:</P>
<P>*Valproate* in Intervention Field of STUDY</P>
<P>In such study-based registers, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics.</P>
<P>This Register is compiled by systematic searches of major resources (including MEDLINE, Embase, AMED, BIOSIS, CINAHL, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group&#8217;s Module</A>). There is no language, date, document type, or publication status limitations for inclusion of records into the Register.</P>
<P>For previous searches, please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-05-21 11:21:17 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Reference searching</HEADING>
<P>We inspected references of all identified studies for further relevant studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Personal contact</HEADING>
<P>We contacted the first author of each included study for information regarding unpublished trials (not done for 2012 update) and we sent requests to all authors for missing data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Pharmaceutical companies</HEADING>
<P>We contacted Sanofi-Synthelabo, France, and Abbott Laboratories, USA, as the main manufacturers of valproic acid drugs to obtain data on unpublished trials (not done again for 2012 update).</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-10-26 10:23:41 +0100" MODIFIED_BY="[Empty name]">
<P>Methods used in data collection and analysis for this update are below, for previous methods please see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<STUDY_SELECTION MODIFIED="2016-10-05 10:33:38 +0100" MODIFIED_BY="[Empty name]">
<P>Two out of four reviewers (YW, JX) independently inspected all citations from the 2012 update searches and identified relevant abstracts. Where disputes arose, we acquired the full report for more detailed scrutiny. If citations met inclusion criteria, we obtained full reports of the papers for more detailed, independent inspection by two out of four reviewers (YW, JX). Where it was not possible to resolve disagreement by discussion, we attempted to contact the authors of the study for clarification.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Extraction</HEADING>
<P>Two reviewers (YW, JX) extracted data from all newly included studies of the 2012 update search. Again, we discussed any disagreement, documented decisions and, if necessary, contacted authors of studies for clarification. With remaining problems SL helped clarify issues and we documented these final decisions. We planned to extract data presented only in graphs and figures whenever possible, with magnified images and ruler, and by two reviewers independently. Since there were no data to be extracted from graphs and figures, this was not performed. We attempted to contact study authors through an open-ended request in order to obtain missing information or for clarification whenever necessary. If studies were multi-centre, where possible, we extracted data relevant to each component centre separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Management</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">2.1 Forms</HEADING>
<P>We extracted data onto standard, simple forms.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.2 Scale-derived data</HEADING>
<P>We included continuous data from rating scales only if:<BR/>a. the psychometric properties of the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>); and<BR/>b. the measuring instrument had not been written or modified by one of the trialists for that particular trial.</P>
<P>Ideally the measuring instrument should either be a self-report, or completed by an independent rater or relative (not the therapist).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.3 Endpoint versus change data</HEADING>
<P>There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult-to-measure conditions such as schizophrenia. We decided to use primarily endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we aimed to use mean differences (MD) rather than standardised mean differences throughout (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.4 Skewed data</HEADING>
<P>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we applied the following standards:</P>
<P>a. We entered skewed data from studies of at least 200 participants in the analysis irrespective of the following rules, because skewed data poses less of a problem in large studies.</P>
<P>b. Endpoint data: when a scale started from the finite number zero, we subtracted the lowest possible value from the mean and divided this by the standard deviation. If this value was lower than one, it strongly suggested a skew and we excluded these data. If this ratio was higher than one but below two, there was suggestion of a skew. We entered these data and tested whether their inclusion or exclusion substantially changed the results. If the ratio was larger than two we included such data because skew was less likely (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>).</P>
<P>c. When continuous data were presented on a scale which included the possibility of negative values (such as change data), it was difficult to tell whether data were skewed or not. We entered such data because change data tend to be less skewed and because excluding data would also lead to bias, as not all the available information would be used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.5 Common measure</HEADING>
<P>To facilitate comparison between trials, where possible, we intended to convert variables that could be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.6 Conversion of continuous to binary</HEADING>
<P>Where possible, we made efforts to convert outcome measures to dichotomous data. This was done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It was generally assumed that if there was a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or the Positive and Negative Syndrome Scale (PANSS, <LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>), this could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2.7 Direction of graphs</HEADING>
<P>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for valproate. Where keeping to this made it impossible to avoid outcome titles with clumsy double-negatives (e.g. 'Not un-improved') we planned to report data where the left of the line indicated an unfavourable outcome and to note this in the relevant graphs.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<P>YW and JX worked independently to assess risk of bias by using criteria described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>) to assess trial quality of Chinese studies. BH alone assessed the non-Chinese articles and SL supervised this task. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.</P>
<P>If the raters disagreed, we made the final rating by consensus, with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. We reported non-concurrence in quality assessment, but if disputes arose as to which category a trial was to be allocated, again, we resolved by discussion.</P>
<P>We noted the level of risk of bias in both the text of the review (<LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK>) and in the 'Summary of findings' table (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Binary data</HEADING>
<P>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). For statistically significant results we had planned to calculate the number needed to treat for an additional beneficial outcome/harmful outcome statistic (NNTB/NNTH), and its 95% CI using Visual Rx (<A HREF="http://www.nntonline.net/">http://www.nntonline.net/</A>) taking account of the event rate in the control group. This, however, has been superseded by <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> and calculations therein.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Continuous data</HEADING>
<P>For continuous outcomes we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we would have presumed there was a small difference in measurement, and we would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>If we had included cluster trials and clustering was not accounted for in primary studies, we planned to present data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error and planned to contact first authors of studies to obtain intra-class correlation coefficients for their clustered data and to adjust for this by using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>If clustering had been incorporated into the analysis of primary studies, we planned to present these data as if from a non-cluster randomised study, but adjust for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra-class correlation coefficient (ICC) (Design effect = 1 + (m - 1)*ICC) (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC is not reported we would have assumed it to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).</P>
<P>If cluster studies have been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>Since we don't have clustered randomised trials in our review, the adjustment for unit of analysis error was not necessary.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Cross-over trials</HEADING>
<P>A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (<LINK REF="REF-Elbourne-2002" TYPE="REFERENCE">Elbourne 2002</LINK>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross-over studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Studies with multiple treatment groups</HEADING>
<P>Where a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary we simply added these and combined within the two-by-two table. If data were continuous we combined data following the formula in section 7.7.3.8  (Combining groups) of the <I>Cochrane Handbook for Systematic Reviews of Interventions (</I>
<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). Where the additional treatment arms were not relevant, we did not reproduce these data.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2016-10-05 12:59:23 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Overall loss of credibility</HEADING>
<P>We share the concern that at some degree of loss of follow-up data must lose credibility (<LINK REF="REF-Xia-2009" TYPE="REFERENCE">Xia 2009</LINK>). However, from which degree of attrition onward this is a problem is unclear. We did therefore not exclude studies on the basis of degree of attrition, but attrition was taken into account in the risk of bias assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Binary</HEADING>
<P>We presented data on a 'once-randomised-always-analyse' basis (an intention to treat analysis). We assumed all those leaving the study early to not have changed in the given outcome. This rule is conservative for response, because it assumes that those who left the studies early would not have responded to treatment. It is not conservative concerning side-effects. But it would often have been an overestimation of the frequency of side-effects if all participants who discontinued had been assumed to experience rare side-effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Continuous</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Attrition</HEADING>
<P>We used intention-to-treat data sets when possible, but included completer data if only these were available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Standard deviations</HEADING>
<P>If standard deviations were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error and confidence intervals available for group means, and either P value or 't' value available for differences in mean, we would have calculated them according to the rules described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>). When only the standard error (SE) was reported, standard deviations (SDs) were calculated by the formula SD = SE* square root (n). Chapters 7.7.3 (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>) and 16.1.3 (<LINK REF="REF-Higgins-2011c" TYPE="REFERENCE">Higgins 2011c</LINK>) of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> presented detailed formulas for estimating SDs from P values, t or F values, confidence intervals, ranges or other statistics. If these formulas did not apply, we would have calculated the SDs according to a validated imputation method which was based on the SDs of the other included studies (<LINK REF="REF-Furukawa-2006" TYPE="REFERENCE">Furukawa 2006</LINK>). Although some of these imputation strategies could introduce error, the alternative would be to exclude a given study&#8217;s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Last observation carried forward</HEADING>
<P>For a long time the method of last observation carried forward (LOCF) was employed to use participants' last assessments before leaving a study in the endpoint calculations (<LINK REF="REF-Leucht-2007a" TYPE="REFERENCE">Leucht 2007a</LINK>). Analyses have shown that more sophisticated statistical methods such as multiple imputation or mixed-model repeated measures analysis (MMRM, also called 'mixed models') overall lead to more valid results, but they have other limitations. LOCF does also not necessarily overestimate effects, it can both overestimate or underestimate them (<LINK REF="REF-Mallinckrodt-2004" TYPE="REFERENCE">Mallinckrodt 2004</LINK>). We therefore decided to use more sophisticated approaches such as multiple imputation or MMRM if available, but would use LOCF results if the former were not available.</P>
</SUBSECTION>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Clinical heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise, and discussed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Methodological heterogeneity</HEADING>
<P>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise, and discussed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Statistical heterogeneity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Visual inspection</HEADING>
<P>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Employing the I<SUP>2</SUP> statistic</HEADING>
<P>We investigated heterogeneity between studies by considering the I<SUP>2 </SUP>method alongside the Chi<SUP>2</SUP> P value. The I<SUP>2 </SUP>provides an estimate of the percentage of inconsistency thought to be due to chance (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). The importance of the observed value of I<SUP>2 </SUP>depends on the magnitude and direction of effects, and the strength of evidence for heterogeneity (e.g. P value from Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>). We interpreted an I<SUP>2 </SUP>estimate greater than or equal to around 50%, accompanied by a statistically significant Chi<SUP>2</SUP> statistic, as evidence of substantial levels of heterogeneity (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). When there were substantial levels of heterogeneity in the primary outcome, we explored reasons for heterogeneity (<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). These are described in Section 10 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>). We were aware that funnel plots might be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar size. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>We understand that there is no closed argument for preference for use of fixed-effect or random-effects models. The random-effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random-effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random effects model. It puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect these studies can either inflate or deflate the effect size. We chose random-effects model for all analyses.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>We reported if inconsistency was high. We first investigated whether data had been entered correctly. Second, if data were correct, we re-inspected outlier studies to find out whether methodological differences were likely to explain the differences. Such reasons were also explored by subgroup analyses. We had <I>a</I> <I>priori </I>decided that the examination of studies in first-episode participants and treatment-resistant participants versus the rest of the studies would be conducted in any case for the primary outcome, but others could arise and would be clearly described as post-hoc. Decisions as to whether the studies should nevertheless be pooled, whether single outlier studies should be removed or at least removed from a sensitivity analysis, or whether studies would not be pooled at all would depend on factors such as whether heterogeneity could be explained by subgroup effects or whether studies differed in direction of effects or just in the degree of differences between intervention and control (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2016-10-26 10:23:41 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">1. Implication of randomisation</HEADING>
<P>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcomes we included these studies and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we employed all data from these studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Assumptions for lost binary data</HEADING>
<P>Where assumptions had to be made regarding people lost to follow-up (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>) we compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption.</P>
<P>Where assumptions had to be made regarding missing SDs data (see <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK>), we compared the findings on the primary outcome when we used our assumption compared with completer data only. A sensitivity analysis was undertaken testing how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported results and discussed them but continued to employ our assumption.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Risk of bias</HEADING>
<P>We analysed the effects of excluding trials that we judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available, allocation concealment, blinding and outcome reporting) for the meta-analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Imputed values</HEADING>
<P>We planned to undertake a sensitivity analysis to assess the effects of including data from trials if we used imputed values for ICC in calculating the design effect in cluster randomised trials.</P>
<P>If substantial differences were noted in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Fixed and random effects</HEADING>
<P>We synthesised all data using a random-effects model, however, we also synthesised data for the primary outcome using a fixed-effect model to evaluate whether the greater weights assigned to larger trials with greater event rates altered the significance of the results, compared to the more evenly distributed weights in the random-effects model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6. Impact of people with schizoaffective disorder</HEADING>
<P>We followed a reviewer request, and post-hoc added a sensitivity analysis excluding studies in participants with schizoaffective disorder for the outcome 'behavior - aggression/agitation'.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-10-26 10:23:41 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-10-26 10:23:41 +0100" MODIFIED_BY="[Empty name]">
<P>For substantive description of studies please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> tables.<BR/>
</P>
<SEARCH_RESULTS MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>The original search in 2004 identified 34 citations of which we ordered and inspected 12 full-text articles. We excluded four studies and a further three studies we added to awaiting assessment. We included five studies.</P>
<P>The update search in 2007 yielded 28 citations of which we inspected five closely. Of the latter, one report provided additional usable information on <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>. Two studies were included (<LINK REF="STD-Wang-2005a" TYPE="STUDY">Wang 2005a</LINK>, <LINK REF="STD-Yin-2004" TYPE="STUDY">Yin 2004</LINK>) and the other two studies (<LINK REF="STD-Liang-2004" TYPE="STUDY">Liang 2004</LINK>, <LINK REF="STD-Zhu-2005" TYPE="STUDY">Zhu 2005</LINK>) were listed in the 'excluded studies table'.</P>
<P>The update search in 2012 yielded 46 citations of which we ordered and inspected 41 full reports. We added 19 studies to the included studies table. We excluded seven studies (see <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK>). There were two identical studies published (<LINK REF="STD-Liang-2004" TYPE="STUDY">Liang 2004</LINK> and <LINK REF="STD-Ma-2010" TYPE="STUDY">Ma 2010</LINK>) from two different author groups and from different hospitals. We assumed that the publications were on the same study and sent a letter to the authors for clarification.</P>
<P>In 2016 we did a scoping search. We identified 81 new references. Eight of these turned out to be additional publications of included studies and nine could be immediately excluded based on the title or abstract. The remaining references had to be classified as 'studies awaiting assessment'. This section now contains 69 reports. They will be examined in detail in the next update.</P>
<P>In summary, after searches carried out in 2004, 2007, 2012 and 2016, the total number of included studies is now 26, 11 are excluded and 69 are awaiting assessment. Please see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> which presents the search up to 2012.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-10-26 10:23:41 +0100" MODIFIED_BY="[Empty name]">
<P>The current version of the review includes 26 studies.</P>
<SUBSECTION>
<HEADING LEVEL="4">1. Length of trials</HEADING>
<P>All studies fell in the short-term category. The mean duration of the trials was six weeks, with the longest study lasting twelve weeks (<LINK REF="STD-Casey-2009" TYPE="STUDY">Casey 2009</LINK>; <LINK REF="STD-Fisk-1987" TYPE="STUDY">Fisk 1987</LINK>), and the shortest only two weeks (<LINK REF="STD-Guo-2007" TYPE="STUDY">Guo 2007</LINK>; <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK>; <LINK REF="STD-Shi-2010" TYPE="STUDY">Shi 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Participants</HEADING>
<P>Participants in all included studies were diagnosed with schizophrenia. To diagnose schizophrenia 15 studies used CCMD-3, three studies used DSM-IV, two studies used ICD-10, one study used DSM-IV-TR, one study used DSM-III, and four studies did not specify which criteria they used. In total 2184 participants participated in these 26 trials, with on average 84 participants in each study.  The biggest study had 402 participants (<LINK REF="STD-Casey-2009" TYPE="STUDY">Casey 2009</LINK>) and the smallest only 12 (<LINK REF="STD-Wassef-2000" TYPE="STUDY">Wassef 2000</LINK>). Twenty-one studies reported gender information, with 1293 male participants and 504 female participants (approximately 13:5); while five studies did not provide gender details. Twenty-one studies reported the age of participants, with a mean age of around 36 years old (five studies did not provide the participants' mean age).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">3.1 Leaving the study early</HEADING>
<P>The number of participants leaving the study early was recorded for the categories 'Acceptability of treatment: leaving for any reason', 'Overall tolerability: Leaving due to adverse events' and 'Leaving due to poor clinical effect'.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.2 Adverse events</HEADING>
<P>Side effects were recorded as the number of participants with an adverse event.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3.3 Scales</HEADING>
<P>Details of scales that provided usable data are shown below.</P>
<SUBSECTION>
<HEADING LEVEL="6">3.3.1 Clinical Global Impression (CGI)</HEADING>
<P>CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) is a rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. A seven-point scoring system is usually used with low scores indicating decreased severity or greater recovery, or both.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.3.2 Brief Psychiatric Rating Scale (BPRS)</HEADING>
<P>BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) is a brief rating scale used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 18 items, and each item can be defined on a seven-point scale varying from 'not present' (1) to 'extremely severe' (7). Scoring goes from 18-126.<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.3.3 Positive and Negative Syndrome Scale (PANSS)</HEADING>
<P>PANSS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>) is a schizophrenia scale that has 30 items, each of which can be defined on a seven-point scoring system varying from 1 - absent to 7 - extreme. It can be divided into three subscales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.3.4 Abnormal Involuntary Movement Scale (AIMS)</HEADING>
<P>The Abnormal Involuntary Movement Scale (<LINK REF="REF-NIMH-1970" TYPE="REFERENCE">NIMH 1970</LINK>) has been used to assess tardive dyskinesia, a long-term, drug-induced movement disorder. However, using this scale in short-term trials may also be helpful to assess some rapidly occurring abnormal movement disorders such as tremor.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.3.5 Treatment Emergent Symptom Scale (TESS)</HEADING>
<P>TESS (<LINK REF="REF-NIMH-1991" TYPE="REFERENCE">NIMH 1991</LINK>) is a comprehensive scale used to measure adverse events emergent during the antipsychotic therapy. The scale has 33 items, each of which is measured for severity, relationship of the symptom with medication, and treatment taken for the symptom. Severity can be defined on a five-point scale varying from 'not present' (0) to 'severe' (4). Relationship of the symptom with medication can be defined on a five-point scale varying from 'not related' (0) to 'definitely related'. Treatment taken for the symptom can be defined on a seven-point scale varying from 'no treatment required' (0) to 'termination of medication' (6).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.3.6 Modified Overt Aggression Scale (MOAS)</HEADING>
<P>MOAS (<LINK REF="REF-Kay-1986" TYPE="REFERENCE">Kay 1986</LINK>) is a brief rating scale used to assess the severity of aggressive behavior. The scale has four items, and each item can be defined on a five-point scale varying from 'absent' (0) to 'extreme' (4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.3.7 Inpatient Multidimensional Psychiatric Scale (IMPS)</HEADING>
<P>IMPS (<LINK REF="REF-Hiller-1986" TYPE="REFERENCE">Hiller 1986</LINK>) is a semi-standardised, multidimensional judgment method for detecting psychopathological findings with 90 operationally defined symptoms (complaints and psychiatrically-relevant behaviours) from the entire spectrum of psychopathology. The estimates are based on observable behaviour and statements are made immediately after a free exploration call. For differential diagnostic problems, individual findings can be entered on profile sheets for depression, mania, schizophrenia and neuroses.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3.3.8 Scale for Assessment of Negative Symptoms (SANS)</HEADING>
<P>SANS (<LINK REF="REF-Andreasen-1989" TYPE="REFERENCE">Andreasen 1989</LINK>) is a rating scale to measure negative symptoms in schizophrenia. The scale has 26 items, each of which can be defined on a six-point scale varying from 'absent' (0) to 'severe' (5).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Eleven studies were excluded from the analysis. Four of them were not randomised or the randomisation was done inappropriately (<LINK REF="STD-Centorrino-1994" TYPE="STUDY">Centorrino 1994</LINK>; <LINK REF="STD-Ping-1994" TYPE="STUDY">Ping 1994</LINK>; <LINK REF="STD-Raja-2000" TYPE="STUDY">Raja 2000</LINK>; <LINK REF="STD-Rifang-2001" TYPE="STUDY">Rifang 2001</LINK>). One study included no placebo group (<LINK REF="STD-Alberti-1999" TYPE="STUDY">Alberti 1999</LINK>;). One study included no adequate intervention group (<LINK REF="STD-Monfort-1991" TYPE="STUDY">Monfort 1991</LINK>). Two studies included people with mania or bipolar disorder (<LINK REF="STD-Bersudsky-2010" TYPE="STUDY">Bersudsky 2010</LINK>; <LINK REF="STD-NCT00183443" TYPE="STUDY">NCT00183443</LINK>). One study only compared valproate with another mood-stabiliser (<LINK REF="STD-Zhu-2005" TYPE="STUDY">Zhu 2005</LINK>). One study only reported data on metabolic measurements (<LINK REF="STD-Haupt-2007" TYPE="STUDY">Haupt 2007</LINK>). One study (<LINK REF="STD-Ma-2010" TYPE="STUDY">Ma 2010</LINK>) reported identical data as <LINK REF="STD-Liang-2004" TYPE="STUDY">Liang 2004</LINK>.</P>
<P>For the comparisons made in excluded studies and suggestions for relevant reviews they could be included in please refer to <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> in Additional tables.</P>
<SUBSECTION>
<HEADING LEVEL="4">Studies awaiting assessment</HEADING>
<P>There are 69 studies in the <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>, 35 are Chinese and awaiting translation, 28 are unclear allocation, six are randomised studies but need the full report for more detailed assessment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ongoing studies</HEADING>
<P>We know of four ongoing studies, see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>For graphical representations of our judgements of risk of bias please refer to <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. Full details of judgements can be seen in the 'Risk of bias' tables.<BR/>
</P>
<ALLOCATION MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>In the trials, participants were randomly assigned to receive either combinational therapy of antipsychotics and valproate or monotherapy of antipsychotics, with or without placebo. Two studies adopted stratified randomisation (<LINK REF="STD-Fisk-1987" TYPE="STUDY">Fisk 1987</LINK>; <LINK REF="STD-Jiang-2009" TYPE="STUDY">Jiang 2009</LINK>); one study randomised participants by drawing lots (<LINK REF="STD-Liu-2007a" TYPE="STUDY">Liu 2007a</LINK>) and another study used a random number table (<LINK REF="STD-Shi-2010" TYPE="STUDY">Shi 2010</LINK>). We considered these studies as low risk for randomisation. Other studies failed to specify the process by which allocation to the intervention group was undertaken, therefore we have rated the allocation concealment and allocation for these studies as 'unclear'. Poor reporting of randomisation has been associated with an overestimate of effect (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>, <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Objective and subjective outcomes were rated separately, because we considered blinding to be less important for objective than for subjective outcomes. We also rated performance and detection bias separately, resulting in four independent assessments of blinding.</P>
<P>Seven studies were described as 'double-blinded', so we rated them as low risk of performance bias and detection bias (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Casey-2009" TYPE="STUDY">Casey 2009</LINK>; <LINK REF="STD-Dose-1998" TYPE="STUDY">Dose 1998</LINK>; <LINK REF="STD-Fisk-1987" TYPE="STUDY">Fisk 1987</LINK>; <LINK REF="STD-Glick-2009" TYPE="STUDY">Glick 2009</LINK>; <LINK REF="STD-Liu-2007a" TYPE="STUDY">Liu 2007a</LINK>; <LINK REF="STD-Yin-2004" TYPE="STUDY">Yin 2004</LINK>). People with schizophrenia and clinicians were not blinded, but raters were blinded in two studies, so we rated them as high risk of performance bias but low risk of detection bias (<LINK REF="STD-Citrome-2007" TYPE="STUDY">Citrome 2007</LINK>; <LINK REF="STD-Hesslinger-1999" TYPE="STUDY">Hesslinger 1999</LINK>). There was no information about blinding reported in other studies, so we assumed they were open-label, and at high risk of both performance bias and detection bias.</P>
<P>As for objective outcomes, we judged the vast majority of studies as having a low risk of bias in that respect.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Twelve studies indicated the numbers of participants who left the study before its completion, but the reasons for leaving the studies early were not consistently indicated. Among these studies, we assessed four as having a low risk of attrition bias, meaning that the problem of incomplete outcome data was addressed in an appropriate way (number of people leaving the study early was not very high and was evenly distributed between groups). We judged three studies as unclear, and five as having high risk of attrition bias.</P>
<P>The rest of the studies did not provide any information about people leaving the study early so we evaluated them as unclear risk of attrition bias.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Five studies did not selectively report any predefined outcomes. Twenty studies failed to report usable continuous data for some major outcomes, for example BPRS (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Yin-2004" TYPE="STUDY">Yin 2004</LINK>), CGI, PANSS (<LINK REF="STD-Citrome-2007" TYPE="STUDY">Citrome 2007</LINK>, <LINK REF="STD-Glick-2009" TYPE="STUDY">Glick 2009</LINK>), and MOAS (<LINK REF="STD-Citrome-2007" TYPE="STUDY">Citrome 2007</LINK>; <LINK REF="STD-Liu-2007a" TYPE="STUDY">Liu 2007a</LINK>) (many of them did not report results of adverse events and TESS). We gave these studies a 'high risk of bias' rank. The other two studies had only some minor flaws and we judged them as 'unclear'.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-07-21 20:25:11 +0100" MODIFIED_BY="[Empty name]">
<P>There were no obvious other potential sources of bias in the included studies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-10-05 13:50:29 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. Comparison 1: VALPROATE + ANTIPSYCHOTICS versus ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1 Clinically significant response: important change - as defined by each of the studies</HEADING>
<P>We detected a significant difference favouring the valproate group, with 14 studies contributing (14 RCTs, n = 1049, RR 1.31, 95% CI 1.16 to 1.47, I<SUP>2 </SUP>= 12%, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2 Leaving the study early: Acceptability/tolerability of treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1 Acceptability of treatment: leaving for any reason</HEADING>
<P>Eleven studies contributed to the outcome of 'number leaving the study early for any reason'. There was no significant difference between participants treated with valproate or placebo (n = 951, RR 0.76, 95% CI 0.47 to 1.24, I<SUP>2 </SUP>= 55%, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.2 Overall tolerability: leaving due to adverse event</HEADING>
<P>Six studies contributed to 'leaving the study early due to side effects', again we found no significant difference between the two groups (n = 974, RR 1.33, 95% CI 0.90 to 1.97, I<SUP>2</SUP> = 0, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.2.3 Leaving due to poor clinical effect</HEADING>
<P>We detected a significant difference favouring the valproate group under the outcome 'leaving the study early due to poor clinical effect', with five studies contributing (n = 810, RR 0.54, 95% CI 0.31 to 0.94, I<SUP>2 </SUP>= 46%, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>We generated a forest plot of the comparison for visual inspection (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.3 Clincial response: 2. Global state: 1a. mean change score CGI severity (high = poor)</HEADING>
<P>
<LINK REF="STD-Casey-2009" TYPE="STUDY">Casey 2009</LINK> reported data on change of CGI severity and improvement.</P>
<P>There were no significant differences between groups in terms of severity (n = 392, MD 0.10, 95% CI -0.12 to 0.32, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.4 Clinical response: 3. Global state: 1b. mean change score CGI Improvement (high = poor)</HEADING>
<P>There were no significant differences between groups in terms of improvement (n = 393, MD 0.00, 95% CI - 0.26 to 0.26, <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.5 Clinical response: 4. Mental state: 2a mean change score PANSS total (high = poor)</HEADING>
<P>Thirteen studies reported usable data about the mean change score on PANSS. There was a statistically significant difference between the valproate group and the placebo group in favour of the valproate group (n = 1363, MD - 5.85, 95% CI - 7.80 to - 3.91, I<SUP>2 </SUP>= 67%, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). There was significant heterogeneity here, because significant improvement in valproate group was only observed in open Chinese studies, whose quality of evidence was low as described elsewhere in this review. The two blinded Western studies did not show significant difference between the valproate group and the placebo group. Therefore, it may be considered that the open studies exaggerated the effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.6 Clinical response 5. Mental sate: 2b. mean endpoint score BPRS total (high = poor)</HEADING>
<P>Seven studies reported usable data about the mean endpoint score on BPRS. There was no statistically significant difference between the valproate group and the placebo group (n = 646, MD - 1.87, 95% CI - 4.46 to 0.73, Z = 1.41, I<SUP>2 </SUP>= 73%, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). There was significant heterogeneity here, but we did not find explanations after looking into individual studies. It may be considered that the heterogeneity was due to natural variation in the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.7 Clinical response: 6. Mental state: 2c. mean change score IMPS total (high = poor)</HEADING>
<P>
<LINK REF="STD-Hesslinger-1999" TYPE="STUDY">Hesslinger 1999</LINK> reported on the mean change score IMPS . There was no statistically significant difference between the valproate group and the placebo group (n = 18, MD - 5.11, 95% CI - 26.04 to 15.82, <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.8 Clinical response: 7. Positive symptoms: 3a. mean endpoint score PANSS positive subscale (high = poor)</HEADING>
<P>Nine studies reported usable data on PANSS-positive subscale. There was a statistically significant difference between the valproate group and the placebo group (n = 1073, MD - 1.72, 95% CI - 3.01 to - 0.43, I<SUP>2 </SUP>= 69%, <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). There was significant heterogeneity here, but we did not find explanations after looking into individual studies. It may be considered that the heterogeneity was due to natural variation in the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.9 Clinical response: 8. Positive symptoms: 3b. mean endpoint score PANSS positive subscale (high = poor, skewed data)</HEADING>
<P>
<LINK REF="STD-Jia-2007" TYPE="STUDY">Jia 2007</LINK> and <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK> also reported on the mean PANSS-positive subscale, but their data were skewed and therefore unusable (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.10 Clinical response: 9. Negative symptoms: 4a. mean endpoint score PANSS negative subscale (high = poor)</HEADING>
<P>Five studies reported usable data on the mean PANSS-negative subscale. There was a statistically significant difference between the valproate group and the placebo group in favour of the valproate group (n = 651, MD - 1.78, 95% CI - 3.13 to - 0.43, I<SUP>2 </SUP>= 67% <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). There was significant heterogeneity here, again, because significant improvement in valproate group was only observed in open Chinese studies, whose quality of evidence was low as described elsewhere in this review. <LINK REF="STD-Casey-2009" TYPE="STUDY">Casey 2009</LINK> did not show significant difference between the valproate group and the placebo group. Therefore, it may be considered that the open studies exaggerated the effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.11 Clinical Response: 10. Negative symptoms: 4b. mean endpoint score PANSS negative subscale (high = poor, data skewed)</HEADING>
<P>Four other studies also reported on the mean PANSS-negative subscale, but their data were skewed and therefore unusable (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.12 Clinical response: 11. Negative symptoms: 4c. mean endpoint score SANS subscale (skewed data)</HEADING>
<P>
<LINK REF="STD-Wassef-2000" TYPE="STUDY">Wassef 2000</LINK> analysed negative symptoms using the SANS total score at endpoint and found a superiority of valproate. The data were skewed and could therefore only be displayed in the other data table (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.13 Clinical response: 12. Negative symptoms: 4d. mean endpoint score BPRS lack of energy sub-score (high = poor)</HEADING>
<P>Three studies reported usable data on the BPRS lack of energy subscore. There was no statistically significant difference between the valproate group and the placebo group (n = 135, MD 0.46, 95% CI - 0.29 to 1.22, I<SUP>2 </SUP>= 89% (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.14 Clinical response: 13. Aggression/agitation: 5b. clinically important change - MOAS (high = poor)</HEADING>
<P>
<LINK REF="STD-Liu-2007a" TYPE="STUDY">Liu 2007a</LINK> reported dichotomous data on the MOAS response. There was a statistically significant difference between the valproate group and the placebo group in favour of the valproate group (n = 36, RR 2.68, 95% CI 1.07 to 6.76, <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.15 Clinical response: 14. Aggression/agitation 5a. mean endpoint score MOAS (high = poor)</HEADING>
<P>Three studies reported continuous data on the mean MOAS at endpoint. There was a statistically significant difference between the valproate group and the placebo group in favour of the valproate group (n = 186, MD -2.55, 95% CI -3.92 to -1.19, I<SUP>2 </SUP>= 82%, <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). There was significant heterogeneity here. As only three studies were involved and all of them reported significant improvement in the valproate group, it may be considered that the heterogeneity was due to natural variation in the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.16 Clinical response: 15. Aggression/agitation: 5c. mean endpoint PANSS-EC subscale (high = poor)</HEADING>
<P>Three studies reported usable data on PANSS-EC sub-score at endpoint. There was a statistically significant difference between the valproate group and the placebo group in favour of the valproate group (n = 204, MD -1.85, 95% CI -2.63 to -1.08, <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.17 Clinical response: 16. Aggression/agitation: 5d. mean endpoint score PANSS-EC subscale (skewed data)</HEADING>
<P>
<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> also reported on PANSS-EC item reduction, but the data were skewed and therefore unusable (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.18 Clinical response: 17. Aggression/agitation: 5e. mean endpoint score PANSS supplementary subscale (high = poor)</HEADING>
<P>
<LINK REF="STD-Jiang-2009" TYPE="STUDY">Jiang 2009</LINK> reported usable data on PANSS supplementary subscore at endpoint. There was a statistically significant difference between the valproate group and the placebo group in favour of the valproate group (n = 120, MD - 0.85, 95% CI - 1.39 to - 0.31, <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.19 Clinical response: 18. Aggression/agitation: 5f. mean endpoint BPRS hostility subscale (high = poor)</HEADING>
<P>Three studies reported usable data on mean BPRS hostility subscore at endpoint. There was no statistically significant difference between the valproate group and the placebo group (n = 135, MD - 0.10, 95% CI - 0.34 to 0.14, <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.20 Clinical response: 19. Depression symptoms: 6a. mild improvement Calgary Depression Scale (high = poor)</HEADING>
<P>
<LINK REF="STD-Glick-2009" TYPE="STUDY">Glick 2009</LINK> reported a number of people with schizophrenia with mild improvement on the Calgary Depression Scale at endpoint. There was no statistically significant difference between groups (n = 16, RR 1.40, 95% CI 0.77 to 2.54, <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.21 Clinical response: 20. Depression symptoms: 6b. mean endpoint score BPRS anxiety and depression subscale (high = poor)</HEADING>
<P>Three studies reported usable data on mean BPRS anxiety and depression sub-score at endpoint. There was no statistically significant difference between the valproate group and the placebo group (n = 135, MD -0.06, 95% CI -0.25 to 0.13, <LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.22 Clinical response: 7. General pathology: 7a. mean change score PANSS general pathology subscale (high = poor)</HEADING>
<P>Eight studies reported usable data. There was a statistically significant difference between the valproate group and the placebo group in favour of the valproate group (n = 873, MD -3.05, 95% CI -4.30 to -1.81, <LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.23 to 1.24 Use of additional medication: mean dose of antiparkinson medication, mean dose chlorprothixene</HEADING>
<P>
<LINK REF="STD-Dose-1998" TYPE="STUDY">Dose 1998</LINK> and <LINK REF="STD-Hesslinger-1999" TYPE="STUDY">Hesslinger 1999</LINK> reported the mean dose of antiparkinson medication that was prescribed. <LINK REF="STD-Dose-1998" TYPE="STUDY">Dose 1998</LINK> found a similar dose in both groups, whereas <LINK REF="STD-Hesslinger-1999" TYPE="STUDY">Hesslinger 1999</LINK> revealed that in the valproate group more antiparkinson medication was used. The data were skewed in both trials and therefore we could only display the data in the other data table, <LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>.</P>
<P>
<LINK REF="STD-Dose-1998" TYPE="STUDY">Dose 1998</LINK> and <LINK REF="STD-Hesslinger-1999" TYPE="STUDY">Hesslinger 1999</LINK> analysed the mean dose of chlorprothixene that was used for additional sedation. <LINK REF="STD-Dose-1998" TYPE="STUDY">Dose 1998</LINK> found a higher mean chlorprothixene dose in the placebo group whereas <LINK REF="STD-Hesslinger-1999" TYPE="STUDY">Hesslinger 1999</LINK> did not find any difference between the two groups The data were skewed and therefore we could only present the data in the other data table (<LINK REF="CMP-001.24" TYPE="ANALYSIS">Analysis 1.24</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.25 Use of additional medication: 3. Medication for sedation at least once</HEADING>
<P>Two studies provided usable data. The number of participants taking sedative medication at least once was similar between groups (n = 309, RR 3.65, 95% CI 0.11 to 122.31, I<SUP>2 </SUP>85%, <LINK REF="CMP-001.25" TYPE="ANALYSIS">Analysis 1.25</LINK>). There was significant heterogeneity here. As only two studies were involved and both of them reported no significant difference between the valproate group and the placebo group, it may be considered that the heterogeneity was due to natural variation in the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.26 Adverse events: 1. Abnormal ECG</HEADING>
<P>
<LINK REF="STD-Citrome-2007" TYPE="STUDY">Citrome 2007</LINK> and <LINK REF="STD-Jiang-2009" TYPE="STUDY">Jiang 2009</LINK> reported the number of participants with abnormal ECG. There was no statistically significant difference between the valproate group and the placebo group (n = 153, RR 0.88, 95% CI 0.35 to 2.18, <LINK REF="CMP-001.26" TYPE="ANALYSIS">Analysis 1.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.27 Adverse events: 2. Abnormal liver function/increase in alanine transaminase/gamma glutamyl transpeptidase</HEADING>
<P>Eight studies provided usable data. There was no statistically significant difference between the valproate group and the placebo group (n = 745, RR 1.26, 95% CI 0.72 to 2.22, <LINK REF="CMP-001.27" TYPE="ANALYSIS">Analysis 1.27</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.28 Adverse events: 3. Akathisia</HEADING>
<P>
<LINK REF="STD-Li-2009" TYPE="STUDY">Li 2009</LINK>, <LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK> and <LINK REF="STD-Xie-2011" TYPE="STUDY">Xie 2011</LINK> reported the number of participants with akathisia. There was no statistically significant difference between the valproate group and the placebo group (n = 186, RR 1.06, 95% CI 0.36 to 3.06, <LINK REF="CMP-001.28" TYPE="ANALYSIS">Analysis 1.28</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.29 Adverse events: 4. Anxiety</HEADING>
<P>
<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> and <LINK REF="STD-Xie-2011" TYPE="STUDY">Xie 2011</LINK> reported the number of participants with anxiety. There was no statistically significant difference between the valproate group and the placebo group (n = 319, RR 0.51, 95% CI 0.21 to 1.24, I<SUP>2 </SUP>= 0, <LINK REF="CMP-001.29" TYPE="ANALYSIS">Analysis 1.29</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.30 Adverse events: 5. Asthenia</HEADING>
<P>
<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> observed seven participants in the valproate group and 11 participants in the placebo group with asthenia. Again the difference did not reach statistical significance (n = 249, RR 1.58, 95% CI 0.63 to 3.95, <LINK REF="CMP-001.30" TYPE="ANALYSIS">Analysis 1.30</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.31 Adverse events: 6. Ataxia</HEADING>
<P>
<LINK REF="STD-Fisk-1987" TYPE="STUDY">Fisk 1987</LINK> and <LINK REF="STD-Pan-2010" TYPE="STUDY">Pan 2010</LINK> reported the number of participants with ataxia. There was no statistically significant difference between the valproate group and the placebo group (n = 115, RR 2.42, 95% CI 0.37 to 15.92, <LINK REF="CMP-001.31" TYPE="ANALYSIS">Analysis 1.31</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.32 Adverse events: 7. At least one adverse event</HEADING>
<P>There was no statistically significant difference between the valproate group and the placebo group (5 RCTs, n = 493, RR 0.92, 95% CI 0.68 to 1.25, I<SUP>2 </SUP>= 74%, <LINK REF="CMP-001.32" TYPE="ANALYSIS">Analysis 1.32</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.33 Adverse events: 8. Blood count changes</HEADING>
<P>
<LINK REF="STD-Dose-1998" TYPE="STUDY">Dose 1998</LINK> reported that four participants in the placebo group and five participants in the valproate group developed eosinophilia (n = 42, RR 1.38, 95% CI 0.43 to 4.42). Monocytosis was found in two participants in the valproate group only (n = 42, RR 5.48, 95% CI 0.28 to 107.62) and transient lymphocystosis was found in three participants of the valproate and one participant of the placebo group (n = 42, RR 3.30, 95% CI 0.37 to 29.21). Five studies reported the number of participants with leukopenia, and there was no statistically significant difference between the valproate group and the placebo group (n = 385, RR 1.18, 95% CI 0.38 to 3.64). <LINK REF="STD-Yin-2004" TYPE="STUDY">Yin 2004</LINK> reported the number of participants with thrombocytopenia, and there was a statistically significant difference between the valproate group and the placebo group in favour of the placebo group (n = 79, RR 17.42, 95% CI 1.04 to 291.96) (All in <LINK REF="CMP-001.33" TYPE="ANALYSIS">Analysis 1.33</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.34 Adverse events: 9. Constipation</HEADING>
<P>Four studies provided usable data. There was no statistically significant difference between the valproate group and the placebo group (n = 515, RR 0.94, 95% CI 0.47 to 1.85, I<SUP>2 </SUP>54%, <LINK REF="CMP-001.34" TYPE="ANALYSIS">Analysis 1.34</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.35 Adverse events: 10. Convulsion</HEADING>
<P>
<LINK REF="STD-Jiang-2009" TYPE="STUDY">Jiang 2009</LINK> reported one participant with convulsion in the placebo group but no participants with convulsion in the valproate group. This difference did not reach statistical significance (n = 120, RR 0.37, 95% CI 0.02 to 8.85, <LINK REF="CMP-001.35" TYPE="ANALYSIS">Analysis 1.35</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.36 Adverse events: 11. Diarrohea</HEADING>
<P>Three studies provided usable data. There was no statistically significant difference between the valproate group and the placebo group (n = 193, RR 1.03, 95% CI 0.32 to 3.34, <LINK REF="CMP-001.36" TYPE="ANALYSIS">Analysis 1.36</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.37 Adverse events: 12. Dizziness</HEADING>
<P>Seven studies provided usable data. There was no statistically significant difference between the valproate group and the placebo group (n = 662, RR 1.37, 95% CI 0.92 to 2.03, <LINK REF="CMP-001.37" TYPE="ANALYSIS">Analysis 1.37</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.38 Adverse events: 13. Dry mouth</HEADING>
<P>
<LINK REF="STD-Citrome-2007" TYPE="STUDY">Citrome 2007</LINK>, <LINK REF="STD-Lu-2006" TYPE="STUDY">Lu 2006</LINK> and <LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK> reported the number of participants with dry mouth. There was no statistically significant difference between the valproate group and the placebo group (n = 179, RR 1.19, 95% CI 0.58 to 2.42, <LINK REF="CMP-001.38" TYPE="ANALYSIS">Analysis 1.38</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.39 Adverse events: 14. Dyspepsia</HEADING>
<P>
<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> reported on dyspepsia as an adverse event and found no statistical significant difference between the two treatment groups (n = 249, RR 1.05, 95% CI 0.62 to 1.79, <LINK REF="CMP-001.39" TYPE="ANALYSIS">Analysis 1.39</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.40 Adverse events: 15. Dystonia</HEADING>
<P>
<LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK> and <LINK REF="STD-Xie-2011" TYPE="STUDY">Xie 2011</LINK> reported the number of people with dystonia. There was no statistically significant difference between the valproate group and the placebo group (n = 130, RR 1.00, 95% CI 0.30 to 3.37, <LINK REF="CMP-001.40" TYPE="ANALYSIS">Analysis 1.40</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.41 Adverse events: 16. Extrapyramidal adverse advents</HEADING>
<P>Extrapyramidal adverse advents were recorded by <LINK REF="STD-Dose-1998" TYPE="STUDY">Dose 1998</LINK> and <LINK REF="STD-Fisk-1987" TYPE="STUDY">Fisk 1987</LINK> using the Simpson Angus Scale (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>). As the data were skewed they could be displayed in the other data table only (<LINK REF="CMP-001.41" TYPE="ANALYSIS">Analysis 1.41</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.42 Adverse events: 17. Headache</HEADING>
<P>Four studies provided usable data. There was no statistically significant difference between the valproate group and the placebo group (n = 469, RR 1.02, 95% CI 0.67 to 1.56, <LINK REF="CMP-001.42" TYPE="ANALYSIS">Analysis 1.42</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.43 Adverse events: 18. Hypersalivation</HEADING>
<P>Three studies reported the number of people with hypersalivation. The difference between the valproate group and placebo group was not statistically significant (n = 248, RR 1.03, 95% CI 0.62 to 1.70, <LINK REF="CMP-001.43" TYPE="ANALYSIS">Analysis 1.43</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.44 Adverse events: 19. Incontinence</HEADING>
<P>In the study by <LINK REF="STD-Fisk-1987" TYPE="STUDY">Fisk 1987</LINK> one participant who received valproate experienced incontinence but this did not lead to a statistically significant difference between both groups (n = 47, RR 3.39, 95% CI 0.15 to 79.22, <LINK REF="CMP-001.44" TYPE="ANALYSIS">Analysis 1.44</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.45 Adverse events: 20. Insomina</HEADING>
<P>
<LINK REF="STD-Li-2009" TYPE="STUDY">Li 2009</LINK> and <LINK REF="STD-Xie-2011" TYPE="STUDY">Xie 2011</LINK> reported the number of participants with insomnia. There was no statistically significant difference between the valproate group and the placebo group (n = 126, RR 0.83 95% CI 0.39 to 1.78, <LINK REF="CMP-001.45" TYPE="ANALYSIS">Analysis 1.45</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.46 Adverse events: 21. Myocardial ischaemia</HEADING>
<P>
<LINK REF="STD-Yao-2010" TYPE="STUDY">Yao 2010</LINK> reported one participant in the valproate group and two participants in the placebo group with myocardial ischaemia. There was no statistically significant difference between the valproate group and the placebo group (n = 62, RR 0.50, 95% CI 0.05 to 5.23, <LINK REF="CMP-001.46" TYPE="ANALYSIS">Analysis 1.46</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.47 Adverse events: 22. Nausea</HEADING>
<P>Nine studies provided usable data. There was no statistically significant difference between the valproate group and the placebo group (n = 728, RR 1.22, 95% CI 0.80 to 1.86, <LINK REF="CMP-001.47" TYPE="ANALYSIS">Analysis 1.47</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.48 Adverse events: 23. Pain</HEADING>
<P>In <LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> more participants in the placebo group (n = 18) experienced pain than in the valproate group (n = 11). This, however, was not statistically significant (n = 249, RR 0.62, 95% CI 0.30 to 1.25, <LINK REF="CMP-001.48" TYPE="ANALYSIS">Analysis 1.48</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.49 Adverse events: 24. Rash</HEADING>
<P>
<LINK REF="STD-Jiang-2009" TYPE="STUDY">Jiang 2009</LINK> and <LINK REF="STD-Xie-2011" TYPE="STUDY">Xie 2011</LINK> reported the number of participants with a rash. There was no statistically significant difference between the valproate group and the placebo group (n = 190, RR 3.15, 95% CI 0.33 to 29.72, <LINK REF="CMP-001.49" TYPE="ANALYSIS">Analysis 1.49</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.50 Adverse events: 25. Rhinitis</HEADING>
<P>In one study (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>) rhinitis was reported as an adverse event, but without significant findings (n = 249, RR 0.30, 95% CI 0.09 to 1.07, <LINK REF="CMP-001.50" TYPE="ANALYSIS">Analysis 1.50</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.51 Adverse events: 26. Rigidity/stiffness</HEADING>
<P>
<LINK REF="STD-Citrome-2007" TYPE="STUDY">Citrome 2007</LINK> reported one participant in the valproate group but no participants in the placebo group with rigidity/stiffness. There was no statistically significant difference between groups (n = 33, RR 2.83, 95% CI 0.12 to 64.89, <LINK REF="CMP-001.51" TYPE="ANALYSIS">Analysis 1.51</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.52 Adverse events: 27. Sedation/somnolence/drowsiness</HEADING>
<P>Eight studies provided usable data. Valproate was significantly more likely to cause sedation than placebo (8 RCTs, n = 770, RR 1.38, 95% CI 1.07 to 1.79, <LINK REF="CMP-001.52" TYPE="ANALYSIS">Analysis 1.52</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.53 Adverse events: 28. Sexual dysfunction</HEADING>
<P>
<LINK REF="STD-Citrome-2007" TYPE="STUDY">Citrome 2007</LINK> reported one participant in the placebo group but no participants in the valproate group with sexual dysfunction. There was no statistically significant difference between groups (n = 33, RR 0.31, 95% CI 0.01 to 7.21, <LINK REF="CMP-001.53" TYPE="ANALYSIS">Analysis 1.53</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.54 Adverse events: 29. Suicidal or depressed</HEADING>
<P>
<LINK REF="STD-Glick-2009" TYPE="STUDY">Glick 2009</LINK> reported one participant in the placebo group but no participants in the valproate group as suicidal or depressed. There was no statistically significant difference between groups (n = 16, RR 0.33, 95% CI 0.02 to 7.14, <LINK REF="CMP-001.54" TYPE="ANALYSIS">Analysis 1.54</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.55 Adverse events: 30. Tachycardia</HEADING>
<P>Three studies provided data. There was no statistically significant difference between the valproate group and the placebo group (n = 218, RR 1.28, 95% CI 0.60 to 2.72, <LINK REF="CMP-001.55" TYPE="ANALYSIS">Analysis 1.55</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.56 Adverse events: 31.Tremor</HEADING>
<P>Four studies reported the number of participants with tremor. There was no statistically significant difference between the valproate group and the placebo group (n = 199, RR 1.17, 95% CI 0.46 to 2.97, <LINK REF="CMP-001.56" TYPE="ANALYSIS">Analysis 1.56</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.57 Adverse events: 32. Unstable gait</HEADING>
<P>A small study by <LINK REF="STD-Liu-2007a" TYPE="STUDY">Liu 2007a</LINK> reported one participant in the valproate group and one participant in the placebo group with unstable gait. There was no statistically significant difference between the valproate group and the placebo group (n = 19, RR 0.27, 95% CI 0.02 to 3.39, <LINK REF="CMP-001.57" TYPE="ANALYSIS">Analysis 1.57</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.58 Adverse events: 33. Vegetative adverse events</HEADING>
<P>
<LINK REF="STD-Fisk-1987" TYPE="STUDY">Fisk 1987</LINK> reported six cases of vegetative adverse events which were not further specified in the valproate group and four cases in the placebo group. The difference was not statistically significant (n = 47, RR 1.70, 95% CI 0.55 to 5.27, <LINK REF="CMP-001.58" TYPE="ANALYSIS">Analysis 1.58</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.59 Adverse events: 34. Vomiting</HEADING>
<P>
<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK> and <LINK REF="STD-Citrome-2007" TYPE="STUDY">Citrome 2007</LINK> found no statistical significance between the two groups regarding vomiting (n = 282, RR 0.99, 95% CI 0.45 to 2.18, <LINK REF="CMP-001.59" TYPE="ANALYSIS">Analysis 1.59</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.60 Adverse events: 35. Weight gain</HEADING>
<P>Four studies provided data. There was no statistically significant difference between groups in the number of participants with weight gain (n = 427, RR 1.17, 95% CI 0.76 to 1.82, <LINK REF="CMP-001.60" TYPE="ANALYSIS">Analysis 1.60</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.61 Adverse events: 36. Mean endpoint score TESS (high = poor)</HEADING>
<P>
<LINK REF="STD-Wang-2009" TYPE="STUDY">Wang 2009</LINK> reported usable continuous data on the mean TESS score at endpoint. There was no statistically significant difference between the valproate group and the placebo group (n = 60, MD 2.06, 95% CI -0.41 to 4.53, <LINK REF="CMP-001.61" TYPE="ANALYSIS">Analysis 1.61</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.62 Adverse events: 37. Tardive dyskinesia - mean endpoint score AIMS (high = poor)</HEADING>
<P>In the small study by <LINK REF="STD-Yin-2004" TYPE="STUDY">Yin 2004</LINK> those in the valproate group had a lower level of tardive dyskinesia than those in the monotherapy group (n = 79, MD -3.31, 95% CI -4.91 to -1.71, <LINK REF="CMP-001.62" TYPE="ANALYSIS">Analysis 1.62</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.63. Sensitivity analysis: Primary outcome 1. Excluding open studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(Pimary outcome: Clinical response: Clincally important change - as defined by studies)</HEADING>
<P>After excluding all open studies, only three studies contributed to the primary outcome (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>, <LINK REF="STD-Fisk-1987" TYPE="STUDY">Fisk 1987</LINK> and <LINK REF="STD-Glick-2009" TYPE="STUDY">Glick 2009</LINK>). There was no statistically significant difference between the valproate group and the placebo group (n = 323, RR 1.15, 95% CI 0.95 to 1.39, <LINK REF="CMP-001.63" TYPE="ANALYSIS">Analysis 1.63</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.64 Sensitivity analysis: Primary outcome 2. fixed-effect model</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(Pimary outcome: Clinical response: Clincally important change - as defined by studies)</HEADING>
<P>We also synthesised data for the primary outcome using a fixed-effect model for all 14 studies to evaluate whether the greater weights assigned to larger trials with greater event rates altered the significance of the results, compared to the more evenly distributed weights in the random-effects model. There was a statistically significant difference between the valproate group and the placebo group in favour of valproate (n = 1049, RR 1.35, 95% CI 1.21 to 1.50, <LINK REF="CMP-001.64" TYPE="ANALYSIS">Analysis 1.64</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.65 Sensitivity analysis: Primary outcome 3. excluding no attrition</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(Pimary outcome: Clinical response: Clincally important change - as defined by studies)</HEADING>
<P>After excluding studies which did not report attrition data, only four studies contributed to the primary outcome (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Fisk-1987" TYPE="STUDY">Fisk 1987</LINK>; <LINK REF="STD-Jiang-2009" TYPE="STUDY">Jiang 2009</LINK>; <LINK REF="STD-Lu-2006" TYPE="STUDY">Lu 2006</LINK>). There was a statistically significant difference between the valproate group and the placebo group in favour of valproate (n = 517, RR 1.28, 95% CI 1.03 to 1.60, <LINK REF="CMP-001.65" TYPE="ANALYSIS">Analysis 1.65</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.66 Sensitivity analysis: Primary outcome 4. Completers</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(Pimary outcome: Clinical response: Clincally important change - as defined by studies)</HEADING>
<P>We performed completer analysis for the primary outcome. Ten studies were removed because they did not report on participants leaving early. Three studies were removed because they used LOCF assumptions for missing data. After removing these studies only one study, <LINK REF="STD-Lu-2006" TYPE="STUDY">Lu 2006</LINK>, reported outcomes of completers only. There was a statistically significant difference between valproate group and placebo group in this single study (n = 80, RR 3.13, 95% CI 1.52 to 6.44, <LINK REF="CMP-001.66" TYPE="ANALYSIS">Analysis 1.66</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.67 Sensitivity analysis: Primary outcome 5. Defined by PANSS reduction</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(Pimary outcome: Clinical response: Clincally important change - as defined by studies)</HEADING>
<P>Twelve studies reported number of people with schizophrenia showing significant clinical response to the treatment, by the criteria of more than 50% reduction in PANSS total score. There was a significant difference between participants treated with valproate and participants treated with antipsychotic monotherapy in favour of combination (n = 975, RR 1.31, 95% CI 1.16 to 1.48, <LINK REF="CMP-001.67" TYPE="ANALYSIS">Analysis 1.67</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.68 to 1.71 Sensitivity analysis: excluding schizoaffective studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Aggression/agitation: 1. MOAS (high = poor)</HEADING>
<P>In the post-hoc sensitivity analysis on the effects of valproate in managing aggression, we excluded studies with schizoaffective participants, and valproate augmentation was still superior to monotherapy with antipsychotic drugs. This held true for the outcome mean overt aggression scale at endpoint (3 RCTs, n = 186, MD - 2.55, 95% CI - 3.92 to - 1.19, I<SUP>2 </SUP>= 82%, <LINK REF="CMP-001.68" TYPE="ANALYSIS">Analysis 1.68</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Aggression/agitation: 2. PANSS-EC subscale (high = poor)</HEADING>
<P>Similar results were found for the PANSS-EC subscore scale (2 RCTs, n = 124, MD - 1.63, 95% CI - 2.62 to - 0.64, <LINK REF="CMP-001.69" TYPE="ANALYSIS">Analysis 1.69</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Aggression/agitation: 3. PANSS supplementary subscale (high = poor)</HEADING>
<P>However, <LINK REF="STD-Jiang-2009" TYPE="STUDY">Jiang 2009</LINK> showed no statistically significant difference between the valproate group and the placebo group (n = 120, MD - 0.85, 95% CI - 1.39 to - 0.31, <LINK REF="CMP-001.70" TYPE="ANALYSIS">Analysis 1.70</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Agression/agitation: 4. mean BPRS hostility sub-score at endpoint or change (high = poor)</HEADING>
<P>There was still no statistically significant difference between the valproate group and the placebo group for the mean BPRS hostility sub-score at endpoint (n = 135, MD - 0.10, 95% CI - 0.34 to 0.14, <LINK REF="CMP-001.71" TYPE="ANALYSIS">Analysis 1.71</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.72 Subgroup analysis: Primary outcome: Treatment-resistant participants vs no treatment-resistant participants</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(Pimary outcome: Clinical response: Clincally important change - as defined by studies)</HEADING>
<P>Among the 14 studies contributing to the primary outcome, two studies included treatment-resistant people with schizophrenia (<LINK REF="STD-Pan-2010" TYPE="STUDY">Pan 2010</LINK>; <LINK REF="STD-Wang-2009" TYPE="STUDY">Wang 2009</LINK>); 12 studies did not focus on treatment-resistant people with schizophrenia. There was no statistically significant difference between the two subgroups (Chi² = 0.77, P = 0.38, I² = 0%, <LINK REF="CMP-001.72" TYPE="ANALYSIS">Analysis 1.72</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Missing outcomes</HEADING>
<P>W found no data for the important 'service utilisation' outcomes such as hospital admission, days in hospital or change in hospital status. Furthermore, there were no data on satisfaction with treatment or costs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Publication bias</HEADING>
<P>We generated a funnel plot from the primary outcome of clinically significant response (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). With visual inspection, the data distribution was not significantly unsymmetrical. Therefore, we concluded that there was no significant publication bias in the primary outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Contacts with study authors</HEADING>
<P>In the current update, we contacted all authors of the 18 newly-included studies (<LINK REF="STD-Guo-2007" TYPE="STUDY">Guo 2007</LINK>; <LINK REF="STD-Jia-2007" TYPE="STUDY">Jia 2007</LINK>; <LINK REF="STD-Jiang-2009" TYPE="STUDY">Jiang 2009</LINK>; <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK>; <LINK REF="STD-Li-2009" TYPE="STUDY">Li 2009</LINK>; <LINK REF="STD-Liang-2004" TYPE="STUDY">Liang 2004</LINK>; <LINK REF="STD-Liu-2003" TYPE="STUDY">Liu 2003</LINK>; <LINK REF="STD-Liu-2007a" TYPE="STUDY">Liu 2007a</LINK>; <LINK REF="STD-Lu-2006" TYPE="STUDY">Lu 2006</LINK>; <LINK REF="STD-Ma-2010" TYPE="STUDY">Ma 2010</LINK>; <LINK REF="STD-Pan-2010" TYPE="STUDY">Pan 2010</LINK>; <LINK REF="STD-Shi-2010" TYPE="STUDY">Shi 2010</LINK>; <LINK REF="STD-Wang-2009" TYPE="STUDY">Wang 2009</LINK>; <LINK REF="STD-Wang-2010" TYPE="STUDY">Wang 2010</LINK>; <LINK REF="STD-Xie-2011" TYPE="STUDY">Xie 2011</LINK>; <LINK REF="STD-Yao-2010" TYPE="STUDY">Yao 2010</LINK>; <LINK REF="STD-Yin-2004" TYPE="STUDY">Yin 2004</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>) in an effort to obtain missing data. Unfortunately, we have not received any response from any of these study authors.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. General</HEADING>
<P>Valproate is widely used in many countries in the treatment of schizophrenia and schizophrenia-like disorders. Although a considerable number of RCTs were available, the individual trials were usually small and individually lacked sufficient power to detect any small to moderate effect. Only two studies (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>; <LINK REF="STD-Casey-2009" TYPE="STUDY">Casey 2009</LINK>) used reasonably large sample sizes involving more than 200 participants. We hope that more large valproate augmentation trials will be undertaken allowing for a better assessment of its effects. Importantly, only seven studies were double-blinded; approximately 70% of the studies included were open-label, or only raters were blinded. When the open RCTs were removed, efficacy effects were no longer statistically significant. Furthermore, all included studies were incompletely reported. We sent letters to all first authors of the studies indicating this and hope that this reporting will be improved by the time an updated version of this review is published.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Valproate as a sole treatment versus placebo or antipsychotic drugs</HEADING>
<P>No studies for these comparisons were found. Researchers may not feel that use of valproate is indicated as a sole treatment for people with schizophrenia.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Valproate plus antipsychotics versus antipsychotics plus placebo or antipsychotics alone</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">3.1 Clinically significant response: important change - as defined by individual studies</HEADING>
<P>Fourteen studies reported data on the outcome 'clinically important change', with a significant difference favouring combination therapy of valproate and antipsychotics with little heterogeneity noted (n = 1049, RR 1.31, 95% CI 1.16 to 1.47, I<SUP>2 </SUP>= 12%). The superiority of valproate augmentation was, however, strongly based on open trials. When such open RCTs were removed, no significant difference remained.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.2 Leaving the study early: acceptability/tolerability of treatment</HEADING>
<P>About 34.8% (331 out of 951) participants in 11 studies left before completion of the study. This rate is similar to those in recent trials assessing new antipsychotic drugs for schizophrenia. There was no significant difference between valproate group and placebo group in the number of people with schizophrenia leaving the study early for any reason and for adverse events, but significantly fewer people with schizophrenia taking valproate left the studies due to poor clinical effect, compared to people with schizophrenia taking placebo (5 RCTs, n = 810, RR 0.54, 95% CI 0.31 to 0.94, I<SUP>2 </SUP>= 45%). Although this finding suggests benefits in terms of overall acceptability for valproate augmentation, the results could be biased by the lack of blinding which limits the conclusion in this regard.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.3 Clinical response: Mental state</HEADING>
<P>Results on mental state are difficult to interpret as the data were reported using four different scales which made it difficult to synthesize the results. There was a significant difference regarding the general mental state, measured by PANSS total score in 14 studies, in that the valproate group had lower PANSS scores. Valproate was also found to be superior to placebo/no treatment regarding the positive (10 RCTs) and negative (five RCTs) symptoms of schizophrenia, measured by PANSS positive and negative subscaless respectively. However, no significant difference was detected in BPRS total score (seven RCTs). <LINK REF="STD-Casey-2009" TYPE="STUDY">Casey 2009</LINK> measured the general mental state by CGI severity and improvement scales, but again identified no significant difference. <LINK REF="STD-Hesslinger-1999" TYPE="STUDY">Hesslinger 1999</LINK> measured the general mental state by IMPS change, but still found no statistically significant difference. Overall, it appears that valproate is beneficial for symptoms of schizophrenia, both for the general mental state and for positive and negative symptoms, but these results have to be inspected with caution as they could be largely biased, which will be discussed in the next sections.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.4 Clinical response: Agitation/aggression</HEADING>
<P>Eleven studies reported measurements on agitation/aggressive behaviour using MOAS, PANSS-EC subscale, PANSS supplementary subscale and BPRS hostility subscale. MOAS (four RCTs), PANSS-EC (three RCTs) and PANSS supplementary (<LINK REF="STD-Jiang-2009" TYPE="STUDY">Jiang 2009</LINK>) showed that valproate reduced such symptoms in people with schizophrenia, whereas the BPRS hostility subscale found no significant difference. The participants of these studies were often specifically selected for being aggressive at the beginning of the study. Post-hoc sensitivity analyses excluding studies in participants with schizoaffective disorder did not change the results, valproate augmentation was still superior. Nevertheless, we can not rule out the possibility that participants with schizophrenia had manic symptoms as well, and that the superiority of valproate on aggression was mediated by improvements of these symptoms. Although we did not formally test this, the information stems almost entirely from open RCTs making replications in blinded trials necessary.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.5 Use of additional medication</HEADING>
<P>A few study authors reported the mean dose of additional antiparkinson medication and additional use of chlorprothixene. The data were skewed so that meta-analytic calculations were not possible, but the original publications reported no clear differences between groups. Other data on sedative medicine in general yielded no significant difference between groups either.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.6 Adverse events</HEADING>
<P>We detected no significant differences between the valproate group and the control group in abnormal ECG, abnormal liver function, akathisia, anxiety, asthenia, ataxia, at least one adverse event, blood count changes, constipation, convulsion, diarrhoea, dry mouth, dyspepsia, dystonia, extrapyramidal adverse events, headache, hypersalivation, incontinence, insomnia, mean TESS score at endpoint, myocardial ischaemia, nausea, pain, rash, rhinitis, rigidity/stiffness, sexual dysfunction, tachycardia, tremor, unstable gait, vegetative adverse events, vomiting, and weight gain. But since many of these adverse events are generally rare, much larger studies would be needed to reveal significant differences between groups.</P>
<P>On the other hand, there were significantly more participants in the valproate groups who experienced dizziness (7 RCTs, n = 662, RR 1.37, 95% CI 0.92 to 2.03, I<SUP>2</SUP> = 0); and sedation (8 RCTs, n = 770, RR 1.38, 95% CI 1.07 to 1.79, I<SUP>2</SUP> = 0). The sedation effect may sometimes be useful for acutely ill people, but it is certainly unwanted in the maintenance phase. There was one study (<LINK REF="STD-Yin-2004" TYPE="STUDY">Yin 2004</LINK>) that reported that the Abnormal Involuntary Movement Scale (AIMS) score assessing tardive dyskinesia was lower in the valproate group (n = 79, MD -3.31, 95% CI -4.91 to -1.71), but we feel that a study based on only 79 participants is not a sufficient basis for saying that valproate is effective for this condition. <LINK REF="STD-Yin-2004" TYPE="STUDY">Yin 2004</LINK> also found that there were significantly more participants with thrombocytopenia in the valproate group (n = 79, RR 17.43, 95% CI 1.04 to 291.96). Again, the study was too small to draw any firm conclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3.7 Missing outcomes</HEADING>
<P>It is hoped that more data on important service outcomes such as duration of hospital stay, satisfaction with treatment or costs will be received for updates of this review.</P>
</SUBSECTION>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2016-10-05 12:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>We believe that the data we gathered is not complete. Firstly, all results were derived from short-term studies, and long-term results are missing. Moreover, most of the trials are based on relatively small sample sizes which can be prone to bias, therefore we cannot conclusively judge the potential applicability of the results. The review <LINK REF="REF-Davey-Smith-1998" TYPE="REFERENCE">Davey Smith 1998</LINK> suggested that meta-analyses based on summation of small trials should be interpreted as inconclusive, regardless of whether the combined estimate was significant. Most of the positive findings came from studies conducted in China, while the Western studies were usually negative. This finding also limits generalisability.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of all identified relevant trials has to be judged as moderate at best. The quality of data provided for our main outcomes of interest was low or very low quality. Although all included studies claimed that the treatment allocation was randomised, few of them presented further descriptions about the randomisation procedure. Therefore, it is unclear whether these trials were adequately randomised and whether researchers were concealed from treatment allocation before randomisation.</P>
<P>The positive evidence supporting use of valproate largely stems from the mostly Chinese included studies, which had a problem with methodological biases. They did not provide detailed information regarding randomisation, nor did they provide any details of blinding of clinicians, participants and raters throughout the procedures. Since it is unlikely that a study would not report blinding when blinding was actually performed, we assumed that these studies were open-label trials, and therefore possibly biased. Many outcomes showed considerable heterogeneity, mainly due to the results from the two, mainly negative, large double-blinded studies (<LINK REF="STD-Casey-2003" TYPE="STUDY">Casey 2003</LINK>, <LINK REF="STD-Casey-2009" TYPE="STUDY">Casey 2009</LINK>) which were different from those of the usually positive, small, open Chinese studies. Only four Chinese studies provided information on people leaving the study early, which made their results even less reliable, as it is quite rare that a study has 100% completion rate. We have sent letters to the first authors of the papers and hope that with their replies we could validate and improve the quality of evidence. We also observed bias in terms of selective reporting in a number of studies. However, this was mainly related to incomplete reporting of the Treatment-Emergent Symptom Scale (TESS), which is a continuous outcome of side effects. Given that these studies still reported dichotomous data for adverse events, we interpret that this issue should not have severely biased our results.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>The evidence presented here is, to our best knowledge, complete. However one can never be certain whether some additional (unpublished) material exists that was not pooled into the analysis.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>We are not aware of any other systematic reviews and meta-analysis on the question of valproate augmentation for schizophrenia.<BR/>
</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. For people with schizophrenia</HEADING>
<P>People with schizophrenia should be informed of the small empirical basis for the use of valproate for their disorder. They should know that valproate might lead to improvement in their general mental state, and also for specific symptoms such as excitement and aggression. But they should also know that this evidence is largely based on open studies without appropriate blinding, and that valproate is associated with sedation, dizziness and other side-effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. For clinicians</HEADING>
<P>Based on available RCT-derived evidence there is no randomised evidence to support or refute the use of valproate as a monotherapy for schizophrenia. There is evidence based on a number of trials that the augmentation of antipsychotics with valproate may be effective for overall mental state, and also for specific symptoms, especially in terms of excitement and aggression. However, this evidence was entirely based on open RCTs. Two large double-blind trials did not find any convincing evidence that valproate augmentation may be beneficial. Moreover, clinicians should take into account that valproate is associated with a number of adverse events among which sedation and dizziness could be documented to appear significantly more frequently than in the control groups of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. For managers and policy makers</HEADING>
<P>Managers and policy makers should support further trials to assess the impact of valproate augmentation for people with schizophrenia and related disorders.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1. General</HEADING>
<P>Any future studies should respect standards of measuring outcomes and of reporting data in order to enhance the comparability of study results (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>). We have written to the first authors of the included studies but we have not received many answers. If study authors consistently provided missing data for meta-analyses, their quality could be much improved.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Specific</HEADING>
<P>Large, double-blind and also longer-term randomised trials should be undertaken to examine the clinical effects of valproate as an adjunct to antipsychotic treatment. Open RCTs are available, but there is a dearth of double-blind studies which should focus on the following groups:</P>
<OL>
<LI>Those with schizophrenia and violent episodes, because valproate is said to have an impact on aggression.</LI>
<LI>Those with schizoaffective disorder, because valproate might have mood-stabilising effects.</LI>
<LI>Those with treatment-resistant forms of the disorder, because here effective adjuncts to antipsychotic drugs are urgently needed.</LI>
</OL>
<P>For the design of a suggested future trial, please refer to <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> in Additional tables.</P>
</SUBSECTION>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-11-18 11:43:17 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank the editorial team of the Cochrane Schizophrenia Group for its study search and its continuous support. Cochrane Schizophrenia Group holds a standardised methods section which was used for this review and modified were necessary. We would like to thank Anja Volz and Christian Schwarz for their contributions as previous authors on this review.</P>
<P>We would also like to thank Dina Bo&#353;njak for peer reviewing the 2012 version.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-11-16 15:57:00 +0000" MODIFIED_BY="[Empty name]">
<P>Yijun Wang: none known.</P>
<P>Jun Xia: none known.</P>
<P>Bartosz Helfer: none known.</P>
<P>Chunbo Li: none known.</P>
<P>Stefan Leucht has received honoraria for lectures from Otsuka, Lundbeck, Janssen, ICON, Lilly, SanofiAventis, AOP Orphan and Servier; for consulting from Janssen, Roche, Lilly, Otsuka, Lundbeck, TEVA and for a publications from Roche.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-11-16 15:57:04 +0000" MODIFIED_BY="[Empty name]">
<P>Yijun Wang: contacted Chinese authors and extracted data from articles in Chinese, data analysis, data interpretation and writing of the update.</P>
<P>Jun Xia: extracted data from articles in Chinese, data analysis and interpretation.</P>
<P>Bartosz Helfer: searching, data checking, data interpretation, and revision of the report.</P>
<P>Chunbo Li: contacted Chinese authors and extracted data from articles in Chinese.</P>
<P>Stefan Leucht: protocol development, searching, data checking, data interpretation, and revision of the report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Compared to original versions, we have adapted the methods to changes made by the Cochrane (e.g. 'Risk of bias' table and 'Summary of findings' table added) and by the Cochrane Schizophrenia Group. This review contains some rewording and reorganisation of the original outcomes noted in the protocol (the original methods can be found in the appendix). The type of outcomes, however, remain the same.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-11-18 11:45:18 +0000" MODIFIED_BY="Claire Irving">
<STUDIES MODIFIED="2016-10-26 09:53:20 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2016-10-26 09:52:18 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-2003" MODIFIED="2016-10-26 09:51:36 +0100" MODIFIED_BY="[Empty name]" NAME="Casey 2003" YEAR="">
<REFERENCE MODIFIED="2016-10-26 09:51:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Casey DE, Daniel DG, Wassef AA, Tracy KA, Wolnlak P, Sommerville W</AU>
<TI>Effect of divalproex combined with olanzapine or risperidone in participants with acute exacerbation of schizophrenia</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>182-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817125"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-03 17:36:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA</AU>
<TI>Adjunctive divalproex and hostility among participants with schizophrenia receiving olanzapine or risperidone</TI>
<SO>Psychiatric Services</SO>
<YR>2004</YR>
<VL>55</VL>
<NO>3</NO>
<PG>290-4</PG>
<CY>United States of America</CY>
<IDENTIFIERS MODIFIED="2016-10-03 17:36:05 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817126"/><IDENTIFIER TYPE="MEDLINE" VALUE="15001730"/><IDENTIFIER MODIFIED="2016-10-03 17:36:05 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Embase 2004111171"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jafari M, Jiang P, Casey DE</AU>
<TI>Adjunctive divalproex sodium lowers cholesterol elevation with olanzapine</TI>
<SO>157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA</SO>
<YR>2004</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817127"/><IDENTIFIER TYPE="OTHER" VALUE="APA Conference Abstracts NR634"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-09-19 14:27:04 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817124"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Casey-2009" MODIFIED="2016-10-26 09:51:54 +0100" MODIFIED_BY="[Empty name]" NAME="Casey 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-10-03 17:38:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P, et al</AU>
<TI>Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>5</NO>
<PG>1330-8</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817129"/><IDENTIFIER TYPE="MEDLINE" VALUE="19052541"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-26 09:51:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>M02-547</AU>
<TI>A randomized, double-blind study of the safety and efficacy of Depakote ER plus an atypical antipsychotic vs. an atypical antipsychotic alone in the treatment of schizophrenia</TI>
<SO>www.abbvie.com/content/dam/abbviecorp/us/desktop/research/clinical-trials-data-and-information-sharing/synopses/divalproex%20sodium_M02-547.pdf</SO>
<YR>[accessed 08 April 2016]</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446072"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-25 06:11:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00073164</AU>
<TI>A study of the safety and efficacy of Depakote ER plus an atypical antipsychotic vs an atypical antipsychotic alone in the treatment of schizophrenia</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00073164</SO>
<YR>[Date Accessed: 17 November 2003]</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446073"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-09-19 14:27:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817128"/><IDENTIFIER MODIFIED="2016-09-19 14:27:24 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00073164"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Citrome-2007" MODIFIED="2016-10-25 06:11:45 +0100" MODIFIED_BY="[Empty name]" NAME="Citrome 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-25 06:11:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 06501&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 06:11:45 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Citrome L, Daniel D, Wassef A, Tracy K, Wozniak P, Casey D</AU>
<TI>Antipsychotic monotherapy versus combination treatment with valproate in hospitalized patients with acute schizophrenia: a double-blind, multi-center study</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<PG>NR316</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446074"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-03 17:40:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L, Shope CB, Nolan KA, Czobor P, Volavka J</AU>
<TI>Risperidone alone versus risperidone plus valproate in the treatment of participants with schizophrenia and hostility</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>6</NO>
<PG>356-62</PG>
<CY>England</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817131"/><IDENTIFIER TYPE="MEDLINE" VALUE="17917554"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-09-13 06:48:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Citrome L</AU>
<TI>Schizophrenia and valproate</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>Suppl 2</NO>
<PG>74-88</PG>
<CY>United States of America</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446075"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-25 06:11:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00308360</AU>
<TI>Risperidone alone vs risperidone plus valproate in the treatment of participants with schizophrenia and hostility</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00308360</SO>
<YR>[Date Accessed: 28 March 2006]</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446076"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-09-13 10:45:13 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 13906&lt;/p&gt;" NOTES_MODIFIED="2016-09-13 10:45:13 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Nolan K, Shope C, Citrome L, Volavka J</AU>
<TI>Staff and patient views of the reasons for aggressive incidents: a prospective, incident-based study</TI>
<SO>Psychiatric Quarterly</SO>
<YR>2009</YR>
<VL>80</VL>
<NO>3</NO>
<PG>167-72</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446077"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-09-19 14:28:17 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817130"/><IDENTIFIER MODIFIED="2016-09-19 14:28:17 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00308360"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dose-1998" MODIFIED="2016-10-03 17:42:00 +0100" MODIFIED_BY="[Empty name]" NAME="Dose 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM</AU>
<TI>Combined treatment of schizophrenic psychoses with haloperidol and valproate</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1998</YR>
<VL>31</VL>
<NO>4</NO>
<PG>122-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817133"/><IDENTIFIER TYPE="MEDLINE" VALUE="98425840"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-03 17:42:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Dose M</AU>
<SO>Die Bedeutung von Antikonvulsiva und Calciumantagonisten für die Pharmakotherapie von Psychosen. Habilitationsschrift</SO>
<YR>1991</YR>
<PB>Technische Universität München</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817134"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817132"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisk-1987" NAME="Fisk 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fisk GG, York SM</AU>
<TI>The effect of sodium valproate on tardive dyskinesia - revisited</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1987</YR>
<VL>150</VL>
<PG>542-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817136"/><IDENTIFIER TYPE="MEDLINE" VALUE="86216395"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817135"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glick-2009" MODIFIED="2016-04-08 14:28:55 +0100" MODIFIED_BY="[Empty name]" NAME="Glick 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-04-08 14:28:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glick ID, Bosch J, Casey DE</AU>
<TI>A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for participants with schizophrenia who are stabilized and partially responsive</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>3</NO>
<PG>267-71</PG>
<CY>United States</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817138"/><IDENTIFIER TYPE="MEDLINE" VALUE="19440081"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817137"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2007" MODIFIED="2016-10-25 06:29:56 +0100" MODIFIED_BY="[Empty name]" NAME="Guo 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-25 06:29:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo CR</AU>
<TI>Study of quetiapine combined with magnesium valproate release tablets in treatment of schizophrenia with symptoms of elation and agitation</TI>
<TO>&#22862;&#30827;&#24179;&#21512;&#24182;&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#20852;&#22859;&#28608;&#36234;&#30740;&#31350;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>3</NO>
<PG>183-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817140"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817139"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hesslinger-1999" MODIFIED="2016-10-03 17:43:30 +0100" MODIFIED_BY="[Empty name]" NAME="Hesslinger 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-10-03 17:43:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hesslinger B, Normann C, Langosch JM, Klose P, Berger M, Walden J</AU>
<TI>Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic participants</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>4</NO>
<PG>310-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817142"/><IDENTIFIER TYPE="MEDLINE" VALUE="99367069"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-09-13 10:46:30 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 05196&lt;/p&gt;" NOTES_MODIFIED="2016-09-13 10:46:30 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Normann C, Klose P, Hesslinger B, Langosch J, Berger M, Walden J</AU>
<TI>Haloperidol plasma levels and psychopathology in schizophrenic patients with antiepileptic co-medication: a clinical trial</TI>
<SO>PharmacoPsychiatry</SO>
<YR>1997</YR>
<VL>30</VL>
<PG>204</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446078"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-09-13 10:51:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 03635&lt;/p&gt;" NOTES_MODIFIED="2016-09-13 10:51:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Walden J, Hesslinger B, Normann C, Langosch J, Berger M</AU>
<TI>Actions of carbamazepine and valproate on haloperidol plasma levels and psychopathological outcome</TI>
<SO>Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK</SO>
<YR>1998</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446079"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817141"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jia-2007" MODIFIED="2016-10-25 05:30:33 +0100" MODIFIED_BY="[Empty name]" NAME="Jia 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-25 05:30:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jia HX, Bian ZY, Zhu H, Jiang T, Wang LF, Liu HB, et al</AU>
<TI>Effect of sodium valproate on serum concentration and clinical efficacy of clozapine</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#23545;&#27695;&#27694;&#24179;&#34880;&#33647;&#27987;&#24230;&#21644;&#30103;&#25928;&#30340;&#24433;&#21709;</TO>
<SO>Linchuang Jingshen Yixue Zazhi [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>5</NO>
<PG>310-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817144"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817143"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2009" MODIFIED="2016-10-25 06:37:24 +0100" MODIFIED_BY="[Empty name]" NAME="Jiang 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-10-25 06:37:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang CY, Chen JX, He GQ</AU>
<TI>The effect of adjuvant magnesium valproate sustained - release tablets for schizophrenia with agitation and agitation.</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#36741;&#21161;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#20852;&#22859;&#28608;&#36234;&#30340;&#25928;&#26524;&#35266;&#23519;</TO>
<SO>Chinese Magazine of Drug Abuse Prevention and Treatment [&#20013;&#22269;&#33647;&#29289;&#28389;&#29992;&#38450;&#27835;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>3</NO>
<PG>175-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817146"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817145"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008" MODIFIED="2016-10-26 08:43:14 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-10-26 08:43:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li WS, Yu XD, Cui Y</AU>
<TI>A comparative study of olanzapine combined with low-dose magnesium valproate sustained-release tablets in the treatment of acute phrase of schizophrenia</TI>
<TO>&#22885;&#27694;&#24179;&#21512;&#24182;&#23567;&#21058;&#37327;&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#24613;&#24615;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Psychiatry [&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>3</NO>
<PG>178-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817148"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817147"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2009" MODIFIED="2016-10-26 08:42:30 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-10-26 08:42:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li SS</AU>
<TI>The effect of aripiprazole combined with magnesium valproate in the treatment of impulse control disorder of schizophrenia</TI>
<TO>&#38463;&#31435;&#21708;&#21777;&#32852;&#21512;&#19993;&#25098;&#37240;&#38209;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#20914;&#21160;&#25511;&#21046;&#38556;&#30861;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chongqing Medical Journal [&#37325;&#24198;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>7</NO>
<PG>788, 798</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817150"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817149"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2004" MODIFIED="2016-10-26 08:43:50 +0100" MODIFIED_BY="[Empty name]" NAME="Liang 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-04-08 14:31:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Liang HX, Du JY, Wu ZJ</AU>
<TI>A study of additive effect of sodium-valproate in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>3</NO>
<PG>151-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817152"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-26 08:43:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma XW</AU>
<TI>The effect of adjuvant magnesium valproate on schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#36741;&#21161;&#27835;&#30103;&#20316;&#29992;</TO>
<SO>China Practical Medicine [&#20013;&#22269;&#23454;&#29992;&#21307;&#33647;]</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>12</NO>
<PG>43&#65123;4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817153"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817151"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003" MODIFIED="2016-10-26 08:42:24 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-10-26 08:42:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu C</AU>
<TI>The effect of sodium valproate in participants with schizophrenia</TI>
<SO>Chinese Journal of Clinical Medicinal Professional Research</SO>
<YR>2003</YR>
<VL>70</VL>
<PG>11, 596-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817155"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817154"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2007a" MODIFIED="2016-10-25 06:47:25 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2007a" YEAR="2007">
<REFERENCE MODIFIED="2016-10-25 06:47:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Z</AU>
<TI>Sodium valproate in treatment of aggression for psychiatric participants</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#27835;&#30103;&#31934;&#31070;&#30149;&#24739;&#32773;&#30340;&#25915;&#20987;&#34892;&#20026;</TO>
<SO>Chongqing Journal of Medicine [&#37325;&#24198;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>6</NO>
<PG>490-1</PG>
<IDENTIFIERS MODIFIED="2016-10-24 10:20:22 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817157"/><IDENTIFIER MODIFIED="2016-10-24 10:20:22 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817156"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-2006" MODIFIED="2016-10-26 09:52:18 +0100" MODIFIED_BY="[Empty name]" NAME="Lu 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-10-25 06:47:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lu W, Jin W, Wang H, Ma Y, Tong Z</AU>
<TI>Comparing study of sodium valproate xr (Depakine) in the supplementary therapy of excitement state in participants with schizophrenia and schizoaffective disorder</TI>
<SO>Proceedings of the Zhejiang Annual Psychiatry Conference, Yiwu, China</SO>
<YR>2005</YR>
<PG>75-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817159"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-10-26 09:52:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lu WM, Jin WD, Shen Y, Ma YC, Tong ZH</AU>
<TI>Clinical evaluation of sodium valproate xr (Depakine) in adjunctive therapy for participants with excitomania associated with schizophrenia and schizoaffective disorder</TI>
<SO>Chinese New Drugs Journal</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>15</NO>
<PG>1291-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817160"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817158"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pan-2010" MODIFIED="2016-10-25 06:48:10 +0100" MODIFIED_BY="[Empty name]" NAME="Pan 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-25 06:48:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pan ZX, Yin DF, Liu NH</AU>
<TI>Sodium valproate combined clozapine in the treatment of refractory schizophrenia 34 cases</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#32852;&#21512;&#27695;&#27694;&#24179;&#27835;&#30103;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;34&#20363;</TO>
<SO>Herald of Medicine [&#21307;&#23398;&#23548;&#25253;]</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>2</NO>
<PG>203-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817162"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817161"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shi-2010" MODIFIED="2016-10-26 08:44:38 +0100" MODIFIED_BY="[Empty name]" NAME="Shi 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-26 08:44:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shi YX, Dai TG, Yi PC</AU>
<TI>A study of olanzapine combined with magnesium valproate sustained-release tablets for the treatment of excitement and agitation in acute phase of schizophrenia</TI>
<TO>&#22885;&#27694;&#24179;&#21512;&#24182;&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#24613;&#24615;&#26399;&#20852;&#22859;&#28608;&#36234;&#30740;&#31350;</TO>
<SO>Modern Practical Medicine [&#29616;&#20195;&#23454;&#29992;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>4</NO>
<PG>398-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817164"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817163"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005a" MODIFIED="2016-10-03 18:05:38 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005a" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang H</AU>
<TI>Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>1</NO>
<PG>10-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817166"/><IDENTIFIER TYPE="OTHER" VALUE="113903"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817165"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2009" MODIFIED="2016-10-26 08:44:56 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-10-26 08:44:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang GP, Xie R, Pei GX, Zhang XJ</AU>
<TI>The effect of adjuvant magnesium valproate sustained-release tablets in the treatment of schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#36741;&#21161;&#20316;&#29992;</TO>
<SO>Journal of Clinical Psychiatry [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>4</NO>
<PG>250-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817168"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817167"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2010" MODIFIED="2016-10-26 08:45:08 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-26 08:45:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang LJ, Zhang J</AU>
<TI>A comparative study of sodium valproate combined with other drugs for schizophrenia with impulsive and aggressive behavior</TI>
<TO>&#21512;&#29992;&#19993;&#25098;&#37240;&#38048;&#27835;&#30103;&#20276;&#26377;&#20914;&#21160;&#21644;&#25915;&#20987;&#34892;&#20026;&#30340;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>5</NO>
<PG>548-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817170"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817169"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wassef-2000" MODIFIED="2016-10-25 04:12:19 +0100" MODIFIED_BY="[Empty name]" NAME="Wassef 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-10-25 04:12:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer WJ 3rd, et al</AU>
<TI>Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>3</NO>
<PG>357-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817172"/><IDENTIFIER TYPE="MEDLINE" VALUE="20289870"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817171"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xie-2011" MODIFIED="2016-10-26 08:45:24 +0100" MODIFIED_BY="[Empty name]" NAME="Xie 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-10-26 08:45:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xie R, Wang G, Pei G</AU>
<TI>The effect of adjuvant magnesium valproate sustained-release tablet in the treatment of schizophrenic participants with aggressive behaviours</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#36741;&#21161;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#25915;&#20987;&#34892;&#20026;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Journal of Clinical Psychiatry [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>3</NO>
<PG>191-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817174"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817173"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yao-2010" MODIFIED="2016-10-26 08:45:40 +0100" MODIFIED_BY="[Empty name]" NAME="Yao 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-26 08:45:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yao F, Jiang F</AU>
<TI>Short-term efficacy of risperidone combined with magnesium valproate sustained-release tablets in the treatment of schizophrenia with aggressive behavior</TI>
<TO>&#21033;&#22521;&#37230;&#32852;&#21512;&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#25915;&#20987;&#34892;&#20026;&#30340;&#36817;&#26399;&#30103;&#25928;</TO>
<SO>Occupation and Health [&#32844;&#19994;&#19982;&#20581;&#24247;]</SO>
<YR>2010</YR>
<VL>26</VL>
<NO>22</NO>
<PG>2713-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817176"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817175"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yin-2004" MODIFIED="2016-04-08 14:37:22 +0100" MODIFIED_BY="[Empty name]" NAME="Yin 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-04-08 14:37:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yin XR, Xie BQ, Jiang L</AU>
<TI>A double-blind comparative study of sodium valproate in treating of TD</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>2</NO>
<PG>92-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817178"/><IDENTIFIER TYPE="OTHER" VALUE="113903"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817177"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007" MODIFIED="2016-10-26 08:45:54 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-10-26 08:45:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang SL, Wang CX, Wang LT, Feng YF</AU>
<TI>The effect of debakin combined with risperidone in the treatment of schizophrenia with psychmotor excitement</TI>
<TO>&#24503;&#24052;&#37329;&#32852;&#21512;&#21033;&#22521;&#37230;&#27835;&#30103;&#20276;&#31934;&#31070;&#36816;&#21160;&#24615;&#20852;&#22859;&#30340;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#25928;&#26524;</TO>
<SO>Medical Journal of Qilu [&#40784;&#40065;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>3</NO>
<PG>265-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817180"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817179"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-10-25 05:26:54 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alberti-1999" NAME="Alberti 1999" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alberti GG, Garini R, Marzolini M, Beltz J, Greco MI, Maresca G</AU>
<TI>Efficacy and tolerability of gabapentin (GBP) and valproate (VPA) as an adjunct in the neuroleptic treatment of acute manic syndromes</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>210</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817182"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817181"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bersudsky-2010" MODIFIED="2016-04-08 14:41:28 +0100" MODIFIED_BY="[Empty name]" NAME="Bersudsky 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-04-08 14:41:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bersudsky Y, Applebaum J, Gaiduk Y, Sharony L, Mishory A, Podberezsky A, et al</AU>
<TI>Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial</TI>
<SO>Bipolar Disorders</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>4</NO>
<PG>376-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817184"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817183"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Centorrino-1994" MODIFIED="2016-04-08 14:41:47 +0100" MODIFIED_BY="[Empty name]" NAME="Centorrino 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-04-08 14:41:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Centorrino F, Baldessarini RJ, Kando J, Frankenburg FR, Volpicelli SA, Puopolo PR, et al</AU>
<TI>Serum concentrations of clozapine and its major metabolites: effects of co-treatment with fluoxetine or valproate</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>151</VL>
<NO>1</NO>
<PG>123-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817186"/><IDENTIFIER TYPE="MEDLINE" VALUE="94091485"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817185"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haupt-2007" MODIFIED="2013-07-19 22:18:34 +0100" MODIFIED_BY="[Empty name]" NAME="Haupt 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-07-19 22:18:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haupt DW, Fahnestock PA, Hessler MJ, Flavin K, Bagley S, Yingling M, et al</AU>
<TI>Changes in direct measures of adiposity in schizophrenia participants during divalproex augmentation of antipsychotic treatment</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>2</NO>
<PG>501</PG>
<CY>England</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817188"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817187"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2010" MODIFIED="2016-10-25 05:26:48 +0100" MODIFIED_BY="[Empty name]" NAME="Ma 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-25 05:26:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma XW</AU>
<TI>The effect of adjuvant magnesium valproate in the treatment of schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#36741;&#21161;&#27835;&#30103;&#20316;&#29992;</TO>
<SO>China Practical Medicine [&#20013;&#22269;&#23454;&#29992;&#21307;&#33647;]</SO>
<YR>April 2010</YR>
<VL>5</VL>
<NO>12</NO>
<PG>43-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817190"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817189"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monfort-1991" MODIFIED="2016-04-08 14:45:11 +0100" MODIFIED_BY="[Empty name]" NAME="Monfort 1991" YEAR="1991">
<REFERENCE MODIFIED="2016-04-08 14:45:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monfort JC, Mager C, Thorpe D, Ropert R, Ferrey G, Mentre F, et al</AU>
<TI>Valproate-diazepam combination versus chlorpromazine: a double-blind study in schizophrenic and schizophreniform disorders</TI>
<TO>Valproate-diazépam versus chlorpromazine: étude en double aveugle dans les troubles schizophréniques et schizophréniformes</TO>
<SO>Encephale</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>2</NO>
<PG>101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817192"/><IDENTIFIER TYPE="MEDLINE" VALUE="20289870"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817191"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00183443" MODIFIED="2016-10-25 05:26:54 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00183443" YEAR="2005">
<REFERENCE MODIFIED="2016-10-25 05:26:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00183443</AU>
<TI>Divalproex extended release and placebo, lithium, or quetiapine for mania</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00183443</SO>
<YR>[Date Accessed: 13 September 2005]</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817194"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-09-19 14:33:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817193"/><IDENTIFIER MODIFIED="2016-09-19 14:33:50 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00183443"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ping-1994" MODIFIED="2016-04-08 14:44:55 +0100" MODIFIED_BY="[Empty name]" NAME="Ping 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-04-08 14:44:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ping Y, Xinjuan OY, Lin T</AU>
<TI>A controlled study of sodium valproate and chlorpromazine for schizophrenia</TI>
<SO>Shanghai Archives of Psychiatry</SO>
<YR>1994</YR>
<VL>6</VL>
<NO>4</NO>
<PG>208-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817196"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817195"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raja-2000" NAME="Raja 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raja M, Azzoni A</AU>
<TI>Second generation antipsychotics in the emergency care setting. A prospective naturalistic study</TI>
<SO>General Hospital Psychiatry</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>2</NO>
<PG>107-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817198"/><IDENTIFIER TYPE="MEDLINE" VALUE="20283566"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817197"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rifang-2001" MODIFIED="2013-05-26 21:22:47 +0100" MODIFIED_BY="[Empty name]" NAME="Rifang 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-05-26 21:22:47 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rifang C, Fenfang Z</AU>
<TI>The impact of sodium valproate for social function rehabilitation in schizophrenia participants</TI>
<SO>Modern Rehabilitation</SO>
<YR>2001</YR>
<VL>5</VL>
<NO>9</NO>
<PG>100</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817200"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817199"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2005" MODIFIED="2013-04-20 22:24:52 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-04-20 22:24:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu C, Fu R, Yang Y</AU>
<TI>Sodium valproate and clonazepam for the treatment of agitated symptoms of participants with schizophrenia: a controlled trial</TI>
<SO>Medical Journal of the Chinese People's Armed Police Forces</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>12</NO>
<PG>934-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817202"/><IDENTIFIER TYPE="OTHER" VALUE="CAJ MEDI0602"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817201"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-10-26 09:53:20 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Boylan-2004" MODIFIED="2016-08-08 16:19:34 +0100" MODIFIED_BY="[Empty name]" NAME="Boylan 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-08-08 16:19:34 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 08776&lt;/p&gt;" NOTES_MODIFIED="2016-08-08 16:19:34 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Boylan L, Labovitz D</AU>
<TI>Unbalanced statistical analysis of combined divalproex and antipsychotic therapy for schizophrenia</TI>
<SO>Neuropyschopharmacology</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>3</NO>
<PG>636</PG>
<CY>United States of America</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446081"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446080"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chien-1978" MODIFIED="2016-08-08 16:19:44 +0100" MODIFIED_BY="[Empty name]" NAME="Chien 1978" YEAR="1978">
<REFERENCE MODIFIED="2016-08-08 16:19:44 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 01960&lt;/p&gt;" NOTES_MODIFIED="2016-08-08 16:19:44 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Chien C, Jung K, Ross-Townsend A</AU>
<TI>Efficacies of agents related to GABA, dopamine, and acetylcholine in the treatment of tardive dyskinesia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1978</YR>
<VL>14</VL>
<NO>2</NO>
<PG>20-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446083"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446082"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cui-2012" MODIFIED="2016-10-26 08:46:29 +0100" MODIFIED_BY="[Empty name]" NAME="Cui 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-26 08:46:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 17860&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:46:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Cui LJ, Shen WM</AU>
<TI>Effects of magnesium valproate treatment on weight and blood insulin levels in patients with schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20307;&#37325;&#21450;&#33008;&#23707;&#32032;&#27700;&#24179;&#30340;&#24433;&#21709;</TO>
<SO>Frontiers of Medicine [&#21307;&#33647;&#21069;&#27839;]</SO>
<YR>2012</YR>
<VL>22</VL>
<PG>97</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446085"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446084"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellenor-1995" MODIFIED="2016-08-08 16:19:56 +0100" MODIFIED_BY="[Empty name]" NAME="Ellenor 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-08-08 16:19:56 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 02569&lt;/p&gt;" NOTES_MODIFIED="2016-08-08 16:19:56 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ellenor G, Lohr J, Ito M, Dishman B, Gammariello A</AU>
<TI>The comparative efficacy of divalproex low and high serum level in bipolar disorder and schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1995</YR>
<VL>31</VL>
<NO>3</NO>
<PG>563</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446087"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446086"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friis-1983" NAME="Friis 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friis T, Christensen TR, Gerlach J</AU>
<TI>Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1983</YR>
<VL>67</VL>
<NO>3</NO>
<PG>178-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817204"/><IDENTIFIER TYPE="MEDLINE" VALUE="83227217"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817203"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gong-2010" MODIFIED="2016-10-25 04:18:13 +0100" MODIFIED_BY="[Empty name]" NAME="Gong 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-25 04:18:13 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 15324&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:18:13 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gong Y, Guo P</AU>
<TI>Effects of magnesium valproate on cognitive function in patients with refractory schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#23545;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#35748;&#30693;&#21151;&#33021;&#30340;&#24433;&#21709;</TO>
<SO>Chronic Pathematology Journal [&#24930;&#24615;&#30149;&#23398;&#26434;&#24535;]</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>2</NO>
<PG>107-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446089"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446088"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gu-2012" MODIFIED="2016-10-25 05:24:50 +0100" MODIFIED_BY="[Empty name]" NAME="Gu 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-25 05:24:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 19264&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 05:24:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gu P, Wang J, Cao J, Li B-z</AU>
<TI>A comparative study of quetiapine with sustained-release tablets of magnesium valproate in treatment of old patients with acute phase of schizophrenia</TI>
<TO>&#22862;&#30827;&#24179;&#21512;&#24182;&#19993;&#25098;&#37240;&#38209;&#27835;&#30103;&#32769;&#24180;&#31934;&#31070;&#20998;&#35010;&#30151;&#24613;&#24615;&#26399;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chinese Journal of Clinical Psychology [&#20013;&#22269;&#20020;&#24202;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2012</YR>
<VL>20</VL>
<NO>4</NO>
<PG>520-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446091"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446090"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gu-2014" MODIFIED="2016-10-25 05:21:36 +0100" MODIFIED_BY="[Empty name]" NAME="Gu 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-25 05:21:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 22462&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 05:21:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Gu Q</AU>
<TI>Prognostic analysis of magnesium valproate combined with antipsychotics for patients with convalescent schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#32852;&#21512;&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#27835;&#30103;&#23545;&#24674;&#22797;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#30340;&#39044;&#21518;&#20998;&#26512;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2014</YR>
<VL>26</VL>
<NO>18</NO>
<PG>59, 99</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446093"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446092"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2013" MODIFIED="2016-10-26 08:47:35 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-26 08:47:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20453&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:47:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Huang WD, Luo HF, Lan L, Li CH, Xu LH, Li ZM</AU>
<TI>Efficacy of ziprasidone combined with low-dose sodium valproate in the treatment of female refractory schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#32852;&#21512;&#23567;&#21058;&#37327;&#19993;&#25098;&#37240;&#38048;&#27835;&#30103;&#22899;&#24615;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#20998;&#26512;</TO>
<SO>Youjiang Medical Journal [&#21491;&#27743;&#21307;&#23398;]</SO>
<YR>2013</YR>
<NO>02</NO>
<PG>159-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446095"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446094"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2014" MODIFIED="2016-10-25 05:21:17 +0100" MODIFIED_BY="[Empty name]" NAME="Jiang 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-25 05:21:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 23118&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 05:21:17 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jiang TC, Xiong Y</AU>
<TI>Efficacy of quetiapine combined with sodium valproate in the treatment of schizophrenia with impulsive and aggression in female patients</TI>
<TO>&#21945;&#30827;&#24179;&#32852;&#21512;&#19993;&#25098;&#37240;&#38048;&#27835;&#30103;&#22899;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#20914;&#21160;&#25915;&#20987;&#34892;&#20026;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>World Latest Medicine Information [&#19990;&#30028;&#26368;&#26032;&#21307;&#23398;&#20449;&#24687;&#25991;&#25688;&#65288;&#36830;&#32493;&#22411;&#30005;&#23376;&#26399;&#21002;&#65289;]</SO>
<YR>2014</YR>
<VL>14</VL>
<NO>32</NO>
<PG>79-80</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446097"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446096"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jin-2013" MODIFIED="2016-10-25 04:21:11 +0100" MODIFIED_BY="[Empty name]" NAME="Jin 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 04:21:11 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20519&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:21:11 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Jin G</AU>
<TI>Efficacy of magnesium valproate for schizophrenia with impulsive and aggressive behavior</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#20914;&#21160;&#25915;&#20987;&#34892;&#20026;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chinese Journal of Modern Drug Application [&#20013;&#22269;&#29616;&#20195;&#33647;&#29289;&#24212;&#29992;]</SO>
<YR>2013</YR>
<NO>14</NO>
<PG>160-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446099"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446098"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1996" NAME="Lee 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lee MS, Choi BH, Kim SH</AU>
<TI>Combined use of carbamazepine and valproic acid in negative symptom schizophrenia</TI>
<SO>9th Congress of the European College of Neuropsychopharmacology; 1996 Sep 21-25; Amsterdam, The Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817206"/><IDENTIFIER TYPE="MEDLINE" VALUE="83227217"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817205"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008a" MODIFIED="2016-10-26 09:52:51 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2008a" YEAR="2008">
<REFERENCE MODIFIED="2016-10-26 09:52:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li W, Yu X, Cui Y</AU>
<TI>A comparative study of olanzapine with small-dose sustained-release tablets of magnesium valproate in treatment of acute phase of schizophrenia</TI>
<SO>Shandong Archives of Psychiatry</SO>
<YR>2008</YR>
<VL>21</VL>
<NO>3</NO>
<PG>178-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446101"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446100"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2012a" MODIFIED="2016-10-25 04:29:51 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2012a" YEAR="2012">
<REFERENCE MODIFIED="2016-10-25 04:29:51 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20043&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:29:51 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Li DM</AU>
<TI>Clinical efficacy of ziprasidone combined with valproate in the treatment of refractory schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#32852;&#21512;&#19993;&#25098;&#37240;&#38048;&#27835;&#30103;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>China Medical Engineering [&#20013;&#22269;&#21307;&#23398;&#24037;&#31243;]</SO>
<YR>2012</YR>
<NO>01</NO>
<PG>92-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446103"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446102"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2013" MODIFIED="2016-10-26 08:48:18 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-26 08:48:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20816&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:48:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Li C, Liu Y, Wang M</AU>
<TI>The effect of adjuvant magnesium valproate sustained-release tablets combined with risperidone in the treatment of schizophrenia with impulsive aggression</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#21512;&#29992;&#21033;&#22521;&#37230;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#20914;&#21160;&#25915;&#20987;&#34892;&#20026;&#30340;&#36741;&#21161;&#27835;&#30103;</TO>
<SO>Journal of Practical Medical Techniques [&#23454;&#29992;&#21307;&#25216;&#26434;&#24535;]</SO>
<YR>2013</YR>
<NO>01</NO>
<PG>69-71</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446105"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446104"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2013a" MODIFIED="2016-10-25 04:30:32 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2013a" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 04:30:32 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20830&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:30:32 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Li J, Chen LS, Chen Wang Y</AU>
<TI>A comparative study of effect of sodium valproate on cognitive dysfunction in patients with schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#25913;&#21892;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#35748;&#30693;&#21151;&#33021;&#38556;&#30861;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Psychiatry [&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2013</YR>
<NO>04</NO>
<PG>292-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446107"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446106"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2014" MODIFIED="2016-10-26 08:48:45 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-26 08:48:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 23113&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:48:45 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Li YM, Sun WB, Yang CQ</AU>
<TI>A study of low-dose quetiapine combined with magnesium valproate in the treatment of schizophrenia</TI>
<TO>&#20302;&#21058;&#37327;&#21945;&#30827;&#24179;&#21512;&#24182;&#19993;&#25098;&#37240;&#38209;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#25915;&#20987;&#34892;&#20026;&#30103;&#25928;&#30740;&#31350;</TO>
<SO>Medical Information [&#21307;&#23398;&#20449;&#24687;]</SO>
<YR>2014</YR>
<VL>27</VL>
<NO>24</NO>
<PG>47-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446109"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446108"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2014a" MODIFIED="2016-10-26 08:49:07 +0100" MODIFIED_BY="[Empty name]" NAME="Li 2014a" YEAR="2014">
<REFERENCE MODIFIED="2016-10-26 08:49:07 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 23018&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:49:07 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Li Y</AU>
<TI>A comparative study of antipsychotic drugs combined with low-dose sodium valproate in the treatment of schizophrenia</TI>
<TO>&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#32852;&#21512;&#23567;&#21058;&#37327;&#19993;&#25098;&#37240;&#38209;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#25915;&#20987;&#34892;&#20026;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>The Chinese and Foreign Health Abstract [&#20013;&#22806;&#20581;&#24247;&#25991;&#25688;]</SO>
<YR>2014</YR>
<NO>11</NO>
<PG>53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446111"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446110"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liang-2004a" MODIFIED="2016-09-09 12:03:03 +0100" MODIFIED_BY="[Empty name]" NAME="Liang 2004a" YEAR="2004">
<REFERENCE MODIFIED="2016-09-09 12:03:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liang H-X, Du J-Y, Wu Z-J</AU>
<TI>A study of additive effect of sodium-valproate in the treatment of schizophrenia</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2004</YR>
<VL>14</VL>
<NO>2</NO>
<PG>92-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446113"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446112"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linnoila-1976a" MODIFIED="2016-10-03 17:57:30 +0100" MODIFIED_BY="[Empty name]" NAME="Linnoila 1976a" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linnoila M, Viukari M, Kietala O</AU>
<TI>Effect of sodium valproate on tardive dyskinesia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1976</YR>
<VL>129</VL>
<PG>114-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817208"/><IDENTIFIER TYPE="MEDLINE" VALUE="77000897"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817207"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Linnoila-1976b" MODIFIED="2016-10-03 17:57:24 +0100" MODIFIED_BY="[Empty name]" NAME="Linnoila 1976b" YEAR="1976">
<REFERENCE MODIFIED="2016-09-09 12:03:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Linnoila M, Viukari M, Hietala O</AU>
<TI>Sodium valproate therapy for tardive dyskinesia</TI>
<SO>International Drug Therapy Newsletter</SO>
<YR>1976</YR>
<VL>11</VL>
<NO>Nov</NO>
<PG>33-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446115"/><IDENTIFIER TYPE="MEDLINE" VALUE="14-01616"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446114"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2007b" MODIFIED="2016-10-25 05:20:54 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2007b" YEAR="2007">
<REFERENCE MODIFIED="2016-10-25 05:20:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Z</AU>
<TI>Sodium valproate in treatment of aggression of psychiatric participants</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#27835;&#30103;&#31934;&#31070;&#30149;&#24739;&#32773;&#30340;&#25915;&#20987;&#34892;&#20026;</TO>
<SO>Chongqing Medical Journal [&#37325;&#24198;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>6</NO>
<PG>490-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446117"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446116"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2012" MODIFIED="2016-10-26 08:49:41 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-26 08:49:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20428&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:49:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Liu Z, Wang L, Sun Y</AU>
<TI>Clinical observation of magnesium valproate sustained-release tablets for schizophrenia with excitement</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#20852;&#22859;&#29366;&#24577;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>China Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2012</YR>
<VL>20</VL>
<NO>11</NO>
<PG>1630-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446119"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446118"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2012a" MODIFIED="2016-10-25 04:32:05 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2012a" YEAR="2012">
<REFERENCE MODIFIED="2016-10-25 04:32:05 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 17998&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:32:05 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Liu J</AU>
<TI>The effect of adjuvant magnesium valproate on schizophrenia with aggressive behavior</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#20852;&#22859;&#28608;&#36234;&#34892;&#20026;&#30340;&#36741;&#21161;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Journal of Community Medicine [&#31038;&#21306;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>14</NO>
<PG>31-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446121"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446120"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2013" MODIFIED="2016-10-26 08:50:12 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-26 08:50:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 21016&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:50:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Liu Z, Song S, Wang L</AU>
<TI>Effects of magnesium valproate sustained-release tablets combined with risperdal on lipid metabolism in patients with schizophrenia</TI>
<TO>&#19993;&#25101;&#37240;&#38209;&#32531;&#37322;&#29255;&#21512;&#24182;&#32500;&#24605;&#36890;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#33026;&#20195;&#35874;&#24433;&#21709;</TO>
<SO>China Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2013</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1631-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446123"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446122"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2014" MODIFIED="2016-10-26 08:50:23 +0100" MODIFIED_BY="[Empty name]" NAME="Liu 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-26 08:50:23 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 22285&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:50:23 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Liu Z, Li HJ, Pei SY</AU>
<TI>Effects of risperidone and magnesium valproate on blood concentration in patients with schizophrenia</TI>
<TO>&#19993;&#25101;&#37240;&#38209;&#21512;&#24182;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#34880;&#33647;&#27987;&#24230;&#21464;&#21270;&#21450;&#20020;&#24202;&#30103;&#25928;</TO>
<SO>China Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2014</YR>
<VL>22</VL>
<NO>8</NO>
<PG>1141-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446125"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-10-23 03:23:40 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446124"/><IDENTIFIER MODIFIED="2016-10-23 03:23:09 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lv-2014" MODIFIED="2016-10-26 08:50:53 +0100" MODIFIED_BY="[Empty name]" NAME="Lv 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-26 08:50:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 22601&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:50:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lv S</AU>
<TI>Effects of magnesium valproate sustained-release tablets on cognitive function in first-episode schizophrenic patients</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#23545;&#39318;&#21457;&#31934;&#31070;&#20998;&#35010;&#30151;&#30149;&#20154;&#35748;&#30693;&#21151;&#33021;&#30340;&#24433;&#21709;</TO>
<SO>China &amp; Foreign Medical Treatment [&#20013;&#22806;&#21307;&#30103;]</SO>
<YR>2014</YR>
<NO>17</NO>
<PG>120-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446127"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446126"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2012" MODIFIED="2016-10-25 05:10:50 +0100" MODIFIED_BY="[Empty name]" NAME="Ma 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-25 05:10:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20429&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 05:10:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ma TB</AU>
<TI>Analysis of effects of valproic acid sodium jointed with ziprasidone in the treatment of refractory schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#32852;&#21512;&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#25928;&#26524;&#20998;&#26512;</TO>
<SO>China Modern Medicine [&#20013;&#22269;&#24403;&#20195;&#21307;&#33647;]</SO>
<YR>2012</YR>
<NO>04</NO>
<PG>73-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446129"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446128"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monteleone-1986" MODIFIED="2016-09-09 12:03:03 +0100" MODIFIED_BY="[Empty name]" NAME="Monteleone 1986" YEAR="1986">
<REFERENCE MODIFIED="2016-09-09 12:03:03 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 01809&lt;/p&gt;" NOTES_MODIFIED="2016-09-09 12:03:03 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Monteleone P, Maj M, Iovino M, Steardo L</AU>
<TI>Growth hormone response to sodium valproate in chronic schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1986</YR>
<VL>21</VL>
<NO>7</NO>
<PG>588-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446131"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446130"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monteleone-1988" MODIFIED="2016-09-09 12:03:03 +0100" MODIFIED_BY="[Empty name]" NAME="Monteleone 1988" YEAR="1988">
<REFERENCE MODIFIED="2016-09-09 12:03:03 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 03517&lt;/p&gt;" NOTES_MODIFIED="2016-09-09 12:03:03 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Monteleone P, Maj M, Ariano M, Iovino M, Fiorenza L, Steardo L</AU>
<TI>Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia</TI>
<SO>Psychopharmacology</SO>
<YR>1988</YR>
<VL>96</VL>
<NO>2</NO>
<PG>223-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446133"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446132"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nair-1980" MODIFIED="2016-10-06 10:51:26 +0100" MODIFIED_BY="[Empty name]" NAME="Nair 1980" YEAR="1980">
<REFERENCE MODIFIED="2016-10-06 10:51:26 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 03519&lt;/p&gt;" NOTES_MODIFIED="2016-10-06 10:51:26 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Nair N, Lal S, Schwartz G</AU>
<TI>Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies</TI>
<SO>Long Term Effects of Neuroleptics. Advances in Biochemistry and Psychopharmacology</SO>
<YR>1980</YR>
<VL>24</VL>
<PG>437-41</PG>
<ED>Cattabeni FRG</ED>
<PB>Raven Press</PB>
<CY>New York, USA</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446135"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446134"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nasrallah-1986" MODIFIED="2016-09-09 12:03:03 +0100" MODIFIED_BY="[Empty name]" NAME="Nasrallah 1986" YEAR="1986">
<REFERENCE MODIFIED="2016-09-09 12:03:03 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 19260&lt;/p&gt;" NOTES_MODIFIED="2016-09-09 12:03:03 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Nasrallah H, Dunner F, McCalley Whitters M, Smith R</AU>
<TI>Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>1986</YR>
<VL>47</VL>
<NO>2</NO>
<PG>56-9</PG>
<CY>United-States</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446137"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446136"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00552500" MODIFIED="2016-10-25 05:10:37 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00552500" YEAR="2007">
<REFERENCE MODIFIED="2016-10-25 05:10:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 12006&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 05:10:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00552500</AU>
<TI>Effects of atypical antipsychotic and valproate combination therapy on glucose and lipid metabolism in schizophrenia</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00552500</SO>
<YR>[Date Accessed: 1 November 2007]</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446139"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-09-19 14:31:04 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446138"/><IDENTIFIER MODIFIED="2016-09-19 14:31:04 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00552500"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2012" MODIFIED="2016-10-25 04:33:45 +0100" MODIFIED_BY="[Empty name]" NAME="Peng 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-25 04:33:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 18041&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:33:45 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Peng ZY, Xia CL, Liu XM</AU>
<TI>A comparative study of clozapine and clozapine unite magnesium valproate in the treatment of patients with treatment-resistant schizophrenia</TI>
<TO>&#27695;&#27694;&#24179;&#21512;&#24182;&#19993;&#25098;&#37240;&#38209;&#27835;&#30103;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>World Health Digest Medical Periodieal [&#20013;&#22806;&#20581;&#24247;&#25991;&#25688;]</SO>
<YR>2012</YR>
<VL>38</VL>
<PG>164-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446141"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446140"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2013" MODIFIED="2016-10-25 04:34:28 +0100" MODIFIED_BY="[Empty name]" NAME="Peng 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 04:34:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20877&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:34:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Peng H</AU>
<TI>Effect of magnesium valproate on aggressive behavior in schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#25915;&#20987;&#34892;&#20026;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chinese Journal of Trauma and Disability Medicine [&#20013;&#22269;&#20260;&#27531;&#21307;&#23398;]</SO>
<YR>2013</YR>
<NO>07</NO>
<PG>187-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446143"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446142"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pu-2013" MODIFIED="2016-10-25 04:34:12 +0100" MODIFIED_BY="[Empty name]" NAME="Pu 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 04:34:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20600&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:34:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Pu QX, Wu HB, Huang X, Yu GH, Wang DF, Gu ZW et al</AU>
<TI>Contrast analysis of olanzapine combined with sodium valproate on refractory schizophrenia</TI>
<TO>&#22885;&#27694;&#24179;&#21512;&#24182;&#19993;&#25098;&#37240;&#38048;&#27835;&#30103;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#23545;&#29031;&#20998;&#26512;</TO>
<SO>Progress in Modern Biomedicine [&#29616;&#20195;&#29983;&#29289;&#21307;&#23398;&#36827;&#23637;]</SO>
<YR>2013</YR>
<NO>18</NO>
<PG>3503-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446145"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446144"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qiu-2014" MODIFIED="2016-10-25 04:34:42 +0100" MODIFIED_BY="[Empty name]" NAME="Qiu 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-25 04:34:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 22538&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:34:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Qiu LL, Wang JF</AU>
<TI>Effect of sodium valproate on risperidone therapy and blood concentration</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#23545;&#21033;&#22521;&#37230;&#30103;&#25928;&#21450;&#34880;&#33647;&#27987;&#24230;&#30340;&#24433;&#21709;</TO>
<SO>Medical Journal of Liaoning [&#36797;&#23425;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2014</YR>
<VL>28</VL>
<NO>1</NO>
<PG>9-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446147"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446146"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qu-2014" MODIFIED="2016-10-25 04:35:03 +0100" MODIFIED_BY="[Empty name]" NAME="Qu 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-25 04:35:03 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 23090&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:35:03 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Qu CH, Liu XL, Sun XH</AU>
<TI>A comparative study of valproate combined with olanzapine in the treatment of schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#21512;&#29992;&#22885;&#27694;&#24179;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#25915;&#20987;&#34892;&#20026;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Information [&#21307;&#23398;&#20449;&#24687;]</SO>
<YR>2014</YR>
<VL>27</VL>
<NO>21</NO>
<PG>602</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446149"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446148"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruiz_x002d_Doblado-2010" MODIFIED="2016-10-25 05:10:20 +0100" MODIFIED_BY="[Empty name]" NAME="Ruiz-Doblado 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-10-25 05:10:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz-Doblado S, Baena-Baldomero A, Esparrago-Llorca G</AU>
<TI>Pharmacological augmentation strategies in clozapine-resistant schizophrenia: overcoming the resistance</TI>
<SO>Psiquiatria Biologica</SO>
<YR>2010</YR>
<VL>17</VL>
<NO>3</NO>
<PG>96-101</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446151"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446150"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shu-2014" MODIFIED="2016-10-26 08:52:10 +0100" MODIFIED_BY="[Empty name]" NAME="Shu 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-26 08:52:10 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 22524&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:52:10 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Shu Z, Zhou W</AU>
<TI>Clinical observation of clozapine combined with magnesium valproate sustained-release tablets in the treatment of schizophrenia</TI>
<TO>&#27695;&#27694;&#24179;&#32852;&#21512;&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#25915;&#20987;&#34892;&#20026;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Guide of China Medicine [&#20013;&#22269;&#21307;&#33647;&#25351;&#21335;]</SO>
<YR>2014</YR>
<VL>12</VL>
<NO>2</NO>
<PG>28-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446153"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446152"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2013" MODIFIED="2016-10-25 05:10:28 +0100" MODIFIED_BY="[Empty name]" NAME="Su 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 05:10:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 18414&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 05:10:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Su L, Xu Y, Shi S, Dutt A, Bramon E</AU>
<TI>Effects of chlorpromazine, clozapine and valproate on auditory P300 in schizophrenia: a prospective longitudinal randomized controlled study</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2013</YR>
<VL>39</VL>
<PG>S51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446155"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446154"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2007" MODIFIED="2016-10-23 03:59:17 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-04-08 15:09:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sun Q, Quo H, Zhang H, Liu Y, Zhu Y, Zhang A</AU>
<TI>The effects of magnesium valproate sustained release tablets on the cognitive function in treatment-resistant schizophrenic participants</TI>
<SO>Proceedings of the Shanghai Regional Meeting and CSP Annual Congress; 2007 Sep 20-23; Shanghai</SO>
<YR>2007</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817212"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817211"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2008" MODIFIED="2016-10-26 09:53:06 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-10-26 09:53:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun Q-X, Guo H, Liu Y</AU>
<TI>Effect of magnesium valproate sustained release tablets on cognition function in difficult cure sex schizophrenic</TI>
<SO>Chinese Journal of Modern Drug Application [&#20013;&#22269;&#29616;&#20195;&#33647;&#29289;&#24212;&#29992;]</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>22</NO>
<PG>25-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446157"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446156"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2012" MODIFIED="2016-10-25 05:10:04 +0100" MODIFIED_BY="[Empty name]" NAME="Sun 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-25 05:10:04 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 18072&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 05:10:04 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sun XG</AU>
<TI>A comparative study of quetiapine combined with haloperidol, sodium valproate and clozapine in the treatment of refractory schizophrenia</TI>
<TO>&#22862;&#30827;&#24179;&#21512;&#24182;&#27679;&#21708;&#21878;&#37255;&#12289;&#19993;&#25098;&#37240;&#38048;&#19982;&#27695;&#27694;&#24179;&#27835;&#30103;&#38590;&#27835;&#24615;&#20998;&#35010;&#30151;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2012</YR>
<VL>24</VL>
<NO>13</NO>
<PG>1566-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446159"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446158"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suzana-2009" MODIFIED="2016-10-26 09:53:20 +0100" MODIFIED_BY="[Empty name]" NAME="Suzana 2009" YEAR="2009">
<REFERENCE MODIFIED="2016-10-26 09:53:20 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 17668&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 09:53:20 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Suzana S, Olivera Z, Gordana N, Violeta S, Dragoslava G, Vladica S</AU>
<TI>Adjunctive mood stabilising treatment: the effects on hostility and impulsivity among patients with schizophrenia</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2009</YR>
<VL>19</VL>
<PG>S532</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446161"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446160"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2012" MODIFIED="2016-10-26 08:53:15 +0100" MODIFIED_BY="[Empty name]" NAME="Tang 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-26 08:53:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 18079&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:53:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Tang SY, Qin CL, Zhang W, Xiong MQ</AU>
<TI>Clinical observation of sodium valproate sustained-release tablets on schizophrenia hostile attack</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#25932;&#24847;&#25915;&#20987;&#34892;&#20026;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>J Medical Forum [&#21307;&#33647;&#35770;&#22363;&#26434;&#24535;]</SO>
<YR>2012</YR>
<VL>9</VL>
<PG>36-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446163"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446162"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2005b" MODIFIED="2016-10-03 18:05:24 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2005b" YEAR="2005">
<REFERENCE MODIFIED="2016-09-09 12:03:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang H</AU>
<TI>Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics</TI>
<SO>Journal of Clinical Psychosomatic Diseases</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>1</NO>
<PG>10-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446165"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446164"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2006" MODIFIED="2016-10-25 04:39:02 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2006" YEAR="2006">
<REFERENCE MODIFIED="2016-10-25 04:39:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang HL</AU>
<TI>Therapeutic effect of risperidone combined with magnesium valproate in aggressive behaviors of schizophrenics</TI>
<SO>Chinese Journal of Health Psychology</SO>
<YR>2006</YR>
<VL>14</VL>
<NO>4</NO>
<PG>441-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817210"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817209"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2012" MODIFIED="2016-10-26 08:53:34 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-26 08:53:34 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20358&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:53:34 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang G, Xie R, Pei G</AU>
<TI>A comparative study of quetiapine combined with magnesium valproate sustained-release tablets in the treatment of schizophrenia with aggressive behavior</TI>
<TO>&#21945;&#30827;&#24179;&#21512;&#24182;&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#25915;&#20987;&#34892;&#20026;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Psychiatry [&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2012</YR>
<NO>01</NO>
<PG>59-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446167"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446166"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2013" MODIFIED="2016-10-25 04:39:23 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 04:39:23 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20702&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:39:23 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang Y</AU>
<TI>Efficacy of olanzapine combined with magnesium valproate in the treatment of schizophrenia</TI>
<TO>&#22885;&#27694;&#24179;&#21512;&#29992;&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#30103;&#25928;&#20998;&#26512;</TO>
<SO>Chinese Journal of General Practice [&#20013;&#21326;&#20840;&#31185;&#21307;&#23398;]</SO>
<YR>2013</YR>
<NO>05</NO>
<PG>730+749</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446169"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446168"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2013a" MODIFIED="2016-10-25 04:40:15 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2013a" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 04:40:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20689&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:40:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang ML, Jiang TC</AU>
<TI>Clinical observation of risperidone combined with sodium valproate in the treatment of schizophrenia with impulse and aggressive behavior</TI>
<TO>&#21033;&#22521;&#37230;&#32852;&#21512;&#19993;&#25098;&#37240;&#38048;&#27835;&#30103;&#20276;&#26377;&#20914;&#21160;&#21644;&#25915;&#20987;&#34892;&#20026;&#30340;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#30340;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Clinical Rational Drug Use [&#20020;&#24202;&#21512;&#29702;&#29992;&#33647;&#26434;&#24535;]</SO>
<YR>2013</YR>
<NO>01</NO>
<PG>72-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446171"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446170"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2014" MODIFIED="2016-10-25 04:40:33 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-25 04:40:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 22366&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:40:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang GL, Fu PX, Li XY, Lin JX, Ji QS, Li ZJ</AU>
<TI>A comparative study of the efficacy of risperidone combined with valproate sodium on the aggressive behavior of the patients with schizophrenia</TI>
<TO>&#21033;&#22521;&#37230;&#21512;&#24182;&#19993;&#25098;&#37240;&#38048;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#25915;&#20987;&#34892;&#20026;&#30103;&#25928;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chinese Journal of Drug Abuse Prevention and Treatment [&#20013;&#22269;&#33647;&#29289;&#28389;&#29992;&#38450;&#27835;&#26434;&#24535;]</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>4</NO>
<PG>200-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446173"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446172"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2014a" MODIFIED="2016-10-25 05:09:37 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2014a" YEAR="2014">
<REFERENCE MODIFIED="2016-10-25 05:09:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 22802&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 05:09:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang ZB</AU>
<TI>The effect of adjuvant sodium valproate for schizophrenia with behavioral disorders</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#34892;&#20026;&#32010;&#20081;&#30340;&#36741;&#21161;&#27835;&#30103;&#20316;&#29992;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2014</YR>
<VL>26</VL>
<NO>22</NO>
<PG>57-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446175"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446174"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wen-2013" MODIFIED="2016-10-26 08:54:13 +0100" MODIFIED_BY="[Empty name]" NAME="Wen 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-26 08:54:13 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20721&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:54:13 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wen J, Li Y, Wang G</AU>
<TI>Clinical efficacy and safety of quetiapine combined with magnesium valproate in the treatment of schizophrenia with aggressive behavior</TI>
<TO>&#21945;&#30827;&#24179;&#21512;&#24182;&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#20855;&#26377;&#25915;&#20987;&#34892;&#20026;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#20020;&#24202;&#30103;&#25928;&#21450;&#23433;&#20840;&#24615;&#25506;&#35752;</TO>
<SO>Medical Journal of Chinese Civil Administration [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2013</YR>
<NO>11</NO>
<PG>55-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446177"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446176"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2013a" MODIFIED="2016-10-25 04:42:03 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 2013a" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 04:42:03 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20735&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:42:03 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wu J, Lin T</AU>
<TI>Efficacy of magnesium valproate combined with quetiapine in the treatment of refractory schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#32852;&#21512;&#21945;&#30827;&#24179;&#27835;&#30103;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#30740;&#31350;</TO>
<SO>Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease [&#23454;&#29992;&#24515;&#33041;&#32954;&#34880;&#31649;&#30149;&#26434;&#24535;]</SO>
<YR>2013</YR>
<NO>04</NO>
<PG>140-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446179"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446178"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2013b" MODIFIED="2016-10-25 04:43:31 +0100" MODIFIED_BY="[Empty name]" NAME="Wu 2013b" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 04:43:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20980&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:43:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wu X, Yang Q, Zhang L, Zhou S</AU>
<TI>A comparative study of olanzapine combined with magnesium valproate sustained-release tablets in the treatment of patients with positive symptoms of schizophrenia</TI>
<TO>&#22885;&#27694;&#24179;&#32852;&#21512;&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#20276;&#38451;&#24615;&#30151;&#29366;&#24739;&#32773;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of West China [&#35199;&#37096;&#21307;&#23398;]</SO>
<YR>2013</YR>
<NO>12</NO>
<PG>1842-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446181"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446180"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-2013" MODIFIED="2016-10-25 04:45:19 +0100" MODIFIED_BY="[Empty name]" NAME="Xiao 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 04:45:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20630&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:45:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Xiao H</AU>
<TI>A retrospective study of risperidone combined with magnesium valproate in the treatment of schizophrenia</TI>
<TO>&#21033;&#22521;&#37230;&#21512;&#24182;&#19993;&#25098;&#37240;&#38209;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#29992;&#33647;&#29616;&#29366;&#22238;&#39038;&#20998;&#26512;</TO>
<SO>Nei Mongol Journal of Traditional Chinese Medicine [&#20869;&#33945;&#21476;&#20013;&#21307;&#33647;]</SO>
<YR>2013</YR>
<NO>06</NO>
<PG>30-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446183"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446182"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2002" MODIFIED="2016-10-25 04:45:41 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-10-25 04:45:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 08381&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:45:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Xu HL, Wang Y</AU>
<TI>The effect of adjuvant sodium valproate on auditory hallucinations in schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#24187;&#21548;&#30151;&#29366;&#30340;&#36741;&#21161;&#30103;&#25928;</TO>
<SO>Journal of Clinical Psychological Medicine [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>3</NO>
<PG>157-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446185"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446184"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2013" MODIFIED="2016-10-26 08:55:09 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-26 08:55:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20582&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:55:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Xu LH, Huang WD, Li CH, Ban RY, Luo HF, Li ZM</AU>
<TI>Ziprasidone combined with low-dose sodium valproate in the treatment and nursing of female refractory schizophrenia</TI>
<TO>&#40784;&#25289;&#35199;&#37230;&#32852;&#21512;&#23567;&#21058;&#37327;&#19993;&#25098;&#37240;&#38048;&#27835;&#30103;&#22899;&#24615;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#35266;&#23519;&#21450;&#25252;&#29702;</TO>
<SO>Journal of Aerospace Medicine [&#33322;&#31354;&#33322;&#22825;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2013</YR>
<NO>09</NO>
<PG>1133-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446187"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446186"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2014" MODIFIED="2016-10-26 08:55:25 +0100" MODIFIED_BY="[Empty name]" NAME="Xu 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-26 08:55:25 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 22406&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:55:25 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Xu BF, Lou YM, Cai XH</AU>
<TI>Effects of magnesium valproate sustained-release tablets combined with clozapine in the treatment of female refractory schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#32852;&#21512;&#27695;&#27694;&#24179;&#27835;&#30103;&#22899;&#24615;&#38590;&#27835;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chinese Journal of Trauma and Disability Medicine [&#20013;&#22269;&#20260;&#27531;&#21307;&#23398;]</SO>
<YR>2014</YR>
<VL>22</VL>
<NO>6</NO>
<PG>148-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446189"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446188"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007a" MODIFIED="2016-10-25 04:54:12 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2007a" YEAR="2007">
<REFERENCE MODIFIED="2016-10-25 04:54:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang S-L, Wang C-X, Wang L-T</AU>
<TI>Therapeutic efficacy of combination of risperidone with Depakine for schizophrenia</TI>
<SO>Medical Journal of Qilu</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>3</NO>
<PG>265-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446191"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446190"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007b" MODIFIED="2016-10-25 05:08:33 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2007b" YEAR="2007">
<REFERENCE MODIFIED="2016-10-25 05:08:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 13142&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 05:08:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhang DW, Dai J, Xie WF, Chen WT</AU>
<TI>Sodium valproate combined with EEG as an adjuvant therapy for schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#23545;&#20276;&#33041;&#30005;&#22270;&#24322;&#24120;&#30340;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#36741;&#21161;&#27835;&#30103;&#20316;&#29992;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>12</NO>
<PG>1049, 1051</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446193"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446192"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2008" MODIFIED="2016-10-25 04:54:36 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-10-25 04:54:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 13157&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:54:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhang X, Wang XM</AU>
<TI>Magnesium valproate combined with risperidone in the treatment of schizophrenia with negative symptoms</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#36741;&#21161;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#38452;&#24615;&#30151;&#29366;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chinese Journal of Misdiagnostics [&#20013;&#22269;&#35823;&#35786;&#23398;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>18</VL>
<NO>18</NO>
<PG>4361-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446195"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446194"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2012" MODIFIED="2016-10-25 04:54:49 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-25 04:54:49 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 18203&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:54:49 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhang X, Ye CP, Liu WP</AU>
<TI>Efficacy of sodium valproate combined with haloperidol in the treatment of early schizophrenia</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#32852;&#21512;&#27679;&#21708;&#21878;&#37255;&#27835;&#30103;&#26089;&#26399;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chinese and Foreign Medical Research [&#20013;&#22806;&#21307;&#23398;&#30740;&#31350;]</SO>
<YR>2012</YR>
<VL>23</VL>
<PG>38-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446197"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446196"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2012" MODIFIED="2016-10-25 04:55:02 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-10-25 04:55:02 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20427&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:55:02 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhou YH, Zhong YF, Zeng DZ, Dai LJ,</AU>
<TI>Efficacy of magnesium valproate sustained-release tablets combined with ziprasidone in the treatment of schizophrenia with aggressive behavior</TI>
<TO>&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#32852;&#21512;&#40784;&#25289;&#35199;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#25915;&#20987;&#34892;&#20026;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>The 10th National conference of Psychiatry of Chinese Medical Association</SO>
<YR>2012</YR>
<PG>1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446199"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446198"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2013" MODIFIED="2016-10-25 04:55:18 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-10-25 04:55:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 20964&lt;/p&gt;" NOTES_MODIFIED="2016-10-25 04:55:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhou LC, Nong YX, Chen QM</AU>
<TI>Effect and safety comparison of risperidone single therapy or combined valproate on excited restless of schizophrenia</TI>
<TO>&#21033;&#22521;&#37230;&#21333;&#33647;&#25110;&#19982;&#19993;&#25098;&#37240;&#38048;&#32852;&#29992;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#20852;&#22859;&#36481;&#21160;&#30340;&#20316;&#29992;&#21450;&#23433;&#20840;&#24615;&#27604;&#36739;</TO>
<SO>Journal of Clinical Psychological Medicine [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2013</YR>
<NO>04</NO>
<PG>261-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446201"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446200"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2014" MODIFIED="2016-10-26 08:57:03 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-26 08:57:03 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 22733&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:57:03 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhou W, Xie WJ, Hu YZ</AU>
<TI>Clinical observation of olanzapine combined sustained-release magnesium valproate tablet treating male schizophrenic patients with aggressive behavior</TI>
<TO>&#22885;&#27694;&#24179;&#21512;&#24182;&#19993;&#25098;&#37240;&#38209;&#32531;&#37322;&#29255;&#27835;&#30103;&#20276;&#25915;&#20987;&#34892;&#20026;&#30340;&#30007;&#24615;&#31934;&#31070;&#20998;&#35010;&#30151;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Journal of Clinical Psychiatry [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2014</YR>
<VL>24</VL>
<NO>3</NO>
<PG>194-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446203"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446202"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2005a" MODIFIED="2016-10-25 05:06:31 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu 2005a" YEAR="2005">
<REFERENCE MODIFIED="2016-10-25 05:06:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu CH, Fu R, Yang Y</AU>
<TI>A comparative study of sodium valproate combined with clonazepam for schizophrenic agitation</TI>
<TO>&#19993;&#25098;&#37240;&#38048;&#19982;&#27695;&#30813;&#35199;&#27886;&#25511;&#21046;&#31934;&#31070;&#20998;&#35010;&#30151;&#28608;&#36234;&#30151;&#29366;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of the Chinese People's Armed Police Forces [&#27494;&#35686;&#21307;&#23398;]</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>12</NO>
<PG>934-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446205"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446204"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2014" MODIFIED="2016-10-26 08:57:27 +0100" MODIFIED_BY="[Empty name]" NAME="Zhu 2014" YEAR="2014">
<REFERENCE MODIFIED="2016-10-26 08:57:27 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;PDF Number: 22302&lt;/p&gt;" NOTES_MODIFIED="2016-10-26 08:57:27 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhu YT, Zeng DF</AU>
<TI>A comparative study of antipsychotic drugs combined with low-dose sodium valproate in the treatment of schizophrenia</TI>
<TO>&#25239;&#31934;&#31070;&#30149;&#33647;&#29289;&#32852;&#21512;&#23567;&#21058;&#37327;&#19993;&#25098;&#37240;&#38209;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#25915;&#20987;&#34892;&#20026;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>China Practical Medicine [&#20013;&#22269;&#23454;&#29992;&#21307;&#33647;]</SO>
<YR>2014</YR>
<VL>9</VL>
<NO>13</NO>
<PG>140-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4446207"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4446206"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-10-25 05:07:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00167934" MODIFIED="2016-10-25 05:07:28 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00167934" YEAR="2005">
<REFERENCE MODIFIED="2016-10-25 05:07:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00167934</AU>
<TI>Metabolic effects of valproate and antipsychotic therapy</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00167934</SO>
<YR>[Date Accessed: 9 September 2005]</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817214"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-09-19 14:31:37 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817213"/><IDENTIFIER MODIFIED="2016-09-19 14:31:37 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00167934"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00306475" MODIFIED="2016-10-25 05:07:37 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00306475" YEAR="2006">
<REFERENCE MODIFIED="2016-10-25 05:07:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00306475</AU>
<TI>Does the addition of divalproex sodium ER to an atypical antipsychotic drug (APD) improve cognition and psychopathology in outpatients with schizophrenia (sch) or schizoaffective disorder (sad)?</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00306475</SO>
<YR>[Date Accessed: 22 March 2006]</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817216"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-09-19 14:32:34 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817215"/><IDENTIFIER MODIFIED="2016-09-19 14:32:34 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00306475"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norrie-2000" NAME="Norrie 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norrie PD</AU>
<TI>Valproate augmentation of antipsychotic therapy</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>3 (Suppl 1)</VL>
<PG>S173</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817218"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817217"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" MODIFIED="2016-04-08 15:10:46 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-04-08 15:10:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang G</AU>
<TI>60 week, randomized, double-blind, placebo-controlled trial of valproate added to risperidone in 200 treatment-naive, first-episode participants with schizophrenia</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>2003</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2817220"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2817219"/></IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-10-26 09:56:43 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2016-10-26 09:56:43 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams-2014" MODIFIED="2015-03-05 12:21:49 +0000" MODIFIED_BY="[Empty name]" NAME="Adams 2014" TYPE="COCHRANE_REVIEW">
<AU>Adams CE, Awad GA, Rathbone J, Thornley B, Soares-Weiser K</AU>
<TI>Chlorpromazine versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-03-05 12:19:36 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-03-05 12:19:36 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000284.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1989" MODIFIED="2016-10-26 09:53:37 +0100" MODIFIED_BY="[Empty name]" NAME="Andreasen 1989" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Scale for the assessment of negative symptoms</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>155</VL>
<PG>53-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baethge-2003" MODIFIED="2016-04-08 15:11:57 +0100" MODIFIED_BY="[Empty name]" NAME="Baethge 2003" TYPE="JOURNAL_ARTICLE">
<AU>Baethge C</AU>
<TI>Long-term treatment of schizoaffective disorder: review and recommendations</TI>
<SO>Pharmacopsychiatry </SO>
<YR>2003</YR>
<VL>36</VL>
<NO>2</NO>
<PG>45-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bagnall-2000" MODIFIED="2016-04-08 15:12:12 +0100" MODIFIED_BY="[Empty name]" NAME="Bagnall 2000" TYPE="COCHRANE_REVIEW">
<AU>Bagnall AM, Lewis RA, Leitner ML</AU>
<TI>Ziprasidone for schizophrenia and severe mental illness</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<PB>Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2014-10-13 15:56:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-10-13 15:56:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001945"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bailer-2012" MODIFIED="2014-11-29 13:34:00 +0000" MODIFIED_BY="[Empty name]" NAME="Bailer 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bailer M</AU>
<TI>Chemical properties of antiepileptic drugs (AEDs)</TI>
<SO>Advanced Drug Delivery Reviews</SO>
<YR>2012</YR>
<VL>64</VL>
<NO>10</NO>
<PG>887-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balen-1999" MODIFIED="2016-04-08 15:12:38 +0100" MODIFIED_BY="[Empty name]" NAME="Balen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Balen RM, Procyshyn RM</AU>
<TI>Valproic acid for seizure prophylaxis during clozapine therapy: where's the evidence?</TI>
<SO>International Journal of Psychiatry in Clinical Practice</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>4</NO>
<PG>249-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2016-04-08 15:13:10 +0100" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials: the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Besag-2006" MODIFIED="2016-04-08 15:13:28 +0100" MODIFIED_BY="[Empty name]" NAME="Besag 2006" TYPE="JOURNAL_ARTICLE">
<AU>Besag FMC, Berry D </AU>
<TI>Interactions between antiepileptic and antipsychotic drugs</TI>
<SO>Drug Safety</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>2</NO>
<PG>95-118</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM, Kerry SM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" MODIFIED="2016-04-08 15:13:55 +0100" MODIFIED_BY="[Empty name]" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al</AU>
<TI>The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" MODIFIED="2012-10-19 10:01:54 +0100" MODIFIED_BY="[Empty name]" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carta-2003" MODIFIED="2014-11-29 13:18:58 +0000" MODIFIED_BY="[Empty name]" NAME="Carta 2003" TYPE="JOURNAL_ARTICLE">
<AU>Carta, MG, Hardoy MC, Hardoy MJ, Grunze H, Carpiniello B</AU>
<TI>The clinical use of gabapentin in bipolar spectrum disorders</TI>
<SO>Journal of Affective Disorders</SO>
<YR>June 2003</YR>
<VL>75</VL>
<NO>1</NO>
<PG>83-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheine-2003" MODIFIED="2014-10-13 16:04:09 +0100" MODIFIED_BY="[Empty name]" NAME="Cheine 2003" TYPE="COCHRANE_REVIEW">
<AU>Cheine M, Ahonen J, Wahlbeck K</AU>
<TI>Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2014-10-13 15:57:15 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-10-13 15:57:15 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000234"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Christison-1991" NAME="Christison 1991" TYPE="JOURNAL_ARTICLE">
<AU>Christison GW, Kirch DG, Wyatt RJ</AU>
<TI>When symptoms persist: choosing among alternative somatic treatments for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1991</YR>
<VL>17</VL>
<PG>217-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Citrome-2000" MODIFIED="2013-04-20 22:24:52 +0100" MODIFIED_BY="[Empty name]" NAME="Citrome 2000" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L, Levine L, Allingham B</AU>
<TI>Changes in use of valproate and other mood stabilizers for participants with schizophrenia from 1994 to 1998</TI>
<SO>Psychiatric Services</SO>
<YR>2000</YR>
<VL>51</VL>
<NO>5</NO>
<PG>634-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crowhurst-2002" MODIFIED="2014-11-29 14:20:06 +0000" MODIFIED_BY="[Empty name]" NAME="Crowhurst 2002" TYPE="JOURNAL_ARTICLE">
<AU>Crowhurst N</AU>
<TI>Philosophy, care and treatment on the psychiatric intensive care unit: themes, trends and future practice</TI>
<SO>Journal of Psychiatric and Mental Health Nursing</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>6</NO>
<PG>689-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davey-Smith-1998" MODIFIED="2016-04-08 15:16:41 +0100" MODIFIED_BY="[Empty name]" NAME="Davey Smith 1998" TYPE="JOURNAL_ARTICLE">
<AU>Davey Smith G, Egger M</AU>
<TI>Meta-analysis: unresolved issues and future developments</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>16</VL>
<PG>221-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-2000" MODIFIED="2016-04-08 15:16:57 +0100" MODIFIED_BY="[Empty name]" NAME="Davis 2000" TYPE="JOURNAL_ARTICLE">
<AU>Davis LL, Ryan W, Adinoff B, Petty F</AU>
<TI>Comprehensive review of the psychiatric uses of valproate</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>1</NO>
<PG>1-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection for meta-analyses of binary data</TI>
<SO>Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa</SO>
<YR>2000</YR>
<ED>Cochrane Collaboration</ED>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2016-10-26 09:53:57 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" MODIFIED="2013-04-20 22:24:52 +0100" MODIFIED_BY="[Empty name]" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazer LM</AU>
<TI>The unit of analysis error in studies about physicians' participant care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dold-2012" MODIFIED="2014-10-13 16:00:19 +0100" MODIFIED_BY="[Empty name]" NAME="Dold 2012" TYPE="COCHRANE_REVIEW">
<AU>Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S</AU>
<TI>Benzodiazepines for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2014-10-13 15:59:46 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-10-13 15:59:46 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006391.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" MODIFIED="2011-02-10 11:12:33 +0000" MODIFIED_BY="[Empty name]" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2014-10-13 16:03:56 +0100" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbourne-2002" MODIFIED="2011-02-10 11:12:33 +0000" MODIFIED_BY="[Empty name]" NAME="Elbourne 2002" TYPE="JOURNAL_ARTICLE">
<AU>Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A</AU>
<TI>Meta-analyses involving cross-over trials: methodological issues</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2002</YR>
<VL>31</VL>
<NO>1</NO>
<PG>140-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Essali-2010" MODIFIED="2014-10-13 16:07:24 +0100" MODIFIED_BY="[Empty name]" NAME="Essali 2010" TYPE="COCHRANE_REVIEW">
<AU>Essali A, Al-Haj Haasan N, Li C, Rathbone J</AU>
<TI>Clozapine versus typical neuroleptic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-10-13 16:05:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-10-13 16:05:30 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000059.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Freeman-1998" MODIFIED="2016-04-08 15:18:25 +0100" MODIFIED_BY="[Empty name]" NAME="Freeman 1998" TYPE="JOURNAL_ARTICLE">
<AU>Freeman MP, Stoll AL</AU>
<TI>Mood stabilizer combinations: a review of safety and efficacy</TI>
<SO>The American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<NO>1</NO>
<PG>12-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Furukawa-2006" MODIFIED="2011-02-10 11:12:33 +0000" MODIFIED_BY="[Empty name]" NAME="Furukawa 2006" TYPE="JOURNAL_ARTICLE">
<AU>Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N</AU>
<TI>Imputing missing standard deviations in meta-analyses can provide accurate results</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>7</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gilbody-2000" MODIFIED="2016-04-08 15:18:49 +0100" MODIFIED_BY="[Empty name]" NAME="Gilbody 2000" TYPE="COCHRANE_REVIEW">
<AU>Gilbody SM, Bagnall AM, Duggan L, Tuunainen A</AU>
<TI>Risperidone versus other atypical antipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<PB>Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-05-14 11:13:30 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2008-05-14 11:13:30 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002306"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goodman-2006" MODIFIED="2016-04-08 15:19:10 +0100" MODIFIED_BY="[Empty name]" NAME="Goodman 2006" TYPE="BOOK">
<AU>Goodman F, Glassman, P, Maglione M, Suttorp M</AU>
<SO>Drug Class Review on Antiepileptic Drugs in Bipolar Mood Disorder, Neuropathic Pain, and Fibromyalgia</SO>
<YR>2006</YR>
<PB>Oregon Health &amp; Science University</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC, Ukoumunne OC, Chinn S</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2016-04-08 15:19:55 +0100" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK_SECTION">
<AU>Guy U</AU>
<TI>ECDEU assessment manual for psychopharmacology</TI>
<SO>Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology</SO>
<YR>1976</YR>
<PB>National Institute of Mental Health</PB>
<CY>Washington DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2016-10-26 09:54:17 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2016-10-26 09:54:28 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ (editors)</AU>
<TI>Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011c" MODIFIED="2016-10-26 09:54:35 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011c" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), <I>Cochrane Handbook for Systematic Reviews of Interventions</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hiller-1986" MODIFIED="2016-10-26 09:54:45 +0100" MODIFIED_BY="[Empty name]" NAME="Hiller 1986" TYPE="BOOK">
<AU>Hiller W, Zerssen D, Mombour W, Wittchen HU</AU>
<SO>Inpatient Multidimensional Psychiatric Scale. Eine multidimensionale Skala zur systematischen Erfassung des psychopathologischen Befundes (Dt. Version). Manual</SO>
<YR>1986</YR>
<PB>Beltz Test GmbH</PB>
<CY>Weinheim</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1986" MODIFIED="2016-04-08 15:21:25 +0100" MODIFIED_BY="[Empty name]" NAME="Kay 1986" TYPE="BOOK">
<AU>Kay SR, Opler LA, Fiszbein A</AU>
<TI>Positive and negative syndrome scale (PANSS) manual</TI>
<SO>Positive and Negative Syndrome Scale (PANSS) Manual</SO>
<YR>1986</YR>
<PB>North Tonawanda, NY: Multi-Health Systems</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Konstantinos-2012" MODIFIED="2016-10-26 09:55:00 +0100" MODIFIED_BY="[Empty name]" NAME="Konstantinos 2012" TYPE="JOURNAL_ARTICLE">
<AU>Konstantinos N, Fountoulakis, Siegfried K, Ole A, Pierre B, Ahmed O, et al</AU>
<TI>Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2012</YR>
<VL>262</VL>
<NO>1</NO>
<PG>1-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" MODIFIED="2016-10-03 19:18:15 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS MODIFIED="2011-02-10 11:12:31 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="16199797"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" MODIFIED="2016-10-03 19:18:06 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>231-8</PG>
<IDENTIFIERS MODIFIED="2011-02-10 11:12:31 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="15982856"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007a" MODIFIED="2016-10-03 19:18:34 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Engel RR, Bauml J, Davis JM</AU>
<TI>Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>1</NO>
<PG>183-91</PG>
<IDENTIFIERS MODIFIED="2011-02-10 11:12:31 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="16905632"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007b" MODIFIED="2016-10-03 19:18:29 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007b" TYPE="COCHRANE_REVIEW">
<AU>Leucht S, Kissling W, McGrath J</AU>
<TI>Lithium for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<PB>Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2014-10-13 16:01:24 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-10-13 16:01:24 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003834.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2007c" MODIFIED="2016-10-03 19:18:22 +0100" MODIFIED_BY="[Empty name]" NAME="Leucht 2007c" TYPE="COCHRANE_REVIEW">
<AU>Leucht S, McGrath J, White P, Kissling W</AU>
<TI>Carbamazepine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<PB>Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2014-10-13 16:01:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-10-13 16:01:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001258.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mallinckrodt-2004" MODIFIED="2016-10-26 09:56:43 +0100" MODIFIED_BY="[Empty name]" NAME="Mallinckrodt 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mallinckrodt CH, Watkin JG, Molenberghs G, Carroll RJ</AU>
<TI>Choice of the primary analysis in longitudinal clinical trials</TI>
<SO>Pharmaceutical Statistics</SO>
<YR>2004</YR>
<VL>3</VL>
<PG>161-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marvaha-2004" MODIFIED="2012-10-19 10:03:03 +0100" MODIFIED_BY="[Empty name]" NAME="Marvaha 2004" TYPE="JOURNAL_ARTICLE">
<AU>Marvaha S, Johnson S</AU>
<TI>Schizophrenia and employment? A review</TI>
<SO>Social Psychiatry and Psychiatric Epidemiology</SO>
<YR>2004</YR>
<VL>39</VL>
<PG>337-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2012-10-19 11:26:57 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials)</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>258</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIMH-1970" MODIFIED="2008-05-14 11:31:23 +0100" MODIFIED_BY="[Empty name]" NAME="NIMH 1970" TYPE="BOOK_SECTION">
<AU>National Institute of Mental Health</AU>
<TI>Clinical Global Impression</TI>
<SO>Manual for the ECDEU Assessment</SO>
<YR>1970</YR>
<EN>2nd</EN>
<ED>Guy W, Bonato RR</ED>
<PB>NIMH</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIMH-1991" MODIFIED="2013-05-16 15:01:44 +0100" MODIFIED_BY="[Empty name]" NAME="NIMH 1991" TYPE="BOOK">
<AU>Guy W</AU>
<TI>ECDEU Assessment Manual for Psychopharmacology</TI>
<SO>ECDEU Assessment Manual for Psychopharmacology, Revised</SO>
<YR>1991</YR>
<PB>National Institute of Mental Health</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>790-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pajonk-2005" MODIFIED="2014-11-29 14:22:04 +0000" MODIFIED_BY="[Empty name]" NAME="Pajonk 2005" TYPE="JOURNAL_ARTICLE">
<AU>Pajonk FG</AU>
<TI>Clinical trial design in schizophrenia: implications for clinical decisions</TI>
<SO>Current Opinion in Psychiatry</SO>
<YR>2005</YR>
<VL>18</VL>
<NO>6</NO>
<PG>692-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Palmer-2005" MODIFIED="2016-04-08 15:33:10 +0100" MODIFIED_BY="[Empty name]" NAME="Palmer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Palmer BA, Pankratz VS, Bostwick JM</AU>
<TI>The lifetime risk of suicide in schizophrenia: a reexamination</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>3</NO>
<PG>247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pantelis-1996" MODIFIED="2014-11-29 13:53:02 +0000" MODIFIED_BY="[Empty name]" NAME="Pantelis 1996" TYPE="JOURNAL_ARTICLE">
<AU>Pantelis C, Barnes TRE</AU>
<TI>Drug strategies and treatment-resistant schizophrenia</TI>
<SO>Australian and New Zealand Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>1</NO>
<PG>20-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perugi-2004" MODIFIED="2016-04-08 15:33:45 +0100" MODIFIED_BY="[Empty name]" NAME="Perugi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Perugi G, Ruffolo G</AU>
<TI>The empirical basis of the use of antiepileptics in the treatment of bipolar disorder</TI>
<SO>Clinical Neuropsychiatry</SO>
<YR>2004</YR>
<VL>1</VL>
<NO>3</NO>
<PG>165-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schooler-1993" NAME="Schooler 1993" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR, Keith SJ</AU>
<TI>Clinical research for the treatment of schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<PG>431-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2016-10-26 09:55:45 +0100" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al</AU>
<TI>Chapter 12: Interpreting results and drawing conclusions In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson M, Angus JW</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavia</SO>
<YR>1970</YR>
<VL>212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sommer-2012" MODIFIED="2016-04-08 15:34:55 +0100" MODIFIED_BY="[Empty name]" NAME="Sommer 2012" TYPE="JOURNAL_ARTICLE">
<AU>Sommer IE, Begemann MJH, Temmerman A, Leucht S</AU>
<TI>Pharmacological augmentation strategies for schizophrenia patients With insufficient response to clozapine: a quantitative literature review</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2012</YR>
<VL>38</VL>
<NO>5</NO>
<PG>1003-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srisurapanont-2004" MODIFIED="2014-10-13 16:02:11 +0100" MODIFIED_BY="[Empty name]" NAME="Srisurapanont 2004" TYPE="COCHRANE_REVIEW">
<AU>Srisurapanont M, Disayavanish C, Taimkaew K</AU>
<TI>Quetiapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<PB>Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2014-10-13 16:02:11 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-10-13 16:02:11 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000967.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stahl-2004" MODIFIED="2016-04-08 15:35:28 +0100" MODIFIED_BY="[Empty name]" NAME="Stahl 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stahl, SM, Grady, MM</AU>
<TI>A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation</TI>
<SO>Current Medicinal Chemistry</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>3</NO>
<PG>313-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2016-10-26 09:56:02 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="OTHER">
<AU>Sterne JAC, Egger M, Moher D (editors)</AU>
<TI>Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention<I>.</I> Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tharyan-2005" MODIFIED="2016-04-08 15:35:41 +0100" MODIFIED_BY="[Empty name]" NAME="Tharyan 2005" TYPE="COCHRANE_REVIEW">
<AU>Tharyan P, Adams CE</AU>
<TI>Electroconvulsive therapy for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PB>Wiley &amp; Sons</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2014-10-13 16:02:34 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2014-10-13 16:02:34 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000076.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tranulis-2006" MODIFIED="2016-04-08 15:36:12 +0100" MODIFIED_BY="[Empty name]" NAME="Tranulis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tranulis C, Mouaffak F, Chouchana L, Stip E, Gourevitch R, Poirier MF, et al</AU>
<TI>Somatic augmentation strategies in clozapine resistance - what facts?</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>1</NO>
<PG>34-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsuang-1978" MODIFIED="2012-10-19 10:03:56 +0100" MODIFIED_BY="[Empty name]" NAME="Tsuang 1978" TYPE="JOURNAL_ARTICLE">
<AU>Tsuang MT</AU>
<TI>Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1978</YR>
<VL>35</VL>
<PG>153-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>3-92</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="10982317"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-2001" NAME="Wahlbeck 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Tuunainen A, Ahokas A, Leucht S</AU>
<TI>Drop-out rates in randomised antipsychotic drug trials</TI>
<SO>Psychopharmacology</SO>
<YR>2001</YR>
<VL>155</VL>
<PG>230-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Xia-2009" MODIFIED="2011-02-10 11:12:33 +0000" MODIFIED_BY="[Empty name]" NAME="Xia 2009" TYPE="JOURNAL_ARTICLE">
<AU>Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al</AU>
<TI>Loss to outcomes stakeholder survey: the LOSS study</TI>
<SO>Psychiatric Bulletin</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>7</NO>
<PG>254-7</PG>
<CY>Sao Paulo</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-10-26 09:56:25 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Leucht-2004" NAME="Leucht 2004" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, White P, McGrath J, Kissling W</AU>
<TI>Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2004</YR>
<VL>65</VL>
<PG>177-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schwarz-2008" MODIFIED="2016-10-26 09:56:25 +0100" MODIFIED_BY="[Empty name]" NAME="Schwarz 2008" TYPE="COCHRANE_REVIEW">
<AU>Schwarz C, Volz A, Li C, Leucht S</AU>
<TI>Valproate for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2016-10-03 18:40:45 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-10-03 18:40:45 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004028.pub3"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2016-09-13 06:45:23 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-11-07 14:13:53 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-11-07 14:13:53 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casey-2003">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: double</P>
<P>Duration: 28 days (preceded by wash-out period of 3 times the mean elimination half-life of the antipsychotic)</P>
<P>Design: parallel</P>
<P>Country: USA<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: DSM-IV schizophrenia</P>
<P>n = 249*</P>
<P>Sex: 184 M, 58 F*</P>
<P>Age: ~ 39 years</P>
<P>History: treated with antipsychotic at the time of enrolment (n = 214)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine: starting dose 5 mg/d, increased to 10mg/d on day 3 and to target dose of 15 mg/d on day 6; n = 65*<BR/>2. Risperidone: starting dose 2 mg/d, increased to 4 mg/don day 3 and to target dose of 6 mg/d on day 6; n = 60*<BR/>3. Olanzapine + divalproex: olanzapine was titrated as described in 1. Divalproex starting dose 15 mg/d, titrated to clinical response (maximum 30 mg/d); n = 66*<BR/>4. Risperidone + divalproex: risperidone was titrated according to 2. and divalproex according to 3; n = 58*</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>Clincally significant response: important change (PANSS reduction &gt; 20%)<BR/>Leaving the study early: acceptability/tolerability of treatment</P>
<P>Clinical response: mental state (PANSS total), positive symptoms (PANSS subscale)<BR/>
</P>
<P>Adverse events: at least one event, various events</P>
<P>Unable to use:<BR/>Clinical response: mental state - BPRS (no data), aggression/agitation - PANSS-EC (data skewed)<BR/>Adverse events: SAS, AIMS, BAS scores (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]">
<P>*The 2 groups with combination therapy and the 2 groups with monotherapy were considered to be one (p 185, Table 1)<BR/>NB. In the original report 7 participants were not included in the ITT analyses due to missing on-treatment PANSS score (n = 4) and randomisation at 2 sites (only the second randomisation was excluded; n = 3)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-26 10:23:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Casey-2009">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: double</P>
<P>Duration: 12 weeks (preceded by wash-out period: 1-5 days)<BR/>Design: parallel<BR/>
</P>
<P>Country: USA<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:23:41 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: current DSM-IV-TR diagnosis of schizophrenia, confirmed by a Structured Clinical Interview for DSM-IV-TR (SCID)*</P>
<P>n = 402</P>
<P>Sex: 304 M, 89 F***.</P>
<P>Age: 18 &#8211; 65 years (mean: 40.0 ± 10.52 years)**<BR/>History: mean age of first diagnosis 24.2 ± 8.3 years</P>
<P>Setting: multi-centre, people with schizophrenia hospitalised for a minimum of 14 d during the acute phase of the study and could be discharged (per investigator discretion) anytime after day 14</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine + placebo: fixed dose of olanzapine, mean dose = 15 mg/d; n = 103</P>
<P>2. Olanzapine + divalproex ER: fixed dose of olanzapine, mean dose = 15 mg/d; mean dose of divalproex ER = 2828 mg with a flexible dose not exceeding 35 mg/d; n = 99</P>
<P>3. Risperidone + placebo: fixed dose of risperidone, mean dose = 6 mg/d; n = 101</P>
<P>4. Risperidone + divalproex ER: fixed dose of risperidone, mean dose = 6 mg/day, mean dose of divalproex ER = 2712 mg with a flexible dose not exceeding 35 mg/day; n = 99</P>
<P>Co-medication: lorazepam, propranolol hydrochloride, and benztropine mesylate could be used as adjunctive medications, but were not to be used prophylactically</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: acceptability/tolerability of treatment</P>
<P>Clinical response: global state (CGI severity and improvement scales), mental state (PANSS total, BPRS total), positive symptoms, negative symptoms, general pathology (PANSS subscales)<BR/>
</P>
<P>Unable to use:&#8232;</P>
<P>Adverse events: EPS, SAS, BAS, and AIMS (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:23:41 +0100" MODIFIED_BY="[Empty name]">
<P>* In the antipsychotic monotherapy group, 172 out of 198 participants (87%) were diagnosed as paranoid type. In the valproate group, 166 out of 195 participants (85%) were diagnosed as paranoid type</P>
<P>** Monotherapy: mean = 39.9 years (SD = 10.49 yrs). Combination: mean = 40.1 years (SD = 10.54 years)</P>
<P>*** Monotherapy: 156 M, 42 F. Combination: 148 M, 47 F</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Citrome-2007">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: single</P>
<P>Duration:  8 weeks</P>
<P>Design: parallel</P>
<P>Country: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia with poor impulse control, aggressive behaviour and/or hostility</P>
<P>n = 33</P>
<P>Sex: 31 M, 2 F</P>
<P>Age: mean 39.6 yrs ± 10.5 years<BR/>History: mean age of onset 16.4 ± 4.6 years</P>
<P>Settings: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>1. Risperidone monotherapy: target dose range of 4&#8211;6 mg/d within 7&#8211;14 d; n = 16</P>
<P>2. Risperidone + valproate: target risperidone dose 4&#8211;6 mg/d within 7&#8211;14 d; target valproate plasma level 50-100 mg/ml, usually achieved with dose 1000&#8211;1500 mg/d; n = 17</P>
<P>Co-medication: no other antipsychotics or mood stabilisers permitted. Benztropine (if needed). Lorazepame (if needed) for agitation and insomnia: for weeks 1-3, max 6 mg/d, for weeks 4&#8211;8, up to 4 doses of lorazepam in any week - evidence of treatment failure and study participation discontinued</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: acceptability/tolerability of treatment</P>
<P>Adverse events: various events</P>
<P>Unable to use:</P>
<P>Clinical response: PANSS, PANSS Hostility, BIS and BDHI (no usable mean and SDs), CGI, NOSIE (results not reported) Overt aggression scale (OAS) (comparison between completers and non-completers, not between study arms)</P>
<P>Adverse events: ESRS score (results not reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>NB. Initially, participants were eligible only if they had at least 2 aggressive incidents during the 2 weeks preceding their transfer to research unit and continued to exhibit aggression during the first 2 weeks after transfer. Aggressive behaviour was defined as at least 2 additional aggressive incidents or &#8805; 4 on PANSS &#8216;Hostility&#8217; item or &#8216;Poor Impulse Control&#8217; item.&#8221; Because of problematic study enrolment (only 16 participants): study entry criteria revised to include participants not exhibiting aggression but scored &#8805; 3 on at least one of the PANSS &#8216;Hostility&#8217;, 'Impulsivity&#8217;, &#8216;Excitement&#8217;, or &#8216;Uncooperativeness&#8217; items</P>
<P>For participants already receiving valproate and antipsychotic drugs other than risperidone, risperidone and valproate were given for 4 weeks before randomisation</P>
<P>For participants already receiving valproate at study entry who were randomised to combination treatment continued valproate at the same dose/plasma level for the remainder of the study</P>
<P>Participants already receiving valproate at study entry who were randomised to RMon, valproate tapered down by 50% every 48 hours</P>
<P>All participants received valproate delayed release except one who received extended release</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-26 10:24:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dose-1998">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: double<BR/>&#8232;Duration: 28 d (followed by 1 week continuation of antipsychotic medication alone)</P>
<P>Design: not reported</P>
<P>Country: Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: DSM-III schizophrenia and schizoaffective disorder</P>
<P>n = 42</P>
<P>Sex: no information</P>
<P>Age: no information</P>
<P>History: no history of epileptic seizures, no ECG abnormalities<BR/>
</P>
<P>Setting: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:24:14 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol + valproate: haloperidol starting dose 3 mg/d with possible increase by 3 mg/d every fifth day, valproate starting dose 300 mg/d, target plasma level 60-90 µg/ml; n = 20<BR/>2. Haloperidol + placebo: haloperidol starting dose 3 mg/d with possible increase by 3 mg/d every fifth day; n = 22. Valproate and placebo discontinued abruptly after 28 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: acceptability/tolerability of treatment</P>
<P>Clinical response: mental state (BPRS total)</P>
<P>Adverse events: various events<BR/>
</P>
<P>Unable to use:</P>
<P>Use of additional medication: mean dose of antiparkinsonian and chlorprothixene medication (data skewed)</P>
<P>Adverse events: SAS (data skewed)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-26 10:24:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fisk-1987">
<CHAR_METHODS MODIFIED="2016-10-26 10:24:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: double</P>
<P>&#8232;Duration: 12 weeks (6 week baseline period)</P>
<P>Design: parallel</P>
<P>Country: UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic functional psychotic illness, all with at least 6 months of pre-trial tardive dyskinesia according to Barnes and Kidger Rating Scale, maintenance antipsychotic treatment &gt; 1 year</P>
<P>&#8232;n = 62*</P>
<P>Sex: no information</P>
<P>Age: &lt; 70 years</P>
<P>History: physically fit, no liver disease, and no acute or chronic organic brain syndromes</P>
<P>Settings: multi-centre</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]">
<P>1. Antipsychotic medication + valproate: constant antipsychotic dose, valproate dose stepwise increased to 1500 mg/d or 1200 mg/d according to weight; n = 29*<BR/>2. Antipsychotic medication + placebo: constant antipsychotic dose; n = 29*</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change (Krawiecka scale)</P>
<P>Leaving the study early: acceptability/tolerability of treatment<BR/>Adverse events: various events<BR/>
</P>
<P>Unable to use:<BR/>Adverse events: SAS score (data skewed)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]">
<P>*During a 6-week baseline period all participants received a stable dose of antipsychotic drugs only. 4 participants left the study during this phase and were not considered in the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glick-2009">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation:  randomised</P>
<P>Blinding: double</P>
<P>Duration:  12 weeks</P>
<P>Design: not reported</P>
<P>Country: USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: DSM-IV schizophrenia or schizoaffective disorder</P>
<P>n = 24*</P>
<P>Sex: no information</P>
<P>Age: adults (no further details provided)</P>
<P>Settings: outpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]">
<P>1. Antipsychotic drugs + lamotrigine: flexible dose of lamotrigine, weeks 1&#8211;6: gradually increase dose from 25 mg/d to target dose of 150 mg/d. Weeks 7-9: between 100 mg/d and 400 mg/d according to clinical judgement of the clinician. Weeks 9&#8211;12: study medications discontinued in a stepwise reduction; n = 8*</P>
<P>2. Antipsychotic drugs + divalproex sodium: flexible dose of divalproex sodium, weeks 1&#8211;6: gradually increase dose from 250 mg/d to target dose of 1500 mg/d. Weeks 7-9: between 1000 mg/d and 4000 mg/d according to clinical judgement of the clinician. Weeks 9-12, study medications discontinued in a stepwise reduction; n = 8</P>
<P>3. Antipsychotic drugs + placebo: n = 8 
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]">
<P>Clincally significant response: important change</P>
<P>Clinical response: depression (CDS)</P>
<P>Adverse events: various events<BR/>
</P>
<P>Unable to use:</P>
<P>Leaving the study early: acceptability/tolerability of treatment (no data for each study arm)</P>
<P>Clinical response: demoralisation (no usable data)</P>
<P>Adverse events: EPS: SAS, BAS, AIMS scores (no data)</P>
<P>Quality of life: Lehman quality of life improvement scale (no data)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]">
<P>*Data from intervention group 1 were not used for this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2007">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open</P>
<P>Duration: 2 weeks</P>
<P>Design: Parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia, with excitement and agitation symptoms</P>
<P>n = 60</P>
<P>Sex: 40 M, 20 F</P>
<P>Age: range 18-60 years, mean 34.5 ± 2.4 years</P>
<P>History: duration of illness (total) - mean 4.75 ± 0.6 years</P>
<P>Setting: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. Magnesium valproate + quetiapine: valproate 0.5-1 g/d, mean dose 0.8 g ± 5.7 mg/d, maximum 1.0 g/d, quetiapine 100-800 mg (517 ± 4 mg/d); n = 30</P>
<P>2. Haloperidol: IM. injection, 5-30 mg/d (15.8 ± 3.8 mg/d); n = 30</P>
<P>Co-medication: 11 participants in valproate group given IM injection of clonazepam 1-2 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change (PANSS reduction)</P>
<P>Clinical response: aggression/agitation (PANSS subscale)<BR/>Use of additional medication<BR/>
</P>
<P>Unable to use:&#8232;</P>
<P>Leaving the study early: (no information provided)</P>
<P>Clinical response: global state - CGI (data not reported)</P>
<P>Adverse events: TESS (data not reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate group &amp; monotherapy group do not differ significantly in demographic data (P &gt; 0.05)</P>
<P>Quetiapine initial dose 100 mg/day; valproate initial dose 0.5 g/day; haloperidol days 1-3, 5-10 mg/d, and days 4-7, 10-30 mg/d</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hesslinger-1999">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: single (rater blind)</P>
<P>Duration: 4 weeks (4-day wash-out)</P>
<P>Design: not reported</P>
<P>Country: Germany<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: ICG-10 schizophrenia and schizoaffective disorder, acute exacerbation within the last 7 days</P>
<P>n = 27*</P>
<P>Sex: no information</P>
<P>Age: no information<BR/>History: no evidence of serious medical conditions, substance abuse, organic psychosis, use of depot neuroleptics, antiepileptic drugs or serotonin reuptake inhibitors 3 months prior to trial</P>
<P>Setting: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol: mean dose 15.5 mg/d; n = 9<BR/>2. Haloperidol + valproate: haloperidol mean dose 15.5 mg/d, valproate dose 757.1 mg/d, target plasma level 50-100 µg/ml; n = 9<BR/>3. Haloperidol + carbamazepine: haloperidol mean dose 15.5 mg/day, carbamazepine mean dose 567.3 mg/day, target plasma level 6-12 µg/ml; n = 9*</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: acceptability/tolerability of treatment</P>
<P>Clinical response: mental state (IMPS), positive symptoms (PANSS subscale)</P>
<P>Unable to use:<BR/>Use of additional medication: (skewed data)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]">
<P>*Data from intervention group 3 were not used for this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jia-2007">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration: 4 weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:35 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: ICD-10 schizophrenia</P>
<P>n = 80</P>
<P>Sex: male only</P>
<P>Age: 18-50 years, mean 38.9 ± 11.0 years</P>
<P>History: duration of illness total, range 10-25 years, mean 15.3 ± 9.1 years<BR/>
</P>
<P>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:35 +0100" MODIFIED_BY="[Empty name]">
<P>1. Sodium valproate + clozapine: valproate 400-800 mg/d, clozapine dosage unclear; n = 40</P>
<P>2. Clozapine alone: dosage not reported; n = 40</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical response: mental state (PANSS total)<BR/>Adverse events: various events<BR/>
<BR/>
</P>
<P>Unable to use:<BR/>Clinical response: positive symptoms, negative symptoms - PANSS subscales (skewed data)<BR/>Leaving the study early (no information provided)</P>
<P>Adverse events: TESS scores (no means and SDs reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-04 11:14:17 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-2009">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration: 6 weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia (at least 2 of the 5 PANSS subscale scores &gt; or = 4)</P>
<P>n = 120</P>
<P>Sex: 64 M, 56 F</P>
<P>Age: 33.92 ± 11.06 years<BR/>History: mean duration of illness 1.73 ± 0.93 years<BR/>
</P>
<P>Setting: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. Magnesium valproate + routine antipsychotics: valproate magnesium flexible dose &#8804; 1.5 g/d, mean 1.05 ± 0.57 g/d; antipsychotic drugs titrated to treatment dose within 2 weeks. Clozapine mean 275 ± 56 mg/d, risperidone mean 4.1 ± 0.98 mg/d, quetiapine mean 670 ± 120 mg/d, and olanzapine mean 12.4 ± 7.8 mg/d; n = 57</P>
<P>2. Routine antipsychotics: antipsychotic drugs titrated to treatment dose within 2 weeks. Clozapine mean 328 ± 78 mg/d, risperidone mean 4.9 ± 0.99 mg/d, quetiapine mean 710 ± 150 mg/d, and olanzapine mean 14 ± 8.6 mg/d; n = 63</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change (PANSS reduction)</P>
<P>Leaving the study early: acceptability/tolerability of treatment<BR/>Clinical response: mental state (PANSS total), positive symptoms, aggression/agitation, general pathology (PANSS subscales)<BR/>
</P>
<P>Adverse events: various events</P>
<P>Unable to use:<BR/>Clinical response: negative symptoms - PANSS subscale (data skewed)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]">
<P>Before antipsychotic drugs and valproate were given, participants were first given an IM injection of clonazepam</P>
<P>Dosage for antipsychotic drugs was adjusted according to clinical conditions, so that in the end the mean dosage used for valproate group was lower than mean dosage used for monotherapy group, but not sure if significant.</P>
<P>Valproate magnesium extended-release tablets were given, initial dose 0.5 g/d, 0.25 g/tablet</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2008">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration:  2 weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: DSM-IV schizophrenia, with obvious excitement<BR/>
</P>
<P>n = 40</P>
<P>Sex: 22 M, 18 F</P>
<P>Age: mean 32.5 ± 4.2 years<BR/>History: mean duration of illness 6.6 ± 0.8 years</P>
<P>Settings: inpatient                                                       </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine + valproate magnesium group: olanzapine flexible dose &#8805; 10 mg/d and &#8804; 20 mg/d. Valproate flexible dose &#8805; 0.5 g/d and &#8804; 1.5 g/d; n = 20</P>
<P>2. Olanzapine monotherapy group: olanzapine flexible dose &#8805; 10 mg/d and &#8804; 20 mg/d; n = 20</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change (PANSS reduction &#8805; 50%)</P>
<P>Clinical response: mental state (PANSS total)<BR/>
<BR/>
</P>
<P>Unable to use:</P>
<P>Leaving the study early: (no data reported)</P>
<P>Adverse events: (no data reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-02-04 11:22:29 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2009">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration:  4 weeks</P>
<P>Design: not reported</P>
<P>Country: China<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia, with poor impulse control</P>
<P>n = 56</P>
<P>Sex: 34 M 22 F</P>
<P>Age: range 16&#8211;63 years, mean 31.8 ± 7.3 years<BR/>History: mean duration of illness 3.6 ± 4.0 years</P>
<P>Settings: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>1.  Aripiprazole + valproate group: aripiprazole titrated to target dose within two weeks, &#8804; 30 mg/d. Valproate titrated to 800-1200 mg/d within 1 week; n = 28</P>
<P>2. Aripiprazole monotherapy group: aripiprazole titrated to 20-30 mg/d; n = 28</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical response: negative symptoms (BPRS subscale), aggression/agitation (MOAS, BPRS subscale), depression (BPRS subscale)</P>
<P>Adverse events: various events<BR/>
<BR/>
</P>
<P>Unable to use:</P>
<P>Leaving the study early (no information provided)</P>
<P>Adverse events: TESS scores (no means and SDs reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>No significant differences in demographic data of valproate group &amp; monotherapy group, P &gt; 0.05</P>
<P>Aripiprazole initial dose 5 mmg/d, valproate initial dose 400 mg/d</P>
<P>Valproate group: once aripiprazole titrated to maximum 30 mg/d and valproate titrated to 800-1200mg/d, they were maintained on these doses as long as possible</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liang-2004">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration: 4 weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia</P>
<P>n = 42</P>
<P>Sex: 31 M, 11 F</P>
<P>Age: mean 37.85 ± 11.8 years<BR/>History: mean duration of illness 5.3 ± 4.6 years</P>
<P>Setting: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>1. Sodium valproate + routine antipsychotic medication: sodium valproate dosage = 600 mg/d, antipsychotic drugs mean dose 385 ± 119 mg/d; n = 21</P>
<P>2. Routine antipsychotic: antipsychotic drugs mean dose 390 ± 120 mg/d; n = 21</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change (PANSS reduction)</P>
<P>Clinical response: mental state (PANSS total), positive symptoms, general pathology (PANSS subscales)</P>
<P>Adverse events: various events</P>
<P>Unable to use:&#8232;</P>
<P>Clinical response: mental state - PANSS negative subscale (skewed data)</P>
<P>Leaving the study early (no information provided)</P>
<P>Adverse events: TESS score no means and SDs reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Another paper (<LINK REF="STD-Ma-2010" TYPE="STUDY">Ma 2010</LINK>) with identical data as <LINK REF="STD-Liang-2004" TYPE="STUDY">Liang 2004</LINK> was not included in the data analysis, the 2 references were combined and letters for clarification were sent to both study authors</P>
<P>Valproate group &amp; monotherapy group were not significantly different in sex, age, duration of illness and PANSS score (P &gt; 0.05)</P>
<P>Every participant received only one antipsychotic drug. In total there were 12 chlorpromazine, 10 clozapine, 10 risperidone, 4 perphenazine, and 6 haloperidol; participants continued with the same antipsychotic drug as they were given before study entry</P>
<P>Valproate group &amp; monotherapy group did not differ significantly in the mean dose of antipsychotic drugs (P &gt; 0.05)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-26 10:26:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2003">
<CHAR_METHODS MODIFIED="2016-10-26 10:25:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration: 8 weeks (wash-out period: 3-7 days)</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:26:05 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia</P>
<P>n = 60</P>
<P>Sex: male only</P>
<P>Age: not stated, but likely to be adult, as their illness onset age is reported as 25 ± 5.27 years<BR/>History: mean duration of illness: 14.73 ± 5.59 years</P>
<P>Setting: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:26:07 +0100" MODIFIED_BY="[Empty name]">
<P>1. Sodium valproate + clozapine: valproate fixed dose of 600 mg/day. n = 30</P>
<P>2. Clozapine: dosage unclear. n = 30</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:26:11 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: acceptability/tolerability of treatment</P>
<P>Clinical response: mental state (BPRS total)</P>
<P>Unable to use:</P>
<P>Adverse events: no information provided</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:26:13 +0100" MODIFIED_BY="[Empty name]">
<P>All participants took clozapine+placebo during wash-out</P>
<P>No information about the dosage of clozapine provided</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-26 10:26:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2007a">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: double</P>
<P>Duration: 3 weeks</P>
<P>Design: not reported</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia</P>
<P>n = 36</P>
<P>Sex: 29 M, 7 F</P>
<P>Age: mean 36.06 ± 11.72 years</P>
<P>History: mean duration of illness 8.32 ± 8.21 years</P>
<P>Settings: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>1. Antipsychotic drugs + sodium valproate group: continue with previous antipsychotics; valproate 0.6-1.2 g/d (0.2 g/capsule, 3-6 capsules/d); n = 19</P>
<P>2. Antipsychotic + starch placebo monotherapy group: continue with previous antipsychotics; placebo 3-6 capsules/d; n = 17</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:41 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early</P>
<P>Clinical response: mental state (BPRS total, BPRS lack of energy subscale), aggression/agitation (important change MOAS, BPRS hostility subscale), depression (BPRS anxiety and depression subscale)<BR/>Adverse events: various events</P>
<P>Unable to use: aggression/agitation - MOAS endpoint data (no mean and SDs given)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:26:44 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate sodium and placebo starch were placed into identical capsules A and B by staff</P>
<P>Standard for people leaving the study early: "still high danger of aggression after 10 days of medication and difficult to manage within the ward, stop medication and treat as no effect"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lu-2006">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration: six weeks</P>
<P>Design: not reported</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia (CCMD-3) and schizoaffective disorder with excitement and agitation (schizophrenia: n = 78, schizoaffective disorder: n = 12)</P>
<P>n = 90</P>
<P>Sex: 78 M, 12 F</P>
<P>Age: mean 34.8 ± 13.8 years</P>
<P>Setting: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]">
<P>1. Sodium valproate + routine antipsychotic mediation: atypical antipsychotics titrated to target dose within 7-10 days, mean dose: clozapine 308 ± 54 mg/d, olanzapine 12.6 ± 5.9 mg/d, risperidone 4.4 ± 0.81 mg/d, quetiapine 786 ± 221 mg/d; Depakine titrated to 1-1.5 g/d within 5 days, mean dose 1.01 ± 0.46 g/d; n = 43</P>
<P>2. Routine antipsychotic medication: atypical antipsychotics titrated to target dose within 7-10 days, mean dose: clozapine 366 ± 71 mg/d, olanzapine 15.2 ± 8.8 mg/d, risperidone 4.9 ± 0.80 mg/d, quetiapine 842 ± 263 mg/d; n = 47</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change</P>
<P>&#8232;Leaving the study early: acceptability/tolerability of treatment</P>
<P>Clinical response: mental state (BPRS total), aggression/agitation (PANSS-EC sub scale)</P>
<P>Adverse events: various events<BR/>
<BR/>
</P>
<P>Unable to use:</P>
<P>Adverse events: TESS scores (no means and SDs reported)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate group and monotherapy group did not differ significantly in sex, age, schizophrenia subtypes (P &gt; 0.05)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pan-2010">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:43 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration:  8 weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:43 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia</P>
<P>n = 68</P>
<P>Sex: 28 M, 40 F</P>
<P>Age: range 21-55 years, mean 32.4 ± 6.5 years</P>
<P>History: duration of illness: range: 5-23 years, mean 11.2 ± 6.4 years</P>
<P>Settings: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:43 +0100" MODIFIED_BY="[Empty name]">
<P>1. Clozapine + sodium valproate group: clozapine: flexible dose of 400&#8211;700 mg/d; valproate: fixed dose of 800 mg/d; n = 34</P>
<P>2. Clozapine monotherapy group: clozapine: flexible dose of 400&#8211;700 mg/day; n = 34</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:43 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change (PANSS reduction &#8805; 50%)</P>
<P>Clinical response: mental state (PANSS total) positive symptoms, negative symptoms, general pathology (PANSS subscales)</P>
<P>Adverse events: various events<BR/>
<BR/>Unable to use:<BR/>
</P>
<P>Leaving the study early (no information provided)</P>
<P>Adverse events: TESS scores (no means and SDs reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:44 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate group &amp; monotherapy group no significant differences in demographic characteristics</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shi-2010">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration: 2 weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:45 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia, with excitement symptoms</P>
<P>n = 64</P>
<P>Sex: total, 37 M, 27 F</P>
<P>Age: total, range 18&#8211;60 years, mean 31.3 ± 4.4 years</P>
<P>History: mean duration of illness 0.1&#8211;10 years</P>
<P>Setting: inpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:45 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine + magnesium valproate group: oral intake, olanzapine mean dose 10 ± 2.5 mg/d, valproate mean dose 1.25 ± 0.25 g/d; n = 33</P>
<P>2. Haloperidol monotherapy group: IM injection, haloperidol mean dose 15 ± 2.5 mg/d; n = 31</P>
<P>Co-medication: benzhexol used for EPS but not used prophylactically</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:45 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change (PANSS reduction &#8805; 50%)</P>
<P>Clinical response: mental state (PANSS total), aggression/agitation (PANSS-EC subscale)</P>
<P>Adverse events: at least one adverse event</P>
<P>Unable to use:</P>
<P>Leaving the study early (no information provided)</P>
<P>Adverse events: TESS (no means and SDs reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:45 +0100" MODIFIED_BY="[Empty name]">
<P>Olanzapine initial dose 5 mg/d; valproate magnesium initial dose 0.5 g/d, haloperidol initial dose 5 mg/d.</P>
<P>Valproate magnesium extended-release tablets used</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005a">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no further description</P>
<P>Blinding: open label</P>
<P>Duration: 4 weeks</P>
<P>Design: not reported</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMN-3 schizophrenia, with aggressive behaviours according to scores of MOAS &gt; = 4</P>
<P>n = 60.</P>
<P>Sex: 35 M, 25 F</P>
<P>Age: total range 18-56 years, mean 32.2 ± 7.3 years</P>
<P>History: mean duration of illness</P>
<P>Settings: inpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]">
<P>1. Antipychotics + magnesium valproate: magnesium valproate starting dose 400 mg/d, increased to 800-1200 mg/d after 7 days; antipsychotic drugs same as before study entry; n = 30<BR/>2. Antipychotics + placebo: antipsychotic drugs same as before study; n = 30</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical response: mental state (BPRS total) negative symptoms (BPRS subscale), aggression/agitation (MOAS, BPRS subscale), depression (BPRS subscale)</P>
<P>Adverse events: at least one adverse event, various events</P>
<P>Unable to use:</P>
<P>Leaving the study early: acceptability/tolerability of treatment (no information provided)</P>
<P>Adverse events: TESS score (not reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]">
<P>No information about blinding provided, assume open-label</P>
<P>Valproate group &amp; monotherapy group no significant differences in demographic data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2009">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration:  8 weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia, treatment-resistant schizophrenia</P>
<P>n = 60</P>
<P>Sex: 35 M, 25 F</P>
<P>Age: mean 30.95 ± 7.26 years</P>
<P>History: mean duration of illness 8.08 ± 4.63 years</P>
<P>Settings: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]">
<P>1. Aripiprazole + magnesium valproate group: aripiprazole initial dose 5 mg/d, &#8804; 20 mg/day; valproate magnesium extended-release tablets initial dose 250 mg/d, &#8804; 1000 mg/d; n = 30</P>
<P>2. Aripiprazole monotherapy group: aripiprazole initial dose 5 mg/d, &#8804; 20 mg/d; n = 30</P>
<P>Co-medication: benzodiazepine could be given; no other antipyschotics or electroconvulsive therapy given</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change (PANSS reduction &#8805; 50%)</P>
<P>Clinical response: mental state (PANSS total), positive symptoms, negative symptoms, general pathology (PANSS subscales)</P>
<P>Adverse events: TESS</P>
<P>Unable to use:</P>
<P>Leaving the study early: acceptability/tolerability of treatment (no information provided)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate group &amp; monotherapy group had no significant differences in demographic data and PANSS score (P &gt; 0.05)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2010">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:49 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration:  8 weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:49 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia, with impulsive and aggressive behaviours</P>
<P>n = 60</P>
<P>Sex: 40 M, 20 F</P>
<P>Age: mean 38.35 ± 10.82 years</P>
<P>History: mean duration of illness 5.75 ± 10.8 years</P>
<P>Settings: inpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:49 +0100" MODIFIED_BY="[Empty name]">
<P>1.  Antipsychotic drugs + valproate group: antipsychotic drugs: mean 345 ± 108 mg; valproate: 600 mg/d; n = 30</P>
<P>2. Antipsychotic monotherapy group: antipsychotic drugs: mean 360 ± 110 mg; n = 30</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change (PANSS reduction &#8805; 60%)</P>
<P>Clinical response: mental state (PANSS total), positive symptoms, negative symptoms, general pathology (PANSS subscales)</P>
<P>Adverse events: at least one event, various events<BR/>
<BR/>
</P>
<P>Unable to use:</P>
<P>Leaving the study early (no information provided)</P>
<P>Adverse events: TESS scores measured (no means and SDs reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate group &amp; monotherapy group not significantly different in sex, age, duration of illness &amp; PANSS total score, P &gt; 0.05</P>
<P>Every participant only received one antipsychotic drug (continued with the drug and dose used before study entry, in total 9 risperidone, 4 quetiapine, 18 chlorpromazine, 12 clozapine, 11 perphenazine, and 6 haloperidol, drug dosage converted to chlorpromazine equivalent dose</P>
<P>Valproate group &amp; monotherapy group antipsychotic dosage not significantly different (P &gt; 0.05)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wassef-2000">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: double</P>
<P>Duration: 21 days</P>
<P>Design: parallel</P>
<P>Country: USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: chronic schizophrenia (Research Diagnostic Criteria)</P>
<P>n = 12</P>
<P>Sex: 7 M, 5 F</P>
<P>&#8232;Age: mean ~ 28,6 years</P>
<P>&#8232;History: discontinued standard oral antipsychotic drugs &gt; 3 weeks prior to trial, discontinued depot neuroleptics &gt; 5 weeks prior to trial, no substance abuse, no seizures, normal EEG</P>
<P>Setting: inpatients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>1. Haloperidol + valproate: haloperidol starting dose 10 mg/d, increased to 15 mg/d after 3 days, valproate dose adjusted to target plasma level 75-100 µg/ml; n = 5<BR/>2. Haloperidol + placebo: haloperidol starting dose 10 mg/d, increased to 15 mg/d after 3 days; n = 7</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: acceptability/tolerability of treatment</P>
<P>Clinical response: mental state (BPRS total)<BR/>
</P>
<P>Unable to use:</P>
<P>Clinical response: global state - CGI (only P values reported); negative symptoms - SANS (skewed data)<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xie-2011">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration: six weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:52 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia</P>
<P>n = 70</P>
<P>Sex: 41 M, 29 F</P>
<P>Age: mean 30.13 ± 5.29 years</P>
<P>History: mean duration illness (valproate group: 4.25 ± 4.05 years, monotherapy group: 4.30 ± 3.85 years)</P>
<P>Settings: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:52 +0100" MODIFIED_BY="[Empty name]">
<P>1. Aripiprazole + magnesium valproate group: aripiprazole initial dose 5 mg/d, &#8804; 20 mg/d; magnesium valproate extended-release tablets initial dose 250 mg/d, &#8804; 1000 mg/d; n = 35</P>
<P>2. Aripiprazole monotherapy group: aripiprazole initial dose 5 mg/d, &#8804; 20 mg/d; n = 35</P>
<P>Co-medication: benzodiazepine given when necessary, no other neuroleptics and electroconvulsive therapy used</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:52 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical response: mental state (PANSS total), positive symptoms, negative symptoms (PANSS subscales), aggression/agitation (MOAS), general pathology (PANSS subscale)</P>
<P>Adverse events: various events<BR/>
<BR/>
</P>
<P>Unable to use:</P>
<P>Leaving the study early: acceptability/tolerability of treatment (no information provided)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate group &amp; monotherapy group do not differ significantly in demographic data and PANSS, MOAS scores (P &gt; 0.05)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yao-2010">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration:  8 weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 and ICD-10 schizophrenia</P>
<P>n = 62</P>
<P>Sex: 33 M, 29 F</P>
<P>Age: mean 26.8 ± 9.2 years</P>
<P>Settings: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>1. Risperidone + magnesium valproate group: risperidone initial dose 1 mg/d, titrated to target flexible dose of 4-6 mg/d within 7-15 days, mean 4.98 ± 1.07 mg/d; valproate 0.5 g/d; n = 31</P>
<P>2. Risperidone monotherapy group: risperidone initial dose 1 mg/d, titrated to flexible dose of 4-6 mg/d; n = 31</P>
<P>Co-medication: benzodiazepine drugs (alprazolam tablets) were given orally to participants with poor sleep quality; no other antipsychotics were used</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical significant response: important change (PANSS reduction &gt; 60%)</P>
<P>Clinical response: mental state (PANSS total)</P>
<P>Adverse events: various events<BR/>
</P>
<P>Unable to use:<BR/>Leaving the study early: acceptability/tolerability of treatment (no information provided)</P>
<P>Adverse events: TESS scores (no means and SDs reported)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol was forbidden during treatment</P>
<P>Food intake was the same as before treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yin-2004">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:55 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: double (participants and researchers did not know what kind of medication given, however unclear if raters blind as rating completed by 6 experienced psychiatrists)</P>
<P>Duration: 6 weeks</P>
<P>Design: not reported</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:55 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia, with tardive dyskinesia according to scores of AIMS great than 3 (&gt; = 3) at least one item, or greater than 2 (&gt; = 2) at least two items</P>
<P>n = 80</P>
<P>Sex: all male</P>
<P>&#8232;Age: mean 44.5 ± 7.5 years<BR/>History: mean duration of illness 22.5 ± 7.5 years</P>
<P>Setting: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:55 +0100" MODIFIED_BY="[Empty name]">
<P>1. Antipsychotics + valproate: antipsychotics mean dose 324 (SD = 141) mg/d, valproate dose 0.6 g per day at first week, it increased to 1.2 g per day after 4 weeks; n = 40<BR/>2. Antipsychotics + placebo: antipsychotics mean dose 356 (SD = 120) mg/d, placebo initial dose 0.2 g x 3 times/d, after 4 weeks increased to 0.4 g x 3 times/d for 2 weeks if no severe adverse events; n = 40</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:55 +0100" MODIFIED_BY="[Empty name]">
<P>Leaving the study early: acceptability/tolerability of treatment<BR/>
</P>
<P>Adverse events: blood count changes, tardive dyskinesia (AIMS)<BR/>
<BR/>
</P>
<P>Unable to use:</P>
<P>Clinical response: mental state - BPRS (results not reported)</P>
<P>Adverse events: TESS score measured but no means and SDs reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>This study was purposed for the treatment of tardive dyskinesia</P>
<P>Participants received the same type and dosage of antipsychotic drugs as before study entry</P>
<P>All antipsychotic drug dosage converted to chlorpromazine equivalent dose</P>
<P>Valproate sodium and placebo (starch) were put into identical oblique capsules and labelled as I and II respectively by researchers</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2007">
<CHAR_METHODS MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blinding: open label</P>
<P>Duration: 8 weeks</P>
<P>Design: parallel</P>
<P>Country: China</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: CCMD-3 schizophrenia, with psychomotor excitement symptoms</P>
<P>n = 60</P>
<P>Sex: no information provided</P>
<P>Age: range 17-55 years, mean: 37.2 ± 12.8 years</P>
<P>History: mean duration of illness 10.0 ± 3.5 years</P>
<P>Settings: inpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>1. Risperidone + Depakine group: risperidone: titrated to flexible dose 4.6 ± 2.4 mg/d; Depakine: titrated to flexible dose 1.6 ± 0.4 g/d, &#8804; 2.0 g/d; n = 30</P>
<P>2. Risperidone monotherapy group: risperidone: titrated to flexible dose 4.6 ± 2.4 mg/d; n = 30</P>
<P>Co-medication: according to the conditions of the participants: zolpidem or benzodiazepines (improve sleep); benzhexol hydrochloride or propranolol (EPS)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>Clinically significant response: important change (PANSS reduction &#8805; 50%)</P>
<P>Clinical response: mental state (PANSS total), general psychopathology (PANSS subscales)</P>
<P>Adverse events: at least one event<BR/>
<BR/>
</P>
<P>Unable to use:<BR/>Leaving the study early: acceptability/tolerability of treatment (no information provided)<BR/>Clinical response: positive symptoms, negative symptoms - PANSS subscale (skewed data)<BR/>
</P>
<P>TESS scores measured but no means and SDs reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate (Depakine) group &amp; monotherapy group not significantly different in age, duration of illness (P &gt; 0.05) and PANSS total score and sub-scores</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>General abbreviations:<BR/>EEG - Electroencephalograph<BR/>ER - Extended release<BR/>IM - intramuscular<BR/>ITT - intention-to-treat<BR/>LOCF - last observation carried forward<BR/>n.i. - not indicated<BR/>lab - Laboratory</P>
<P>Diagnostic abbreviations:<BR/>ICD-10 - International Classification of Diseases, tenth revision<BR/>DSM-III Diagnostic and Statistical Manual of Mental disorders, third edition<BR/>CCMD-3 Chinese Classification of Mental Disorders, version 3</P>
<P>Global effect scales:<BR/>CGI - Clinical Global Impression.</P>
<P>Mental state scales:<BR/>BPRS - Brief Psychiatric Rating Scale<BR/>CDS - Calgary Depression Scale<BR/>IMPS - Inpatient Multidimensional Psychiatric Scale<BR/>SANS - Scale for Assessment of Negative Symptoms<BR/>PANSS - Positive and Negative Symptom Scale<BR/>pPANSS - Positive and Negative Symptom Scale, positive sub-score<BR/>MOAS Modified Overt Aggression Scale</P>
<P>Adverse events:<BR/>AIMS - Abnormal Involuntary Movement Scale<BR/>BAS - Barnes Akathisia Scale<BR/>SAS - Simpson Angus ScaleTESS - Treatment Emergent Symptom Scale<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-10-05 12:59:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alberti-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-05 12:59:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised<BR/>Participants: those with schizoaffective, bipolar and schizophrenic disorders<BR/>Intervention: Valproate combined with antipsychotics versus gabapentin combined with antipsychotics. No placebo group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-05 12:59:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bersudsky-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-05 12:59:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: "assigned by the control psychiatrist according to random order"</P>
<P>Participants: people with mania or schizoaffective disorder</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-05 12:59:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Centorrino-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-05 12:59:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, matched groups<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haupt-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised (open label)<BR/>Participants: people with schizophrenia<BR/>Interventions: valproate combined with antipsychotic medications versus antipsychotic monotherapy<BR/>Outcomes: metabolic processes, no usable data<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>As noted above, this study reported identical data as <LINK REF="STD-Liang-2004" TYPE="STUDY">Liang 2004</LINK> and we sent mails to the editor and author of both studies to rule out that it was just a copy, but have not received a reply. We therefore decided that it would be more careful to exclude this study at this stage</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monfort-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: possibly randomised (double-blind)<BR/>Participants: people with schizophrenia or schizophreniform disorder<BR/>Interventions: valproate combined with diazepam versus chlorpromazine, no adequate intervention group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-19 14:49:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00183443">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-19 14:49:46 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Participants: people with mania</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-19 14:12:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ping-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-19 14:12:20 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: quasi-randomisation, randomised according to hospitalisation order</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Raja-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not randomised, prospective naturalistic study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-19 14:12:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rifang-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-19 14:12:20 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: quasi-randomisation, randomised according to hospitalisation order</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised, no further details<BR/>Participants: people with schizophrenia<BR/>Interventions: antipsychotics combined with valproate versus antipsychotics combined with clonazepam</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-10-26 10:22:21 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-10-26 09:58:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boylan-2004">
<CHAR_METHODS MODIFIED="2016-10-26 09:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 09:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 09:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 09:58:02 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-14 06:35:15 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment, probably only a statistical paper</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 09:58:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chien-1978">
<CHAR_METHODS MODIFIED="2016-10-26 09:58:12 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 09:58:12 +0100" MODIFIED_BY="[Empty name]">
<P>People with tardive dyskinesia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 09:58:12 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 09:58:12 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 09:58:12 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 09:58:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cui-2012">
<CHAR_METHODS MODIFIED="2016-10-26 09:58:20 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 09:58:20 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 09:58:20 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 09:58:21 +0100" MODIFIED_BY="[Empty name]">
<P>Weight, insulin levels, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 09:58:21 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 09:58:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ellenor-1995">
<CHAR_METHODS MODIFIED="2016-10-26 09:58:32 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 09:58:32 +0100" MODIFIED_BY="[Empty name]">
<P>People with bipolar disorder or depression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 09:58:32 +0100" MODIFIED_BY="[Empty name]">
<P>Divalproex</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 09:58:32 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 09:58:32 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment, possibly only about serum levels</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 09:58:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Friis-1983">
<CHAR_METHODS MODIFIED="2016-10-26 09:58:37 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: people were treated in three consecutive phases with sodium valproate, biperiden and placebo in randomized orde</P>
<P>Blindness: double-blinded</P>
<P>Duration: 2-week wash-out period followed by three 4-week treatment phases</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 09:58:37 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: people with akathisia, unclear whether they had schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 09:58:37 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate or biperiden or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 09:58:37 +0100" MODIFIED_BY="[Empty name]">
<P>Akathisia, parkinsonism and hyperkinesia</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 09:58:37 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 09:58:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gong-2010">
<CHAR_METHODS MODIFIED="2016-10-26 09:58:46 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 09:58:46 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 09:58:46 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_OUTCOMES MODIFIED="2016-10-26 09:58:46 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_NOTES MODIFIED="2016-10-26 09:58:46 +0100" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 09:58:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gu-2012">
<CHAR_METHODS MODIFIED="2016-10-26 09:58:57 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 09:58:57 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 09:58:57 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 09:58:57 +0100" MODIFIED_BY="[Empty name]">
<P>Cognitive function, unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 09:58:57 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 09:59:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gu-2014">
<CHAR_METHODS MODIFIED="2016-10-26 09:59:07 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 09:59:07 +0100" MODIFIED_BY="[Empty name]">
<P>Stable people with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 09:59:07 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with antipsychotics, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 09:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>"Prognosis", details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 09:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 09:59:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2013">
<CHAR_METHODS MODIFIED="2016-10-26 09:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 09:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>Women with treatment-resistant schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 09:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>Small dose of valproate combined with ziprasidone, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 09:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 09:59:13 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 09:59:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiang-2014">
<CHAR_METHODS MODIFIED="2016-10-26 09:59:21 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 09:59:21 +0100" MODIFIED_BY="[Empty name]">
<P>Women with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 09:59:21 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with quetiapine, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 09:59:21 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive and impulsive behaviour</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 09:59:21 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:07:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jin-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:07:50 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:07:50 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia and aggression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:07:50 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:07:50 +0100" MODIFIED_BY="[Empty name]">
<P>Aggresssive behaviour, unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:07:50 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:08:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-1996">
<CHAR_METHODS MODIFIED="2016-10-26 10:08:01 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - divided into 3 groups randomly</P>
<P>Blindness: not mentioned, assume open-label</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:08:01 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: people with chronic schizophrenia, residual type according to DSM-III-R and had predominant negative symptoms evaluated by PANSS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:08:01 +0100" MODIFIED_BY="[Empty name]">
<P>Haloperidol + carbamazepine or haloperidol + valproate or haloperidol only</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:08:01 +0100" MODIFIED_BY="[Empty name]">
<P>Mental states: BPRS, PANSS, CGI</P>
<P>Depression: HRDS</P>
<P>Adverse events: SAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:08:01 +0100" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-09-14 06:51:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2008a">
<CHAR_METHODS MODIFIED="2016-09-14 06:43:03 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-09-14 06:50:54 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia, acutely ill.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-09-14 06:51:14 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, unclear.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-09-14 06:51:17 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-09-14 06:43:07 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:08:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2012a">
<CHAR_METHODS MODIFIED="2016-10-26 10:08:17 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:08:17 +0100" MODIFIED_BY="[Empty name]">
<P>People with treatment resistant schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:08:17 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with ziprasidone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:08:17 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:08:17 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:08:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:08:26 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:08:26 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:08:26 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, rest unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:08:26 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:08:26 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:08:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2013a">
<CHAR_METHODS MODIFIED="2016-10-26 10:08:33 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:08:33 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:08:34 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:08:34 +0100" MODIFIED_BY="[Empty name]">
<P>Cognitive function, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:08:34 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:08:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2014">
<CHAR_METHODS MODIFIED="2016-10-26 10:08:41 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:08:41 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:08:41 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with low dose quetiapine, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:08:42 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive behaviour</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:08:42 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:08:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2014a">
<CHAR_METHODS MODIFIED="2016-10-26 10:08:47 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:08:47 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:08:47 +0100" MODIFIED_BY="[Empty name]">
<P>Low dose valproate combined with antipsychotics, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:08:47 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive behaviour</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:08:47 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:08:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liang-2004a">
<CHAR_METHODS MODIFIED="2016-10-26 10:08:54 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:08:54 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:08:54 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, other unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:08:54 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:08:54 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:08:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linnoila-1976a">
<CHAR_METHODS MODIFIED="2016-10-26 10:08:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not clear</P>
<P>Blindness: double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:08:59 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia and various forms of psychosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:08:59 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate or placebo + neuroleptics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:08:59 +0100" MODIFIED_BY="[Empty name]">
<P>Mental states: BPRS</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:08:59 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:09:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Linnoila-1976b">
<CHAR_METHODS MODIFIED="2016-10-26 10:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>People with tardive dyskinesia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, other unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:09:07 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment, could be part of Linnoila 1976</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:09:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2007b">
<CHAR_METHODS MODIFIED="2016-10-26 10:09:15 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:09:15 +0100" MODIFIED_BY="[Empty name]">
<P>Psychiatric patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:09:15 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, other unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:09:15 +0100" MODIFIED_BY="[Empty name]">
<P>Aggression, other unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:09:16 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:09:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2012">
<CHAR_METHODS MODIFIED="2016-10-26 10:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia and excitement</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, other unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:09:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2012a">
<CHAR_METHODS MODIFIED="2016-10-26 10:09:28 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:09:28 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:09:28 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:09:28 +0100" MODIFIED_BY="[Empty name]">
<P>Agitated behaviour, rest unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:09:28 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:09:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:09:33 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:09:33 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:09:33 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate + risperidone, other unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:09:33 +0100" MODIFIED_BY="[Empty name]">
<P>Lipids, other unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:09:33 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:09:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2014">
<CHAR_METHODS MODIFIED="2016-10-26 10:09:40 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:09:40 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:09:40 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with risperidone, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:09:41 +0100" MODIFIED_BY="[Empty name]">
<P>Serum levels, efficacy, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:09:41 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:09:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lv-2014">
<CHAR_METHODS MODIFIED="2016-10-26 10:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>People with a first episode of schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>Cognitive function, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:09:45 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:09:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2012">
<CHAR_METHODS MODIFIED="2016-10-26 10:09:53 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:09:53 +0100" MODIFIED_BY="[Empty name]">
<P>People with treatment-resistant schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:09:53 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with ziprasidone, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:09:53 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:09:53 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:10:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monteleone-1986">
<CHAR_METHODS MODIFIED="2016-10-26 10:10:03 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: probably randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:10:03 +0100" MODIFIED_BY="[Empty name]">
<P>People with chronic schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:10:03 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, rest unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:10:03 +0100" MODIFIED_BY="[Empty name]">
<P>Prolactin, other unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:10:03 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:10:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monteleone-1988">
<CHAR_METHODS MODIFIED="2016-10-26 10:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: probably randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, other unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:10:12 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:10:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nair-1980">
<CHAR_METHODS MODIFIED="2016-10-26 10:10:18 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:10:18 +0100" MODIFIED_BY="[Empty name]">
<P>People with tardive dyskinesia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:10:18 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, other unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:10:18 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:10:18 +0100" MODIFIED_BY="[Empty name]">
<P>Needs more detailed assessment</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:10:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nasrallah-1986">
<CHAR_METHODS MODIFIED="2016-10-26 10:10:24 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:10:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00552500">
<CHAR_METHODS MODIFIED="2016-10-26 10:10:34 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:10:34 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:10:34 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, other unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:10:34 +0100" MODIFIED_BY="[Empty name]">
<P>Lipid metabolism, other unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:10:34 +0100" MODIFIED_BY="[Empty name]">
<P>Need to contact author</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:10:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peng-2012">
<CHAR_METHODS MODIFIED="2016-10-26 10:10:46 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:10:46 +0100" MODIFIED_BY="[Empty name]">
<P>People with treatment resistant schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:10:46 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with clozapine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:10:46 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:10:46 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:10:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peng-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:10:51 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:10:51 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:10:51 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, other unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:10:51 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:10:51 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:10:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pu-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:10:58 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:10:58 +0100" MODIFIED_BY="[Empty name]">
<P>People with treatment-resistant schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:10:58 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with olanzapine, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:10:58 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:10:58 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:11:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qiu-2014">
<CHAR_METHODS MODIFIED="2016-10-26 10:11:04 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:11:04 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:11:04 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with risperidone, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:11:04 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy, serum levels, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:11:04 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:11:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qu-2014">
<CHAR_METHODS MODIFIED="2016-10-26 10:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with olanzapine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive behaviour, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:11:14 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:11:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruiz_x002d_Doblado-2010">
<CHAR_METHODS MODIFIED="2016-10-26 10:11:41 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:11:41 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia resistant to clozapine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:11:41 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:11:41 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:11:41 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment, possibly only review</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:11:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shu-2014">
<CHAR_METHODS MODIFIED="2016-10-26 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with clozapine, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive behaviour</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:11:56 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:12:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:12:02 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:12:02 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:12:02 +0100" MODIFIED_BY="[Empty name]">
<P>Chlorpromazine, clozapine, valproate, details are unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:12:02 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:12:02 +0100" MODIFIED_BY="[Empty name]">
<P>Abstract only, more details are necessary. Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:12:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2007">
<CHAR_METHODS MODIFIED="2015-12-19 14:12:20 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation: stratified randomisation according to hospitalisation order</P>
<P>Blindness: open label</P>
<P>Duration: 12 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:12:12 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (CCMD-3), used at least two different types of typical antipsychotics, each treated for at least six weeks at the dosage of at least 500mg chlorpromazine equivalents per day, but no significant response; PANSS &#8805; 60</P>
<P>History: duration of illness 7.4 ± 4.7 years<BR/>n = 86</P>
<P>Sex: male and female<BR/>Age: 26.7 ± 3.6 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:12:12 +0100" MODIFIED_BY="[Empty name]">
<P>1. Magnesium valproate + risperidol: valproate 250-750 mg/d, mean dose 425 ± 195 mg/d; risperidol 2-6 mg/d, mean dose 3.25 ± 1.85 mg/d; n = 42</P>
<P>2. Risperidol alone: 2-6 mg/day, mean dose 3.25 ± 1.85 mg/day, n = 44</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:12:12 +0100" MODIFIED_BY="[Empty name]">
<P>Neurocognitive tests: WAIS-R, WMS, WCST</P>
<P>Mental states: PANSS</P>
<P>Adverse events</P>
<P>Unable to use:</P>
<P>Adverse events: TESS - no data reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:12:12 +0100" MODIFIED_BY="[Empty name]">
<P>We suspect randomisation of this study was not properly done as it is not clear how they did stratified randomisation according to hospitalisation order; we were unable to contact the study author to verify</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:12:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2008">
<CHAR_METHODS MODIFIED="2016-10-25 05:03:25 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-25 05:03:25 +0100" MODIFIED_BY="[Empty name]">
<P>Difficult-to-treat people with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-25 05:03:25 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>Cognitive function, other unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:12:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sun-2012">
<CHAR_METHODS MODIFIED="2016-10-26 10:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>People with treatment resistant schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with quetiapine or clozapine, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:12:27 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:12:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suzana-2009">
<CHAR_METHODS MODIFIED="2016-10-26 10:12:35 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear, possibly not randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:12:35 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:12:36 +0100" MODIFIED_BY="[Empty name]">
<P>Mood-stabilisers, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:12:36 +0100" MODIFIED_BY="[Empty name]">
<P>Hostility, impulsivity, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:12:36 +0100" MODIFIED_BY="[Empty name]">
<P>Needs detailed assessment and full report from authors</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:12:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2012">
<CHAR_METHODS MODIFIED="2016-10-26 10:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive behaviour, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:12:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2005b">
<CHAR_METHODS MODIFIED="2016-10-26 10:12:47 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:12:47 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia and aggression</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:12:47 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, antipsychotic drugs</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:12:47 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:12:48 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:12:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2006">
<CHAR_METHODS MODIFIED="2016-10-26 10:12:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised - no further details<BR/>Blindness: no further details<BR/>Duration: 28 days</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:12:58 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis: schizophrenia (CCMD-3), with aggressive behaviours according to scores of MOAS &gt; = 4, or BPRS score &gt; 38</P>
<P>History: no information<BR/>n = 64</P>
<P>Sex: male and female<BR/>Age: 31.15 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:12:58 +0100" MODIFIED_BY="[Empty name]">
<P>1. Magnesium valproate + risperidol: valproate 800-1200 mg/d, risperidol 4-6 mg/d, n = 32</P>
<P>2. Risperidol alone: 4-6 mg/d, n = 32</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:12:58 +0100" MODIFIED_BY="[Empty name]">
<P>Mental state: BPRS scores</P>
<P>Behaviour: MOAS scores</P>
<P>Adverse events</P>
<P>Unable to use</P>
<P>Adverse events: TESS - no data reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:12:58 +0100" MODIFIED_BY="[Empty name]">
<P>Data of this study apears to be very closely related to <LINK REF="STD-Wang-2005a" TYPE="STUDY">Wang 2005a</LINK>, which was conducted by the same author one year earlier. Both studies measured exactly the same outcomes (<LINK REF="STD-Wang-2005a" TYPE="STUDY">Wang 2005a</LINK>, n = 60; <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK>, n = 64), had the same inclusion criteria, with the same dosage of drugs. The numbers in the continuous outcomes are very similar. We suspect that <LINK REF="STD-Wang-2006" TYPE="STUDY">Wang 2006</LINK> could be a follow up study of 2005, but we were unable to contact the author to verify.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:13:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2012">
<CHAR_METHODS MODIFIED="2016-10-26 10:13:07 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:13:07 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:13:07 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:13:07 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:13:07 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:13:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:13:11 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:13:11 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:13:11 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, olanzapine, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:13:11 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:13:11 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:13:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2013a">
<CHAR_METHODS MODIFIED="2016-10-26 10:13:19 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:13:19 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:13:19 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with risperidone, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:13:19 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive and impulsive behaviour</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:13:19 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:13:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2014">
<CHAR_METHODS MODIFIED="2016-10-26 10:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with risperidone, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive behaviour</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:13:26 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:14:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2014a">
<CHAR_METHODS MODIFIED="2016-10-26 10:14:41 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:14:41 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:14:41 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:14:41 +0100" MODIFIED_BY="[Empty name]">
<P>Behaviour disorder, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:14:41 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:14:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wen-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:14:47 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:14:47 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:14:47 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, other unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:14:47 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive behaviour, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:14:47 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:14:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2013a">
<CHAR_METHODS MODIFIED="2016-10-26 10:14:54 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:14:55 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:14:55 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, quetiapine, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:14:55 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:14:55 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:15:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2013b">
<CHAR_METHODS MODIFIED="2016-10-26 10:15:00 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:15:00 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia and positive symptoms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:15:00 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, olanzapine, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:15:00 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:15:00 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:15:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiao-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear, possibly retrospective analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, risperidone, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:15:06 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:15:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2002">
<CHAR_METHODS MODIFIED="2016-10-26 10:15:12 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:15:12 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:15:12 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:15:12 +0100" MODIFIED_BY="[Empty name]">
<P>Auditory hallucinations</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:15:12 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:15:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:15:19 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:15:19 +0100" MODIFIED_BY="[Empty name]">
<P>Women with treatment-resistant schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:15:19 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with ziprasidone, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:15:19 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:15:19 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:15:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2014">
<CHAR_METHODS MODIFIED="2016-10-26 10:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>Women with treatment-resistant schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with clozapin</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:15:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2007a">
<CHAR_METHODS MODIFIED="2016-10-26 10:15:31 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:15:31 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:15:31 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate, risperidone, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:15:31 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:15:31 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:15:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2007b">
<CHAR_METHODS MODIFIED="2016-10-26 10:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:15:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2008">
<CHAR_METHODS MODIFIED="2016-10-26 10:15:42 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:15:42 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:15:42 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with risperidone, control unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:15:42 +0100" MODIFIED_BY="[Empty name]">
<P>Negative symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:15:42 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:15:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2012">
<CHAR_METHODS MODIFIED="2016-10-26 10:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with haloperidol, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:15:48 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:15:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2012">
<CHAR_METHODS MODIFIED="2016-10-26 10:15:55 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:15:55 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:15:55 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with ziprasidone, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:15:55 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive behaviour, rest unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:15:55 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:16:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2013">
<CHAR_METHODS MODIFIED="2016-10-26 10:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with risperidone, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>Agitated behaviour, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:16:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2014">
<CHAR_METHODS MODIFIED="2016-10-26 10:16:11 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:16:11 +0100" MODIFIED_BY="[Empty name]">
<P>Men with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:16:11 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with olanzapine, details unclear</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:16:11 +0100" MODIFIED_BY="[Empty name]">
<P>Agitated behaviour, rest unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:16:12 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:16:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2005a">
<CHAR_METHODS MODIFIED="2016-10-26 10:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with clonazapam</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Agitation, details unclear</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2016-10-26 10:22:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2014">
<CHAR_METHODS MODIFIED="2016-10-26 10:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-26 10:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-26 10:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>Low-dose valproate combined with antipsychotics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-26 10:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>Aggressive behaviour</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-10-26 10:22:21 +0100" MODIFIED_BY="[Empty name]">
<P>Needs translation from Chinese</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00167934">
<CHAR_STUDY_NAME MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Determining metabolic effects of valproate and antipsychotic therapy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised (single-blind)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>People with schizophrenia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Valproate combined with antipsychotic medications versus antipsychotic monotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Blood glucose, metabolism disorders and weight gain</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-07-20 11:12:28 +0100" MODIFIED_BY="[Empty name]">
<P>December 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-07-20 11:13:32 +0100" MODIFIED_BY="[Empty name]">
<P>Martha J Hessler, BS 314-362-2423 hesslema@psychiatry.wustl.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>This study is recruiting participants</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00306475">
<CHAR_STUDY_NAME MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Does the addition of divalproex sodium ER to an atypical antipsychotic drug (APD) improve cognition and psychopathology in outpatients with schizophrenia (SCH) or schizoaffective disorder (SAD)?</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: randomised</P>
<P>Blindness: double-blinded</P>
<P>Duration: six weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:58 +0100" MODIFIED_BY="[Empty name]">
<P>DSM-IV diagnosis of schizophrenia or schizoaffective disorder</P>
<P>Sex: Male or female</P>
<P>Age: 18-65</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-27 14:32:21 +0100" MODIFIED_BY="[Empty name]">
<P>1. Divalproex sodium + atypical antipsychotics</P>
<P>2. Atypical antipsychotics + placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-05-29 15:13:56 +0100" MODIFIED_BY="[Empty name]">
<P>Cognition</P>
<P>Psychopathology (positive, negative, and mood symptoms)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-27 14:33:06 +0100" MODIFIED_BY="[Empty name]">
<P>March 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-27 14:33:28 +0100" MODIFIED_BY="[Empty name]">
<P>Kara L Watts, M.A. 615-343-9717 kara.l.watts@vanderbilt.edu<BR/>Claudia Diaz-Byrd, M.S. 615-322-2916 claudia.c.diaz-byrd@vanderbilt.edu</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-05-26 21:36:08 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Norrie-2000">
<CHAR_STUDY_NAME MODIFIED="2008-05-14 10:14:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Norrie-2000" TYPE="STUDY">Norrie 2000</LINK>
</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]">
<P>Participants with schizophrenia treated as inpatients or outpatients<BR/>n = 50<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]">
<P>1. Olanzapine (10-20 mg/d) + valproate (500-2000 mg/d)<BR/>2.Olanzapine (10-20 mg/d) + placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]">
<P>PANSS, REHAB and Life Skills Profile Scales, adverse events, laboratory parameters</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Unclear</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Norrie PD<BR/>Glenside Hospital, Adelaide, Australia</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003">
<CHAR_STUDY_NAME MODIFIED="2016-10-03 18:19:00 +0100" MODIFIED_BY="[Empty name]">
<P>60 week, randomised, double-blind, placebo-controlled trial of valproate added to risperidone in 200 treatment-naive, first-episode people with schizophrenia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation: not stated</P>
<P>Blindness: double-blinded</P>
<P>Duration: 52 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]">
<P>Those with schizophrenia, n = 200</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-05-27 14:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>1. Valproate + antipsychotics</P>
<P>2. Placebo + antipsychotics</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-27 14:40:43 +0100" MODIFIED_BY="[Empty name]">
<P>Global state: CGI- HAM-D</P>
<P>Mental state: PANSS</P>
<P>Cognitive battery</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-05-27 14:41:17 +0100" MODIFIED_BY="[Empty name]">
<P>2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-05-27 14:42:33 +0100" MODIFIED_BY="[Empty name]">
<P>Gang Wang MD<BR/>Capital University of Medical Sciences</P>
<P>Beijing Anding Hospital<BR/>No.5 An Kang Hutong<BR/>De Shengmen Wai Street<BR/>Beijing<BR/>Xicheng District<BR/>100088<BR/>China<BR/>wangg@intra.nimh.nih.gov</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-05-26 21:36:27 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-11-07 14:13:53 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-10-26 10:26:25 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>"randomized" (p 182) no further description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casey-2009">
<DESCRIPTION>
<P>"randomized", no further details provided (p 1331)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Citrome-2007">
<DESCRIPTION>
<P>"randomized", no details provided (p 357)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dose-1998">
<DESCRIPTION>
<P>"randomly assigned" (p 122)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fisk-1987">
<DESCRIPTION>
<P>"randomised (...) stratified for age, sex, setting and pretrial tardive dyskinesia score (p 542) - no further details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Glick-2009">
<DESCRIPTION>
<P>"randomised" (...) randomly assigned in a 1:1: ratio. No further details provided (p 268)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guo-2007">
<DESCRIPTION>
<P>"randomly assigned", p183</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hesslinger-1999">
<DESCRIPTION>
<P>"randomly assigned" (p 311)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jia-2007">
<DESCRIPTION>
<P>"randomly assigned", p 3 "Pairs of participants with no significant differences in age, BMI, duration of illness, smoking, Clozapine dosage taken, co-medication and PANSS score", were randomly divided into two equal groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2009">
<DESCRIPTION>
<P>Stratified randomisation, p176</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>"randomly divided into two groups" (p 178)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>"randomized", no further details provided (p 788)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liang-2004">
<DESCRIPTION>
<P>"randomly assigned", p151</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 10:26:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>"randomly assigned in a 1:1 ratio", p11596</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2007a">
<DESCRIPTION>
<P>"draw lots" (p 490)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>"randomly assigned", p1291</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pan-2010">
<DESCRIPTION>
<P>"randomized", no further details provided (p 203)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shi-2010">
<DESCRIPTION>
<P>Randomized "using a random number table into two groups" (p 398)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2005a">
<DESCRIPTION>
<P>"randomly divided" (p 10)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2009">
<DESCRIPTION>
<P>"randomized", no further details provided (p 250)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>"randomized", no further details provided (p 548)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wassef-2000">
<DESCRIPTION>
<P>"randomized" (p 357)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xie-2011">
<DESCRIPTION>
<P>"randomized", no further details provided (p 191)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yao-2010">
<DESCRIPTION>
<P>"randomly divided", no further details provided (p 2713)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yin-2004">
<DESCRIPTION>
<P>"divided randomly" (p 92)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>"randomised" no details provided (p 265)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-10-26 10:26:26 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casey-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Citrome-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dose-1998">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fisk-1987">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Glick-2009">
<DESCRIPTION>
<P>"all drugs identically encapsulated by an independent pharmacy", not sure if the pharmacy ran the randomisation (p 268)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guo-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hesslinger-1999">
<DESCRIPTION>
<P>"sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jia-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jiang-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 19:42:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 19:42:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liang-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 10:26:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2007a">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pan-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shi-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2005a">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-03 19:47:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wassef-2000">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xie-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yao-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yin-2004">
<DESCRIPTION>
<P>Not indicated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-08-30 19:32:04 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-10-26 10:28:43 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>"double-blind" (p 182)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>"double-blind" (p 182)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-03 13:13:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casey-2009">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casey-2009">
<DESCRIPTION>
<P>"double-blind"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-11-03 15:34:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Citrome-2007">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Citrome-2007">
<DESCRIPTION>
<P>Open label, &#8220;study participants, treating psychiatrists and other staff were aware&#8221; (p 358)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dose-1998">
<DESCRIPTION>
<P>"double-blind"; "Plasma VPA levels were (...) communicated to the project leader only in order to maintain the blind conditions" (p 122)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dose-1998">
<DESCRIPTION>
<P>"double-blind"; "psychiatrist, who was not aware whether the participant was receiving an anticonvulsant or placebo"; "VPA tablets and placebo of identical appearance" (p 122)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisk-1987">
<DESCRIPTION>
<P>"double-blind" (p 542); "double-blind procedures were used throughout (...) Hospital pharmacists acted as coordinators of treatment"; "further blind ratings by experienced independent raters" (p 543)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisk-1987">
<DESCRIPTION>
<P>"double-blind" (p 542); "double-blind procedures were used throughout (...) Hospital pharmacists acted as coordinators of treatment"; "further blind ratings by experienced independent raters" (p 543)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-04 14:42:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glick-2009">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glick-2009">
<DESCRIPTION>
<P>Clinicians, participants and family were blind to study assignment (p 268)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-11-03 15:34:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guo-2007">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guo-2007">
<DESCRIPTION>
<P>"opening", personnel and participants not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hesslinger-1999">
<DESCRIPTION>
<P>"psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts" (p 311). People with schizophrenia were not aware of the treatment (information received by letter)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hesslinger-1999">
<DESCRIPTION>
<P>"psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts" (p 311). People with schizophrenia were not aware of the treatment (information received by letter)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jia-2007">
<DESCRIPTION>
<P>Not stated. No information about blinding provided, therefore assuming open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jia-2007">
<DESCRIPTION>
<P>Not stated. No information about blinding provided, therefore assuming open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2009">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jiang-2009">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-02-04 14:48:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liang-2004">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2013-03-20 10:19:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liang-2004">
<DESCRIPTION>
<P>No details about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-26 10:26:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-26 10:26:28 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-26 10:26:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2007a">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2007a">
<DESCRIPTION>
<P>Sodium valproate and placebo starch were placed into identical capsules A and B by staff, clinicians and participants did not know the contents of capsules (p 490)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-26 10:27:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-26 10:27:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pan-2010">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pan-2010">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-26 10:27:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shi-2010">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes<BR/>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shi-2010">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2005a">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcome.<BR/>No information provided about blinding provided, assume open-label.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2005a">
<DESCRIPTION>
<P>No information provided about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2009">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2009">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
<P>No information about blinding provided, assume open-label<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wassef-2000">
<DESCRIPTION>
<P>"double-blind" (p 357); "identical appearing tablets"; "doses were adjusted by an unblinded investigator who was not involved in medication assignment, participant assessment or clinical care. Dose adjustments were done in a blinded fashion" (p 358)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wassef-2000">
<DESCRIPTION>
<P>"double-blind" (p 357); "identical appearing tablets"; "doses were adjusted by an unblinded investigator who was not involved in medication assignment, participant assessment or clinical care. Dose adjustments were done in a blinded fashion" (p 358)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-26 10:28:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xie-2011">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xie-2011">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-05 12:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yao-2010">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yao-2010">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-26 10:28:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yin-2004">
<DESCRIPTION>
<P>We don't think binding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yin-2004">
<DESCRIPTION>
<P>Double-blind, "Valproate sodium and placebo (starch) were put into identical oblique capsules and labelled as I and II respectively by researchers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-10-26 10:28:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-10-26 10:28:44 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>"double-blind" (p 182)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>"double-blind" (p 182)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-04 14:38:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casey-2009">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casey-2009">
<DESCRIPTION>
<P>"raters completed a rater-training program", no further details provided (p 1331)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-04 10:43:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Citrome-2007">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcome. Raters were blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Citrome-2007">
<DESCRIPTION>
<P>Blinded raters (p 358)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dose-1998">
<DESCRIPTION>
<P>"double-blind"; "Plasma VPA levels were (...) communicated to the project leader only in order to maintain the blind conditions" (p 122)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dose-1998">
<DESCRIPTION>
<P>"double-blind"; "psychiatrist, who was not aware whether the participant was receiving an anticonvulsant or placebo"; "VPA tablets and placebo of identical appearance" (p 122)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fisk-1987">
<DESCRIPTION>
<P>"double-blind" (p 542); "double-blind procedures were used throughout (...) Hospital pharmacists acted as coordinators of treatment"; "further blind ratings by experienced independent raters" (p 543)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisk-1987">
<DESCRIPTION>
<P>"double-blind" (p 542); "double-blind procedures were used throughout (...) Hospital pharmacists acted as coordinators of treatment"; "further blind ratings by experienced independent raters" (p 543)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-03 15:34:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glick-2009">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glick-2009">
<DESCRIPTION>
<P>Raters were blind to study assignment (p 268)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-03 15:34:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guo-2007">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guo-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hesslinger-1999">
<DESCRIPTION>
<P>"psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts" (p 311). People with schizophrenia were not aware of the treatment (information received by letter)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hesslinger-1999">
<DESCRIPTION>
<P>"psychiatrist (...) was blind to medication and drug levels. However, he had access to the nursing charts" (p 311). People with schizophrenia were not aware of the treatment (information received by letter)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jia-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jia-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-05 12:59:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2009">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jiang-2009">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-04 14:47:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-04 14:48:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liang-2004">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liang-2004">
<DESCRIPTION>
<P>No details about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-26 10:26:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-03-20 13:35:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-26 10:26:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2007a">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2007a">
<DESCRIPTION>
<P>Raters did not know contents of capsules (p 490)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-26 10:27:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-26 10:27:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pan-2010">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pan-2010">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-26 10:27:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shi-2010">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shi-2010">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-02-04 13:21:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2005a">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcome.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2005a">
<DESCRIPTION>
<P>No information provided about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-11-03 15:34:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2009">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2009">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-26 10:27:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-05 12:59:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wassef-2000">
<DESCRIPTION>
<P>"double-blind" (p 357); "identical appearing tablets"; "doses were adjusted by an unblinded investigator who was not involved in medication assignment, participant assessment or clinical care. Dose adjustments were done in a blinded fashion" (p 358)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wassef-2000">
<DESCRIPTION>
<P>"double-blind" (p 357); "identical appearing tablets"; "doses were adjusted by an unblinded investigator who was not involved in medication assignment, participant assessment or clinical care. Dose adjustments were done in a blinded fashion" (p 358)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-26 10:28:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xie-2011">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2013-06-03 19:48:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xie-2011">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-05 12:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yao-2010">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yao-2010">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-26 10:28:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yin-2004">
<DESCRIPTION>
<P>We don't think binding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yin-2004">
<DESCRIPTION>
<P>Outcomes measured by "6 experienced psychiatrists", no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-10-26 10:28:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>We don't think blinding causes significant bias in objective outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2016-10-05 12:59:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>No information about blinding provided, assume open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-11-07 14:13:53 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-03 12:54:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>Attrition data for different treatment groups for the reasons of treatment-emergent adverse events and lack of efficacy were reported and distributed relatively even between groups, but there were no data for the total number of people leaving the study in different treatment groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Casey-2009">
<DESCRIPTION>
<P>Used technique of LOCF but reported data for people leaving the study early very high (62%) (p 1332)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Citrome-2007">
<DESCRIPTION>
<P>People leaving the study early 13/33 = 39.4% (p 359) AND reasons for missing outcome data likely to be related to true outcome, with imbalance in numbers: significantly fewer participants randomised to risperidone-alone completed the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dose-1998">
<DESCRIPTION>
<P>31% rate for people leaving the study early, evenly distributed between groups (6/20 and 7/22)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fisk-1987">
<DESCRIPTION>
<P>26% rate for people leaving the study early, not evenly distributed between groups (11/29 and 4/29)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-07 14:13:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Glick-2009">
<DESCRIPTION>
<P>7 out of 25 (28%) participants left early, no data for people leaving the study early in each group (p 269)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guo-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-02-04 11:05:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hesslinger-1999">
<DESCRIPTION>
<P>No participants left the study early.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jia-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jiang-2009">
<DESCRIPTION>
<P>Two participants left early from each group due to leukopenia. It is unclear, if these four people were included in the final analysis. (p 177)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-03 19:42:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liang-2004">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-07 14:13:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>Three and four participants left early from the experiment and control groups respectively. Valproate group: 3/30 = 10%, monotherapy group: 4/30 = 13.3%, no reason provided for people leaving the study early. They are not included in the final analysis. (p 11,596)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2007a">
<DESCRIPTION>
<P>People leaving the study early due to inefficacy: group A (monotherapy group) 13/17 = 76.5%, group B (valproate group) 4/19 = 21.1%, not balanced and too high in group A (p 490)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>Attrition was unaccounted for in the final analysis</P>
<P>Valproate group 2 (out of 43), monotherapy group 8 (out of 47), no significant difference (P &gt; 0.05) However, 2/43 = 4.6% BUT 8/47 = 17%. Also, due to inefficacy, it is 1/43 vs 6/47</P>
<P>Authors stated that they would use ITT in methods section but in analysis they used completers not ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pan-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shi-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2005a">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2009">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wassef-2000">
<DESCRIPTION>
<P>No people leaving the study early</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xie-2011">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yao-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-11-07 14:13:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yin-2004">
<DESCRIPTION>
<P>Only one participant in one group left early (out of 40 participants in each group) due to low blood pressure and disturbances of consciousness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-10-05 12:59:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-10-26 10:28:35 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>No data for those leaving the study early for the different treatment groups; BPRS and movement adverse effect were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Casey-2009">
<DESCRIPTION>
<P>No data reported for extrapyramidal symptoms, measured by SAS, BAS and AIMS</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Citrome-2007">
<DESCRIPTION>
<P>Endpoint data of CGI, NOISE, ESRS not reported, PANSS, PANSS hostility, BIS, BDHI no endpoint mean and SDs reported; Overt aggression scale comparison between completers and non-completers, not between study arms</P>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dose-1998">
<DESCRIPTION>
<P>No numerical values for EEG and lab tests provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fisk-1987">
<DESCRIPTION>
<P>Data from physiological monitoring not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Glick-2009">
<DESCRIPTION>
<P>Almost no usable data reported apart from dichotomous data for PANSS, CGI, CDS and adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guo-2007">
<DESCRIPTION>
<P>CGI, TESS score were measured, but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hesslinger-1999">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jia-2007">
<DESCRIPTION>
<P>TESS scores measured but no means and SDs reported; study authors only stated that no significant difference in TESS score between groups (P &gt; 0.05). Study authors also selectively reported binary outcomes of a few adverse events, but didn't provide numbers for all adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jiang-2009">
<DESCRIPTION>
<P>TESS scores were measured but no means and SDs were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>Adverse events: no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>TESS scores measured but no means and SDs reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liang-2004">
<DESCRIPTION>
<P>TESS score was measured, but not reported. Study authors only stated that there was no difference between groups on TESS score, but the actual measurements were not reported. Authors also selectively reported binary outcomes of a few adverse events, but didn't provide numbers for all adverse events</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 10:26:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>Adverse events not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2007a">
<DESCRIPTION>
<P>Aggression: MOAS, endpoint data unusable, no mean and SDs given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>TESS scores measured but no means and SDs reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pan-2010">
<DESCRIPTION>
<P>TESS scores measured but no means and SDs reported; authors only stated that valproate group &amp; monotherapy group TESS scores not significantly different</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shi-2010">
<DESCRIPTION>
<P>TESS scores measured but no means and SDs reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2005a">
<DESCRIPTION>
<P>TESS score measured but not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2009">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>TESS scores measured but no means and SDs reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wassef-2000">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xie-2011">
<DESCRIPTION>
<P>All outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yao-2010">
<DESCRIPTION>
<P>TESS scores measured but no means and SDs reported</P>
<P>Authors also selectively reported binary outcomes of a few adverse events, but didn't provide numbers for all adverse events (p 2714)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 10:28:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yin-2004">
<DESCRIPTION>
<P>BPRS results not reported</P>
<P>TESS score measured but no means and SDs reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>TESS scores measured but no means and SDs reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-10-26 10:26:34 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Casey-2003">
<DESCRIPTION>
<P>The 2 groups with combination therapy and the 2 groups with monotherapy were considered to be 1<BR/>In the original report 7 people with schizophrenia were not included in the ITT analyses due to missing on-treatment PANSS score and randomisation at 2 sites (only the second randomisation was excluded)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Casey-2009">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Citrome-2007">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dose-1998">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fisk-1987">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glick-2009">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guo-2007">
<DESCRIPTION>
<P>None obvious</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hesslinger-1999">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jia-2007">
<DESCRIPTION>
<P>None obvious</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jiang-2009">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liang-2004">
<DESCRIPTION>
<P>None obvious</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-26 10:26:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2003">
<DESCRIPTION>
<P>None obvious</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2007a">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lu-2006">
<DESCRIPTION>
<P>None obvious</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pan-2010">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shi-2010">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2005a">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2009">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2010">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wassef-2000">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xie-2011">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yao-2010">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yin-2004">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-10-05 12:59:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>No obvious other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-10-05 13:47:58 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-10-05 13:47:58 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2016-10-05 13:47:58 +0100" MODIFIED_BY="[Empty name]">VALPROATE + ANTIPSYCHOTICS versus ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Valproate plus antipsychotics versus antipsychotics plus placebo or antipsychotics alone</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with schizophrenia<BR/>
<B>Settings: </B>inpatient/outpatient<BR/>
<B>Intervention:</B> Valproate plus antipsychotics versus antipsychotics plus placebo or antipsychotics alone<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Antipsychotics and valproate versus antipsychotics and placebo/no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinically significant response: important change</B>
<BR/>As defined by each of the studies<BR/>Follow-up: short term</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>550 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>721 per 1000</B>
<BR/>(638 to 809)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.31 </B>
<BR/>(1.16 to 1.47)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1049<BR/>(14 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Leaving the study early: Acceptability of treatment</B>
<BR/>Leaving the study early for any reason<BR/>
<B>Follow-up: short term</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>364 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>327 per 1000</B>
<BR/>(284 to 378)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.76 </B>
<BR/>(0.47 to 1.24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>951<BR/>(11 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Leaving the study early: Overall tolerability</B>
<BR/>Leaving the study early due adverse events<BR/>
<B>Follow-up: short term</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>77 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>102 per 1000</B>
<BR/>(69 to 150)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.33 </B>
<BR/>(0.90 to 1.97)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>974<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Clinical response: Aggression/agitation</B>
<BR/>Mean Modified Overt Aggression Rating Scale. Scale from: 0-16<BR/>
<B>Follow-up: short term</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean aggression in the control groups was<BR/>
<B>5.74</B> <B>points</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean aggression in the intervention groups was<BR/>
<B>2.55 lower</B>
<BR/>(3.92 to 1.19 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>186<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>7,8</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events: Sedation</B>
<BR/>Number of participants with sedation/somnolence/drowsiness<BR/>
<B>Follow-up: short term</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>186 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>276 per 1000</B>
<BR/>(214 to 356)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.38 </B>
<BR/>(1.07 to 1.79)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>770<BR/>(8 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events: Weight gain</B>
<BR/>Number of participants with weight gain<BR/>
<B>Follow-up: short term</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>143 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>169 per 1000</B>
<BR/>(109 to 260)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.17 </B>
<BR/>(0.76 to 1.82)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>427<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>9,10</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Quality of life: Clinically important change in quality of life - as defined by individual studies</B>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>No study reported on the predefined outcome quality of life so it could not be presented in this summary of findings table</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Risk of bias: almost all studies were open RCTs, there was no blinding. Moreover, several studies did not report rates.<BR/>
<SUP>2</SUP> Risk of bias: half of the studies were open RCTs without blinding.<BR/>
<SUP>3</SUP> Inconsistency: considerable heterogeneity based on both visual inspection, Chi<SUP>2</SUP> and I<SUP>2</SUP> statistics.<BR/>
<SUP>4</SUP> Indirectness: acceptability of treatment was measured by the number of participants leaving the study early for any reason which comprised efficacy and tolerability. Nevertheless, this is an indirect measure.<BR/>
<SUP>5</SUP> Imprecision: overall sample size was too small to provide a precise estimate for the small RR found.<BR/>
<SUP>6</SUP> Imprecision: too few events for a precise estimate and relatively broad confidence interval.<BR/>
<SUP>7</SUP> Risk of bias: all open RCTs, no blinding. Unclear whether ITT results were presented.<BR/>
<SUP>8</SUP> Inconsistency: results were significantly heterogeneous. However, all studies showed a statistically significant superiority of valproate augmentation therefore, the heterogeneity expressed a difference in the degree of the effect, but not of the direction of the effect.<BR/>
<SUP>9</SUP> Risk of bias: weight gain is an objective outcome. Therefore, we did not downgrade for lack of blinding.<BR/>
<SUP>10</SUP>Imprecision: relatively few events, relatively small overall sample size for a relatively small effect size the confidence interval of which overlaps widely with zero.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-11-29 12:04:11 +0000" MODIFIED_BY="[Empty name]">Excluded studies and suggestions for relevant reviews</TITLE>
<TABLE COLS="3" ROWS="12">
<TR>
<TD ALIGN="CENTER">
<P>Excluded study</P>
</TD>
<TD ALIGN="CENTER">
<P>Comparison</P>
</TD>
<TD ALIGN="CENTER">
<P>Existing review</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Alberti-1999" TYPE="STUDY">Alberti 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Valproate + antipsychotics versus gabapentin + antipsychotics in schizoaffective, bipolar and schizophrenic disorders</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="REF-Carta-2003" TYPE="REFERENCE">Carta 2003</LINK>; <LINK REF="REF-Perugi-2004" TYPE="REFERENCE">Perugi 2004</LINK>; <LINK REF="REF-Goodman-2006" TYPE="REFERENCE">Goodman 2006</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Bersudsky-2010" TYPE="STUDY">Bersudsky 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Valnoctamide + risperidone versus placebo + risperidone in mania or schizoaffective disorder</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="REF-Bailer-2012" TYPE="REFERENCE">Bailer 2012</LINK>; <LINK REF="REF-Konstantinos-2012" TYPE="REFERENCE">Konstantinos 2012</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Centorrino-1994" TYPE="STUDY">Centorrino 1994</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Clozapine + valproate in schizophrenia</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="REF-Pantelis-1996" TYPE="REFERENCE">Pantelis 1996</LINK>; <LINK REF="REF-Freeman-1998" TYPE="REFERENCE">Freeman 1998</LINK>; <LINK REF="REF-Balen-1999" TYPE="REFERENCE">Balen 1999</LINK>; <LINK REF="REF-Davis-2000" TYPE="REFERENCE">Davis 2000</LINK>; <LINK REF="REF-Baethge-2003" TYPE="REFERENCE">Baethge 2003</LINK>; <LINK REF="REF-Stahl-2004" TYPE="REFERENCE">Stahl 2004</LINK>; <LINK REF="REF-Besag-2006" TYPE="REFERENCE">Besag 2006</LINK>; <LINK REF="REF-Tranulis-2006" TYPE="REFERENCE">Tranulis 2006</LINK>; <LINK REF="REF-Sommer-2012" TYPE="REFERENCE">Sommer 2012</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Haupt-2007" TYPE="STUDY">Haupt 2007</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Valproate + antipsychotics versus antipsychotic monotherapy in schizophrenia&#8232;</P>
</TD>
<TD ALIGN="CENTER">
<P>Probably relevant for a new review</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ma-2010" TYPE="STUDY">Ma 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Magnesium valproate + risperidone versus risperidone monotherapy in schizophrenia with impulsive and aggressive symptoms</P>
</TD>
<TD ALIGN="CENTER">
<P>Probably relevant for a new review</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Monfort-1991" TYPE="STUDY">Monfort 1991</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Valproate + diazepam versus chlorpromazine in schizophrenia or schizophreniform disorder</P>
</TD>
<TD ALIGN="CENTER">
<P>Probably relevant for a new review</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-NCT00183443" TYPE="STUDY">NCT00183443</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Divalproex-extended release (DV-ER) + lithium versus DV-ER + quetiapine versus DV-ER + placebo in mania</P>
</TD>
<TD ALIGN="CENTER">
<P>Probably relevant for a new review</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Ping-1994" TYPE="STUDY">Ping 1994</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Sodium valproate versus clozapine versus sodium valproate + clozapine in schizophrenia</P>
</TD>
<TD ALIGN="CENTER">
<P>Probably relevant for a new review</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Raja-2000" TYPE="STUDY">Raja 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Antipsychotics versus valproate + antipsychotics in schizophrenia, bipolar, schizoaffective disorder, unipolar depression, personality disorder, mental retardation</P>
</TD>
<TD ALIGN="CENTER">
<P>
<LINK REF="REF-Crowhurst-2002" TYPE="REFERENCE">Crowhurst 2002</LINK>; <LINK REF="REF-Adams-2014" TYPE="REFERENCE">Adams 2014</LINK>; <LINK REF="REF-Pajonk-2005" TYPE="REFERENCE">Pajonk 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Rifang-2001" TYPE="STUDY">Rifang 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Sodium valproate + chlorpromazine versus chlorpromazine monotherapy in schizophrenia</P>
</TD>
<TD ALIGN="CENTER">
<P>Probably relevant for a new review</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<LINK REF="STD-Zhu-2005" TYPE="STUDY">Zhu 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>Valproate + antipsychotics versus clonazepam + antipsychotics in schizophrenia</P>
</TD>
<TD ALIGN="CENTER">
<P>Probably relevant for a new review</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-11-29 14:41:37 +0000" MODIFIED_BY="[Empty name]">Suggested future trial</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TD>
<P>Methods</P>
</TD>
<TD>
<P>Allocation: random</P>
<P>&#8232;Blinding: blind participants, treating team and raters.</P>
<P>Duration: minimum one-year follow-up<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Participants</P>
</TD>
<TD>
<P>Diagnosis: people with schizophrenia and aggression, on those with treatment-resistant forms of the disorder and on those with schizoaffective disorders (alternatively, several trials are necessary)</P>
<P>Age:</P>
<P>Sex: male and female.</P>
<P>n = 300</P>
</TD>
</TR>
<TR>
<TD>
<P>Interventions</P>
</TD>
<TD>
<P>1. Valproate in combination with any antipsychotic treatment: any dose</P>
<P>2. Placebo (or no intervention) in combination with any antipsychotic treatment</P>
</TD>
</TR>
<TR>
<TD>
<P>Outcome</P>
</TD>
<TD>
<P>Leaving the study early (due to any reason, inefficacy- and tolerability-related adverse events)<BR/>Service utilisation<BR/>Global state - clinically important change*<BR/>Relapse<BR/>Mental state - clinically important change (general and specific)<BR/>Behaviour - clinically important change<BR/>Aggression - clinically important change<BR/>Social functioning - clinically important change</P>
<P>Adverse effects - clinically important general adverse effects*; sudden and unexpected death<BR/>Economic outcomes<BR/>Satisfaction with treatment<BR/>Quality of life<BR/>Pharmacokinetic interactions</P>
<P/>
<P>All outcomes by time - short term (up to 12 weeks), medium term (13-26 weeks) and long term (over 26 weeks)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Notes</P>
</TD>
<TD>
<P>*Primary outcomes of interest<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-10-05 13:58:42 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2016-10-05 13:58:42 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>VALPROATE + ANTIPSYCHOTICS versus ANTIPSYCHOTICS + PLACEBO or ANTIPSYCHOTICS alone</NAME>
<DICH_OUTCOME CHI2="14.851167203661273" CI_END="1.4741330946173576" CI_START="1.1628423724236556" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3092686603646606" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="291" I2="12.464792687842765" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.16853669631029405" LOG_CI_START="0.06552084849785719" LOG_EFFECT_SIZE="0.11702877240407557" METHOD="MH" MODIFIED="2016-08-08 09:43:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3167362119509667" P_Q="1.0" P_Z="8.462213801691752E-6" Q="0.0" RANDOM="YES" SCALE="13.63" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="YES" TAU2="0.006140701990128334" TOTALS="YES" TOTAL_1="520" TOTAL_2="529" WEIGHT="99.99999999999999" Z="4.453143549030358">
<NAME>Clinically significant response: 1. Important change - as defined by the studies</NAME>
<GROUP_LABEL_1>Valproate + Antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + Antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3819161595464036" CI_START="0.9306791944551314" EFFECT_SIZE="1.1340725806451613" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="53" LOG_CI_END="0.14048169531685484" LOG_CI_START="-0.031199994730449643" LOG_EFFECT_SIZE="0.05464085029320262" MODIFIED="2013-06-03 17:06:30 +0100" MODIFIED_BY="[Empty name]" ORDER="792" O_E="0.0" SE="0.10084667457185839" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.010170051772202308" WEIGHT="22.44963347345011"/>
<DICH_DATA CI_END="129.74412565322564" CI_START="0.3776664242276759" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="2.1130877036754665" LOG_CI_START="-0.4228916236469528" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-06-03 17:06:31 +0100" MODIFIED_BY="[Empty name]" ORDER="793" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Fisk-1987" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="0.1645570580153196"/>
<DICH_DATA CI_END="3.0031630760051726" CI_START="0.5202847665796584" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.477578915644285" LOG_CI_START="-0.28375888962817214" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-06-03 17:06:31 +0100" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Glick-2009" TOTAL_1="8" TOTAL_2="8" VAR="0.2" WEIGHT="1.7763131691360758"/>
<DICH_DATA CI_END="3.0028281703186757" CI_START="0.550501437554572" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.47753048144390436" LOG_CI_START="-0.2592415425937682" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-03-19 10:38:14 +0000" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.4327835340000672" STUDY_ID="STD-Guo-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.1873015873015873" WEIGHT="1.8929182702538554"/>
<DICH_DATA CI_END="1.6044985664275577" CI_START="0.9749038199559569" EFFECT_SIZE="1.2506925207756232" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.20533933340230553" LOG_CI_START="-0.011038227914572225" LOG_EFFECT_SIZE="0.09715055274386665" MODIFIED="2013-03-20 14:09:08 +0000" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.12710125060373678" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.016154727905033903" WEIGHT="16.423565069695005"/>
<DICH_DATA CI_END="1.5497352673789209" CI_START="0.8288153928488928" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.19025751640515565" LOG_CI_START="-0.08154219175997034" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2013-03-16 20:34:46 +0000" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.15965649400644924" STUDY_ID="STD-Li-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.025490196078431365" WEIGHT="11.57635305979454"/>
<DICH_DATA CI_END="4.8944142941476345" CI_START="1.11237915657334" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.6897007280004384" LOG_CI_START="0.04625284258875047" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2013-03-20 10:21:31 +0000" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Liang-2004" TOTAL_1="21" TOTAL_2="21" VAR="0.14285714285714285" WEIGHT="2.457555302329103"/>
<DICH_DATA CI_END="2.969306179643863" CI_START="1.117638417744806" EFFECT_SIZE="1.821705426356589" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="32" LOG_CI_END="0.47265498212749046" LOG_CI_START="0.04830132181748406" LOG_EFFECT_SIZE="0.2604781519724873" MODIFIED="2013-03-20 13:10:58 +0000" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.24926744065059406" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="0.062134256968497434" WEIGHT="5.363173398052387"/>
<DICH_DATA CI_END="2.238900905940909" CI_START="0.8226521905487535" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.35003487207146966" LOG_CI_START="-0.08478374152228778" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2013-03-16 16:03:26 +0000" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.2554146060118237" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" VAR="0.06523662096417512" WEIGHT="5.130066924399036"/>
<DICH_DATA CI_END="1.9728646309214037" CI_START="0.5323231368788075" EFFECT_SIZE="1.024793388429752" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.29509728694465825" LOG_CI_START="-0.2738246572530884" LOG_EFFECT_SIZE="0.010636314845784953" MODIFIED="2013-03-16 16:04:27 +0000" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.33418756623079937" STUDY_ID="STD-Shi-2010" TOTAL_1="33" TOTAL_2="31" VAR="0.11168132942326492" WEIGHT="3.1078266029488635"/>
<DICH_DATA CI_END="4.494870270135582" CI_START="1.021572694812251" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.6527171617472683" LOG_CI_START="0.00926927633558044" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2013-03-16 16:55:35 +0000" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Wang-2009" TOTAL_1="30" TOTAL_2="30" VAR="0.14285714285714285" WEIGHT="2.457555302329103"/>
<DICH_DATA CI_END="3.667788466538238" CI_START="1.202359416371218" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="0.5644042805246219" LOG_CI_START="0.08003430894321663" LOG_EFFECT_SIZE="0.3222192947339193" MODIFIED="2013-03-16 16:04:33 +0000" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.2845213189769459" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.08095238095238097" WEIGHT="4.204357352715734"/>
<DICH_DATA CI_END="1.6053050368500235" CI_START="0.8238309664779027" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.20555756835057928" LOG_CI_START="-0.08416188764335593" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2013-03-16 17:23:14 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.17018264258527413" STUDY_ID="STD-Yao-2010" TOTAL_1="31" TOTAL_2="31" VAR="0.028962131837307156" WEIGHT="10.4313641867236"/>
<DICH_DATA CI_END="1.9129637444510341" CI_START="1.0556345291828615" EFFECT_SIZE="1.4210526315789473" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.28170673911560595" LOG_CI_START="0.0235135872967107" LOG_EFFECT_SIZE="0.15261016320615833" MODIFIED="2013-03-16 21:07:32 +0000" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.15166393545513313" STUDY_ID="STD-Zhang-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.023001949317738787" WEIGHT="12.564760830157269"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.50694305549028" CI_END="1.1932110459748801" CI_START="0.6991321651681582" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9133521895057682" ESTIMABLE="YES" EVENTS_1="256" EVENTS_2="297" I2="44.938617224231415" I2_Q="73.317265314696" ID="CMP-001.02" LOG_CI_END="0.07671726512560413" LOG_CI_START="-0.15544071670421442" LOG_EFFECT_SIZE="-0.039361725789305135" METHOD="MH" MODIFIED="2016-10-05 13:53:55 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.016002101306336836" P_Q="0.023571011032251787" P_Z="0.5062982850392774" Q="7.495483591123575" RANDOM="YES" SCALE="115.78" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11306712911129738" TOTALS="SUB" TOTAL_1="1347" TOTAL_2="1388" WEIGHT="300.0" Z="0.6646126427212988">
<NAME>Leaving the study early: Acceptability/tolerability of treatment</NAME>
<GROUP_LABEL_1>Vaproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="17.705910765677274" CI_END="1.236745694046651" CI_START="0.4703525033637163" DF="8" EFFECT_SIZE="0.7626968160541507" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="176" I2="54.81734825238181" ID="CMP-001.02.01" LOG_CI_END="0.09228040696422833" LOG_CI_START="-0.3275765401812917" LOG_EFFECT_SIZE="-0.11764806660853169" MODIFIED="2016-07-25 14:01:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.023542705216436643" P_Z="0.2720287610162101" STUDIES="11" TAU2="0.23433462521367726" TOTAL_1="467" TOTAL_2="484" WEIGHT="100.0" Z="1.0984025629261371">
<NAME>Acceptability of treatment: Leaving for any reason</NAME>
<DICH_DATA CI_END="1.134091165385337" CI_START="0.8371865217097025" EFFECT_SIZE="0.9743951139299977" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="129" LOG_CI_END="0.054647967283869815" LOG_CI_START="-0.07717777220413594" LOG_EFFECT_SIZE="-0.011264902460133081" MODIFIED="2013-03-25 13:13:36 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.07743509192318919" STUDY_ID="STD-Casey-2009" TOTAL_1="198" TOTAL_2="204" VAR="0.005996193461152759" WEIGHT="25.308617687712484"/>
<DICH_DATA CI_END="1.0922092565959627" CI_START="0.1602032172325206" EFFECT_SIZE="0.41830065359477125" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.03830585290957073" LOG_CI_START="-0.7953287665769939" LOG_EFFECT_SIZE="-0.3785114568337116" MODIFIED="2013-03-25 12:53:54 +0000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.4896811020443268" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="0.23978758169934639" WEIGHT="12.828846064854396"/>
<DICH_DATA CI_END="2.3349446452133584" CI_START="0.38072833703323317" EFFECT_SIZE="0.9428571428571428" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.3682765891576574" LOG_CI_START="-0.41938479810243373" LOG_EFFECT_SIZE="-0.025554104472388168" MODIFIED="2013-02-19 14:43:10 +0000" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.46267619786332653" STUDY_ID="STD-Dose-1998" TOTAL_1="20" TOTAL_2="22" VAR="0.21406926406926408" WEIGHT="13.564647751255844"/>
<DICH_DATA CI_END="7.642211565358725" CI_START="0.9895695683537408" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.8832190564348329" LOG_CI_START="-0.004553668774307619" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2013-02-19 14:43:10 +0000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.5214820933337132" STUDY_ID="STD-Fisk-1987" TOTAL_1="29" TOTAL_2="29" VAR="0.2719435736677116" WEIGHT="12.014028693819427"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-19 14:43:10 +0000" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.0" STUDY_ID="STD-Hesslinger-1999" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.59143967944538" CI_START="0.16091896923149823" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8803241455328684" LOG_CI_START="-0.7933927579706879" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2013-02-25 14:23:37 +0000" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.9831495941502806" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.9665831244778613" WEIGHT="5.06482713739432"/>
<DICH_DATA CI_END="3.0683219164168825" CI_START="0.18332496241361632" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4869009221574032" LOG_CI_START="-0.736778395374003" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-02-25 14:00:07 +0000" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.7187952884282608" STUDY_ID="STD-Liu-2003" TOTAL_1="30" TOTAL_2="30" VAR="0.5166666666666666" WEIGHT="8.09910831602848"/>
<DICH_DATA CI_END="0.6837969840698686" CI_START="0.1108400563526766" EFFECT_SIZE="0.27530364372469635" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.16507281901866133" LOG_CI_START="-0.9553032620881975" LOG_EFFECT_SIZE="-0.5601880405534294" MODIFIED="2013-04-13 16:58:09 +0100" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.46418527396282594" STUDY_ID="STD-Liu-2007a" TOTAL_1="19" TOTAL_2="17" VAR="0.2154679685639438" WEIGHT="13.52246717239549"/>
<DICH_DATA CI_END="1.2164281145095956" CI_START="0.06138360250698928" EFFECT_SIZE="0.27325581395348836" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.08508644915318392" LOG_CI_START="-1.2119476270968468" LOG_EFFECT_SIZE="-0.5634305889718315" MODIFIED="2013-03-20 13:00:08 +0000" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.7618842368114928" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="0.5804675903018307" WEIGHT="7.4649291479503335"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-02-19 14:43:10 +0000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="0.0" SE="0.0" STUDY_ID="STD-Wassef-2000" TOTAL_1="5" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-02-19 14:43:10 +0000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Yin-2004" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="2.132528028589224"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9174556844451904" CI_END="1.9681536462807128" CI_START="0.8995824937489278" DF="5" EFFECT_SIZE="1.3306075924938385" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="38" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.294058999139642" LOG_CI_START="-0.04595900470618807" LOG_EFFECT_SIZE="0.124049997216727" MODIFIED="2016-07-25 14:08:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.968945071827129" P_Z="0.15268215390139708" STUDIES="6" TAU2="0.0" TOTAL_1="479" TOTAL_2="495" WEIGHT="100.0" Z="1.430121488139315">
<NAME>Overall tolerability: Leaving due to adverse event</NAME>
<DICH_DATA CI_END="5.882049299298417" CI_START="0.30713228354302136" EFFECT_SIZE="1.3440860215053763" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7695286601444508" LOG_CI_START="-0.5126745312362081" LOG_EFFECT_SIZE="0.12842706445412128" MODIFIED="2013-05-16 15:07:24 +0100" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.7531725016251596" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.567268817204301" WEIGHT="7.032182285309172"/>
<DICH_DATA CI_END="2.1141268254054806" CI_START="0.8926400958187115" EFFECT_SIZE="1.3737373737373737" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="30" LOG_CI_END="0.32513103686054384" LOG_CI_START="-0.04932360931520873" LOG_EFFECT_SIZE="0.13790371377266758" MODIFIED="2013-03-25 13:14:06 +0000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.21995651274402983" STUDY_ID="STD-Casey-2009" TOTAL_1="198" TOTAL_2="204" VAR="0.04838086749851456" WEIGHT="82.45279453649424"/>
<DICH_DATA CI_END="13.815573537721964" CI_START="0.0641170014672433" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.14036891886509" LOG_CI_START="-1.1930267963097887" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2013-03-25 12:54:20 +0000" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="1.370648193588798" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="1.8786764705882353" WEIGHT="2.1233766376513605"/>
<DICH_DATA CI_END="7.59143967944538" CI_START="0.16091896923149823" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8803241455328684" LOG_CI_START="-0.7933927579706879" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2013-03-20 14:08:27 +0000" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.9831495941502806" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.9665831244778613" WEIGHT="4.1270508726368105"/>
<DICH_DATA CI_END="5.8145010647209014" CI_START="0.05136725509428902" EFFECT_SIZE="0.5465116279069767" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7645124543808894" LOG_CI_START="-1.2893136409965902" LOG_EFFECT_SIZE="-0.26240059330785026" MODIFIED="2013-02-19 14:47:57 +0000" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="1.2064276150278685" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="1.4554675903018308" WEIGHT="2.7407946105657466"/>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-03-20 10:58:04 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Yin-2004" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="1.5238010573426766"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.427592781234447" CI_END="0.9432411248681555" CI_START="0.3079542549025092" DF="4" EFFECT_SIZE="0.5389574359837496" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="83" I2="46.14675147369603" ID="CMP-001.02.03" LOG_CI_END="-0.02537727246560419" LOG_CI_START="-0.51151379102846" LOG_EFFECT_SIZE="-0.26844553174703206" MODIFIED="2016-07-25 13:59:15 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.11494494116009668" P_Z="0.030418955380866475" STUDIES="5" TAU2="0.1725836154847045" TOTAL_1="401" TOTAL_2="409" WEIGHT="99.99999999999999" Z="2.164591854116625">
<NAME>Leaving due to poor clinical effect</NAME>
<DICH_DATA CI_END="2.3364102067637647" CI_START="0.43493820808376893" EFFECT_SIZE="1.0080645161290323" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3685490948162007" LOG_CI_START="-0.36157243912455805" LOG_EFFECT_SIZE="0.003488327845821341" MODIFIED="2013-05-16 15:07:47 +0100" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.42887700319668315" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.18393548387096775" WEIGHT="22.872250365821408"/>
<DICH_DATA CI_END="1.1088238517623021" CI_START="0.5090037815492515" EFFECT_SIZE="0.7512626262626263" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="48" LOG_CI_END="0.044862559419010836" LOG_CI_START="-0.29327899114089867" LOG_EFFECT_SIZE="-0.12420821586094391" MODIFIED="2013-03-25 13:14:43 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.19862602062656123" STUDY_ID="STD-Casey-2009" TOTAL_1="198" TOTAL_2="204" VAR="0.03945229606994313" WEIGHT="38.45760862333208"/>
<DICH_DATA CI_END="1.3339501646373932" CI_START="0.07378362836030244" EFFECT_SIZE="0.3137254901960784" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.12513960497238483" LOG_CI_START="-1.1320399918564081" LOG_EFFECT_SIZE="-0.5034501934420116" MODIFIED="2013-03-25 12:54:43 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.7384735183166028" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="0.5453431372549019" WEIGHT="11.3582535677114"/>
<DICH_DATA CI_END="0.6837969840698686" CI_START="0.1108400563526766" EFFECT_SIZE="0.27530364372469635" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-0.16507281901866133" LOG_CI_START="-0.9553032620881975" LOG_EFFECT_SIZE="-0.5601880405534294" MODIFIED="2013-03-16 20:41:32 +0000" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.46418527396282594" STUDY_ID="STD-Liu-2007a" TOTAL_1="19" TOTAL_2="17" VAR="0.2154679685639438" WEIGHT="21.013685901196613"/>
<DICH_DATA CI_END="1.4526570127265406" CI_START="0.022845108179997912" EFFECT_SIZE="0.1821705426356589" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.1621630850041194" LOG_CI_START="-1.6412067810591449" LOG_EFFECT_SIZE="-0.7395218480275128" MODIFIED="2013-02-19 14:48:15 +0000" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="1.0593083861503683" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="1.1221342569684976" WEIGHT="6.298201541938502"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.32174479229572717" CI_START="-0.1217447922957274" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2016-10-05 13:54:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.3767595155662705" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="194" TOTAL_2="198" UNITS="" WEIGHT="100.0" Z="0.8838827574025592">
<NAME>Clinical response: 2. Global state: 1a. mean change score CGI severity (high = poor)</NAME>
<GROUP_LABEL_1>Valproate + Antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Anitipsychotic alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.32174479229572717" CI_START="-0.1217447922957274" EFFECT_SIZE="0.09999999999999987" ESTIMABLE="YES" MEAN_1="-1.1" MEAN_2="-1.2" MODIFIED="2013-03-25 13:21:33 +0000" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="1.11" SD_2="1.13" SE="0.11313717703224237" STUDY_ID="STD-Casey-2009" TOTAL_1="194" TOTAL_2="198" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.264286063825087" CI_START="-0.264286063825087" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2016-10-05 13:54:29 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="195" TOTAL_2="198" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Clinical response: 3. Global state: 1b. mean change score CGI improvement (high = poor)</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.264286063825087" CI_START="-0.264286063825087" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="2.7" MODIFIED="2013-03-25 13:23:34 +0000" MODIFIED_BY="[Empty name]" ORDER="214" SD_1="1.26" SD_2="1.41" SE="0.13484230624120735" STUDY_ID="STD-Casey-2009" TOTAL_1="195" TOTAL_2="198" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="36.03804934719707" CI_END="-3.909756648021286" CI_START="-7.80020133853526" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.854978993278273" ESTIMABLE="YES" I2="66.7018603465747" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2016-08-08 09:49:41 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="3.19462671717452E-4" P_Q="1.0" P_Z="3.649357862122686E-9" Q="0.0" RANDOM="YES" SCALE="25.67" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="7.672725612032721" TOTALS="YES" TOTAL_1="678" TOTAL_2="685" UNITS="" WEIGHT="100.00000000000001" Z="5.899350264531299">
<NAME>Clinical response: 4. Mental state: 2a. mean change score PANSS total (high = poor)</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.814235426985151" CI_START="-9.814235426985151" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-28.0" MEAN_2="-26.5" MODIFIED="2013-05-16 14:11:47 +0100" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="33.13" SD_2="32.86" SE="4.24203479888752" STUDY_ID="STD-Casey-2003" TOTAL_1="122" TOTAL_2="120" WEIGHT="3.8375788434747555"/>
<CONT_DATA CI_END="6.876550932336702" CI_START="-2.076550932336705" EFFECT_SIZE="2.3999999999999986" ESTIMABLE="YES" MEAN_1="-20.5" MEAN_2="-22.9" MODIFIED="2013-05-16 14:11:46 +0100" MODIFIED_BY="[Empty name]" ORDER="214" SD_1="22.9" SD_2="22.37" SE="2.283996526286792" STUDY_ID="STD-Casey-2009" TOTAL_1="195" TOTAL_2="198" WEIGHT="7.64206575617382"/>
<CONT_DATA CI_END="-2.465757452086897" CI_START="-11.3342425479131" EFFECT_SIZE="-6.899999999999999" ESTIMABLE="YES" MEAN_1="44.9" MEAN_2="51.8" MODIFIED="2013-03-19 11:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="100" SD_1="10.7" SD_2="9.5" SE="2.262410219213129" STUDY_ID="STD-Jia-2007" TOTAL_1="40" TOTAL_2="40" WEIGHT="7.700699179232738"/>
<CONT_DATA CI_END="-0.9393367547446836" CI_START="-8.640663245255329" EFFECT_SIZE="-4.790000000000006" ESTIMABLE="YES" MEAN_1="49.48" MEAN_2="54.27" MODIFIED="2013-03-20 14:10:25 +0000" MODIFIED_BY="[Empty name]" ORDER="207" SD_1="11.12" SD_2="10.32" SE="1.9646602058144245" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" WEIGHT="8.541113849652751"/>
<CONT_DATA CI_END="-1.919839184595744" CI_START="-6.8401608154042535" EFFECT_SIZE="-4.379999999999999" ESTIMABLE="YES" MEAN_1="23.18" MEAN_2="27.56" MODIFIED="2013-03-19 11:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="187" SD_1="4.15" SD_2="3.78" SE="1.2552071542179801" STUDY_ID="STD-Li-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.65078918039046"/>
<CONT_DATA CI_END="-4.668881212752625" CI_START="-21.211118787247386" EFFECT_SIZE="-12.940000000000005" ESTIMABLE="YES" MEAN_1="62.74" MEAN_2="75.68" MODIFIED="2013-03-19 11:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="13.32" SD_2="14.02" SE="4.220036109075936" STUDY_ID="STD-Liang-2004" TOTAL_1="21" TOTAL_2="21" WEIGHT="3.8656142581661657"/>
<CONT_DATA CI_END="-3.0930226722926646" CI_START="-14.166977327707325" EFFECT_SIZE="-8.629999999999995" ESTIMABLE="YES" MEAN_1="58.94" MEAN_2="67.57" MODIFIED="2013-03-19 11:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="130" SD_1="11.21" SD_2="12.07" SE="2.8250403432829896" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" WEIGHT="6.29257905705958"/>
<CONT_DATA CI_END="0.8006217485520373" CI_START="-5.640621748552027" EFFECT_SIZE="-2.4199999999999946" ESTIMABLE="YES" MEAN_1="61.45" MEAN_2="63.87" MODIFIED="2013-03-19 11:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="103" SD_1="5.96" SD_2="7.32" SE="1.6432045557754555" STUDY_ID="STD-Shi-2010" TOTAL_1="33" TOTAL_2="33" WEIGHT="9.496079739902596"/>
<CONT_DATA CI_END="-2.3218586056309376" CI_START="-9.77814139436907" EFFECT_SIZE="-6.050000000000004" ESTIMABLE="YES" MEAN_1="42.15" MEAN_2="48.2" MODIFIED="2013-03-19 11:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="6.85" SD_2="7.85" SE="1.9021479087249409" STUDY_ID="STD-Wang-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="8.723967791082995"/>
<CONT_DATA CI_END="-4.866443574054412" CI_START="-14.033556425945594" EFFECT_SIZE="-9.450000000000003" ESTIMABLE="YES" MEAN_1="50.66" MEAN_2="60.11" MODIFIED="2013-03-19 11:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="9.6" SD_2="8.48" SE="2.3385921690909113" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" WEIGHT="7.495307963539634"/>
<CONT_DATA CI_END="-2.3183707335065527" CI_START="-7.261629266493445" EFFECT_SIZE="-4.789999999999999" ESTIMABLE="YES" MEAN_1="45.38" MEAN_2="50.17" MODIFIED="2013-03-19 11:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="162" SD_1="4.63" SD_2="5.85" SE="1.2610585122937679" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" WEIGHT="10.633859702495707"/>
<CONT_DATA CI_END="-4.777226006159026" CI_START="-10.422773993840977" EFFECT_SIZE="-7.600000000000001" ESTIMABLE="YES" MEAN_1="45.61" MEAN_2="53.21" MODIFIED="2013-03-19 11:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="157" SD_1="5.63" SD_2="5.71" SE="1.440217277514616" STUDY_ID="STD-Yao-2010" TOTAL_1="31" TOTAL_2="31" WEIGHT="10.105865551474993"/>
<CONT_DATA CI_END="-8.918788968314297" CI_START="-22.481211031685696" EFFECT_SIZE="-15.699999999999996" ESTIMABLE="YES" MEAN_1="32.1" MEAN_2="47.8" MODIFIED="2013-03-19 11:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="191" SD_1="13.4" SD_2="13.4" SE="3.459865122611959" STUDY_ID="STD-Zhang-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="5.014479127353813"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="22.48801596223286" CI_END="0.7271799698719257" CI_START="-4.459426211329322" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.866123120728698" ESTIMABLE="YES" I2="73.31912246026238" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2016-08-08 09:50:17 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="9.874051842371223E-4" P_Q="1.0" P_Z="0.15842849840349" Q="0.0" RANDOM="YES" SCALE="26.58" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="6.709320430661539" TOTALS="YES" TOTAL_1="327" TOTAL_2="319" UNITS="" WEIGHT="100.0" Z="1.4103766430551063">
<NAME>Clinical response: 5. Mental state: 2b. mean endpoint score BPRS total (high = poor)</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.8302062965740933" CI_START="-1.6302062965740904" EFFECT_SIZE="1.1000000000000014" ESTIMABLE="YES" MEAN_1="-13.2" MEAN_2="-14.3" MODIFIED="2013-04-12 20:26:48 +0100" MODIFIED_BY="[Empty name]" ORDER="214" SD_1="13.96" SD_2="13.65" SE="1.3929879926925242" STUDY_ID="STD-Casey-2009" TOTAL_1="195" TOTAL_2="198" WEIGHT="20.239860822142834"/>
<CONT_DATA CI_END="0.5743341842696448" CI_START="-0.0543341842696452" EFFECT_SIZE="0.2599999999999998" ESTIMABLE="YES" MEAN_1="2.01" MEAN_2="1.75" MODIFIED="2013-03-19 11:07:34 +0000" MODIFIED_BY="[Empty name]" ORDER="794" SD_1="0.52" SD_2="0.31" SE="0.16037753078580674" STUDY_ID="STD-Dose-1998" TOTAL_1="14" TOTAL_2="15" WEIGHT="25.993819843904884"/>
<CONT_DATA CI_END="8.06366100572563" CI_START="-6.643661005725628" EFFECT_SIZE="0.7100000000000009" ESTIMABLE="YES" MEAN_1="63.4" MEAN_2="62.69" MODIFIED="2013-03-19 11:07:34 +0000" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="12.01" SD_2="15.07" SE="3.7519368027833" STUDY_ID="STD-Liu-2003" TOTAL_1="27" TOTAL_2="26" WEIGHT="8.422327664284339"/>
<CONT_DATA CI_END="7.77800667642742" CI_START="-11.178006676427412" EFFECT_SIZE="-1.6999999999999957" ESTIMABLE="YES" MEAN_1="38.1" MEAN_2="39.8" MODIFIED="2013-03-19 11:07:34 +0000" MODIFIED_BY="[Empty name]" ORDER="177" SD_1="11.1" SD_2="7.79" SE="4.835806551134981" STUDY_ID="STD-Liu-2007a" TOTAL_1="15" TOTAL_2="4" WEIGHT="5.817353720333173"/>
<CONT_DATA CI_END="-2.540659067166682" CI_START="-9.059340932833319" EFFECT_SIZE="-5.800000000000001" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="18.8" MODIFIED="2013-03-19 11:07:34 +0000" MODIFIED_BY="[Empty name]" ORDER="74" SD_1="6.4" SD_2="8.3" SE="1.6629596046369135" STUDY_ID="STD-Lu-2006" TOTAL_1="41" TOTAL_2="39" WEIGHT="18.477464686258635"/>
<CONT_DATA CI_END="2.254765341935605" CI_START="-6.014765341935603" EFFECT_SIZE="-1.879999999999999" ESTIMABLE="YES" MEAN_1="28.68" MEAN_2="30.56" MODIFIED="2013-03-19 11:07:34 +0000" MODIFIED_BY="[Empty name]" ORDER="795" SD_1="8.26" SD_2="8.08" SE="2.109612918681213" STUDY_ID="STD-Wang-2005a" TOTAL_1="30" TOTAL_2="30" WEIGHT="15.687526188914873"/>
<CONT_DATA CI_END="-4.0170937395247375" CI_START="-23.98290626047526" EFFECT_SIZE="-14.0" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="38.0" MODIFIED="2013-03-19 11:07:34 +0000" MODIFIED_BY="[Empty name]" ORDER="796" SD_1="3.0" SD_2="13.0" SE="5.093413113311853" STUDY_ID="STD-Wassef-2000" TOTAL_1="5" TOTAL_2="7" WEIGHT="5.361647074161264"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="15.817606651199686" CI_START="-26.037606651199685" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.109999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2016-08-08 09:50:50 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.6322414639928753" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="0.4785743600750226">
<NAME>Clinical response: 6. Mental state 2c. mean change score IMPS total (high = poor)</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="15.817606651199686" CI_START="-26.037606651199685" EFFECT_SIZE="-5.109999999999999" ESTIMABLE="YES" MEAN_1="-37.86" MEAN_2="-32.75" MODIFIED="2013-03-19 11:08:19 +0000" MODIFIED_BY="[Empty name]" ORDER="797" SD_1="22.8" SD_2="22.5" SE="10.677546534667972" STUDY_ID="STD-Hesslinger-1999" TOTAL_1="9" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="25.88626049231388" CI_END="-0.42665544956411816" CI_START="-3.0138333496383605" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.7202443996012393" ESTIMABLE="YES" I2="69.09557484220113" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2016-10-05 13:54:44 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0010984166803786888" P_Q="1.0" P_Z="0.009149812724649256" Q="0.0" RANDOM="YES" SCALE="11.15" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="2.42661266695949" TOTALS="YES" TOTAL_1="533" TOTAL_2="540" UNITS="" WEIGHT="100.0" Z="2.60640527868486">
<NAME>Clincal response: 7. Positive symptoms: 3a. mean endpoint score PANSS positive subscale (high = poor)</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.576845816345548" CI_START="-4.076845816345548" EFFECT_SIZE="-1.25" ESTIMABLE="YES" MEAN_1="-8.25" MEAN_2="-7.0" MODIFIED="2013-04-12 20:29:10 +0100" MODIFIED_BY="[Empty name]" ORDER="215" SD_1="13.03" SD_2="9.09" SE="1.4422947761506575" STUDY_ID="STD-Casey-2003" TOTAL_1="122" TOTAL_2="120" WEIGHT="9.665526937054493"/>
<CONT_DATA CI_END="1.714174110609866" CI_START="-1.1141741106098664" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-7.5" MODIFIED="2013-04-12 20:30:22 +0100" MODIFIED_BY="[Empty name]" ORDER="216" SD_1="7.26" SD_2="7.04" SE="0.7215306616676077" STUDY_ID="STD-Casey-2009" TOTAL_1="195" TOTAL_2="198" WEIGHT="14.78032487055518"/>
<CONT_DATA CI_END="3.2773645363981077" CI_START="-7.277364536398108" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-13.0" MEAN_2="-11.0" MODIFIED="2013-04-12 20:35:01 +0100" MODIFIED_BY="[Empty name]" ORDER="217" SD_1="7.5" SD_2="3.0" SE="2.692582403567252" STUDY_ID="STD-Hesslinger-1999" TOTAL_1="9" TOTAL_2="9" WEIGHT="4.501663773105413"/>
<CONT_DATA CI_END="2.543304035455335" CI_START="-2.3233040354553327" EFFECT_SIZE="0.11000000000000121" ESTIMABLE="YES" MEAN_1="15.14" MEAN_2="15.03" MODIFIED="2013-03-20 14:11:35 +0000" MODIFIED_BY="[Empty name]" ORDER="208" SD_1="6.46" SD_2="7.14" SE="1.2415044636783765" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" WEIGHT="10.97818788007947"/>
<CONT_DATA CI_END="-1.9871305863115811" CI_START="-9.872869413688422" EFFECT_SIZE="-5.9300000000000015" ESTIMABLE="YES" MEAN_1="14.28" MEAN_2="20.21" MODIFIED="2013-02-18 16:02:23 +0000" MODIFIED_BY="[Empty name]" ORDER="50" SD_1="5.94" SD_2="7.05" SE="2.0117050337604523" STUDY_ID="STD-Liang-2004" TOTAL_1="21" TOTAL_2="21" WEIGHT="6.729031735035598"/>
<CONT_DATA CI_END="2.0022861020908223" CI_START="-2.642286102090823" EFFECT_SIZE="-0.3200000000000003" ESTIMABLE="YES" MEAN_1="18.19" MEAN_2="18.51" MODIFIED="2013-03-16 11:48:17 +0000" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="4.42" SD_2="5.31" SE="1.1848616201158384" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" WEIGHT="11.372078341432728"/>
<CONT_DATA CI_END="-0.2039420960465066" CI_START="-3.5960579039534943" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="10.45" MEAN_2="12.35" MODIFIED="2013-03-16 16:58:10 +0000" MODIFIED_BY="[Empty name]" ORDER="152" SD_1="3.25" SD_2="3.45" SE="0.8653515663204947" STUDY_ID="STD-Wang-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="13.718027856624714"/>
<CONT_DATA CI_END="-2.9066902332123927" CI_START="-6.633309766787606" EFFECT_SIZE="-4.77" ESTIMABLE="YES" MEAN_1="14.66" MEAN_2="19.43" MODIFIED="2013-03-16 16:06:33 +0000" MODIFIED_BY="[Empty name]" ORDER="146" SD_1="4.54" SD_2="2.55" SE="0.9506857174341756" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" WEIGHT="13.079704362876724"/>
<CONT_DATA CI_END="-0.3142041358071379" CI_START="-2.925795864192864" EFFECT_SIZE="-1.620000000000001" ESTIMABLE="YES" MEAN_1="12.51" MEAN_2="14.13" MODIFIED="2013-03-16 17:44:43 +0000" MODIFIED_BY="[Empty name]" ORDER="163" SD_1="2.23" SD_2="3.25" SE="0.6662346219077566" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" WEIGHT="15.175454243235672"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.09" MODIFIED="2016-10-05 13:54:50 +0100" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Clinical response: 8. Positive symptoms: 3b. mean endpoint score PANSS positive subscale (high = poor, skewed data)</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2013-04-15 10:35:03 +0100" MODIFIED_BY="[Empty name]" ORDER="69" STUDY_ID="STD-Jia-2007">
<TR>
<TD>
<P>Valproate</P>
</TD>
<TD>
<P>8.3</P>
</TD>
<TD>
<P>1.8</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>9.4</P>
</TD>
<TD>
<P>2.7</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-04-12 20:40:35 +0100" MODIFIED_BY="[Empty name]" ORDER="70" STUDY_ID="STD-Zhang-2007">
<TR>
<TD>
<P>Valproate + Risperidone</P>
</TD>
<TD>
<P>8.6</P>
</TD>
<TD>
<P>6.5</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
<TR>
<TD>
<P>Risperidone monotherapy</P>
</TD>
<TD>
<P>13.5</P>
</TD>
<TD>
<P>5.3</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="12.190888086613876" CI_END="-0.4313065687232265" CI_START="-3.1284673216889334" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.77988694520608" ESTIMABLE="YES" I2="67.18860864294068" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2016-10-05 13:54:55 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.01598684506572301" P_Q="1.0" P_Z="0.009687042765774664" Q="0.0" RANDOM="YES" SCALE="11.98" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.4839761670028506" TOTALS="YES" TOTAL_1="324" TOTAL_2="327" UNITS="" WEIGHT="100.00000000000001" Z="2.586804887562657">
<NAME>Clinical response: 9. Negative symptoms: 4a. mean endpoint score PANSS negative subscale (high = poor)</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.714174110609866" CI_START="-1.1141741106098664" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="-7.2" MEAN_2="-7.5" MODIFIED="2013-04-15 10:43:47 +0100" MODIFIED_BY="[Empty name]" ORDER="215" SD_1="7.26" SD_2="7.04" SE="0.7215306616676077" STUDY_ID="STD-Casey-2009" TOTAL_1="195" TOTAL_2="198" WEIGHT="23.617478016577934"/>
<CONT_DATA CI_END="-0.16165589700691596" CI_START="-4.218344102993083" EFFECT_SIZE="-2.1899999999999995" ESTIMABLE="YES" MEAN_1="15.37" MEAN_2="17.56" MODIFIED="2013-03-16 11:49:37 +0000" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="3.87" SD_2="4.63" SE="1.0348884566208374" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" WEIGHT="18.529838587109325"/>
<CONT_DATA CI_END="-1.5069579601544845" CI_START="-4.693042039845515" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="12.05" MEAN_2="15.15" MODIFIED="2013-03-16 17:01:20 +0000" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="2.85" SD_2="3.42" SE="0.8127914861758826" STUDY_ID="STD-Wang-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="22.075469005848785"/>
<CONT_DATA CI_END="-0.28283603149375036" CI_START="-7.35716396850625" EFFECT_SIZE="-3.8200000000000003" ESTIMABLE="YES" MEAN_1="16.32" MEAN_2="20.14" MODIFIED="2013-04-15 10:54:20 +0100" MODIFIED_BY="[Empty name]" ORDER="218" SD_1="8.24" SD_2="5.46" SE="1.8047086560809014" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" WEIGHT="9.986013764978187"/>
<CONT_DATA CI_END="-0.3077279004946094" CI_START="-2.6322720995053883" EFFECT_SIZE="-1.4699999999999989" ESTIMABLE="YES" MEAN_1="13.56" MEAN_2="15.03" MODIFIED="2013-03-16 17:46:23 +0000" MODIFIED_BY="[Empty name]" ORDER="164" SD_1="2.54" SD_2="2.42" SE="0.59300686577572" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" WEIGHT="25.79120062548578"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.11" MODIFIED="2016-10-05 13:55:01 +0100" MODIFIED_BY="[Empty name]" NO="11" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Clinical response: 10. Negative symptoms: 4b. mean endpoint score PANSS negative subscale (high = poor, data skewed)</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2013-02-25 14:57:12 +0000" MODIFIED_BY="[Empty name]" ORDER="76" STUDY_ID="STD-Jia-2007">
<TR>
<TD>
<P>Valproate + Clozapine</P>
</TD>
<TD>
<P>12.9</P>
</TD>
<TD>
<P>6.9</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
<TR>
<TD>
<P>Clozapine alone</P>
</TD>
<TD>
<P>12.8</P>
</TD>
<TD>
<P>5.6</P>
</TD>
<TD>
<P>40</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-03-29 09:43:12 +0000" MODIFIED_BY="[Empty name]" ORDER="77" STUDY_ID="STD-Jiang-2009">
<TR>
<TD>
<P>Valproate + Antipsychotics</P>
</TD>
<TD>
<P>11.01</P>
</TD>
<TD>
<P>6.43</P>
</TD>
<TD>
<P>57</P>
</TD>
</TR>
<TR>
<TD>
<P>Antipsychotics monotherapy</P>
</TD>
<TD>
<P>14.19</P>
</TD>
<TD>
<P>7.28</P>
</TD>
<TD>
<P>63</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-04-15 10:45:10 +0100" MODIFIED_BY="[Empty name]" ORDER="78" STUDY_ID="STD-Liang-2004">
<TR>
<TD>
<P>Valproate</P>
</TD>
<TD>
<P>11.17</P>
</TD>
<TD>
<P>4.32</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>13.87</P>
</TD>
<TD>
<P>4.26</P>
</TD>
<TD>
<P>21</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2013-04-15 10:45:18 +0100" MODIFIED_BY="[Empty name]" ORDER="79" STUDY_ID="STD-Zhang-2007">
<TR>
<TD>
<P>Valproate + Risperidone</P>
</TD>
<TD>
<P>9.2</P>
</TD>
<TD>
<P>5.8</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
<TR>
<TD>
<P>Risperidone monotherapy</P>
</TD>
<TD>
<P>12.9</P>
</TD>
<TD>
<P>5.7</P>
</TD>
<TD>
<P>30</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.12" MODIFIED="2016-10-05 13:55:06 +0100" MODIFIED_BY="[Empty name]" NO="12" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Clinical response: 11. Negative symptoms: 4c. mean endpoint score SANS subscale (skewed data)</NAME>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>Mean score</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2016-02-29 14:48:32 +0000" MODIFIED_BY="[Empty name]" ORDER="80" STUDY_ID="STD-Wassef-2000">
<TR>
<TD>
<P>Valproate - mean SANS - high = poor</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>5</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo - mean SANS - high = poor</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>18</P>
</TD>
<TD>
<P>7</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="17.958933800865346" CI_END="1.2171420484054756" CI_START="-0.2917085189381303" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4627167647336726" ESTIMABLE="YES" I2="88.86348141723407" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2016-10-05 13:55:18 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.2597054714558187E-4" P_Q="1.0" P_Z="0.22931784517167908" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.385955737057028" TOTALS="YES" TOTAL_1="73" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="1.2021179745023278">
<NAME>Clinical response: 12. Negative symptoms: 4d. mean endpoint score BPRS lack of energy subscale (high = poor)</NAME>
<GROUP_LABEL_1>Antipsychotic+Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4907866368375622" CI_START="0.8092133631624381" EFFECT_SIZE="1.1500000000000001" ESTIMABLE="YES" MEAN_1="2.89" MEAN_2="1.74" MODIFIED="2013-03-16 10:00:42 +0000" MODIFIED_BY="[Empty name]" ORDER="110" SD_1="0.56" SD_2="0.73" SE="0.1738739280546191" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" WEIGHT="35.59974268961218"/>
<CONT_DATA CI_END="0.6102279892682861" CI_START="-0.7502279892682858" EFFECT_SIZE="-0.06999999999999984" ESTIMABLE="YES" MEAN_1="1.87" MEAN_2="1.94" MODIFIED="2013-03-16 20:11:30 +0000" MODIFIED_BY="[Empty name]" ORDER="179" SD_1="0.82" SD_2="0.55" SE="0.34706147390147857" STUDY_ID="STD-Liu-2007a" TOTAL_1="15" TOTAL_2="4" WEIGHT="29.257434481672156"/>
<CONT_DATA CI_END="0.5800302652922791" CI_START="-0.1600302652922787" EFFECT_SIZE="0.2100000000000002" ESTIMABLE="YES" MEAN_1="2.12" MEAN_2="1.91" MODIFIED="2013-03-20 11:27:41 +0000" MODIFIED_BY="[Empty name]" ORDER="194" SD_1="0.63" SD_2="0.82" SE="0.1887944208215204" STUDY_ID="STD-Wang-2005a" TOTAL_1="30" TOTAL_2="30" WEIGHT="35.14282282871567"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.757190105945713" CI_START="1.0662695642149762" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.684210526315789" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.8297661374837727" LOG_CI_START="0.027867012806441972" LOG_EFFECT_SIZE="0.4288165751451073" METHOD="MH" MODIFIED="2016-09-08 17:33:11 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.036065653688647156" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0" Z="2.0961864588551875">
<NAME>Clinical response: 13. Aggression/Agitation: 5a. clinically important change - Modified Overt Aggression Scale (high = poor)</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.757190105945715" CI_START="1.0662695642149764" EFFECT_SIZE="2.6842105263157894" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.8297661374837728" LOG_CI_START="0.027867012806442062" LOG_EFFECT_SIZE="0.4288165751451074" MODIFIED="2013-05-26 19:18:37 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.4710395153001499" STUDY_ID="STD-Liu-2007a" TOTAL_1="19" TOTAL_2="17" VAR="0.22187822497420018" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="11.171432584839529" CI_END="-1.1866423817976213" CI_START="-3.915906827829552" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5512746048135866" ESTIMABLE="YES" I2="82.0971931324712" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2016-09-08 17:33:20 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0037510685545388833" P_Q="1.0" P_Z="2.48026966897299E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.1847986812150204" TOTALS="YES" TOTAL_1="93" TOTAL_2="93" UNITS="" WEIGHT="100.0" Z="3.6642886308626967">
<NAME>Clinical response: 14. Aggression/Agitation: 5b. mean endpoint score Modified Overt Aggression Scale (high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.8592770850756333" CI_START="-3.6207229149243663" EFFECT_SIZE="-2.7399999999999998" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="5.84" MODIFIED="2013-03-15 20:40:10 +0000" MODIFIED_BY="[Empty name]" ORDER="107" SD_1="1.17" SD_2="2.07" SE="0.4493566830163189" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" WEIGHT="34.9579734708725"/>
<CONT_DATA CI_END="-2.528375785944215" CI_START="-5.051624214055784" EFFECT_SIZE="-3.7899999999999996" ESTIMABLE="YES" MEAN_1="3.43" MEAN_2="7.22" ORDER="803" SD_1="1.48" SD_2="3.2" SE="0.6436976515932513" STUDY_ID="STD-Wang-2005a" TOTAL_1="30" TOTAL_2="30" WEIGHT="30.314270603141363"/>
<CONT_DATA CI_END="-0.37945192519683757" CI_START="-2.1805480748031627" EFFECT_SIZE="-1.2800000000000002" ESTIMABLE="YES" MEAN_1="3.12" MEAN_2="4.4" MODIFIED="2013-04-15 11:08:48 +0100" MODIFIED_BY="[Empty name]" ORDER="221" SD_1="1.83" SD_2="2.01" SE="0.4594717463721634" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" WEIGHT="34.72775592598614"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7925097992041681" CI_END="-1.080793888841301" CI_START="-2.625891029947807" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.853342459394554" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2016-10-05 13:55:38 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.672835384055023" P_Q="1.0" P_Z="2.5768906713581984E-6" Q="0.0" RANDOM="YES" SCALE="24.27" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="100" UNITS="" WEIGHT="100.0" Z="4.701949637717723">
<NAME>Clinical response: 15. Aggression/Agitation: 5c. mean endpoint score PANSS-EC subscale (high = poor))</NAME>
<GROUP_LABEL_1>Antipsychotic+Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.48584075629130274" CI_START="-2.9658407562913016" EFFECT_SIZE="-1.2399999999999993" ESTIMABLE="YES" MEAN_1="6.23" MEAN_2="7.47" MODIFIED="2013-04-15 11:17:48 +0100" MODIFIED_BY="[Empty name]" ORDER="222" SD_1="3.8" SD_2="2.97" SE="0.8805471783688443" STUDY_ID="STD-Guo-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="20.037804958867433"/>
<CONT_DATA CI_END="-0.9685767353183008" CI_START="-3.4314232646816976" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="5.9" MEAN_2="8.1" MODIFIED="2013-03-20 13:20:31 +0000" MODIFIED_BY="[Empty name]" ORDER="203" SD_1="1.6" SD_2="3.6" SE="0.6282887208106924" STUDY_ID="STD-Lu-2006" TOTAL_1="41" TOTAL_2="39" WEIGHT="39.35834951473296"/>
<CONT_DATA CI_END="-0.6076103788903859" CI_START="-3.0323896211096146" EFFECT_SIZE="-1.8200000000000003" ESTIMABLE="YES" MEAN_1="5.79" MEAN_2="7.61" MODIFIED="2013-03-20 13:21:32 +0000" MODIFIED_BY="[Empty name]" ORDER="204" SD_1="2.04" SD_2="2.82" SE="0.6185774997259077" STUDY_ID="STD-Shi-2010" TOTAL_1="33" TOTAL_2="31" WEIGHT="40.60384552639962"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.17" MODIFIED="2016-10-05 13:55:42 +0100" MODIFIED_BY="[Empty name]" NO="17" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Clinical response: 16. Aggression/Agitation: 5d. mean endpoint score PANSS-EC subscale (skewed data)</NAME>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>Mean score</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2016-02-29 14:48:32 +0000" MODIFIED_BY="[Empty name]" ORDER="91" STUDY_ID="STD-Casey-2003">
<TR>
<TD>
<P>Valproate - mean chlorprothixene dose - high = poor</P>
</TD>
<TD>
<P>-0.6 mg/d</P>
</TD>
<TD>
<P>1.48</P>
</TD>
<TD>
<P>122</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo - mean chlorprothixene dose - high = poor</P>
</TD>
<TD>
<P>-0.6 mg/d</P>
</TD>
<TD>
<P>1.27</P>
</TD>
<TD>
<P>120</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.31102010086444853" CI_START="-1.3889798991355509" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8499999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2016-10-05 13:55:51 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.001995054250281677" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="3.0909675658239366">
<NAME>Clinical response: 17. Aggression/Agitation: 5e. mean endpoint score PANSS supplementary subscale (high = poor)</NAME>
<GROUP_LABEL_1>Antipsychotic+Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.31102010086444853" CI_START="-1.3889798991355509" EFFECT_SIZE="-0.8499999999999996" ESTIMABLE="YES" MEAN_1="4.62" MEAN_2="5.47" MODIFIED="2013-03-20 14:16:27 +0000" MODIFIED_BY="[Empty name]" ORDER="211" SD_1="1.49" SD_2="1.52" SE="0.2749947975508508" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.308574721796562" CI_END="0.13989914491709574" CI_START="-0.3372178720944887" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09865936358869648" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2016-10-05 13:55:57 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.8570257263622736" P_Q="1.0" P_Z="0.4176116249285623" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="62" UNITS="" WEIGHT="100.00000000000001" Z="0.8105717988540849">
<NAME>Clinical response: 18. Aggression/Agitation: 5f. mean endpoint score BPRS hostility subscale (high = poor)</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.22597161667782845" CI_START="-0.4259716166778286" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.3" MODIFIED="2013-04-15 11:25:50 +0100" MODIFIED_BY="[Empty name]" ORDER="223" SD_1="0.52" SD_2="0.71" SE="0.16631510540451305" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" WEIGHT="53.55872735849436"/>
<CONT_DATA CI_END="0.8676519808695604" CI_START="-1.7876519808695603" EFFECT_SIZE="-0.45999999999999996" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.36" MODIFIED="2013-04-15 11:30:10 +0100" MODIFIED_BY="[Empty name]" ORDER="224" SD_1="1.18" SD_2="1.21" SE="0.6773859067523229" STUDY_ID="STD-Liu-2007a" TOTAL_1="15" TOTAL_2="4" WEIGHT="3.228652661832869"/>
<CONT_DATA CI_END="0.29290220891602525" CI_START="-0.43290220891602493" EFFECT_SIZE="-0.06999999999999984" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.41" MODIFIED="2013-04-15 11:31:08 +0100" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="0.66" SD_2="0.77" SE="0.1851575905366381" STUDY_ID="STD-Wang-2005a" TOTAL_1="30" TOTAL_2="30" WEIGHT="43.21261997967278"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.5439593689779265" CI_START="0.7704525567118075" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.40551017066757294" LOG_CI_START="-0.11325409931109694" LOG_EFFECT_SIZE="0.146128035678238" METHOD="MH" MODIFIED="2016-09-08 14:12:49 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.26951320633089026" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="1.1041843227665114">
<NAME>Clinical response: 19. Depression symptoms: 6a. mild improvement at endpoint, Calgary Depression Scale (high = poor)</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5439593689779265" CI_START="0.7704525567118075" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.40551017066757294" LOG_CI_START="-0.11325409931109694" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2013-05-16 21:07:49 +0100" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.304724700110022" STUDY_ID="STD-Glick-2009" TOTAL_1="8" TOTAL_2="8" VAR="0.09285714285714286" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.201336875621861" CI_END="0.12739587310864275" CI_START="-0.24961042801637306" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.06110727745386517" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.21" MODIFIED="2016-10-05 13:56:26 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.9042328718239573" P_Q="1.0" P_Z="0.5251912278029633" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="0.6353637201578599">
<NAME>Clinical response: 20. Depression symptoms: 6b. mean endpoint score BPRS anxiety and depression subscale (high = poor)</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.18825129153290943" CI_START="-0.3482512915329091" EFFECT_SIZE="-0.07999999999999985" ESTIMABLE="YES" MEAN_1="1.31" MEAN_2="1.39" MODIFIED="2013-03-16 09:54:26 +0000" MODIFIED_BY="[Empty name]" ORDER="109" SD_1="0.42" SD_2="0.59" SE="0.13686541877750877" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" WEIGHT="49.38028398349816"/>
<CONT_DATA CI_END="1.0074569998404415" CI_START="-0.7474569998404411" EFFECT_SIZE="0.13000000000000012" ESTIMABLE="YES" MEAN_1="1.58" MEAN_2="1.45" MODIFIED="2013-04-15 11:33:42 +0100" MODIFIED_BY="[Empty name]" ORDER="226" SD_1="0.32" SD_2="0.88" SE="0.447690369191327" STUDY_ID="STD-Liu-2007a" TOTAL_1="15" TOTAL_2="4" WEIGHT="4.615147022544425"/>
<CONT_DATA CI_END="0.21791893066400353" CI_START="-0.33791893066400364" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="1.46" MEAN_2="1.52" MODIFIED="2013-03-20 11:26:24 +0000" MODIFIED_BY="[Empty name]" ORDER="193" SD_1="0.44" SD_2="0.64" SE="0.14179797835888447" STUDY_ID="STD-Wang-2005a" TOTAL_1="30" TOTAL_2="30" WEIGHT="46.00456899395742"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="14.618668738999805" CI_END="-1.811576003528501" CI_START="-4.296952076452287" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.054264039990394" ESTIMABLE="YES" I2="52.11602284053854" I2_Q="0.0" ID="CMP-001.22" MODIFIED="2016-10-05 13:56:34 +0100" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="0.041210336186908836" P_Q="1.0" P_Z="1.4560393718318494E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.5382719933139042" TOTALS="YES" TOTAL_1="432" TOTAL_2="441" UNITS="" WEIGHT="100.00000000000001" Z="4.817176428849079">
<NAME>Clinical response: 21.General pathology: 7a. mean change score PANSS general pathology subscale (high = poor)</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3700650521760758" CI_START="-3.3700650521760758" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-10.5" MEAN_2="-9.5" MODIFIED="2013-04-15 11:34:52 +0100" MODIFIED_BY="[Empty name]" ORDER="227" SD_1="11.73" SD_2="12.24" SE="1.2092390834070659" STUDY_ID="STD-Casey-2009" TOTAL_1="195" TOTAL_2="198" WEIGHT="13.397689616221452"/>
<CONT_DATA CI_END="-1.0332825422620986" CI_START="-4.306717457737898" EFFECT_SIZE="-2.669999999999998" ESTIMABLE="YES" MEAN_1="28.96" MEAN_2="31.63" MODIFIED="2013-03-20 14:13:24 +0000" MODIFIED_BY="[Empty name]" ORDER="210" SD_1="4.53" SD_2="4.61" SE="0.8350752721213849" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" WEIGHT="17.981650045691133"/>
<CONT_DATA CI_END="-1.5685055156497407" CI_START="-9.491494484350255" EFFECT_SIZE="-5.529999999999998" ESTIMABLE="YES" MEAN_1="20.35" MEAN_2="25.88" MODIFIED="2013-02-18 16:14:08 +0000" MODIFIED_BY="[Empty name]" ORDER="53" SD_1="6.1" SD_2="6.97" SE="2.021207795448294" STUDY_ID="STD-Liang-2004" TOTAL_1="21" TOTAL_2="21" WEIGHT="7.148538561892794"/>
<CONT_DATA CI_END="0.7627426645455198" CI_START="-5.002742664545522" EFFECT_SIZE="-2.120000000000001" ESTIMABLE="YES" MEAN_1="25.38" MEAN_2="27.5" MODIFIED="2013-03-16 11:50:44 +0000" MODIFIED_BY="[Empty name]" ORDER="133" SD_1="4.84" SD_2="7.08" SE="1.4708141003019581" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.860318006507017"/>
<CONT_DATA CI_END="-0.8911796614450171" CI_START="-4.808820338554979" EFFECT_SIZE="-2.849999999999998" ESTIMABLE="YES" MEAN_1="18.85" MEAN_2="21.7" MODIFIED="2013-03-16 17:02:38 +0000" MODIFIED_BY="[Empty name]" ORDER="154" SD_1="3.45" SD_2="4.25" SE="0.9994164964284576" STUDY_ID="STD-Wang-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="15.844901930133773"/>
<CONT_DATA CI_END="-2.076929583449627" CI_START="-9.203070416550375" EFFECT_SIZE="-5.640000000000001" ESTIMABLE="YES" MEAN_1="34.48" MEAN_2="40.12" MODIFIED="2013-03-16 16:10:38 +0000" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="8.24" SD_2="5.59" SE="1.8179264744941326" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" WEIGHT="8.300457805163235"/>
<CONT_DATA CI_END="-0.1809908808552647" CI_START="-3.219009119144741" EFFECT_SIZE="-1.7000000000000028" ESTIMABLE="YES" MEAN_1="19.31" MEAN_2="21.01" MODIFIED="2013-03-16 17:47:30 +0000" MODIFIED_BY="[Empty name]" ORDER="165" SD_1="3.45" SD_2="3.02" SE="0.7750188937789103" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" WEIGHT="18.794563179339793"/>
<CONT_DATA CI_END="-3.729084982668518" CI_START="-11.270915017331482" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="18.3" MEAN_2="25.8" MODIFIED="2013-03-16 21:15:24 +0000" MODIFIED_BY="[Empty name]" ORDER="194" SD_1="7.3" SD_2="7.6" SE="1.9239715867617866" STUDY_ID="STD-Zhang-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="7.6718808550508015"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.23" MODIFIED="2016-10-03 18:44:27 +0100" MODIFIED_BY="[Empty name]" NO="23" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Use of additional medication: 1. Mean dose of antiparkinson medication (skewed data)</NAME>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>Mean score</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N </P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2016-02-29 14:48:32 +0000" MODIFIED_BY="[Empty name]" ORDER="108" STUDY_ID="STD-Dose-1998">
<TR>
<TD>
<P>Valproate - mean biperiden dose - high = poor</P>
</TD>
<TD>
<P>3.0 mg/d</P>
</TD>
<TD>
<P>2.4</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo - mean biperiden dose - high = poor</P>
</TD>
<TD>
<P>2.4 mg/d</P>
</TD>
<TD>
<P>1.8</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2016-02-29 14:48:32 +0000" MODIFIED_BY="[Empty name]" ORDER="109" STUDY_ID="STD-Hesslinger-1999">
<TR>
<TD>
<P>Valproate - mean biperiden dose - high = poor</P>
</TD>
<TD>
<P>3.6 mg/</P>
</TD>
<TD>
<P>3.3</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo - mean biperiden dose - high = poor</P>
</TD>
<TD>
<P>2.9 mg/d</P>
</TD>
<TD>
<P> 3</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.24" MODIFIED="2016-06-14 13:53:47 +0100" MODIFIED_BY="[Empty name]" NO="24" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Use of additional medication: 2. Mean chlorprothixene dose (skewed data)</NAME>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>Mean score</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2016-02-29 14:48:32 +0000" MODIFIED_BY="[Empty name]" ORDER="110" STUDY_ID="STD-Dose-1998">
<TR>
<TD>
<P>Valproate - mean chlorprothixene dose - high = poor<BR/>
</P>
</TD>
<TD>
<P>11.8 mg/d</P>
</TD>
<TD>
<P>13.4</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo - mean chlorprothixene dose - high = poor</P>
</TD>
<TD>
<P>21.0 mg/d</P>
</TD>
<TD>
<P>25.4</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2016-02-29 14:48:32 +0000" MODIFIED_BY="[Empty name]" ORDER="111" STUDY_ID="STD-Hesslinger-1999">
<TR>
<TD>
<P>Valproate - mean chlorprothixene dose - high = poor</P>
</TD>
<TD>
<P>21.1 mg/d</P>
</TD>
<TD>
<P>6.7</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo - mean chlorprothixene dose - high = poor</P>
</TD>
<TD>
<P>21.6 mg/d</P>
</TD>
<TD>
<P>17.4</P>
</TD>
<TD>
<P>9</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="6.469781731363698" CI_END="122.30931322512285" CI_START="0.10884460699356702" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.6486585383729153" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="78" I2="84.54352802734785" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="2.0874595275864474" LOG_CI_START="-0.9631930844084446" LOG_EFFECT_SIZE="0.5621332215890011" METHOD="MH" MODIFIED="2016-09-08 17:34:09 +0100" MODIFIED_BY="[Empty name]" NO="25" P_CHI2="0.010972427325510736" P_Q="1.0" P_Z="0.47010293437616524" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="5.559746019817385" TOTALS="YES" TOTAL_1="154" TOTAL_2="155" WEIGHT="100.0" Z="0.7223115896552045">
<NAME>Use of additional medication: 3. Medication for sedation at least once</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1527898119167608" CI_START="0.7721168690253442" EFFECT_SIZE="0.9434449958643507" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="78" LOG_CI_END="0.061750129631155115" LOG_CI_START="-0.11231695907956143" LOG_EFFECT_SIZE="-0.025283414724203153" ORDER="808" O_E="0.0" SE="0.10224786955466046" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.010454626828466863" WEIGHT="57.64874754988148"/>
<DICH_DATA CI_END="373.4591403134775" CI_START="1.4164869537159084" EFFECT_SIZE="23.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.572243093147161" LOG_CI_START="0.15121257888802483" LOG_EFFECT_SIZE="1.3617278360175928" MODIFIED="2013-02-19 15:49:31 +0000" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="1.4221253083701424" STUDY_ID="STD-Guo-2007" TOTAL_1="30" TOTAL_2="30" VAR="2.0224403927068724" WEIGHT="42.351252450118515"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.45525224628344363" CI_END="2.1822018596618022" CI_START="0.3548477214622941" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.879971225479431" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="0.33889492154215667" LOG_CI_START="-0.44995797910503804" LOG_EFFECT_SIZE="-0.055531528781440645" METHOD="MH" MODIFIED="2016-09-08 17:34:28 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.49985127094499227" P_Q="1.0" P_Z="0.7825907202640808" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="79" WEIGHT="100.00000000000001" Z="0.27594446652545296">
<NAME>Adverse events: 1. Abnormal ECG</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.209822556158871" CI_START="0.01374629775627757" EFFECT_SIZE="0.3148148148148148" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857924576254886" LOG_CI_START="-1.8618142531442754" LOG_EFFECT_SIZE="-0.5019448384446946" MODIFIED="2013-03-25 13:00:56 +0000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="8.412743548539977"/>
<DICH_DATA CI_END="2.4981430041790627" CI_START="0.37439513609232145" EFFECT_SIZE="0.9671052631578947" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.39761729558664366" LOG_CI_START="-0.4266698019798365" LOG_EFFECT_SIZE="-0.01452625319659647" MODIFIED="2013-02-25 14:32:31 +0000" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.48419032139748946" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.23444026733500417" WEIGHT="91.58725645146004"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.52246389220602" CI_END="2.2190057343653002" CI_START="0.7152781951957805" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2598438065117037" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.34615842453934914" LOG_CI_START="-0.1455250139468866" LOG_EFFECT_SIZE="0.1003167052962312" METHOD="MH" MODIFIED="2016-10-05 13:56:47 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.7180106305265896" P_Q="1.0" P_Z="0.4238433731876481" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="366" TOTAL_2="379" WEIGHT="100.0" Z="0.7997712106540105">
<NAME>Adverse events: 2. Abnormal liver function/increase in alanine transaminase/gamma-glutamyl transpeptidase</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7009850774752642" CI_START="0.02389660161361968" EFFECT_SIZE="0.20161290322580644" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23070050361928493" LOG_CI_START="-1.62166385659968" LOG_EFFECT_SIZE="-0.6954816764901975" MODIFIED="2013-04-12 17:38:50 +0100" MODIFIED_BY="[Empty name]" ORDER="823" O_E="0.0" SE="1.0880879945440844" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="1.1839354838709677" WEIGHT="7.045605577357785"/>
<DICH_DATA CI_END="5.612438628376065" CI_START="0.053898139477300114" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.749151605057554" LOG_CI_START="-1.2684262260690662" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2013-04-12 17:42:40 +0100" MODIFIED_BY="[Empty name]" ORDER="824" O_E="0.0" SE="1.1851352051751118" STUDY_ID="STD-Dose-1998" TOTAL_1="20" TOTAL_2="22" VAR="1.4045454545454545" WEIGHT="5.938962260991835"/>
<DICH_DATA CI_END="10.308519609286225" CI_START="0.3880285580867189" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0131963013959688" LOG_CI_START="-0.41113631006800627" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-04-12 17:38:50 +0100" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.8366600265340756" STUDY_ID="STD-Jia-2007" TOTAL_1="40" TOTAL_2="40" VAR="0.7" WEIGHT="11.916489211990111"/>
<DICH_DATA CI_END="9.56874551934013" CI_START="0.28724924838823607" EFFECT_SIZE="1.6578947368421053" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9808550046796909" LOG_CI_START="-0.5417410990061478" LOG_EFFECT_SIZE="0.21955695283677157" MODIFIED="2013-02-25 14:31:03 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.8943804882773296" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.7999164578111946" WEIGHT="10.428017034701321"/>
<DICH_DATA CI_END="3.7127635215396326" CI_START="0.5279086558109723" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.5696972884232897" LOG_CI_START="-0.27744121706681374" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2013-04-12 17:38:50 +0100" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.4976133515281193" STUDY_ID="STD-Liang-2004" TOTAL_1="21" TOTAL_2="21" VAR="0.24761904761904763" WEIGHT="33.68699834927973"/>
<DICH_DATA CI_END="6.142937823152934" CI_START="0.3457483835603573" EFFECT_SIZE="1.4573643410852712" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7883761195523095" LOG_CI_START="-0.46123984162344767" LOG_EFFECT_SIZE="0.16356813896443087" MODIFIED="2013-04-12 17:38:50 +0100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.7340306012934092" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="0.538800923635164" WEIGHT="15.481678079010408"/>
<DICH_DATA CI_END="27.234348125670902" CI_START="0.33046504210308847" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4351169845729048" LOG_CI_START="-0.4808744751335797" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-05-10 10:51:14 +0100" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="1.1254628677422753" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="1.2666666666666664" WEIGHT="6.585428248731378"/>
<DICH_DATA CI_END="6.657108978057516" CI_START="0.15021535674060588" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8232856664877436" LOG_CI_START="-0.8232856664877436" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-04-12 17:38:50 +0100" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.9672041516493516" STUDY_ID="STD-Yao-2010" TOTAL_1="31" TOTAL_2="31" VAR="0.935483870967742" WEIGHT="8.916821237937427"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3804382054988233" CI_END="3.063874211095477" CI_START="0.3644985082552228" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0567769771460527" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.4862709311470797" LOG_CI_START="-0.4383042447338004" LOG_EFFECT_SIZE="0.023983343206639605" METHOD="MH" MODIFIED="2016-09-08 17:35:00 +0100" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.5014662371572627" P_Q="1.0" P_Z="0.919008811168059" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="93" TOTAL_2="93" WEIGHT="99.99999999999999" Z="0.10168235128980624">
<NAME>Adverse events: 3. Akathisia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.300053252016756" CI_START="0.27108259810902935" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9190808787595482" LOG_CI_START="-0.5668983606481857" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-03-16 10:21:40 +0000" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.8728715609439694" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" VAR="0.7619047619047619" WEIGHT="38.71319130698762"/>
<DICH_DATA CI_END="3.0260386806300987" CI_START="0.036718338011454264" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48087447513357967" LOG_CI_START="-1.4351169845729046" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-05-10 10:46:30 +0100" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="1.1254628677422753" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="1.2666666666666664" WEIGHT="23.286130109466242"/>
<DICH_DATA CI_END="8.433620569181464" CI_START="0.2667893322379308" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9260140580948332" LOG_CI_START="-0.5738315399834707" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-03-16 17:50:17 +0000" MODIFIED_BY="[Empty name]" ORDER="168" O_E="0.0" SE="0.8810167286666446" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.7761904761904761" WEIGHT="38.00067858354613"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4498314096363268" CI_END="1.2442636013495696" CI_START="0.21157081838388642" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5130788130714523" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="0.09491239682114735" LOG_CI_START="-0.6745442340320439" LOG_EFFECT_SIZE="-0.2898159186054482" METHOD="MH" MODIFIED="2016-08-08 13:40:35 +0100" MODIFIED_BY="[Empty name]" NO="29" P_CHI2="0.5024150531120035" P_Q="1.0" P_Z="0.13982547055182823" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="160" WEIGHT="100.0" Z="1.4764412699471496">
<NAME>Adverse events: 4. Anxiety</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2515074568095153" CI_START="0.12991616638309864" EFFECT_SIZE="0.4032258064516129" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.09743344159232617" LOG_CI_START="-0.8863368032447586" LOG_EFFECT_SIZE="-0.3944516808262163" ORDER="810" O_E="0.0" SE="0.5778715115585538" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.3339354838709677" WEIGHT="61.17597894067599"/>
<DICH_DATA CI_END="3.1082378709914233" CI_START="0.1809707053793092" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4925142476146918" LOG_CI_START="-0.7423917208312916" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-03-16 17:56:30 +0000" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.7253898787483019" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.5261904761904761" WEIGHT="38.824021059324004"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.953129001417551" CI_START="0.6347825201510184" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5841013824884795" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="0.5969409867916607" LOG_CI_START="-0.19737504081208151" LOG_EFFECT_SIZE="0.19978297298978964" METHOD="MH" MODIFIED="2016-08-08 13:41:06 +0100" MODIFIED_BY="[Empty name]" NO="30" P_CHI2="1.0" P_Q="1.0" P_Z="0.3241706511805964" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="125" WEIGHT="100.0" Z="0.9859235321376795">
<NAME>Adverse events: 5. Asthenia</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.95312900141755" CI_START="0.6347825201510184" EFFECT_SIZE="1.5841013824884793" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.5969409867916606" LOG_CI_START="-0.19737504081208151" LOG_EFFECT_SIZE="0.19978297298978956" ORDER="811" O_E="0.0" SE="0.4665851665421882" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.2177017176372015" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06941156588756181" CI_END="15.918639052717163" CI_START="0.3667314379067201" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.416167500261733" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="1.201905935439335" LOG_CI_START="-0.4356518587217476" LOG_EFFECT_SIZE="0.3831270383587937" METHOD="MH" MODIFIED="2016-08-08 13:41:41 +0100" MODIFIED_BY="[Empty name]" NO="31" P_CHI2="0.7921954784660996" P_Q="1.0" P_Z="0.3590818876190037" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="56" TOTAL_2="59" WEIGHT="100.0" Z="0.917115963008101">
<NAME>Adverse events: 6. Ataxia</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="79.22290951700097" CI_START="0.1451719616169367" EFFECT_SIZE="3.391304347826087" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.898850788131076" LOG_CI_START="-0.8381172547853013" LOG_EFFECT_SIZE="0.5303667666728875" ORDER="812" O_E="0.0" SE="1.6077085766193955" STUDY_ID="STD-Fisk-1987" TOTAL_1="22" TOTAL_2="25" VAR="2.584726867335563" WEIGHT="35.797592480982566"/>
<DICH_DATA CI_END="21.032408972995952" CI_START="0.1901826845006534" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3228890179912565" LOG_CI_START="-0.7208290266632941" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-03-16 11:58:29 +0000" MODIFIED_BY="[Empty name]" ORDER="139" O_E="0.0" SE="1.200490095997562" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" VAR="1.4411764705882355" WEIGHT="64.20240751901744"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.646494311147693" CI_END="1.2518635860589695" CI_START="0.6764713354484947" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9202444413636263" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="167" I2="74.43516790115656" I2_Q="0.0" ID="CMP-001.32" LOG_CI_END="0.09755700694981986" LOG_CI_START="-0.16975060131365008" LOG_EFFECT_SIZE="-0.03609679718191512" METHOD="MH" MODIFIED="2016-09-08 17:35:12 +0100" MODIFIED_BY="[Empty name]" NO="32" P_CHI2="0.0035321243269377245" P_Q="1.0" P_Z="0.596569003321737" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07775751911493411" TOTALS="YES" TOTAL_1="247" TOTAL_2="246" WEIGHT="100.00000000000003" Z="0.529340881042696">
<NAME>Adverse events: 7. At least one adverse event</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2609324057938183" CI_START="0.9845011710813604" EFFECT_SIZE="1.1141765704584041" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="95" LOG_CI_END="0.10069180617849774" LOG_CI_START="-0.0067837629246743835" LOG_EFFECT_SIZE="0.04695402162691167" ORDER="809" O_E="0.0" SE="0.06313168130385052" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.003985609184250949" WEIGHT="30.161059270279843"/>
<DICH_DATA CI_END="0.6183476941737036" CI_START="0.17265814244964547" EFFECT_SIZE="0.32674571805006586" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" LOG_CI_END="-0.20876725436217627" LOG_CI_START="-0.762812935776352" LOG_EFFECT_SIZE="-0.4857900950692641" MODIFIED="2013-03-15 20:21:01 +0000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="0.3254491758330414" STUDY_ID="STD-Shi-2010" TOTAL_1="33" TOTAL_2="31" VAR="0.10591716605040588" WEIGHT="13.42296754367896"/>
<DICH_DATA CI_END="1.2879222518327607" CI_START="0.7764443844160338" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.10988964670457298" LOG_CI_START="-0.109889646704573" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-20 11:32:31 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.12909944487358055" STUDY_ID="STD-Wang-2005a" TOTAL_1="30" TOTAL_2="30" VAR="0.016666666666666663" WEIGHT="26.11046435997145"/>
<DICH_DATA CI_END="1.8090743038231916" CI_START="0.6345561269912683" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.2574564049348178" LOG_CI_START="-0.19752995817993138" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2013-03-16 16:16:58 +0000" MODIFIED_BY="[Empty name]" ORDER="149" O_E="0.0" SE="0.26726124191242445" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.07142857142857145" WEIGHT="16.526067065554173"/>
<DICH_DATA CI_END="2.2043893085187447" CI_START="0.633596892109113" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.34328829599225885" LOG_CI_START="-0.19818696169503536" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2013-03-16 21:15:57 +0000" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.31806524671127023" STUDY_ID="STD-Zhang-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.10116550116550119" WEIGHT="13.7794417605156"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.667338375045034" CI_END="3.686108756975173" CI_START="0.8860631690740608" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.8072424316502391" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="10" I2="0.0" I2_Q="1.7570293750162451" ID="CMP-001.33" LOG_CI_END="0.5665681447347619" LOG_CI_START="-0.05253531535633657" LOG_EFFECT_SIZE="0.2570164146892127" METHOD="MH" MODIFIED="2016-08-08 13:42:23 +0100" MODIFIED_BY="[Empty name]" NO="33" P_CHI2="0.6844381681936132" P_Q="0.39641103713215675" P_Z="0.10366696149438083" Q="4.071538120797395" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="287" TOTAL_2="303" WEIGHT="500.0" Z="1.627330321017248">
<NAME>Adverse events: 8. Blood count changes</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.417125700736633" CI_START="0.428021552496164" DF="0" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-001.33.01" LOG_CI_END="0.6451397584070254" LOG_CI_START="-0.3685343620744625" LOG_EFFECT_SIZE="0.13830269816628146" NO="1" P_CHI2="1.0" P_Z="0.5927719997536856" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.00000000000001" Z="0.5348233754687748">
<NAME>Eosinophilia</NAME>
<DICH_DATA CI_END="4.417125700736633" CI_START="0.428021552496164" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6451397584070254" LOG_CI_START="-0.3685343620744625" LOG_EFFECT_SIZE="0.13830269816628146" ORDER="813" O_E="0.0" SE="0.5954371961386479" STUDY_ID="STD-Dose-1998" TOTAL_1="20" TOTAL_2="22" VAR="0.35454545454545455" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="107.61816341755213" CI_START="0.278657999534568" DF="0" EFFECT_SIZE="5.476190476190478" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.33.02" LOG_CI_END="2.0318855762216383" LOG_CI_START="-0.5549284849822532" LOG_EFFECT_SIZE="0.7384785456196926" NO="2" P_CHI2="1.0" P_Z="0.2631174367492455" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="1.1190532589702311">
<NAME>Monocytosis</NAME>
<DICH_DATA CI_END="107.61816341755203" CI_START="0.27865799953456794" EFFECT_SIZE="5.476190476190476" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.031885576221638" LOG_CI_START="-0.5549284849822533" LOG_EFFECT_SIZE="0.7384785456196924" ORDER="814" O_E="0.0" SE="1.5195073844872842" STUDY_ID="STD-Dose-1998" TOTAL_1="20" TOTAL_2="22" VAR="2.308902691511387" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="29.211966069392776" CI_START="0.37279243629582803" DF="0" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.33.03" LOG_CI_END="1.465560787523156" LOG_CI_START="-0.42853290776738123" LOG_EFFECT_SIZE="0.5185139398778874" NO="3" P_CHI2="1.0" P_Z="0.28322973697392817" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="1.0730922658889266">
<NAME>Transient lymphocytosis</NAME>
<DICH_DATA CI_END="29.211966069392776" CI_START="0.37279243629582803" EFFECT_SIZE="3.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.465560787523156" LOG_CI_START="-0.42853290776738123" LOG_EFFECT_SIZE="0.5185139398778874" ORDER="815" O_E="0.0" SE="1.1126000125286661" STUDY_ID="STD-Dose-1998" TOTAL_1="20" TOTAL_2="22" VAR="1.2378787878787878" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.156408784402132" CI_END="3.6409230849105803" CI_START="0.38106680190637077" DF="4" EFFECT_SIZE="1.1778942719760346" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.33.04" LOG_CI_END="0.5612115044896323" LOG_CI_START="-0.41899888480663977" LOG_EFFECT_SIZE="0.07110630984149628" MODIFIED="2013-03-25 13:03:23 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.8852221587205245" P_Z="0.7761353022965414" STUDIES="5" TAU2="0.0" TOTAL_1="188" TOTAL_2="197" WEIGHT="100.0" Z="0.2843589659622653">
<NAME>Leukopenia</NAME>
<DICH_DATA CI_END="64.88840300542985" CI_START="0.1237166798064982" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.812167085694211" LOG_CI_START="-0.9075717437049503" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2013-03-25 13:03:23 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="12.989253698005713"/>
<DICH_DATA CI_END="7.59143967944538" CI_START="0.16091896923149823" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8803241455328684" LOG_CI_START="-0.7933927579706879" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2013-02-25 14:22:57 +0000" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.9831495941502806" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.9665831244778613" WEIGHT="34.29845821782876"/>
<DICH_DATA CI_END="16.940760799187863" CI_START="0.07052220687794664" EFFECT_SIZE="1.0930232558139534" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2289329103317448" LOG_CI_START="-1.1516741056194828" LOG_EFFECT_SIZE="0.03862940235613092" MODIFIED="2013-02-19 15:17:47 +0000" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="1.3983803453645332" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="1.9554675903018308" WEIGHT="16.953648873231984"/>
<DICH_DATA CI_END="5.2337006044292" CI_START="0.0477673483631121" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718808875055234" LOG_CI_START="-1.3208688663831967" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-03-16 17:29:26 +0000" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="1.1981168018885897" STUDY_ID="STD-Yao-2010" TOTAL_1="31" TOTAL_2="31" VAR="1.435483870967742" WEIGHT="23.094868273659127"/>
<DICH_DATA CI_END="71.50812704867249" CI_START="0.12585982001561988" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8543554030852154" LOG_CI_START="-0.9001128936458906" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-03-20 11:07:36 +0000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="1.6179883123378205" STUDY_ID="STD-Yin-2004" TOTAL_1="40" TOTAL_2="40" VAR="2.6178861788617884" WEIGHT="12.663770937274421"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="291.9596131102538" CI_START="1.0399747477584804" DF="0" EFFECT_SIZE="17.424999999999997" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" ID="CMP-001.33.05" LOG_CI_END="2.465322779474288" LOG_CI_START="0.017022794065805775" LOG_EFFECT_SIZE="1.241172786770047" MODIFIED="2013-05-13 20:45:21 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.046898148034788686" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0" Z="1.9872188662817252">
<NAME>Thrombocytopenia</NAME>
<DICH_DATA CI_END="291.9596131102538" CI_START="1.0399747477584804" EFFECT_SIZE="17.425" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.465322779474288" LOG_CI_START="0.017022794065805775" LOG_EFFECT_SIZE="1.241172786770047" MODIFIED="2013-05-13 20:45:21 +0100" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="1.4381435307093275" STUDY_ID="STD-Yin-2004" TOTAL_1="39" TOTAL_2="40" VAR="2.0682568149210905" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.490589732800408" CI_END="1.8511168769591098" CI_START="0.47265597559245015" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9353830517038234" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="37" I2="53.77923850525628" I2_Q="0.0" ID="CMP-001.34" LOG_CI_END="0.2674338403714574" LOG_CI_START="-0.32545484713153283" LOG_EFFECT_SIZE="-0.0290105033800377" METHOD="MH" MODIFIED="2016-09-08 14:15:35 +0100" MODIFIED_BY="[Empty name]" NO="34" P_CHI2="0.09003451323180955" P_Q="1.0" P_Z="0.8478948633342044" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.26049691990082624" TOTALS="YES" TOTAL_1="254" TOTAL_2="261" WEIGHT="99.99999999999999" Z="0.19180511619380364">
<NAME>Adverse events: 9. Constipation</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8724216805919611" CI_START="0.14509580755993434" EFFECT_SIZE="0.3557874762808349" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" LOG_CI_END="-0.059273550286761935" LOG_CI_START="-0.8383451360108559" LOG_EFFECT_SIZE="-0.448809343148809" ORDER="816" O_E="0.0" SE="0.4576305059208784" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.2094256799493991" WEIGHT="25.810427628301202"/>
<DICH_DATA CI_END="2.5901657210550595" CI_START="0.47163262113662974" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.41332755150877737" LOG_CI_START="-0.32639616394659665" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2013-02-25 14:27:52 +0000" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.4345173721499332" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.18880534670008353" WEIGHT="26.99497455487091"/>
<DICH_DATA CI_END="4.933147055536565" CI_START="0.6567815561799818" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6931240618347644" LOG_CI_START="-0.18257905162815227" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2013-02-19 15:07:19 +0000" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.5143923436484397" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="43" VAR="0.2645994832041344" WEIGHT="23.098431416817306"/>
<DICH_DATA CI_END="3.0649506760372986" CI_START="0.4440890751530474" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4864234898504567" LOG_CI_START="-0.3525299105892302" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2013-05-10 10:30:15 +0100" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.49280538030458115" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.24285714285714288" WEIGHT="24.096166400010567"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.852065708840955" CI_START="0.01528328888987024" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.35" LOG_CI_END="0.9470446290330247" LOG_CI_START="-1.8157831776304496" LOG_EFFECT_SIZE="-0.4343692742987126" METHOD="MH" MODIFIED="2016-09-08 17:35:18 +0100" MODIFIED_BY="[Empty name]" NO="35" P_CHI2="1.0" P_Q="1.0" P_Z="0.5377047847080345" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="63" WEIGHT="100.0" Z="0.6162875091693869">
<NAME>Adverse events: 10. Convulsion</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.852065708840955" CI_START="0.01528328888987024" EFFECT_SIZE="0.367816091954023" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9470446290330247" LOG_CI_START="-1.8157831776304496" LOG_EFFECT_SIZE="-0.4343692742987126" MODIFIED="2013-02-25 14:39:08 +0000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="1.622898729852335" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="2.6338002873563218" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.204777217585425" CI_END="3.3439588966189073" CI_START="0.31821243540765953" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0315470441992516" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" I2="9.287887046006771" I2_Q="0.0" ID="CMP-001.36" LOG_CI_END="0.5242609305249614" LOG_CI_START="-0.49728285258572913" LOG_EFFECT_SIZE="0.01348903896961615" METHOD="MH" MODIFIED="2016-09-08 17:35:24 +0100" MODIFIED_BY="[Empty name]" NO="36" P_CHI2="0.33207720304462407" P_Q="1.0" P_Z="0.9587191833283428" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1501035766265639" TOTALS="YES" TOTAL_1="95" TOTAL_2="98" WEIGHT="100.00000000000001" Z="0.051760934780492165">
<NAME>Adverse events: 11. Diarrohea</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.88840300542985" CI_START="0.1237166798064982" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.812167085694211" LOG_CI_START="-0.9075717437049503" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2013-03-25 12:57:22 +0000" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="13.324194478014242"/>
<DICH_DATA CI_END="1.9859227497485805" CI_START="0.196435671789761" EFFECT_SIZE="0.6245847176079734" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.29796235090134343" LOG_CI_START="-0.7067796435616706" LOG_EFFECT_SIZE="-0.2044086463301635" MODIFIED="2013-03-20 13:27:48 +0000" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.5901904211006594" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="0.34832473315897367" WEIGHT="72.2414530681327"/>
<DICH_DATA CI_END="100.52959945656309" CI_START="0.24868297630890304" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.002293952184388" LOG_CI_START="-0.6043539435123508" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-03-16 17:55:13 +0000" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="1.531157877047447" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" VAR="2.3444444444444446" WEIGHT="14.434352453853062"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.422981470726258" CI_END="2.0324999874775216" CI_START="0.9245902279462427" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3708499650664097" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-001.37" LOG_CI_END="0.3080305515903649" LOG_CI_START="-0.034050700960072976" LOG_EFFECT_SIZE="0.13698992531514592" METHOD="MH" MODIFIED="2016-09-08 14:16:08 +0100" MODIFIED_BY="[Empty name]" NO="37" P_CHI2="0.6196343174838479" P_Q="1.0" P_Z="0.11646743742073676" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="331" TOTAL_2="331" WEIGHT="100.0" Z="1.5697751213240185">
<NAME>Adverse events: 12. Dizziness</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.4145750701261117" CI_START="0.761868391348847" EFFECT_SIZE="1.6129032258064515" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.5333366652117344" LOG_CI_START="-0.1181200442082422" LOG_EFFECT_SIZE="0.2076083105017461" ORDER="817" O_E="0.0" SE="0.38266889587601416" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.14643548387096775" WEIGHT="27.573216121789148"/>
<DICH_DATA CI_END="2.232682499679584" CI_START="0.6281029975549022" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.3488269682837201" LOG_CI_START="-0.20196913396665322" LOG_EFFECT_SIZE="0.07342891715853349" MODIFIED="2013-02-25 14:31:45 +0000" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.3235403569465476" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.10467836257309943" WEIGHT="38.57241501894283"/>
<DICH_DATA CI_END="4.744947953259762" CI_START="0.4741885521535085" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6762314530676203" LOG_CI_START="-0.3240489349562579" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-03-16 10:33:13 +0000" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.5875696513930031" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" VAR="0.34523809523809523" WEIGHT="11.695398915604443"/>
<DICH_DATA CI_END="35.53815689422276" CI_START="0.1346484080264133" EFFECT_SIZE="2.1875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.5506949003565917" LOG_CI_START="-0.8707987769678901" LOG_EFFECT_SIZE="0.3399480616943509" MODIFIED="2013-03-16 20:18:02 +0000" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="1.4223973726474206" STUDY_ID="STD-Liu-2007a" TOTAL_1="15" TOTAL_2="4" VAR="2.0232142857142854" WEIGHT="1.9956844280819588"/>
<DICH_DATA CI_END="278.21510566953293" CI_START="0.9624516770824836" EFFECT_SIZE="16.363636363636363" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.444380706284441" LOG_CI_START="-0.01662106639427895" LOG_EFFECT_SIZE="1.213879819945081" MODIFIED="2013-02-19 15:07:59 +0000" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="1.4456046234267261" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="2.089772727272727" WEIGHT="1.9321226619424727"/>
<DICH_DATA CI_END="3.101182859150094" CI_START="0.18138240327890823" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4915273748727626" LOG_CI_START="-0.7414048480893625" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-03-16 11:55:55 +0000" MODIFIED_BY="[Empty name]" ORDER="136" O_E="0.0" SE="0.7242304908808856" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" VAR="0.5245098039215685" WEIGHT="7.698039606666209"/>
<DICH_DATA CI_END="4.206513090488437" CI_START="0.3714477921233738" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6239222447595453" LOG_CI_START="-0.43010221874343246" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-05-10 10:35:13 +0100" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.38333333333333336" WEIGHT="10.533123246972945"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6247607903257233" CI_END="2.4206953524770767" CI_START="0.5808643396587131" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1857890231535764" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.38" LOG_CI_END="0.38394013637966523" LOG_CI_START="-0.2359252848507201" LOG_EFFECT_SIZE="0.07400742576447258" METHOD="MH" MODIFIED="2016-09-08 17:35:31 +0100" MODIFIED_BY="[Empty name]" NO="38" P_CHI2="0.4438005925814238" P_Q="1.0" P_Z="0.6397767912474523" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="89" WEIGHT="100.00000000000001" Z="0.46801090726748756">
<NAME>Adverse events: 13. Dry mouth</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.209822556158871" CI_START="0.01374629775627757" EFFECT_SIZE="0.3148148148148148" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857924576254886" LOG_CI_START="-1.8618142531442754" LOG_EFFECT_SIZE="-0.5019448384446946" MODIFIED="2013-03-25 13:01:12 +0000" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="5.194460128200871"/>
<DICH_DATA CI_END="4.180597127541194" CI_START="0.6644452199132422" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.621238317821652" LOG_CI_START="-0.17754081858893925" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2013-02-19 15:06:38 +0000" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.4692068187480761" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="43" VAR="0.22015503875968995" WEIGHT="60.220089231348325"/>
<DICH_DATA CI_END="2.6921683779126004" CI_START="0.23772658695895926" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4301022187434325" LOG_CI_START="-0.6239222447595453" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2013-05-10 10:27:36 +0100" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="0.6191391873668903" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.38333333333333336" WEIGHT="34.58545064045081"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.788825223803868" CI_START="0.6208962772838615" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0538856304985338" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.39" LOG_CI_END="0.2525679101338775" LOG_CI_START="-0.20698094405146147" LOG_EFFECT_SIZE="0.022793483041208012" METHOD="MH" MODIFIED="2016-09-08 14:16:29 +0100" MODIFIED_BY="[Empty name]" NO="39" P_CHI2="1.0" P_Q="1.0" P_Z="0.8458413688039965" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="125" WEIGHT="100.0" Z="0.19442723199555517">
<NAME>Adverse events: 14. Dyspepsia</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.788825223803868" CI_START="0.6208962772838615" EFFECT_SIZE="1.0538856304985338" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.2525679101338775" LOG_CI_START="-0.20698094405146147" LOG_EFFECT_SIZE="0.022793483041208012" ORDER="818" O_E="0.0" SE="0.26994127175198385" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.0728682901950784" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4262435294322668" CI_END="3.3693748294903196" CI_START="0.29530901610104043" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9975002585324962" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.40" LOG_CI_END="0.5275493271949218" LOG_CI_START="-0.5297232933561029" LOG_EFFECT_SIZE="-0.0010869830805906417" METHOD="MH" MODIFIED="2016-09-08 17:35:37 +0100" MODIFIED_BY="[Empty name]" NO="40" P_CHI2="0.5138379906224091" P_Q="1.0" P_Z="0.9967844684804338" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="65" WEIGHT="100.0" Z="0.004030082021137921">
<NAME>Adverse events: 15. Dystonia</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7086562974712898" CI_START="0.11983975024794946" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.569216586623787" LOG_CI_START="-0.9213991047351496" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-05-10 10:49:47 +0100" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="50.30864197530864"/>
<DICH_DATA CI_END="8.433620569181464" CI_START="0.2667893322379308" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9260140580948332" LOG_CI_START="-0.5738315399834707" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-03-16 17:53:08 +0000" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.8810167286666446" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.7761904761904761" WEIGHT="49.69135802469136"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.41" MODIFIED="2016-07-26 09:52:59 +0100" MODIFIED_BY="[Empty name]" NO="41" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Adverse events: 16. Extrapyramidal adverse events (skewed data)</NAME>
<TR>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>Mean score</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2016-02-29 14:48:32 +0000" MODIFIED_BY="[Empty name]" ORDER="167" STUDY_ID="STD-Dose-1998">
<TR>
<TD>
<P>Valproate - (mean EPS) - high = poor</P>
</TD>
<TD>
<P>3.4</P>
</TD>
<TD>
<P>1.0</P>
</TD>
<TD>
<P>14</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo - (mean EPS) - high = poor</P>
</TD>
<TD>
<P>2.4</P>
</TD>
<TD>
<P>1.7</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2016-02-29 14:48:32 +0000" MODIFIED_BY="[Empty name]" ORDER="168" STUDY_ID="STD-Fisk-1987">
<TR>
<TD>
<P>Valproate - (mean tardive dyskinesia score) - high = poor</P>
</TD>
<TD>
<P>4.4</P>
</TD>
<TD>
<P>0.75</P>
</TD>
<TD>
<P>22</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo - (mean tardive dyskinesia score) - high = poor</P>
</TD>
<TD>
<P>3.5</P>
</TD>
<TD>
<P>0.7</P>
</TD>
<TD>
<P>25</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="2.612890479940429" CI_END="1.5597774174479198" CI_START="0.6722933394492567" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0240253750633328" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.42" LOG_CI_END="0.1930626283089322" LOG_CI_START="-0.1724411913702402" LOG_EFFECT_SIZE="0.010310718469346026" METHOD="MH" MODIFIED="2016-08-08 13:48:33 +0100" MODIFIED_BY="[Empty name]" NO="42" P_CHI2="0.4552342073433767" P_Q="1.0" P_Z="0.9119497087765722" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="232" TOTAL_2="237" WEIGHT="100.00000000000001" Z="0.11057962060362936">
<NAME>Adverse events: 17. Headache</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7934794450999798" CI_START="0.6649736930660859" EFFECT_SIZE="1.0920698924731183" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="24" LOG_CI_END="0.2536964036321082" LOG_CI_START="-0.1771955354220417" LOG_EFFECT_SIZE="0.038250434105033274" ORDER="821" O_E="0.0" SE="0.25310805794990576" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.06406368899917286" WEIGHT="71.95270088179096"/>
<DICH_DATA CI_END="2.9326796442861944" CI_START="0.008281641316704065" EFFECT_SIZE="0.15584415584415584" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.46726462475435243" LOG_CI_START="-2.0818835830040667" LOG_EFFECT_SIZE="-0.8073094791248571" MODIFIED="2013-02-19 15:14:27 +0000" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="1.4973822757244322" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="2.242153679653679" WEIGHT="2.0558606190872495"/>
<DICH_DATA CI_END="2.1256236089204403" CI_START="0.20908896691741605" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3274863650599791" LOG_CI_START="-0.6796688831713416" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-05-10 10:37:31 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.35" WEIGHT="13.170158434118763"/>
<DICH_DATA CI_END="4.858187752692993" CI_START="0.46313566180162113" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6864742948212909" LOG_CI_START="-0.3342917767099283" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-03-16 17:56:01 +0000" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="0.5996030432909839" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.35952380952380947" WEIGHT="12.821280065003036"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6437233130517814" CI_END="1.701963182370689" CI_START="0.621082880731212" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0281343278994475" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-001.43" LOG_CI_END="0.23095016099757415" LOG_CI_START="-0.20685044130095195" LOG_EFFECT_SIZE="0.012049859848311077" METHOD="MH" MODIFIED="2016-09-08 17:35:43 +0100" MODIFIED_BY="[Empty name]" NO="43" P_CHI2="0.7247985081375962" P_Q="1.0" P_Z="0.9140824502012433" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="121" TOTAL_2="127" WEIGHT="100.0" Z="0.10789062964943552">
<NAME>Adverse events: 18. Hypersalivation</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9186175801990297" CI_START="0.45587065154133033" EFFECT_SIZE="0.9352226720647774" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.28298841957127874" LOG_CI_START="-0.34115836630632146" LOG_EFFECT_SIZE="-0.029084973367521395" MODIFIED="2013-02-25 14:31:56 +0000" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.3666269116009205" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.13441529231002916" WEIGHT="49.201600756621396"/>
<DICH_DATA CI_END="2.5659974089424886" CI_START="0.5821623807131866" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.40925621350323255" LOG_CI_START="-0.23495586206543212" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2013-05-20 14:45:30 +0100" MODIFIED_BY="[Empty name]" ORDER="742" O_E="0.0" SE="0.3784133620902376" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" VAR="0.1431966726084373" WEIGHT="46.18436607047911"/>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-05-10 10:41:03 +0100" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="4.614033172899501"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="79.22290951700097" CI_START="0.1451719616169367" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.391304347826087" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.44" LOG_CI_END="1.898850788131076" LOG_CI_START="-0.8381172547853013" LOG_EFFECT_SIZE="0.5303667666728875" METHOD="MH" MODIFIED="2016-09-08 17:35:50 +0100" MODIFIED_BY="[Empty name]" NO="44" P_CHI2="1.0" P_Q="1.0" P_Z="0.44749403183940184" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="25" WEIGHT="100.0" Z="0.7595994874446385">
<NAME>Adverse events: 19. Incontinence</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="79.22290951700097" CI_START="0.1451719616169367" EFFECT_SIZE="3.391304347826087" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.898850788131076" LOG_CI_START="-0.8381172547853013" LOG_EFFECT_SIZE="0.5303667666728875" ORDER="822" O_E="0.0" SE="1.6077085766193955" STUDY_ID="STD-Fisk-1987" TOTAL_1="22" TOTAL_2="25" VAR="2.584726867335563" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18449915681728424" CI_END="1.7772474569272885" CI_START="0.3864848111318898" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8287817250188221" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.45" LOG_CI_END="0.24974790146646675" LOG_CI_START="-0.41286756920031376" LOG_EFFECT_SIZE="-0.08155983386692356" METHOD="MH" MODIFIED="2016-09-08 17:35:56 +0100" MODIFIED_BY="[Empty name]" NO="45" P_CHI2="0.6675349171053604" P_Q="1.0" P_Z="0.6294543271278716" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="63" WEIGHT="100.0" Z="0.48249503381918074">
<NAME>Adverse events: 20. Insomnia</NAME>
<GROUP_LABEL_1>Antipsychotic+Vaproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.9830689537366482" CI_START="0.25728005103972207" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.2973378154189655" LOG_CI_START="-0.5895938867754416" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2013-03-16 10:32:30 +0000" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.5209880722517277" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" VAR="0.27142857142857146" WEIGHT="55.81395348837209"/>
<DICH_DATA CI_END="3.1507401619812847" CI_START="0.3173857406797927" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4984125888703692" LOG_CI_START="-0.49841258887036916" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-16 17:55:38 +0000" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.5855400437691199" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.34285714285714286" WEIGHT="44.18604651162791"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.2337006044292" CI_START="0.0477673483631121" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.46" LOG_CI_END="0.718808875055234" LOG_CI_START="-1.3208688663831967" LOG_EFFECT_SIZE="-0.3010299956639812" METHOD="MH" MODIFIED="2016-10-05 13:57:14 +0100" MODIFIED_BY="[Empty name]" NO="46" P_CHI2="1.0" P_Q="1.0" P_Z="0.5629059762047044" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="31" TOTAL_2="31" WEIGHT="100.0" Z="0.5785305568433214">
<NAME>Adverse events: 21. Myocardial ischaemia</NAME>
<GROUP_LABEL_1>Antipsychotic+Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.2337006044292" CI_START="0.0477673483631121" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.718808875055234" LOG_CI_START="-1.3208688663831967" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2013-03-16 17:28:09 +0000" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.1981168018885897" STUDY_ID="STD-Yao-2010" TOTAL_1="31" TOTAL_2="31" VAR="1.435483870967742" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.313495876210003" CI_END="1.862273465736348" CI_START="0.8037714159954452" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.223455017777789" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-001.47" LOG_CI_END="0.27004345534556784" LOG_CI_START="-0.09486744240397343" LOG_EFFECT_SIZE="0.08758800647079724" METHOD="MH" MODIFIED="2016-08-08 15:37:42 +0100" MODIFIED_BY="[Empty name]" NO="47" P_CHI2="0.6121605079096882" P_Q="1.0" P_Z="0.3467645281570806" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="362" TOTAL_2="366" WEIGHT="100.00000000000001" Z="0.9408835922365355">
<NAME>Adverse events: 22. Nausea</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.025740296940819" CI_START="0.5016408422210241" EFFECT_SIZE="1.0080645161290323" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.30658376736434056" LOG_CI_START="-0.2996071116726979" LOG_EFFECT_SIZE="0.003488327845821341" ORDER="825" O_E="0.0" SE="0.3560795230396022" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.1267926267281106" WEIGHT="36.237219922505616"/>
<DICH_DATA CI_END="118.7294157404545" CI_START="0.36812099049658376" EFFECT_SIZE="6.611111111111111" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0745583306739395" LOG_CI_START="-0.43400941809549015" LOG_EFFECT_SIZE="0.8202744562892247" MODIFIED="2013-03-25 12:56:22 +0000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="1.4735451132377881" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="2.1713352007469657" WEIGHT="2.116030863276248"/>
<DICH_DATA CI_END="129.5480077181774" CI_START="0.37823815945202377" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1124307384823604" LOG_CI_START="-0.42223465845384694" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-03-16 10:29:36 +0000" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="1.4888750009563954" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" VAR="2.2167487684729066" WEIGHT="2.0726806594614167"/>
<DICH_DATA CI_END="4.093837051800057" CI_START="0.6253302140773703" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6121305523195395" LOG_CI_START="-0.2038905870076899" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2013-02-18 16:14:46 +0000" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.4793348566106003" STUDY_ID="STD-Liang-2004" TOTAL_1="21" TOTAL_2="21" VAR="0.22976190476190478" WEIGHT="19.99727632855396"/>
<DICH_DATA CI_END="4.154590675464391" CI_START="0.12780505882384557" EFFECT_SIZE="0.7286821705426356" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6185282420445675" LOG_CI_START="-0.893451955443668" LOG_EFFECT_SIZE="-0.13746185669955033" MODIFIED="2013-02-19 15:13:46 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.8881446524272744" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="0.788800923635164" WEIGHT="5.8248059321794186"/>
<DICH_DATA CI_END="8.417860424098468" CI_START="0.2672888224136799" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9252017204680284" LOG_CI_START="-0.573019202356666" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-03-16 11:55:14 +0000" MODIFIED_BY="[Empty name]" ORDER="135" O_E="0.0" SE="0.8800623863804024" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" VAR="0.7745098039215685" WEIGHT="5.932284234537573"/>
<DICH_DATA CI_END="160.170939238357" CI_START="0.5057097147907748" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.204583722276951" LOG_CI_START="-0.29609870339830113" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2013-03-20 11:33:07 +0000" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="1.4689132354192893" STUDY_ID="STD-Wang-2005a" TOTAL_1="30" TOTAL_2="30" VAR="2.1577060931899643" WEIGHT="2.1293967300736534"/>
<DICH_DATA CI_END="2.438041198591854" CI_START="0.2848370424771889" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.38704104015436036" LOG_CI_START="-0.54540353224961" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2013-05-10 10:39:45 +0100" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="15.31537433099569"/>
<DICH_DATA CI_END="3.6851354381687162" CI_START="0.2713604470659396" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5664534539232672" LOG_CI_START="-0.5664534539232672" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-16 17:54:46 +0000" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.44285714285714284" WEIGHT="10.374930998416437"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2502174074197727" CI_START="0.30355086465671877" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6160394265232975" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.48" LOG_CI_END="0.09698554151424943" LOG_CI_START="-0.5177685257127688" LOG_EFFECT_SIZE="-0.2103914920992597" METHOD="MH" MODIFIED="2016-08-08 15:38:17 +0100" MODIFIED_BY="[Empty name]" NO="48" P_CHI2="1.0" P_Q="1.0" P_Z="0.17974396583324032" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="125" WEIGHT="100.0" Z="1.3415437787283964">
<NAME>Adverse events: 23. Pain</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2502174074197727" CI_START="0.30355086465671877" EFFECT_SIZE="0.6160394265232975" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="18" LOG_CI_END="0.09698554151424943" LOG_CI_START="-0.5177685257127688" LOG_EFFECT_SIZE="-0.2103914920992597" ORDER="826" O_E="0.0" SE="0.36110958217086153" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.1304001303356142" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0018476159746576713" CI_END="29.72328580535793" CI_START="0.3339740551401892" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.15068346434646" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.49" LOG_CI_END="1.47309681747943" LOG_CI_START="-0.47628727015581784" LOG_EFFECT_SIZE="0.49840477366180613" METHOD="MH" MODIFIED="2016-09-08 17:36:08 +0100" MODIFIED_BY="[Empty name]" NO="49" P_CHI2="0.9657143728052242" P_Q="1.0" P_Z="0.31623758879411534" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="98" WEIGHT="100.0" Z="1.0022195341555062">
<NAME>Adverse events: 24. Rash</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="79.66859137956857" CI_START="0.13754960000883215" EFFECT_SIZE="3.310344827586207" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9012871384723493" LOG_CI_START="-0.8615406681911248" LOG_EFFECT_SIZE="0.5198732351406123" MODIFIED="2013-02-25 14:37:21 +0000" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.622898729852335" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="2.6338002873563218" WEIGHT="49.78370295967402"/>
<DICH_DATA CI_END="71.21510406800243" CI_START="0.12637768515238015" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.85257211326778" LOG_CI_START="-0.8983296038284552" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-03-16 17:56:50 +0000" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="1.6158932858054431" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" VAR="2.611111111111111" WEIGHT="50.21629704032598"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0726417415707787" CI_START="0.08526375828627639" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3024193548387097" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.50" LOG_CI_END="0.030454693411241747" LOG_CI_START="-1.0692355282802741" LOG_EFFECT_SIZE="-0.5193904174345162" METHOD="MH" MODIFIED="2016-08-08 15:39:13 +0100" MODIFIED_BY="[Empty name]" NO="50" P_CHI2="1.0" P_Q="1.0" P_Z="0.06411117314586101" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="124" TOTAL_2="125" WEIGHT="100.0" Z="1.8514059541623187">
<NAME>Adverse events: 25. Rhinitis</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0726417415707787" CI_START="0.08526375828627639" EFFECT_SIZE="0.3024193548387097" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.030454693411241747" LOG_CI_START="-1.0692355282802741" LOG_EFFECT_SIZE="-0.5193904174345162" ORDER="827" O_E="0.0" SE="0.6459634797759863" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.4172688172043011" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="64.88840300542985" CI_START="0.1237166798064982" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.833333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.51" LOG_CI_END="1.812167085694211" LOG_CI_START="-0.9075717437049503" LOG_EFFECT_SIZE="0.45229767099463036" METHOD="MH" MODIFIED="2016-10-05 13:57:21 +0100" MODIFIED_BY="[Empty name]" NO="51" P_CHI2="1.0" P_Q="1.0" P_Z="0.5144712519853463" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0" Z="0.6518913771118701">
<NAME>Adverse events: 26. Rigidity/stiffness</NAME>
<GROUP_LABEL_1>Antipsychotic+Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="64.88840300542985" CI_START="0.1237166798064982" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.812167085694211" LOG_CI_START="-0.9075717437049503" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2013-03-25 13:00:00 +0000" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.6416760742524925" CI_END="1.7942246717504644" CI_START="1.0683897922703558" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.384532890305545" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-001.52" LOG_CI_END="0.2538768242109443" LOG_CI_START="0.028729729984083387" LOG_EFFECT_SIZE="0.1413032770975139" METHOD="MH" MODIFIED="2016-10-05 13:57:29 +0100" MODIFIED_BY="[Empty name]" NO="52" P_CHI2="0.5821547248191392" P_Q="1.0" P_Z="0.013887372544500256" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="378" TOTAL_2="392" WEIGHT="100.0" Z="2.4601635207386083">
<NAME>Adverse events: 27. Sedation/somnolence/drowsiness</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1840189060412913" CI_START="0.975939390427466" EFFECT_SIZE="1.4599555061179088" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="29" LOG_CI_END="0.33925639353538684" LOG_CI_START="-0.010577152845855416" LOG_EFFECT_SIZE="0.16433962034476574" ORDER="828" O_E="0.0" SE="0.20549395684832486" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.042227766301181205" WEIGHT="41.41997068629762"/>
<DICH_DATA CI_END="5.895147872889128" CI_START="0.6708355196591071" EFFECT_SIZE="1.9886363636363635" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7704947033368447" LOG_CI_START="-0.1733839502645932" LOG_EFFECT_SIZE="0.2985553765361258" ORDER="829" O_E="0.0" SE="0.5544389934001733" STUDY_ID="STD-Fisk-1987" TOTAL_1="22" TOTAL_2="25" VAR="0.3074025974025974" WEIGHT="5.6898440583182035"/>
<DICH_DATA CI_END="3.4945080447131307" CI_START="0.508734778981949" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5433860446010865" LOG_CI_START="-0.29350857138448677" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2013-03-20 13:58:43 +0000" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.49159604012508745" STUDY_ID="STD-Jia-2007" TOTAL_1="40" TOTAL_2="40" VAR="0.2416666666666666" WEIGHT="7.237542795901044"/>
<DICH_DATA CI_END="1.952113761312073" CI_START="0.6257866075276108" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="17" LOG_CI_END="0.2905051229979224" LOG_CI_START="-0.20357373543574167" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2013-02-25 14:25:33 +0000" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.29022436717372774" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.08423018330139073" WEIGHT="20.765392805619985"/>
<DICH_DATA CI_END="129.5480077181774" CI_START="0.37823815945202377" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1124307384823604" LOG_CI_START="-0.42223465845384694" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-04-12 17:44:25 +0100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="1.4888750009563954" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" VAR="2.2167487684729066" WEIGHT="0.789026193323508"/>
<DICH_DATA CI_END="278.21510566953293" CI_START="0.9624516770824836" EFFECT_SIZE="16.363636363636363" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.444380706284441" LOG_CI_START="-0.01662106639427895" LOG_EFFECT_SIZE="1.213879819945081" MODIFIED="2013-02-19 15:09:51 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="1.4456046234267261" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="2.089772727272727" WEIGHT="0.8369679724097998"/>
<DICH_DATA CI_END="2.5659974089424886" CI_START="0.5821623807131866" EFFECT_SIZE="1.2222222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.40925621350323255" LOG_CI_START="-0.23495586206543212" LOG_EFFECT_SIZE="0.0871501757189002" MODIFIED="2013-04-12 17:44:25 +0100" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.3784133620902376" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" VAR="0.1431966726084373" WEIGHT="12.21447964175457"/>
<DICH_DATA CI_END="2.7265448845959694" CI_START="0.5730696049889299" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4356126514715481" LOG_CI_START="-0.24179262545543537" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-05-10 10:31:56 +0100" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.39791121287711073" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.15833333333333335" WEIGHT="11.046775846375272"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.209822556158871" CI_START="0.01374629775627757" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.31481481481481477" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.53" LOG_CI_END="0.857924576254886" LOG_CI_START="-1.8618142531442754" LOG_EFFECT_SIZE="-0.5019448384446946" METHOD="MH" MODIFIED="2016-10-05 13:57:35 +0100" MODIFIED_BY="[Empty name]" NO="53" P_CHI2="1.0" P_Q="1.0" P_Z="0.46940514875382067" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="16" WEIGHT="100.0" Z="0.7234472626143409">
<NAME>Adverse events: 28. Sexual dysfunction</NAME>
<GROUP_LABEL_1>Antipsychotic+Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.209822556158871" CI_START="0.01374629775627757" EFFECT_SIZE="0.3148148148148148" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.857924576254886" LOG_CI_START="-1.8618142531442754" LOG_EFFECT_SIZE="-0.5019448384446946" MODIFIED="2013-03-25 13:02:44 +0000" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.140168426766256" CI_START="0.015561413186640009" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.54" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" METHOD="MH" MODIFIED="2016-08-08 15:40:43 +0100" MODIFIED_BY="[Empty name]" NO="54" P_CHI2="1.0" P_Q="1.0" P_Z="0.4822584525845881" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="8" WEIGHT="100.0" Z="0.7026747808233531">
<NAME>Adverse events: 29. Suicidal or depressed</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.140168426766256" CI_START="0.015561413186640009" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-05-16 15:54:05 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Glick-2009" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8323411786482422" CI_END="2.719115009952667" CI_START="0.6027401129942074" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2802029871637997" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.55" LOG_CI_END="0.43442757725703574" LOG_CI_START="-0.21986990481160404" LOG_EFFECT_SIZE="0.10727883622271582" METHOD="MH" MODIFIED="2016-09-08 17:36:28 +0100" MODIFIED_BY="[Empty name]" NO="55" P_CHI2="0.6595677611011344" P_Q="1.0" P_Z="0.5204105334021404" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="109" WEIGHT="100.0" Z="0.6427127142079885">
<NAME>Adverse events: 30. Tachycardia</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.5459985274982095" CI_START="0.5521999302407835" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.743979749933605" LOG_CI_START="-0.2579036525610162" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2013-02-19 15:09:17 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.588511270028167" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="43" VAR="0.34634551495016613" WEIGHT="42.64971505738761"/>
<DICH_DATA CI_END="3.748275808525094" CI_START="0.11857303655019144" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5738315399834706" LOG_CI_START="-0.9260140580948332" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-03-16 17:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.8810167286666446" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.7761904761904761" WEIGHT="19.03081521500639"/>
<DICH_DATA CI_END="4.220835945185061" CI_START="0.3701873326260002" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6253984723900229" LOG_CI_START="-0.4315784463739101" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-03-16 17:25:54 +0000" MODIFIED_BY="[Empty name]" ORDER="158" O_E="0.0" SE="0.6208734742020647" STUDY_ID="STD-Yao-2010" TOTAL_1="31" TOTAL_2="31" VAR="0.38548387096774195" WEIGHT="38.319469727606"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.941241316956704" CI_END="2.971636047011886" CI_START="0.46257992115448826" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1724415415391054" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.56" LOG_CI_END="0.47299561785656136" LOG_CI_START="-0.3348132222378161" LOG_EFFECT_SIZE="0.06909119780937269" METHOD="MH" MODIFIED="2016-09-08 17:36:34 +0100" MODIFIED_BY="[Empty name]" NO="56" P_CHI2="0.5846916812757954" P_Q="1.0" P_Z="0.7374228708513342" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="101" WEIGHT="100.0" Z="0.3352680798573143">
<NAME>Adverse events: 31.Tremor</NAME>
<GROUP_LABEL_1>Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotics</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="13.815573537721964" CI_START="0.0641170014672433" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.14036891886509" LOG_CI_START="-1.1930267963097887" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2013-03-25 13:00:24 +0000" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="1.370648193588798" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="1.8786764705882353" WEIGHT="11.985065473107792"/>
<DICH_DATA CI_END="7.140168426766256" CI_START="0.015561413186640009" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8537084563073322" LOG_CI_START="-1.8079509657466573" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2013-05-16 15:49:26 +0100" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Glick-2009" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="9.211115660231073"/>
<DICH_DATA CI_END="8.205804789926459" CI_START="0.5823681495405606" EFFECT_SIZE="2.186046511627907" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.9141211812067952" LOG_CI_START="-0.23480238516657093" LOG_EFFECT_SIZE="0.33965939802011214" MODIFIED="2013-02-19 15:11:38 +0000" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.6748833901510918" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="0.4554675903018308" WEIGHT="49.43504429780843"/>
<DICH_DATA CI_END="3.7086562974712898" CI_START="0.11983975024794946" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.569216586623787" LOG_CI_START="-0.9213991047351496" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2013-05-10 10:48:17 +0100" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.8755950357709131" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.7666666666666666" WEIGHT="29.368774568852697"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.3911422965883524" CI_START="0.02096966299015297" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.57" LOG_CI_END="0.5303460137021568" LOG_CI_START="-1.6784085491575944" LOG_EFFECT_SIZE="-0.5740312677277188" METHOD="MH" MODIFIED="2016-09-08 17:36:40 +0100" MODIFIED_BY="[Empty name]" NO="57" P_CHI2="1.0" P_Q="1.0" P_Z="0.308323292835158" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="4" WEIGHT="100.0" Z="1.0187466092108646">
<NAME>Adverse events: 32. Unstable gait</NAME>
<GROUP_LABEL_1>Antipsychotic+Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.3911422965883524" CI_START="0.02096966299015297" EFFECT_SIZE="0.26666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.5303460137021568" LOG_CI_START="-1.6784085491575944" LOG_EFFECT_SIZE="-0.5740312677277188" MODIFIED="2013-03-16 20:20:05 +0000" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="1.2974333637352375" STUDY_ID="STD-Liu-2007a" TOTAL_1="15" TOTAL_2="4" VAR="1.6833333333333333" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.266036368124056" CI_START="0.551738537963535" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7045454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.58" LOG_CI_END="0.7214838540904168" LOG_CI_START="-0.25826668027939154" LOG_EFFECT_SIZE="0.23160858690551261" METHOD="MH" MODIFIED="2016-08-08 15:42:11 +0100" MODIFIED_BY="[Empty name]" NO="58" P_CHI2="1.0" P_Q="1.0" P_Z="0.35410662930450165" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="25" WEIGHT="99.99999999999999" Z="0.9266532100173941">
<NAME>Adverse events: 33. Vegetative adverse events</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.266036368124056" CI_START="0.551738537963535" EFFECT_SIZE="1.7045454545454546" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7214838540904168" LOG_CI_START="-0.25826668027939154" LOG_EFFECT_SIZE="0.23160858690551261" ORDER="831" O_E="0.0" SE="0.5755103137321878" STUDY_ID="STD-Fisk-1987" TOTAL_1="22" TOTAL_2="25" VAR="0.3312121212121212" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4689952192109716" CI_END="2.176959028192698" CI_START="0.4458591231380512" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9851989867115477" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.59" LOG_CI_END="0.337850255408908" LOG_CI_START="-0.35080234242802427" LOG_EFFECT_SIZE="-0.006476043509558145" METHOD="MH" MODIFIED="2016-08-08 15:42:48 +0100" MODIFIED_BY="[Empty name]" NO="59" P_CHI2="0.4934498133073435" P_Q="1.0" P_Z="0.970594445913385" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="141" TOTAL_2="141" WEIGHT="100.0" Z="0.0368627435107823">
<NAME>Adverse events: 34. Vomiting</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0797954983269307" CI_START="0.4038040324160551" EFFECT_SIZE="0.9164222873900293" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3180206338500452" LOG_CI_START="-0.3938293484748526" LOG_EFFECT_SIZE="-0.037904357312403714" ORDER="832" O_E="0.0" SE="0.41814420333188723" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.17484457478005866" WEIGHT="93.5887018029308"/>
<DICH_DATA CI_END="64.88840300542985" CI_START="0.1237166798064982" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.812167085694211" LOG_CI_START="-0.9075717437049503" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2013-03-25 12:56:50 +0000" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Citrome-2007" TOTAL_1="17" TOTAL_2="16" VAR="2.5522875816993467" WEIGHT="6.411298197069206"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6342928013254833" CI_END="1.815877396214339" CI_START="0.7561247374081911" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1717635509683841" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-001.60" LOG_CI_END="0.2590865226294165" LOG_CI_START="-0.12140655330911711" LOG_EFFECT_SIZE="0.0688399846601497" METHOD="MH" MODIFIED="2016-08-08 15:43:15 +0100" MODIFIED_BY="[Empty name]" NO="60" P_CHI2="0.8885388834150717" P_Q="1.0" P_Z="0.47819696750765006" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="210" TOTAL_2="217" WEIGHT="100.0" Z="0.7092054976158322">
<NAME>Adverse events: 35. Weight gain</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.1419084327296063" CI_START="0.544630804803975" EFFECT_SIZE="1.080069124423963" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" LOG_CI_END="0.3308009006647107" LOG_CI_START="-0.26389779821818166" LOG_EFFECT_SIZE="0.033451551223264535" ORDER="833" O_E="0.0" SE="0.3493289595298475" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.12203072196620585" WEIGHT="40.93544722467049"/>
<DICH_DATA CI_END="64.26151584089634" CI_START="0.14005271867976013" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8079509657466573" LOG_CI_START="-0.8537084563073322" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2013-05-16 15:51:07 +0100" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="1.563471919941143" STUDY_ID="STD-Glick-2009" TOTAL_1="8" TOTAL_2="8" VAR="2.444444444444444" WEIGHT="2.043565436796569"/>
<DICH_DATA CI_END="2.1820138350427336" CI_START="0.559852842626693" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.3388574999020333" LOG_CI_START="-0.2519261123398525" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2013-02-25 14:26:38 +0000" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.3470292182569289" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.12042927832401518" WEIGHT="41.479798337709646"/>
<DICH_DATA CI_END="4.556980530838007" CI_START="0.4937479949220314" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6586771731144472" LOG_CI_START="-0.3064946550030847" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2013-02-18 16:15:11 +0000" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.5669467095138409" STUDY_ID="STD-Liang-2004" TOTAL_1="21" TOTAL_2="21" VAR="0.3214285714285714" WEIGHT="15.541189000823291"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.527401869915684" CI_START="-0.4074018699156823" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0600000000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.61" MODIFIED="2016-09-08 17:36:46 +0100" MODIFIED_BY="[Empty name]" NO="61" P_CHI2="1.0" P_Q="1.0" P_Z="0.10176697112385033" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="100.0" Z="1.6363470650569318">
<NAME>Adverse events: 36. Mean endpoint score TESS (high = poor)</NAME>
<GROUP_LABEL_1>Antipsychotic+Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.527401869915684" CI_START="-0.4074018699156823" EFFECT_SIZE="2.0600000000000005" ESTIMABLE="YES" MEAN_1="7.65" MEAN_2="5.59" MODIFIED="2013-03-16 17:09:36 +0000" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="4.35" SD_2="5.35" SE="1.2589016376720357" STUDY_ID="STD-Wang-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9658643545747647E-31" CI_END="-1.7117575190822887" CI_START="-4.908242480917711" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.31" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.62" MODIFIED="2016-09-08 17:36:52 +0100" MODIFIED_BY="[Empty name]" NO="62" P_CHI2="0.0" P_Q="1.0" P_Z="4.9254991890567755E-5" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="40" UNITS="" WEIGHT="100.0" Z="4.059134246702332">
<NAME>Adverse events: 37. Tardive dyskinesia - mean endpoint score AIMS (high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.7117575190822882" CI_START="-4.9082424809177105" EFFECT_SIZE="-3.3099999999999996" ESTIMABLE="YES" MEAN_1="6.05" MEAN_2="9.36" ORDER="830" SD_1="3.01" SD_2="4.16" SE="0.8154448211928607" STUDY_ID="STD-Yin-2004" TOTAL_1="39" TOTAL_2="40" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.593686929149056" CI_END="1.3920857495950933" CI_START="0.9474441656980797" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1484439566671545" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="86" I2="0.0" I2_Q="0.0" ID="CMP-001.63" LOG_CI_END="0.14366598773789085" LOG_CI_START="-0.02344637422924302" LOG_EFFECT_SIZE="0.06010980675432392" METHOD="MH" MODIFIED="2016-08-08 15:44:12 +0100" MODIFIED_BY="[Empty name]" NO="63" P_CHI2="0.45074970246531254" P_Q="1.0" P_Z="0.15854377811112383" Q="0.0" RANDOM="YES" SCALE="138.99" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="161" TOTAL_2="162" WEIGHT="100.0" Z="1.4099861311194652">
<NAME>Sensitivity analysis: Primary outcome 1. Excluding open studies</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3819161595464036" CI_START="0.9306791944551314" EFFECT_SIZE="1.1340725806451613" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="53" LOG_CI_END="0.14048169531685484" LOG_CI_START="-0.031199994730449643" LOG_EFFECT_SIZE="0.05464085029320262" MODIFIED="2013-05-05 11:33:26 +0100" MODIFIED_BY="[Empty name]" ORDER="792" O_E="0.0" SE="0.10084667457185839" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.010170051772202308" WEIGHT="94.74781325756182"/>
<DICH_DATA CI_END="129.74412565322564" CI_START="0.3776664242276759" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="2.1130877036754665" LOG_CI_START="-0.4228916236469528" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-05-05 11:33:26 +0100" MODIFIED_BY="[Empty name]" ORDER="793" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Fisk-1987" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="0.4342359117763854"/>
<DICH_DATA CI_END="3.0031630760051726" CI_START="0.5202847665796584" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.477578915644285" LOG_CI_START="-0.28375888962817214" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-05-16 21:25:31 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Glick-2009" TOTAL_1="8" TOTAL_2="8" VAR="0.2" WEIGHT="4.8179508306617995"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.851167203661271" CI_END="1.5028910405313176" CI_START="1.206031261646852" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3463036721816275" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="291" I2="12.464792687842753" I2_Q="0.0" ID="CMP-001.64" LOG_CI_END="0.17692749541636635" LOG_CI_START="0.08135856533710041" LOG_EFFECT_SIZE="0.12914303037673336" METHOD="MH" MODIFIED="2016-10-05 13:58:07 +0100" MODIFIED_BY="[Empty name]" NO="64" P_CHI2="0.3167362119509666" P_Q="1.0" P_Z="1.1770212509168013E-7" Q="0.0" RANDOM="NO" SCALE="138.99" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="520" TOTAL_2="529" WEIGHT="100.00000000000001" Z="5.29702881852549">
<NAME>Sensitivity analysis: Primary outcome 2. Fixed-effect model</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3819161595464036" CI_START="0.9306791944551314" EFFECT_SIZE="1.1340725806451613" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="53" LOG_CI_END="0.14048169531685484" LOG_CI_START="-0.031199994730449643" LOG_EFFECT_SIZE="0.05464085029320262" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="792" O_E="0.0" SE="0.10084667457185839" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.010170051772202308" WEIGHT="30.387505146643306"/>
<DICH_DATA CI_END="129.74412565322564" CI_START="0.3776664242276759" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="2.1130877036754665" LOG_CI_START="-0.4228916236469528" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="793" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Fisk-1987" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="0.2118752458981346"/>
<DICH_DATA CI_END="3.0031630760051726" CI_START="0.5202847665796584" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.477578915644285" LOG_CI_START="-0.28375888962817214" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-05-16 21:26:03 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Glick-2009" TOTAL_1="8" TOTAL_2="8" VAR="0.2" WEIGHT="1.695001967185077"/>
<DICH_DATA CI_END="3.0028281703186757" CI_START="0.550501437554572" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.47753048144390436" LOG_CI_START="-0.2592415425937682" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.4327835340000672" STUDY_ID="STD-Guo-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.1873015873015873" WEIGHT="2.9662534425738847"/>
<DICH_DATA CI_END="1.6044985664275577" CI_START="0.9749038199559569" EFFECT_SIZE="1.2506925207756232" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.20533933340230553" LOG_CI_START="-0.011038227914572225" LOG_EFFECT_SIZE="0.09715055274386665" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.12710125060373678" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.016154727905033903" WEIGHT="15.297392753845319"/>
<DICH_DATA CI_END="1.5497352673789209" CI_START="0.8288153928488928" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.19025751640515565" LOG_CI_START="-0.08154219175997034" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.15965649400644924" STUDY_ID="STD-Li-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.025490196078431365" WEIGHT="6.356257376944038"/>
<DICH_DATA CI_END="4.8944142941476345" CI_START="1.11237915657334" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.6897007280004384" LOG_CI_START="0.04625284258875047" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Liang-2004" TOTAL_1="21" TOTAL_2="21" VAR="0.14285714285714285" WEIGHT="2.5425029507776156"/>
<DICH_DATA CI_END="2.969306179643863" CI_START="1.117638417744806" EFFECT_SIZE="1.821705426356589" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="32" LOG_CI_END="0.47265498212749046" LOG_CI_START="0.04830132181748406" LOG_EFFECT_SIZE="0.2604781519724873" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.24926744065059406" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="0.062134256968497434" WEIGHT="6.073757049079859"/>
<DICH_DATA CI_END="2.238900905940909" CI_START="0.8226521905487535" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.35003487207146966" LOG_CI_START="-0.08478374152228778" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.2554146060118237" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" VAR="0.06523662096417512" WEIGHT="5.932506885147769"/>
<DICH_DATA CI_END="1.9728646309214037" CI_START="0.5323231368788075" EFFECT_SIZE="1.024793388429752" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.29509728694465825" LOG_CI_START="-0.2738246572530884" LOG_EFFECT_SIZE="0.010636314845784953" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.33418756623079937" STUDY_ID="STD-Shi-2010" TOTAL_1="33" TOTAL_2="31" VAR="0.11168132942326492" WEIGHT="4.806919641313929"/>
<DICH_DATA CI_END="4.494870270135582" CI_START="1.021572694812251" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.6527171617472683" LOG_CI_START="0.00926927633558044" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Wang-2009" TOTAL_1="30" TOTAL_2="30" VAR="0.14285714285714285" WEIGHT="2.9662534425738847"/>
<DICH_DATA CI_END="3.667788466538238" CI_START="1.202359416371218" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="0.5644042805246219" LOG_CI_START="0.08003430894321663" LOG_EFFECT_SIZE="0.3222192947339193" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.2845213189769459" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.08095238095238097" WEIGHT="4.237504917962692"/>
<DICH_DATA CI_END="1.6053050368500235" CI_START="0.8238309664779027" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.20555756835057928" LOG_CI_START="-0.08416188764335593" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.17018264258527413" STUDY_ID="STD-Yao-2010" TOTAL_1="31" TOTAL_2="31" VAR="0.028962131837307156" WEIGHT="8.475009835925384"/>
<DICH_DATA CI_END="1.9129637444510341" CI_START="1.0556345291828615" EFFECT_SIZE="1.4210526315789473" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.28170673911560595" LOG_CI_START="0.0235135872967107" LOG_EFFECT_SIZE="0.15261016320615833" MODIFIED="2013-05-05 11:53:49 +0100" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.15166393545513313" STUDY_ID="STD-Zhang-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.023001949317738787" WEIGHT="8.051259344129114"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.706045892021405" CI_END="1.5967083817172134" CI_START="1.0286119152375435" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.281558920453516" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="139" I2="36.25221536648893" I2_Q="0.0" ID="CMP-001.65" LOG_CI_END="0.20322560507043846" LOG_CI_START="0.012251550795827739" LOG_EFFECT_SIZE="0.10773857793313309" METHOD="MH" MODIFIED="2016-08-08 15:45:20 +0100" MODIFIED_BY="[Empty name]" NO="65" P_CHI2="0.19463156086655453" P_Q="1.0" P_Z="0.027005454057371838" Q="0.0" RANDOM="YES" SCALE="138.99" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="YES" TAU2="0.01724355951666584" TOTALS="YES" TOTAL_1="253" TOTAL_2="264" WEIGHT="100.00000000000001" Z="2.2114389653252084">
<NAME>Sensitivity analysis: Primary outcome 3. Exluding no attrition</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3819161595464036" CI_START="0.9306791944551314" EFFECT_SIZE="1.1340725806451613" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="53" LOG_CI_END="0.14048169531685484" LOG_CI_START="-0.031199994730449643" LOG_EFFECT_SIZE="0.05464085029320262" MODIFIED="2013-05-13 21:13:32 +0100" MODIFIED_BY="[Empty name]" ORDER="792" O_E="0.0" SE="0.10084667457185839" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.010170051772202308" WEIGHT="45.90475667397868"/>
<DICH_DATA CI_END="129.74412565322564" CI_START="0.3776664242276759" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="2.1130877036754665" LOG_CI_START="-0.4228916236469528" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-05-05 12:10:11 +0100" MODIFIED_BY="[Empty name]" ORDER="793" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Fisk-1987" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="0.5627241961301476"/>
<DICH_DATA CI_END="1.6044985664275577" CI_START="0.9749038199559569" EFFECT_SIZE="1.2506925207756232" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.20533933340230553" LOG_CI_START="-0.011038227914572225" LOG_EFFECT_SIZE="0.09715055274386665" MODIFIED="2013-05-05 12:10:11 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.12710125060373678" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.016154727905033903" WEIGHT="37.67903245700264"/>
<DICH_DATA CI_END="2.969306179643863" CI_START="1.117638417744806" EFFECT_SIZE="1.821705426356589" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="32" LOG_CI_END="0.47265498212749046" LOG_CI_START="0.04830132181748406" LOG_EFFECT_SIZE="0.2604781519724873" MODIFIED="2013-05-05 12:10:11 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.24926744065059406" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="0.062134256968497434" WEIGHT="15.853486672888534"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.4441992774161125" CI_START="1.5158356988375816" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1254355400696863" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-001.66" LOG_CI_END="0.8091689618750563" LOG_CI_START="0.18065213074514322" LOG_EFFECT_SIZE="0.49491054631009973" METHOD="MH" MODIFIED="2016-08-08 15:45:49 +0100" MODIFIED_BY="[Empty name]" NO="66" P_CHI2="1.0" P_Q="1.0" P_Z="0.002024233859170964" Q="0.0" RANDOM="YES" SCALE="138.99" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="39" WEIGHT="100.0" Z="3.0866535255484346">
<NAME>Sensitivity analysis: Primary outcome 4. Completers</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.4441992774161125" CI_START="1.5158356988375816" EFFECT_SIZE="3.1254355400696863" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="32" LOG_CI_END="0.8091689618750563" LOG_CI_START="0.18065213074514322" LOG_EFFECT_SIZE="0.49491054631009973" MODIFIED="2013-07-21 10:44:59 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.369193897814202" STUDY_ID="STD-Lu-2006" TOTAL_1="41" TOTAL_2="39" VAR="0.13630413418324341" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.362857068124207" CI_END="1.4844211813147035" CI_START="1.1593183171715244" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3118371339063124" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="258" I2="17.68227450221384" I2_Q="0.0" ID="CMP-001.67" LOG_CI_END="0.17155714270077188" LOG_CI_START="0.06420269774998048" LOG_EFFECT_SIZE="0.11787992022537615" METHOD="MH" MODIFIED="2016-08-08 15:46:15 +0100" MODIFIED_BY="[Empty name]" NO="67" P_CHI2="0.2702722365961714" P_Q="1.0" P_Z="1.675493686262467E-5" Q="0.0" RANDOM="YES" SCALE="138.99" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="YES" TAU2="0.00800302830780096" TOTALS="YES" TOTAL_1="483" TOTAL_2="492" WEIGHT="100.0" Z="4.304253973798571">
<NAME>Sensitivity analysis: Primary outcome 5. Defined by PANSS reduction</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.3819161595464036" CI_START="0.9306791944551314" EFFECT_SIZE="1.1340725806451613" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="53" LOG_CI_END="0.14048169531685484" LOG_CI_START="-0.031199994730449643" LOG_EFFECT_SIZE="0.05464085029320262" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="792" O_E="0.0" SE="0.10084667457185839" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.010170051772202308" WEIGHT="21.881985476240345"/>
<DICH_DATA CI_END="3.0028281703186757" CI_START="0.550501437554572" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.47753048144390436" LOG_CI_START="-0.2592415425937682" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.4327835340000672" STUDY_ID="STD-Guo-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.1873015873015873" WEIGHT="2.0361171349094764"/>
<DICH_DATA CI_END="1.6044985664275577" CI_START="0.9749038199559569" EFFECT_SIZE="1.2506925207756232" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.20533933340230553" LOG_CI_START="-0.011038227914572225" LOG_EFFECT_SIZE="0.09715055274386665" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.12710125060373678" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.016154727905033903" WEIGHT="16.46109311087047"/>
<DICH_DATA CI_END="1.5497352673789209" CI_START="0.8288153928488928" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.19025751640515565" LOG_CI_START="-0.08154219175997034" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.15965649400644924" STUDY_ID="STD-Li-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.025490196078431365" WEIGHT="11.872940920332741"/>
<DICH_DATA CI_END="4.8944142941476345" CI_START="1.11237915657334" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.6897007280004384" LOG_CI_START="0.04625284258875047" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Liang-2004" TOTAL_1="21" TOTAL_2="21" VAR="0.14285714285714285" WEIGHT="2.635971252706568"/>
<DICH_DATA CI_END="2.969306179643863" CI_START="1.117638417744806" EFFECT_SIZE="1.821705426356589" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="32" LOG_CI_END="0.47265498212749046" LOG_CI_START="0.04830132181748406" LOG_EFFECT_SIZE="0.2604781519724873" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.24926744065059406" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="0.062134256968497434" WEIGHT="5.669781383790843"/>
<DICH_DATA CI_END="2.238900905940909" CI_START="0.8226521905487535" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.35003487207146966" LOG_CI_START="-0.08478374152228778" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.2554146060118237" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" VAR="0.06523662096417512" WEIGHT="5.4296146735009465"/>
<DICH_DATA CI_END="1.9728646309214037" CI_START="0.5323231368788075" EFFECT_SIZE="1.024793388429752" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.29509728694465825" LOG_CI_START="-0.2738246572530884" LOG_EFFECT_SIZE="0.010636314845784953" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.33418756623079937" STUDY_ID="STD-Shi-2010" TOTAL_1="33" TOTAL_2="31" VAR="0.11168132942326492" WEIGHT="3.322598557638955"/>
<DICH_DATA CI_END="4.494870270135582" CI_START="1.021572694812251" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.6527171617472683" LOG_CI_START="0.00926927633558044" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Wang-2009" TOTAL_1="30" TOTAL_2="30" VAR="0.14285714285714285" WEIGHT="2.635971252706568"/>
<DICH_DATA CI_END="3.667788466538238" CI_START="1.202359416371218" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="0.5644042805246219" LOG_CI_START="0.08003430894321663" LOG_EFFECT_SIZE="0.3222192947339193" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.2845213189769459" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.08095238095238097" WEIGHT="4.47036417095307"/>
<DICH_DATA CI_END="1.6053050368500235" CI_START="0.8238309664779027" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.20555756835057928" LOG_CI_START="-0.08416188764335593" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.17018264258527413" STUDY_ID="STD-Yao-2010" TOTAL_1="31" TOTAL_2="31" VAR="0.028962131837307156" WEIGHT="10.75778037503809"/>
<DICH_DATA CI_END="1.9129637444510341" CI_START="1.0556345291828615" EFFECT_SIZE="1.4210526315789473" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.28170673911560595" LOG_CI_START="0.0235135872967107" LOG_EFFECT_SIZE="0.15261016320615833" MODIFIED="2013-05-16 10:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.15166393545513313" STUDY_ID="STD-Zhang-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.023001949317738787" WEIGHT="12.825781691311946"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="11.171432584839527" CI_END="-1.1866423817976213" CI_START="-3.915906827829552" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5512746048135866" ESTIMABLE="YES" I2="82.09719313247122" I2_Q="0.0" ID="CMP-001.68" MODIFIED="2016-09-08 17:36:58 +0100" MODIFIED_BY="[Empty name]" NO="68" P_CHI2="0.0037510685545386613" P_Q="1.0" P_Z="2.48026966897299E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.1847986812150202" TOTALS="YES" TOTAL_1="93" TOTAL_2="93" UNITS="" WEIGHT="100.0" Z="3.6642886308626967">
<NAME>Sensitivity analysis: Aggresssion/Agitation: 1. Modified Overt Aggression Scale - excluding schizoaffective studies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.8592770850756333" CI_START="-3.6207229149243663" EFFECT_SIZE="-2.7399999999999998" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="5.84" MODIFIED="2014-09-09 05:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="107" SD_1="1.17" SD_2="2.07" SE="0.4493566830163189" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" WEIGHT="34.9579734708725"/>
<CONT_DATA CI_END="-2.528375785944215" CI_START="-5.051624214055784" EFFECT_SIZE="-3.7899999999999996" ESTIMABLE="YES" MEAN_1="3.43" MEAN_2="7.22" MODIFIED="2014-09-09 05:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="803" SD_1="1.48" SD_2="3.2" SE="0.6436976515932513" STUDY_ID="STD-Wang-2005a" TOTAL_1="30" TOTAL_2="30" WEIGHT="30.314270603141363"/>
<CONT_DATA CI_END="-0.37945192519683757" CI_START="-2.1805480748031627" EFFECT_SIZE="-1.2800000000000002" ESTIMABLE="YES" MEAN_1="3.12" MEAN_2="4.4" MODIFIED="2014-09-09 05:58:12 +0100" MODIFIED_BY="[Empty name]" ORDER="221" SD_1="1.83" SD_2="2.01" SE="0.4594717463721634" STUDY_ID="STD-Xie-2011" TOTAL_1="35" TOTAL_2="35" WEIGHT="34.72775592598613"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.29050049817433815" CI_END="-0.636285386614453" CI_START="-2.620416112004333" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.628350749309393" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.69" MODIFIED="2016-10-05 13:58:24 +0100" MODIFIED_BY="[Empty name]" NO="69" P_CHI2="0.5899000534038654" P_Q="1.0" P_Z="0.0012952287483541098" Q="0.0" RANDOM="YES" SCALE="24.27" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="61" UNITS="" WEIGHT="100.0" Z="3.2170348273983733">
<NAME>Sensitivity analysis: Aggression/Agitation: 2. PANSS-EC subscale - excluding schizoaffective studies</NAME>
<GROUP_LABEL_1>Antipsychotic+Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.48584075629130274" CI_START="-2.9658407562913016" EFFECT_SIZE="-1.2399999999999993" ESTIMABLE="YES" MEAN_1="6.23" MEAN_2="7.47" MODIFIED="2014-09-09 06:15:55 +0100" MODIFIED_BY="[Empty name]" ORDER="222" SD_1="3.8" SD_2="2.97" SE="0.8805471783688443" STUDY_ID="STD-Guo-2007" TOTAL_1="30" TOTAL_2="30" WEIGHT="33.04297425700119"/>
<CONT_DATA CI_END="-0.6076103788903859" CI_START="-3.0323896211096146" EFFECT_SIZE="-1.8200000000000003" ESTIMABLE="YES" MEAN_1="5.79" MEAN_2="7.61" MODIFIED="2014-09-09 06:15:55 +0100" MODIFIED_BY="[Empty name]" ORDER="204" SD_1="2.04" SD_2="2.82" SE="0.6185774997259077" STUDY_ID="STD-Shi-2010" TOTAL_1="33" TOTAL_2="31" WEIGHT="66.95702574299881"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.31102010086444853" CI_START="-1.3889798991355509" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8499999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.70" MODIFIED="2016-10-05 13:58:42 +0100" MODIFIED_BY="[Empty name]" NO="70" P_CHI2="1.0" P_Q="1.0" P_Z="0.001995054250281677" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="57" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="3.0909675658239366">
<NAME>Sensitivity analysis: Aggression/Agitation: 3. PANSS supplementary subscale - excluding schizoaffective studies</NAME>
<GROUP_LABEL_1>Antipsychotic+Valproate</GROUP_LABEL_1>
<GROUP_LABEL_2>Antipsychotic Monotherapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.31102010086444853" CI_START="-1.3889798991355509" EFFECT_SIZE="-0.8499999999999996" ESTIMABLE="YES" MEAN_1="4.62" MEAN_2="5.47" MODIFIED="2014-09-09 06:20:20 +0100" MODIFIED_BY="[Empty name]" ORDER="211" SD_1="1.49" SD_2="1.52" SE="0.2749947975508508" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3085747217965619" CI_END="0.13989914491709576" CI_START="-0.33721787209448867" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09865936358869647" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.71" MODIFIED="2016-10-05 13:58:36 +0100" MODIFIED_BY="[Empty name]" NO="71" P_CHI2="0.8570257263622736" P_Q="1.0" P_Z="0.4176116249285624" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="62" UNITS="" WEIGHT="100.0" Z="0.8105717988540848">
<NAME>Sensitivity analysis: Aggression/Agitation: 4. BPRS hostility subscale - excluding schizoaffective studies</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.22597161667782845" CI_START="-0.4259716166778286" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.3" MODIFIED="2014-09-09 06:23:00 +0100" MODIFIED_BY="[Empty name]" ORDER="223" SD_1="0.52" SD_2="0.71" SE="0.16631510540451305" STUDY_ID="STD-Li-2009" TOTAL_1="28" TOTAL_2="28" WEIGHT="53.55872735849436"/>
<CONT_DATA CI_END="0.8676519808695604" CI_START="-1.7876519808695603" EFFECT_SIZE="-0.45999999999999996" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.36" MODIFIED="2014-09-09 06:23:00 +0100" MODIFIED_BY="[Empty name]" ORDER="224" SD_1="1.18" SD_2="1.21" SE="0.6773859067523229" STUDY_ID="STD-Liu-2007a" TOTAL_1="15" TOTAL_2="4" WEIGHT="3.228652661832869"/>
<CONT_DATA CI_END="0.29290220891602525" CI_START="-0.43290220891602493" EFFECT_SIZE="-0.06999999999999984" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.41" MODIFIED="2014-09-09 06:23:00 +0100" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="0.66" SD_2="0.77" SE="0.1851575905366381" STUDY_ID="STD-Wang-2005a" TOTAL_1="30" TOTAL_2="30" WEIGHT="43.21261997967278"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="14.851167203661273" CI_END="1.4743746386779164" CI_START="1.1634721311484606" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3097304314147384" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="291" I2="12.464792687842765" I2_Q="0.0" ID="CMP-001.72" LOG_CI_END="0.16860785179799195" LOG_CI_START="0.06575598501561898" LOG_EFFECT_SIZE="0.11718191840680545" METHOD="MH" MODIFIED="2016-08-08 15:47:59 +0100" MODIFIED_BY="[Empty name]" NO="72" P_CHI2="0.3167362119509667" P_Q="0.38129391346955044" P_Z="7.966577847911757E-6" Q="0.7665261191063215" RANDOM="YES" SCALE="138.99" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="YES" TAU2="0.006140701990128334" TOTALS="SUB" TOTAL_1="520" TOTAL_2="529" WEIGHT="200.0" Z="4.466080138392036">
<NAME>Subgroup analysis: Primary outcome 6. As defined by the studies</NAME>
<GROUP_LABEL_1>Valproate + antipsychotic</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo + antipsychotic</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours adjunct valproate</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours adjunct placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0272756823320317" CI_END="2.3941016931618786" CI_START="1.0290777607310053" DF="1" EFFECT_SIZE="1.569623142464883" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="43" I2="2.6551472794637587" ID="CMP-001.72.01" LOG_CI_END="0.3791425937901305" LOG_CI_START="0.01244819281920883" LOG_EFFECT_SIZE="0.19579539330466966" MODIFIED="2015-11-03 16:58:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3107996981024139" P_Z="0.036346122097593796" STUDIES="2" TAU2="0.002837949698633551" TOTAL_1="64" TOTAL_2="64" WEIGHT="100.0" Z="2.093033971611901">
<NAME>Treatment resistant participants</NAME>
<DICH_DATA CI_END="2.238900905940909" CI_START="0.8226521905487535" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.35003487207146966" LOG_CI_START="-0.08478374152228778" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2013-05-05 12:27:42 +0100" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.2554146060118237" STUDY_ID="STD-Pan-2010" TOTAL_1="34" TOTAL_2="34" VAR="0.06523662096417512" WEIGHT="68.15517710143902"/>
<DICH_DATA CI_END="4.494870270135582" CI_START="1.021572694812251" EFFECT_SIZE="2.142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.6527171617472683" LOG_CI_START="0.00926927633558044" LOG_EFFECT_SIZE="0.3309932190414244" MODIFIED="2013-05-05 12:27:42 +0100" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Wang-2009" TOTAL_1="30" TOTAL_2="30" VAR="0.14285714285714285" WEIGHT="31.844822898560984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.696051519669059" CI_END="1.458968007388512" CI_START="1.1399679463547048" DF="11" EFFECT_SIZE="1.2896421066248953" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="248" I2="13.358889707099019" ID="CMP-001.72.02" LOG_CI_END="0.1640457686809995" LOG_CI_START="0.05689264000578281" LOG_EFFECT_SIZE="0.11046920434339115" MODIFIED="2015-11-03 16:58:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3136547593788215" P_Z="5.316970213249158E-5" STUDIES="12" TAU2="0.00613642696080864" TOTAL_1="456" TOTAL_2="465" WEIGHT="100.0" Z="4.041238265102005">
<NAME>No Treatment resistant participants</NAME>
<DICH_DATA CI_END="1.3819161595464036" CI_START="0.9306791944551314" EFFECT_SIZE="1.1340725806451613" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="53" LOG_CI_END="0.14048169531685484" LOG_CI_START="-0.031199994730449643" LOG_EFFECT_SIZE="0.05464085029320262" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="792" O_E="0.0" SE="0.10084667457185839" STUDY_ID="STD-Casey-2003" TOTAL_1="124" TOTAL_2="125" VAR="0.010170051772202308" WEIGHT="24.2954377209092"/>
<DICH_DATA CI_END="129.74412565322564" CI_START="0.3776664242276759" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" LOG_CI_END="2.1130877036754665" LOG_CI_START="-0.4228916236469528" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="793" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Fisk-1987" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="0.17804057116797134"/>
<DICH_DATA CI_END="3.0031630760051726" CI_START="0.5202847665796584" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.477578915644285" LOG_CI_START="-0.28375888962817214" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2013-05-16 21:27:36 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.4472135954999579" STUDY_ID="STD-Glick-2009" TOTAL_1="8" TOTAL_2="8" VAR="0.2" WEIGHT="1.9218972810687147"/>
<DICH_DATA CI_END="3.0028281703186757" CI_START="0.550501437554572" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.47753048144390436" LOG_CI_START="-0.2592415425937682" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.4327835340000672" STUDY_ID="STD-Guo-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.1873015873015873" WEIGHT="2.04806195936128"/>
<DICH_DATA CI_END="1.6044985664275577" CI_START="0.9749038199559569" EFFECT_SIZE="1.2506925207756232" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="25" LOG_CI_END="0.20533933340230553" LOG_CI_START="-0.011038227914572225" LOG_EFFECT_SIZE="0.09715055274386665" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.12710125060373678" STUDY_ID="STD-Jiang-2009" TOTAL_1="57" TOTAL_2="63" VAR="0.016154727905033903" WEIGHT="17.77265650387036"/>
<DICH_DATA CI_END="1.5497352673789209" CI_START="0.8288153928488928" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.19025751640515565" LOG_CI_START="-0.08154219175997034" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.15965649400644924" STUDY_ID="STD-Li-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.025490196078431365" WEIGHT="12.526567822737675"/>
<DICH_DATA CI_END="4.8944142941476345" CI_START="1.11237915657334" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="15" LOG_CI_END="0.6897007280004384" LOG_CI_START="0.04625284258875047" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Liang-2004" TOTAL_1="21" TOTAL_2="21" VAR="0.14285714285714285" WEIGHT="2.6589942035033043"/>
<DICH_DATA CI_END="2.969306179643863" CI_START="1.117638417744806" EFFECT_SIZE="1.821705426356589" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="32" LOG_CI_END="0.47265498212749046" LOG_CI_START="0.04830132181748406" LOG_EFFECT_SIZE="0.2604781519724873" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="0.24926744065059406" STUDY_ID="STD-Lu-2006" TOTAL_1="43" TOTAL_2="47" VAR="0.062134256968497434" WEIGHT="5.802974508288695"/>
<DICH_DATA CI_END="1.9728646309214037" CI_START="0.5323231368788075" EFFECT_SIZE="1.024793388429752" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="20" LOG_CI_END="0.29509728694465825" LOG_CI_START="-0.2738246572530884" LOG_EFFECT_SIZE="0.010636314845784953" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.33418756623079937" STUDY_ID="STD-Shi-2010" TOTAL_1="33" TOTAL_2="31" VAR="0.11168132942326492" WEIGHT="3.3625919442372947"/>
<DICH_DATA CI_END="3.667788466538238" CI_START="1.202359416371218" EFFECT_SIZE="2.1" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="0.5644042805246219" LOG_CI_START="0.08003430894321663" LOG_EFFECT_SIZE="0.3222192947339193" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="140" O_E="0.0" SE="0.2845213189769459" STUDY_ID="STD-Wang-2010" TOTAL_1="30" TOTAL_2="30" VAR="0.08095238095238097" WEIGHT="4.549069484337234"/>
<DICH_DATA CI_END="1.6053050368500235" CI_START="0.8238309664779027" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.20555756835057928" LOG_CI_START="-0.08416188764335593" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="0.17018264258527413" STUDY_ID="STD-Yao-2010" TOTAL_1="31" TOTAL_2="31" VAR="0.028962131837307156" WEIGHT="11.287444615146583"/>
<DICH_DATA CI_END="1.9129637444510341" CI_START="1.0556345291828615" EFFECT_SIZE="1.4210526315789473" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.28170673911560595" LOG_CI_START="0.0235135872967107" LOG_EFFECT_SIZE="0.15261016320615833" MODIFIED="2013-05-05 12:37:53 +0100" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.15166393545513313" STUDY_ID="STD-Zhang-2007" TOTAL_1="30" TOTAL_2="30" VAR="0.023001949317738787" WEIGHT="13.596263385371707"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-11-07 14:13:54 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-08-08 16:16:02 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArQAAAJRCAYAAAC0tyTrAABJeklEQVR42u3dD4SV6f8//jdJkiSS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-11-07 14:13:54 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtYAAAEyCAMAAADp82f9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAsF0lEQVR42u19fXAcV5Xvka3+mhlp1C2JWAnltSzBq3reV/Uwz07k
WIaM7CRaeCShKrWpkLCBPwSBFBQFtZC8ehBqX2Fv2OxuNmQLTHZNCGGhQnlx+LCJ7QEyMrvIr/xq
X615W6wkCwdrlJWmZ2R99PT0SHr3q7/mw/q0LY3OL7Fm+t5z7jn39unbp6/6/gSAQNQc6kDHQUDU
GLJbcAwQtQcMawSGNQKBYY1AYFgjEBjWCASGNQLDGoHYwKjHIagNZHEIAr9ZxLDeHPfdzXBXLmIS
gsDcGoHAsEYgMKwRCAxrBALD+ibAvOGKiBoL6wSBHElXrLpZPt1WxbYeW8TDKoqJytILBoZvzc7W
yWRyTOpYVy51Ea8qzcXW71am6Pa05Lho4exey0mIcakI0KrJCpm+Ek2qTD4GIgr9lZMTlaMOLVTk
Y5YqpZi4JSlqitZJMYdKqnqCT4XknxlRoiZTUCxSp9ImRRmwVpuIkBPjrcZ7ZctrJxFXhQ8J9h8t
51Ku3VetZrBkRWO2ZaoDXluO2uMrRpSI7wOzq7GWAFo0WSX9Ssmy2gLSbAfGby3n1jslgKloITpD
vs+PxshHQk3PkYPmEwW5mRamz36ibfRqD5NujNmnD5K6QYfWJX42Gpj0tk/ap3SmkIsD3KWNWH4Z
wB45PU9bzRYU2iq8crbRawe2jsJ0tJCbIbMqm1ebT/BycO1+pp/Zfp3aznG/WFv0W5P2L7Ouoq7Y
6nbPB2b3yiCXnjELkVmAnljh9DRAfwHjt1bDmubWxRxAfgLMO8nxiEE/ioNGhhzYu2EoTz4zRnfX
sKHtZxqKk9plk7o2MMmHs8sI/NK1KEG3xlqhwsWhNssvA9CGeasS04RLRne31w4MGmBNgHan29RD
wvYl1+7cLmK7wG2LFti3rE0tTeQ9H4ZgsOj5QJE12ri0pbFOSnbLLiK+q4jxWwUbfed5IgmWcZXM
1pmdxfmuJD2m/+QC+6BH5KsoZP9IIDd96KXGcZZ2kPlOcjxJ+sEL3aOk+6jGJ8a+o56QfKqCSmbn
3Bz3QSgrdsAu9YnabpgI6AS0IaAYcBoCLZntc8V9Schsd+pG2rg/LrL4TkhRX+JgbAhoymfJz0dg
4mrgajWB5q7nzAqLZtLMkcgUCSbysEkC7QCXFMtr53ihwDmm7Jd9m8tSzVOeUL+v8giM+4sd/cT2
QtBut8ltTwebFNp1ATep090hjx0w/0Qslchv0MxlZkx7hDj8Ek7LNXwV514kT2FnT1vNflG+A1po
vtEJHWqpuJoyXiOJt9oKehTgvMYkz1kmvdbJ3H1M8yTrO9MaK7N4I9ZOaCYJsurAmYjfHG+H4uyE
ZXtXg1pq+58vkkKL2VbSrg5pSydt/XNHq8quBOqDBp2/DnkcB+177Mv8vw0e5D34EenyRXz9sqZv
TpOHTJg80Bboy/mCWkdzalsuZEqlGw7JLGOw5DwJ2pEWhUrm4tu+RRfR4vLj/qSfm20ngZZskvUp
fm+zFWoj0yQ9G/WERDvMjwbmQ/02qGRbJplyg8Ftv8PVIW3dQdr6uXWVBLd8C1vIa5at8GLepNrK
W4p8lBmIHVJ6JgH2yxi/NZpbr1WCvuTFRMtaqRXzQ99pXkuvnQ+8YmBuXTm33goahvXo3NLkPve/
t8798psrtfLnmZlfraXX8fSXA0f5ukWmr9rHvBYYDJytawK46Suw6SuLTx21dkoRgG/wITCsEQgM
awQCwxqBWCvgI2ONAFdCkP4GJ6haBNLfIDC3RiAwrBEIDGsEAsMagcCwXjrMm980EiRgWC8XRoK+
KZ2oSotz2+oIc66l+0X+YT23iM4Xl0V/E7MwfDGsCwMt16y/NvfMqvAbPhfrXYvLLYP+5rKOs/um
D2vTyRa9MDA5w4yjUf6atCarZ1zuGTMia6bHogOMVsfyeXTimpxy9URZq6YoXDShK32WpUpWgCGH
yif4RHtB2QuGImsW49GJcGfMqEy/pTXF8nlzZMGnI3PeHGiNMJ88W5YsaSkwZKS/qYZNszvm6dic
+j8kaL9E/39BmW74iwLE5Vy8CL+5sKXh28VL7Ulac6RhppHUtF958+szbM/MFiajSzNRzYb29OXe
xLzQ07PQ8KlfwXxsanrLHGv4yu8/Ud90+Y++PwefPw0xUsfladMEx396DOYjM42HBuEffv71q8/W
MXuzkPxPdfAXsUjdnHCB2IowW29SWwTtb14++kUmLWxFI7NTrxbhzEuO3788PiUFdsdsmsE4KoPs
0Wo4gzBIQqIwLOUBTmqQ3efWqEOsRrDoEDzMZOwhGPYZb7ge5bB5nvHuuDQ1GWOia9joJkfPS5B9
3pPneHgXQL1pDZ4k9veCxnela5xb52PD47YrF7YF7Ns4lxa2vlq0LEp/4+C0XAWbZdOX+eACwLm0
UcYwQ6p2PHZ0X/Ja3DNQUhyixXFaigfsZIBCpxqNDqW/Md8+txAfL6G/STmL09/wAmFr4L1FSO5n
nDgecJ9TjdHfLAnaPyWTya0XxRFlmKlzCT1u2/KdKU9O1ECwADiXTVkZZ66Jw8RrZeb6QzQ6/vqd
MZuOXQ3S39BvjssQInTLOHtaXJ+Erb2zY9EeXA/ER0ag7DKgXhBHz1yETglA2umQ4nlpkM50qQFa
Q7lnpKAil1E7YadaWsZZcIoh3h03l3E8ThwaqCxbkEmy0Wuwp0tpAAyRVnC+HbnDUVy5T4VssZVB
eCdn6BO2NMMYJTcfDSfozR7WxUHyY/DzYoJ79B4lfxng3+3YaYDo9BdorCksQb7czGp8cJlLdp+T
KSnLNEn/nYTu5LfbjpeZyzT15X3iJ4lRmP3wFoDzljSTI1buUh4WjDpxhfLtZK1P5ly5w7bkhDl7
BjWLv04tbL1uyU1E9JYTGL+bPLdeD+l9W2rvWrbnxNIG5taVc2sM6xsHw55Zy+ae+3IwucawxrCu
QeCmL6S/qeVTigB8gw+BYY1AYFgjEBjWCMRaAR8ZawS4EoL0N3jfrUXM42Ag8BpHIDCsEQgMawQC
wxqBuPlhba6RTA3BxBG58WGdSCQUraUCUUzimhwvKbmxYvmHAlrV1D90bR9XwUojVI1YhTpL/twq
mix1aiHw7nNKldWW6qK3Lt6l2zAy13q2TibT2jT/VlZVvaGes1crltsBrWrq9vWeHm+v9MuKxsm/
WEWbpX0pWt4M23owVjg95VQV3bc40U4XRubaJyGGueDNz02Kwvha5CZREO9lDDBRRedTDmd6Sez/
EtMwFG2ATFcRWW1isoLSZUBTdK5uCc4YmfK4JHTKMkMlLFnq5WQvvi63I2hoIJFimoK5hvgFBtch
vlGbvC1fT4p5gdXxU4l6xhhveHkiria63+ez1PTyjlpMN6VJqs5kJHLU2qtYofYGNKbjyaVkOjdL
sx3uJGxFJ6A7QserNRLhvDUDUTkyINriQ6KmwdHccnrpaYqQFQKeXWatSek7ZjF/hM+WxO6piGXk
1rrPiTOfzpETtEcd836H88rZlwGaT6TFX1Sulwon6sn0wyegYlrdA3D3zwqUvAi2viLK71JHBGPc
0TG5GeCPo4Uo3SoyNxqbZrpNP3WOH2ICrq6wc3LM/dsJ+8dOEM3vT9oZ+kvS19IwQ3S+Qn0rUJsw
Pxqb8fUuO7K3c9buJz8yafX7fvnWUWqV+079pB09Y2xjunebTmSW5hWjV3tI/Hy28dOh9vZcOcV/
NyvkesjcPM0IEsQYOHTf5BB12/595GWukytkDpK2/mn602KorP8Mb5PccoKXVVvd7s/vSdfuCW53
Pv3oJ9qYP/XZwklS8umY/foHMX6XHtYkuX6XfzRiaHcCqIOGu2v0ktFNTpvdaIzwY3UIGv2N0hlj
iBxY3ZCl7DGDbsJ5x1BbXtxejSHy7WsTwOhlRgyTU8fUn2KMLuDrCjt/6NqB80YjyVY+I4FGA+EP
DajvsayT1DegNomC6es91Ayml9vM7aIXnDH4A7+ce0Z9V8RRxuju4rqW5jpHuWYKu8ePhtrLGt28
v0JOso/tomQ0d7jm7qRtGwtsNATZgkq8thlvjkvB8y0HCopbTi/TIRi8PXgauN38bqDjxbwbZv4Q
lQNE5btOatdRjN8qKN/0RclWWh84GuBiIf8kB8IFlHmljBmGHxDZgUNzc13JAPtLkN6F6jqtznxI
QPDC0Hv8obnivmvYAY9Yxnx7ESiXDLcZoJoRtDLn7ADxTEBdlPveBHhrmC/tOW1fspzr5pwd7q+Q
c5qcupE25gOHQrfOmm12QLSc5ca8Na9ZbjlUINjxex320GXd0e0tDRP+acviUu38YvQ34y+VFGw1
wSldguI5YQlbiwPmVoADdXL4AfKcz+rIpOMLE+HFCWM2/Q2uQnSnKtkhn4yyxieWMWbHGJcMabKs
G1TMm63rTO5ZXUk5832hfBmirvkNCMqE23NcMhohJ82M/aQdAj5IlPKxgyYqHm9NOcuNsVXf6pVD
kHfHDNkt81Aw60jTb0WmcVpeXm69taRA7oDw84nSDgf7eeKqwQU/UJqhQyZZKWeUoehkZ+eZzrRI
VHZAB7ntFyeswPJHyqSMLg/dxVfKfF1q5wIcFF8PwgWi+dcOGCLzJzpXaBRdhI58aQ+UDOgeUccz
GguxznxJOdidQd+9q/7/DR4Mdt3pC+nFQVOCck+kjDvJg8dFz+vsgy3Q8iCV9nhr8txrznIjczac
d4175dzHzmdIGBvmDh7T3G7+X6EjzIWjOvAGaVu1jNfmMH6Xk1sr9mRJ2YithiUzRUUUFFuk+/y/
iLdFKZBcOPrftrl533e30Z+fmG0Xa2xb5QLJ0icbHgy0p2yD12+X43xaDuhSO/cr7iX2Vfl+ovnu
Jnn2l7yA6kRJFN2j2GULeJk/kC0vfJ+mgVEn2+dLyqFoywHfXUQ/ui3gXNb65KMhvUm1NROU+94h
JU7Ga/9fuish0vEZefo4zahyvbPneSNxxYrRtmJnyFXMblT/0W955fSZo1nOd5E2Z7bR/n58m7Bb
7GXjFexZk3SY9LpBlxNJjN8l59ZLxpn7ymkvFh3plZ+KVZxE89Yp6XrHgNMwalQ23jlj34ATibl1
MLdeaVgvqPNyTiorVhY7g3JhpU5Lq6C91c26lRte4oAYVfanNFk5DcN6g4Q1Yp0BN30h/U0tn1IE
4IupCAxrBALDGoHAsEYg1gr4yFgjwJUQpL/B++7izWy838wvYBKCwGscgcCwRiAwrBEIDGsE4maG
NRLfrLzTSH+zdmGdSCSkFRDfGMpCxfJbl0B8swjNyxoQ30Qr1FlVPF5ak6VOPee/Zz0QUeRGZzGF
25D+5obO1snkW+ryiW9mcnUVy/ctgfjmetO8mLNvViiNR+tW0WZpX7pmvbn1PUp6DJ5cVAHpb25w
EmJkP+zNz01qH+Nf6TMgyIRjRtQzfLLhTDSJO9/HNKy+aAag9QnOa9PUJ4hv0hpVYsQ3jN8lpcnq
GXJ0RpVTgvhGfoIT37Q+oXBdYUcRG2UTbwjmmr4oI75Ric69VCcTlalN3panF2XSHBcou44lRxyv
nKgn9v9X0rrMj/ogofcpRqpPJrotmtKnMxnqiMN+BtpLa4KhRsgZiqxZsFe+4E6/80OGcfWqS2JD
WnCZcszP9tFvzhOkT3xg+hxy5JYD4/lhfQGX/obJen5yHwP9M2RZszB+l5hbn3nV+7ow+mgc4En5
iLuXbj6dIwU75NFT/Hi7aivbPeIb9Yh0GGDqe4UonfDrjojyw0qj+J2mmqYcSF95vaAROTg1OtnD
dOPRwrs58c3U92ymy+3oavo1Yfj9acoJ1Zw7quygLo8SnVNUp10uSF5bnl7OfmGH24f73qKXy5hS
75fXMeKb7S8UlO3MTxIoR3L59x2ZJLrTr9tddCfb/Cgl52l6rnE21N6zVyKcoUbIzUQK5gcB3rrf
nX7r2/UBCOzErL9yis/d+pGjE83k4zsNh8WANbZC68tuOdBxLkjt/vyehKb/QmQ9P80jZ/LvPxLo
30yU2UYsHtYkuf6Kn3VeMrr3Azw/5O1mEnQww8ZhfuwMwpCfSGaN4ecB8hPACG2G3ITzG8PjYlt4
0RhUAU52Q5baeIo1RiA/nbpPbM8WutyONmg8JdrgnDoPSWA+BIyrRuI69hBQm25bQk+Cj3gbvByL
eTak+OXcM+c+7js9yhraHVw33w0f4S1RXpvig9T1QHuHjQneXyFXbxqUf8fyBuHNucJ+Le0P6Hmj
+3n25WMSaMR3Z3jipKj6sywUf+yWAx1nGA7tmCs+SGVdP7NG9x2Xgv0TthEVEdz0RXextkznwzw3
gjqmjAkHKhDfkAOn1TlgVyW+Ibrmjr6vhbhlXPYYcgpbigHdcjvgMdc4eqGuYaKcMqaMacZlz6EM
Mn65EPZV3X9Oa7FYifimlKFGyJm3zUPjeHiDptm+72S5kRAbD6e/abPVfEVWnTL6m7Cfwh+fL0jM
KvhOyEJ1+puJD5cUPGaWrDZt8ZhwfMYWviZlPsZ4bV4LifcHiW+2UM6YP3sjJCDYY6BU17dDCWe2
hBhopOmxn0wzDpLylTCfUYbgT0xwGXdC5SW+u2hcGL8EQZmwXtrluBFyhpWOPBBcjVNMMCbP+kt0
rWxMwPP9XID+Rmqygn3y+2KGrJf5KfwxZtPRB3BaXmJu3fRK6ZneCTtCBcpOeJIT30gnoMPffL4D
LjSSW+dpy2V07OcsLx2tiitwgnybl609gaB3KI+Lwmkri2c8XWrnVW9N4UnosBhVjMtAI3QaNdip
lvaIiB3ztnq/0kkTW8a4Eyov8d2boSasZwOZ8YlWNaTXCRetoFyvZdS9RIplz+d2x4yTZvst8yts
kQg0zvqtcN/rO1p6yVzLCFGk3YZXTse5E3Z+imimOP2NI2TL/RT+CNuIpeTWkpMrETjs9IUpnkZs
5UU+f1z+pGxf9sq3SveTXHjyQNtxN3IYr4uWf0A0eVx5YgQgOr0twKdBZBp0uYdPcJPv8XSpnc+o
L4qvf6cUSH5fbJLzQ7ygQVeozuFWycmU9igbVx73mNJOUHIbQ6ZSoXLqe/5y2WicbWh70T/KPT4V
CelFtHuyQbmnDGkmShyT3JWQkVxsW5F092wjb2dSbeXPIRnue86aIj1U2EPFUGrIK6fjbEsOkT3b
w8aAjAuXLfdT+ENt5zB+l5BbLxmGVb60tHmJbwYOVCG+ES5c7CncgBOJuXUwt15+WC987KUtV8vv
332LsdIqK+Y2UlbBimQd/fT1Jr6JjV+T3kZ/8NFuDOt1H9aIdQnc9IX0N7V8ShGAL6YiMKwRCAxr
BALDGoFYK+AjY40AV0KQ/gbvu7XY8SIOBgKvcQQCwxqBwLBGIDCsEYiNFNbmTbZj3ih/kP7mumMr
rO6PBiba20dlfRYSl+j/wYrSghBSr0TL3jZ93rkxXRZ2dKtO+FnFPjmu1ANRVloVi/p/oDr1D1vl
nx+rKvo3xWsNzQrHIl+3WUPY6/i8F8r5Vc/WyWRa5XvqlkOZ03P2alnZHTdoGLgdM19cxP4d1+xB
adXv8t4M2/ryaTv6cmtV0SXQ39wBiJuchBhZvqfOZ8gZiMhNoiDeS2llnEifzrdFUZYXMgvu/xI9
IHKRgRDlS698zJUhjfUohtXD9KNyjM9fqV5ZIW1bsqKm6IfUSz4GoqwdQ5FVi9VplA3nG3KPkeL+
8PpEk0rZcPgGrROS5PrpxJhP1D63M0B5bwR9T0iXd0EVnDa+L8Res/Squ/VrtqsbJrroBiJHE/0z
Iwql7mH94w33OuTILQffTvWxsEJjkZJltQXj9zrm1rq/TXY+nSMnek9mbN4teeVsI5BzfkTMZc1y
4US9S5mzRy2oCX9OS4L+2fjjVJrKkMZebZhte5XpDxZkvnv37uOFCDm3jTE7dhAg/lPn+CHSzpuF
zEHGRhMxWN3r5Aj6xn5sv5/7w+thfjQ249p+Qvb8bM7S1mm5sHOXNmJ5PircR6bLuzt6qtQXak/+
jDsJF+8jP+6jl2HzlQjfj7x90j6lA+8fb/jc2+Bt59zygB1vLOr5WMjeWBhiLHLMx55Y4fQ0xu/1
CutEIvEuP60bMbQ72cZwd+fsJaO7G8C+5HLo2EOw27sK1EEYDCWRhd2UcMYe5jIjxsS+Ya7fBibP
xS0NssSCUkj9lhTU91gWUVAN0CgjjGMMWqxuFxU+b2i3X+L+8HrBaiPm3N96ftoSZHnrwk5xqM0q
9dHXTRrd+RJfqL3feruk7qTTukEvmIwxwTtblKBbc/vH8JMCOLJbXmksFD4WQ95YdImxkJiPkp3a
lcf4rZpvr25bBd3/+uu/O1qRIaeMQ0fI33sqcNB3tCLli2KXUr70sy2JZvvcY7+hnDkfeqlhwuWA
8Rhhio/94zipK2wR3DjljDieEeqj6ydvPfQNgi5Jni4ECWk8X5g9nwRHSVPqvjY70L/yhn36G96x
sJ3QWIjxCo9FZrvLGsSRxXdCivqaDsbtpXwVB3zmGnHxmDDAv/WbYCYDxeZLwQUtzpVDZcJMvf3J
ZJIHza118l/RoJw5EplmHDDfIM+edS4jzNirV2ndW5Hw7bkuxHwjBsP0/PRbF98CLDXMx/AgtbqE
NLfWjXNfmD3T24j7DCUn6ZS46LdZ0TnecH+I/qbeKw/ZKRuL8POlUGmeGdMewWn5eubWW0sKzndA
+GlGaYeDnDLH7oQL3tLery+ys3/OMul1ljJBvuCoJTL8Dp12WWIWpEGaapL04TVy09cM4yFyAZwZ
AIPcyjXLqPPrAhD17vIbi5f6i56fKuegIeXCjtSZ1lw54mMJ/8w0XFSEL1bAl4sfcAX+10wrtMzQ
rMuCd/JshszDFukZ7x+/aqTd4165byc4Fq0Vx0IhPkaJ1ZSRTmH8Xr/cWrEnS8pGbDXcbqaoiIKi
Ld3vraxdvluh3C65+LZv0fO1DbRnY6dLZLj+O1yWGMGe02DI9J78+u1yPEbuOe9VLDJNv84ZYURd
AKLejYtt9Kfc6/mZaZLuiLJyYSc72266csRHO8w/80vt3kwFX3qfdldCxhumlJkGei1ovRZ/pkg2
yfoUiP5JrOH/OGd55b4dMhbN7lhcrToW5KKLHVLiZzF+r1NuvWS8ce/suuq4eeuV5rVsL3NbFRIc
U2uyb0B/MLcO5tY3JqwXDqaknLS+RsMorOn62Of+vsovvPXd/8fEsK7JsEZc/7DGIUD6mxo+pQjA
F1MRGNYIBIY1AoFhjUCsFfCRsUaAKyFIf4P33dUqr0dS9wVMQhB4jSMQGNYIBIY1AoFhjUBsjLDe
NMQ3S24e6W9uVlgnEok+rYXTJoQrSgtCMJSFsrIv3qDOCjvWc66fVex/sXIPElCixxHz//aqE1Xk
RnMxhduuOUCuCOLmzNbJ5BGVv7K8HOKbmVw5/dBvblBnuR1T71rE/m+WRXxzWfcCufEv0/0lfyIe
VkR/04WRefOSECM7783PcVVKMW4WA4JMOGZEPcOnJjOiRAYgcef7+LTGOFwCZC+aqtOdJArjgNFl
xWjh+lElwqOmVVMU0ralSBojvmHsL4IdJiWxI0NmdcR0n2X1Cn8Ye0xclVMu8c0FZa/rJ2WfGWDl
wk5aU1x+Gl9Xk8WmwdaIZjKnhS/cnqHsdKffuQeNvVfzbr8CTDmiLcfn1VEHyJFbTkVjUjQ8IlSW
eshs6oqqpxTq9ECEeSrGAXEdcuumqPd1YTTZQ9laxlyGkPl0Lg6gy6On+PF21VYSLqlMs1yob/Zn
syToSuwOIqPZjAPGHMvlC1w/Z7/Ap7+pqB0lN4e45piHyAdnf2nOFZQnyVlvKJyeApiOsDpi+rjR
9grzh9cDjJ71bN//Y8/P7b+wJ/Zw+9zOO5TGjwd8lJiPVyZFzmD/Pqa7vuSmPXs/dtzpV2rXHQj8
LWqPKUf40aQ1zIrm5bvhbYrvHzTXO3J9cESYLBkXW9tORySdLbw/TRl4Er+wM7o3Doi1DmuSXO/2
8+QRo3s/ZWtxeW4oEw4p0IaNwyLvHIQhj9XAHoLh0A4/Z3jiJJNhHDBZQ7tD6EvwER4n+QkwScFX
i4zxRvoSY3+hXDDPU4oOxkAj6ijrDOWK2e/VCxYejod3eX46e0HjG7+FnYeHx+1SHy8ZmtC9ZIyr
ri+a78sur1tv5goRrTWQnxjdD/G2uB/FoQmXsuatIjg/9vwDeGgYhj4WHBEuqw55I3L7JcbAI3x2
+4qohJVv+qK7rVum7Io8N9WIb+RC+UEp2YtfHGCuoSHYUjxgJ2HgvUVI7genyen+lwmXC4Yc1TVM
uHXlXDEh4hvqkusnBIlvBENO0KWAM0Hvwr5Qrh4PA3d3nQza4zw+S6O/8Tl/QiMSYN/xm3Jtu8ji
OyELa0V/M1G6qvGYWbI2tcVjwjlnurQxwFldQktZnDsjJMPLPeaaOEy8Rj72zo5FeyjnzNiT0x5f
DTnSpr26AHxmm/DqmfDTZ58RdgL8NAEfXXjEN2FffCnFhL25M36/HI/LpoxXx8jHraB/56qPyJay
ESlU6itizXLr0t3kjR0ls7+8E57kxDcS57rhUDthJ7mTplImTZz7HZA6WnpLZPjt3oFjnLmmeNqi
eapmGKMLjHNGIc+rn3JcLpgfzXl1AYh6N1DZBSJrnp8S58Uh5cKO3OEorpzwMYBZeKdSwRfNy4nz
O00zrnj9gkaXKUf4Ud9JKW34tXP23c1B//Kd0EGSiv6U+RUezVxW0kpHRPhc3lfEGuXWfYVcSdlT
H+0Ls2WMFJQX+Qx3+R7GdcORsfsc8sx2taftOD1TMcg+OHW8RIbfTuLy45y5ZvLbTPZ1S26KATTo
cs9ZgMNNffkIQOz7975MpIZ5XQCi3o0IVvnDWzw/L9+lPBzj9rmdbP6TOVfuEvcxgEHNGgn6Iuzd
csJdCcnOt32h+DuvX3D1iR9mgn7kZqfIT/kLtGh3/2DQv6ItF0i4n3257UVy9Ewb5B6mspeb5ZIR
oT5f9cYBsca59dKXAfPrjfjmjb1r2d7AgSrEN8KcFi/cgF5hbh3Mra93WDfasOXqeiO+sWfWsrnn
+q75d0qM6bPdGNY1FtaIGwTc9IX0N7V8ShGAL6YiMKwRCAxrBALDGoFYK+AjY40AV0KQ/mZT33fX
9w16FQviSH+DwGscgcCwRiAwrBEIDGsEAsN65TBXVLVcFTNYhaQ3a4WtoG2GbiYuLVvwb4pVhf7v
4LJbey7UmrG14JcLQ0SWtFvJUVFWWhWLBrfo5uuWOhZ16/pMrWbHjxfKeZytq+EaDDQr+Ku4+0JT
tJUNlAtDSdbuMmh3snmc3TEJSegqZY/hrDIDEVljPDuKorcwVpmE4fLsDETliODEiXhlQh5ccppW
TT5GOWs4Qw6l+rF6ZYvy3EgxwWfDGXZaVGLCVVH4NpqOWckvZ+3pqmg3EfCN+cuacll0UhFZbQKw
JEVrAUnqwPjF3HpuNDYN8Lda4+0Ae9SCuofOm+mc7aRpOWTS6stMbk+ukDnIGGhenmRMM+DLi2kz
CdaP4o8D1EuFE/T3tPPpM8a2V842AjRfdmTBeMMZdqZP27kHmcofRwtRvi3H7g+UczacUdFuwBb3
l+JvXRadu39W0Mi10xizX58CkJ/G+MWwHjEofc6fDo2fBFAHYYjuKqc8O5dYORSNwdeYnCqBxtOM
z5NvPF9z5T0Udo9zcppGWpwxurs4w47dDCZXtoeM8zTN6waNp+JfmwBKX0MDdlewnGIosBvStcX9
ZfmQ0c3TaKsbsqQJxWFsP7/9U4zfqs8Pm2Jbhc/HU5VVxuO28ZlwwuQ0vvwidD1cRTDsOK1f/kJX
UnDmzHd5BDx+ecg3cRDwLciMM3BorriPtKTbWxomeDtepo3vhKwZ/c0GBGeV+VUZqwylquElPuOO
z47jy4fIacoZcnyVOl4Xn9/NCSEoZ45gQCBVgfIKHpb45rHoHKiTSfIB0vRbEZKfmHWA2PRJCMcz
HWlyh7cuMrKZIJqhkxNV5x3OiWPCX/Nv4Mmfs0w6I3SaIF2g5DS2BhfCyyJKBnRO/KFcYJTAj2R2
0bz4nAOPTFhC9hktWO4zSXWyb5JW6lvcZdFZGB+kqbxqGa99GODiMxi/GNYiT7V2kLAr3qMUSt5Q
3iLb5/kdLK5YlBNnG7y7SZ79JSsT8rn4tm+Ro+9uA+3Zq+S42CLfF17ezvyBnOc0TZn7FBqCXQ1t
dIzrY/Bcw4NitJ9Wg+Uf3+Yqf5d9SzYrdti3X6j3chad6Ae2HQXO/fMowH58ZNzkufWSsu8bBvPW
qTWgTnEarxiYW1fOrTGsBeTCDTSmr0VavNAczOsxrINhjbtjBG5kVNPZZA1utOGn1fml6s1vgrOJ
YV0jwJvupn5kRGBYIxAY1ggEhjUCgY+MiGsB6W+Q/mZT33crCM7VxAgg/Q0Cr3EEAsMagcCwRiAw
rBEIDOs1gHkDNFanh8CwLocTUeRGP6QSJdW3lRctgluraOgLK9JLVPbrOQtPHYZ1dTQq6bG6HVWr
u65JSlMJ+yprmFZxRXoCpVVdOs7uGNbV8Z4hw5jMk7CLyFEeKWaU8d6kNcUSpDRqBhzNLadT5xnV
lU+k5EiGat9L6xJNqqCxSTQplBDHjKhn+ETbYUkr0iN+MAnGpdOnAxiyrFmwV76A564KNgkH3zWR
fj4ytXUO4IWff/3qs3XQfgmOzC4cvdcG52Kkbu5Se5IUOd/Mt9TZopygfcc3/9yVf+bKC39lw5GG
f234Ejkau/xxpgHtV37/P+NzcCR2+Via0edtaZpdkV77yA+//tUCrZo//c0n/nEO5qMzUx8chNyP
AnsfVsXBt1AbJxI5+IJ4c64Q0VpIjr3XZbvRJPgICZlvDI+7+8r7C/C07JZT3Gd48lljiMz12hAM
UtYan8lmxND2k/Jh4zA/nvvtyvTgsDHBGR7y3fCROwHqTcM6CWA5eO6qXrq4rYJmHTtty6WuCTHg
gOClMdvs3pNuOQi2G09esNOUM+SQf5Lj7v8VhDjL1vNJdpzW4lxXEsy3z0Hj+BrS39TIOyGbmP6m
AhQTjNyjQeoawYDjM3iA8UxTKsiM40pRec5zU85aI6LIBKHibj5crh6kXYnGhZPD1JnZdOQBXA/E
R8ZrIr/TMeOvkM8Bl+0m78Ax8k3uaFVIcLPoatw97pW7ekJ+B3QQsbwGnYK15lwwO1B2wpP97Fv9
xZXpQSdc5It5cxO7niUfvZZR9xJJU2Q8dxjWVZHNxm6Zy5HP98qznEDsfFx5nHzT8g+cIRkCoxh7
5Jzllbt6Qn6r7GRopqzkOX8O5bTxccZWXuRPafL+lelBRLuHv059tqHtRfLxlCHNEH9vwbeKMbe+
blicOMew2GRbwnqzZL0qGDgwulb0NzWXW2NYrxqLEOc0PvTSlqs8nN/4o+kV6VVGbDy4NothjWFd
i5kUDgEgq1PtnlIEPjIiMKwRCAxrBALDGoFYM+AjY40AV0KQ/gbvu7XY3SImIQi8xhEIDGsEAsMa
gcCwRiAwrDcYcMcLhnUNwdKkXvpydTWunSoUOAgM63WMFt10ntLTjGvnWkjiUGFYbxzkVQ261Wc5
/43eQ+lvnKgUo5vP4yqTGNCiDqfA0SRVB0jJstqCA4dhvZ5RoBvKh58nszGZj+dfPdsI0DzoyM2k
dOsok9hzZYL/RnjGdCKzAD2xwulpHLgqwN0x6wIekQjlCfmBQT8Um9OI/IBtWKQfglSEi0fh1K7A
VsZNR41R6ZfnyBOyznCOroC4qyA8Wu9MJBIL3hF4IWzGYzQtuQw9bWkcOExC1jOkneTHTjtY1O+R
8TA4btTfBvIb5KN5Zkx7BAcOw3o949/zKbDyrWLaZlBbQY/6EnHQFPZl/t8G95APLWX8KIUDh2G9
ntF2+m6p+fQEmba3uUUZS84HGBMm1dYR9iX60TaaQ0YPKT2TOHD4yFjbwEdGfGRE1Dhwd0ytYB67
i2Fdc8BcEh8ZERjWCASGNQKBYY1AYFgjEBjWCAxrBALDGoHAsEZcV2Rvsv76agDDGoGzNQKBYY1A
3BTg+9aYW9cM8A/Y1fA5XeFlsdrpbR00gEkIAnNrBALDGoHAR0YEYq2fn/GRsXbOJX9szNKfS338
8nTY57JU/cc0fWW2/cc8fcke8Crf62pGMaxrJqr5yWX/Lzmq3YDQxdHSVV3oK7Xtq2dhqR5kS3pa
1Sjm1psZenAOXOm1tEbX45paw9m6RifuleQvK1DNli6YL9+2vmQP9CV3GMO61ibgLP0/u+SVADcH
IZ/LVQVPc4W2y9pZkQeVdDCsazGxEJnnMnORFajqq7a9Wg8q62BuvblzkOwqU4jV5z/66rP1ch0M
a7wCVvGa1Fq9YLXWL2rhr2NqJ0SDq21LO62BVePlqoaNrqIBfTnOV1q3rqCTxbBG1OAVjkkIogaB
YY3AsEYgMKwRCAxrBALDGoGogsAvz3HvMmKDQ68Q1riCjdjYyGISgsDcGoHAsEYgMKwRCAxrBGIx
1F/7iVKgBtdIsI+bLqxL5/D5TdDzYi32sS58uIBJCAKBYY1AbMiwzi6xtkwum/VL1/kv6LMVnczW
VL+9PlZzvRZO5VoRKixGm1arzywbuN96DZ/K5Sch2ay40r0rN8v+EzXBGYFLZkuudCHmS6/Ladt1
Mthr9yNbE/3mPkGon7VyKpc9W1diTMvq4Zrgscv65xGUhIkB121c6/7/5U77fdrY/ab+hJyslVO5
wiREz4r/Su5Hetm9quyepW+I+5he0Uc9/Lkx+50tOZPlHdn4p3INycr0AFny4sOqZzdUpn2N56SN
1u8lMN5s+FNZv7bjRa/uRSjUsgGS7o0T13rI95rv90bv0krXrXXGb6lXv7ld69aXXa/rQ+yOXK1X
2Sq93Nj9zi65cCOdyvplDoBe/Y7j1/B4D0vqWa+S16zLJKTEq6DT9JvwvWb6XbE/tXAqA2Rl/ixV
yvU0X4uvAZW+E1KLfSx9J0SvkknUSn/1KicXsamQhRp9qw/DejOjZl9UrRzW85vglBY3QR8XNuv1
Wr+pLmLs4yYBvpiKwLBGIDCsEQgMawQCwxqBwLBGbB4EF/iQCRhRe2GNPMAITEIQCAxrBALDGoHA
sEYgMKwRGNYIBIY1AoFAINYe/x+xMJzhiHnF5AAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-11-07 14:13:54 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAYMAAATZCAIAAAC5K+9zAABXIklEQVR42u2dvW4rybW2GxAgKNiB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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-11-07 14:13:54 +0000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_ROB_TABLE:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA+YAAALQCAMAAAAq6poRAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.01" SETTINGS="SHOW_STUDY_NAMES:NO;SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Antipsychotics and valproate versus antipsychotics and placebo/no treatment, outcome: 1.1 Global mental state. 1. Clinically significant response - as defined by the studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-11-07 14:14:10 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2016-09-19 14:14:55 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-02-10 11:13:14 +0000" MODIFIED_BY="[Empty name]">Previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2016-09-19 14:14:55 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">1.1 Search in 2002 and 2007</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.1.1 Electronic searches</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1.1.1 Cochrane Schizophrenia Group's Study-Based Register of Trials (July 2002 and February 2007)</HEADING>
<P>This register is compiled by methodical searches of BIOSIS, CINAHL, Dissertation abstracts, EMBASE, LILACS, MEDLINE, PSYNDEX, PsycINFO, RUSSMED, Sociofile, supplemented with hand searching of relevant journals and numerous conference proceedings. The following phrase was used: {[(valproat* or *valproat* or valproic acid* or *valproic acid* or sodium valproate* or *sodium valproate* or sodium dipropylacetate* or *sodium dipropylacetate* or calcium valproate* or *calcium valproate* or convulex* or *convulex* or depakene* or *depakene* or ergenyl* or *ergenyl*) in abstract or title or index terms of REFERENCE] or [valproic acid in interventions of STUDY]}<BR/>All references of articles selected for inclusion were searched for further relevant trials.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.1.2 Other search methods</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.1.2.1 Contacting pharmaceutical companies</HEADING>
<P>We contacted Sanofi-Synthelabo, France, and Abbott Laboratories, USA, as the main manufacturers of valproic acid drugs to obtain data on unpublished trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">1.1.2.2 Personal contact</HEADING>
<P>We contacted the first author of each included study for information regarding unpublished trials.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">1.2 Search in 2012</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1.2.1 Electronic searches</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2.1.1 Cochrane Schizophrenia Group's Study-Based Register of Trials (July 2012)</HEADING>
<P>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register (July 2012).</P>
<P>(*valproate* or *valproic acid* or *sodium valproate* or *sodium dipropylacetate* or *calcium valproate* or *convulex* or *depakene* or *ergenyl*) in Intervention Field of STUDY</P>
<P>The Cochrane Schizophrenia Group's Trials Register was compiled by systematic searches of major databases, handsearches and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group's Module</A>). Incoming trials were assigned to existing or new review titles.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">1.2.2 Searching other resources</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">1.2.2.1 Reference searching</HEADING>
<P>We inspected references of all identified studies for further relevant studies.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-11-07 14:14:10 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-02-10 11:14:02 +0000" MODIFIED_BY="[Empty name]">Previous data collection and analyses</TITLE>
<APPENDIX_BODY MODIFIED="2016-11-07 14:14:10 +0000" MODIFIED_BY="[Empty name]">
<P>[For definitions of terms used in this, and other sections, please refer to the Glossary]</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Study selection</HEADING>
<P>All study citations identified by the searches were independently inspected by two reviewers, and full reports of the studies of agreed relevance were obtained. Where agreement could not be reached, we acquired the full report for more detailed scrutiny. We then independently inspected these articles to assess their relevance to this review. Again, if the disagreement could not be resolved from published information, the article was added to those awaiting assessment and we contacted the authors of the study for further clarification.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Quality assessment</HEADING>
<P>We assessed the methodological quality of the trials included in this review using the criteria described in the Cochrane Handbook (Higgins 2005). These criteria are based on the evidence of a strong relationship between allocation concealment and the potential for bias in the results (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) and are defined as below:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)</P>
<P>For the purpose of the analysis in this review, we included trials if they meet the criteria A or B.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Data extraction</HEADING>
<P>We independently extracted the data from included studies. Again, any disagreement was discussed, the decisions documented and, if necessary, we contacted the authors of the studies for clarification. We documented justification for excluding references from the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Data management</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">4.1 Intention to treat</HEADING>
<P>For studies that did not specify the reasons for people leaving the study early, we assumed that these people had no change in the clinical outcome variables. Wahlbeck highlighted the problem of high rate of people leaving the study early in randomised controlled trials of antipsychotics (<LINK REF="REF-Wahlbeck-2001" TYPE="REFERENCE">Wahlbeck 2001</LINK>). As there is no consensus on the level of people leaving the study early that makes results meaningless, all trials were included in the main analyses. We performed a sensitivity analysis on those trials with a greater than 50% drop-out rate to test whether including them significantly changed the results of the primary outcome parameters. When insufficient data were provided to identify the original group size (prior to drop outs), we contacted the authors and allocated the trials to the 'awaiting assessment' list.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.2 Crossover design</HEADING>
<P>We expected that some trials would use a crossover design. In order to exclude the potential additive effect in the second or later stages on these trials, we only analysed data from the first stage.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.3 Data types</HEADING>
<P>Outcomes are assessed using continuous (for example changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). Currently RevMan does not support categorical data so they could not be analysed as such.</P>
<SUBSECTION>
<HEADING LEVEL="5">4.3.1 Dichotomous data</HEADING>
<P>Where possible we made efforts to convert outcome measures to dichotomous data. This may be done by identifying cut off points on rating scales and dividing subjects accordingly into 'clinically improved' or 'not clinically improved'. If the authors of a study had used a predefined cut off point for determining clinical effectiveness we used this where appropriate. Otherwise we generally assumed that a 50% reduction of a scale (e.g. the Brief Psychiatric Rating Scale - <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or a rating of 'at least much improved' according to the Clinical Global Impression Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) could be considered as a clinically significant response.</P>
<P>For dichotomous outcomes, we estimated a relative risk (RR) with the 95% confidence interval (CI) based on a fixed effects model in case of homogeneous outcomes, and based on a random effects model in the case of heterogeneous outcomes. If overall results were significant, the Number Needed to Treat (NNT) and/or the Number Needed to Harm (NNH) was calculated as the inverse of the risk reduction. It has been shown that RR is more intuitive than odds ratios (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the impression of the effect. Data were inspected to see if an analysis using a Mantel-Haenszel odds ratio and a random effects model made a substantive difference.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.3.2 Continuous data</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">4.3.2.1 Normal distribution</HEADING>
<P>Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards were applied to data derived from continuous measures of endpoint ('state' data).</P>
<P>When a scale starts from zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). Endpoint scores on scales often have a finite start and end point and this rule can be applied.<BR/>When continuous data are presented on a scale which includes a possibility of negative values (such as change on a scale) it is impossible to tell whether data are non-normally distributed (skewed) or not. It is thus preferable to use scale end point data, which typically cannot have negative values. If end point data were not available, we chose to use change data, because the statistics used in Metaview are rather robust towards skewness. If a scale starts from a positive value (such as PANSS, which can have values from 30-210) the calculation described above should be modified to take the scale starting point into account. In these cases skewness is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.3.2.2 Intention-to-treat versus completer analyses</HEADING>
<P>In the case of continuous data we assumed that in many cases an intention-to-treat analysis would not be available, so the data had to be analysed as they were presented in the original publications.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.3.2.3 Summary statistic</HEADING>
<P>For continuous outcomes, we estimated a weighted mean difference (WMD) between groups. Again, a fixed effects model was used for homogeneous outcomes and a random effects model for heterogeneous outcomes. Whenever possible we took the opportunity to make direct comparisons between trials that used the same measurement instrument to quantify specific outcomes. Where continuous data was presented from different scales rating the same effect, we presented both sets of data and inspected the general direction of effect.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">4.3.2.4 Rating scales</HEADING>
<P>A wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid, or even ad hoc. For outcome instruments some minimum standards have to be set. We only included continuous data from rating scales if the measuring instrument had been described in a peer-reviewed journal (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>), the instrument was either a self report or completed by an independent rater or relative (not the therapist), and the instrument could be considered a global assessment of an area of functioning. However, as it was expected that therapists would frequently also be the rater, we commented on such data as 'prone to bias'.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4.4 Cluster trials</HEADING>
<P>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a "unit of analysis" error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type 1 errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Where clustering was not accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a "design effect". This is calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect = 1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC was not reported it was assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).<BR/>
<BR/>If cluster studies had been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4.5 Data display</HEADING>
<P>We entered data into RevMan in such a way that the area to the left of the line of no effect indicated a favourable outcome for valproate alone or valproate augmentation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Heterogeneity</HEADING>
<P>Firstly, we undertook consideration of all the included studies within any comparison to judge clinical heterogeneity. Then we visually inspected graphs to investigate the possibility of statistical heterogeneity. We supplemented this using, primarily, the I-squared statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I-squared estimate was greater than or equal to 50% we interpreted this as indicating the presence of considerable levels of heterogeneity <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>. If inconsistency was high and clear reasons explaining the heterogeneity were found we presented the data separately. If not, we commented upon the heterogeneity of the data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Publication bias</HEADING>
<P>We entered data from all included trials into a funnel graph (trial effect versus trial size or 'precision') in an attempt to investigate the likelihood of overt publication bias. We undertook a formal test of funnel plot asymmetry (suggesting potential publication bias) where appropriate (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>). Significance levels of p &lt; 0.1 were set a priori to accept the presence of asymmetry.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">7. Sensitivity analysis</HEADING>
<P>We planned to carry out a sensitivity analysis to investigate whether the exclusion of schizoaffective participants significantly changed the results.</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-11-12 11:06:58 +0000" MODIFIED_BY="[Empty name]">Previous plain language summary</TITLE>
<APPENDIX_BODY MODIFIED="2016-10-05 12:59:59 +0100" MODIFIED_BY="[Empty name]">
<P>Most people with schizophrenia or schizophrenia-like conditions who are in contact with medical services will be treated with antipsychotic medication. Despite this, about 30% will continue to experience some signs of illness. Various other drugs have been added to the antipsychotic medication to try and reduce the symptoms these people experience. One such group of drugs are sodium and magnesium valproate, medication usually used to treat epilepsy or to stabilize mood in people who have bipolar disorder and those who have symptoms of schizophrenia and mood disorder together (schizoaffective disorder). This review looks at trials which attempt to compare valproate with placebo and also looks at valproate in combination with an antipsychotic compared to the antipsychotic alone. The studies included 2184 people in 26 trials, with the largest trial containing 402 people and the smallest, 12 people. All of the trials used an antipsychotic, and compared it to the antipsychotic plus valproate. There were no trials comparing just valproate with placebo. Risperidone was used in 8 trials, haloperidol, olanzapine and clozapine were used in 6 trials, quetiapine was used in 4 trials, aripiprazole in 3 trials, chlopromazine and perphenazine in only one trial. 6 other trials used more than one type of antipsychotic and did not specify the drugs used. For 14 studies reported measures including becoming more well and improvement in mental state there was a significant advantage for those on valproate plus antipsychotic compared to antipsychotic alone. Valproate was also reported to be effective in controlling excitement and aggression. However, such positive evidences were largely based on open Chinese studies. Moreover, it was also found that valproate increased sedation and dizziness. None of the studies were longer than 12 weeks so it is not known whether there would be a difference between the groups in the longer term. In addition, it was difficult to compare one trial with another because they recruited people with different groups of symptoms, used several different antipsychotics and looked at a diverse range of outcomes. The use of valproate for schizophrenia would benefit from some bigger and longer trials, with proper randomisation and double-blindness.</P>
<P>(Plain language summary prepared for this review by Janey Antoniou of RETHINK, UK <A HREF="http://www.rethink.org">www.rethink.org</A>)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;26 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;44 full-text articles included - reporting on 26 studies&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;58 full-text articles acquired and inspected&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;98 citations screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;2004 search: &lt;span&gt;34 citations identified&lt;/span&gt;&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2007 search: 28 citations identified&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2012 search: 46 new citations found&lt;/p&gt;"/>
<OUT TEXT="&lt;p&gt;40 citations excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;11 excluded, with reasons&lt;/p&gt;&lt;p&gt;3 awaiting assessment&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
<EXTENSION ID="AFF_z1303130939086112491133527493155_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="z1303130939086112491133527493155"><ADDRESS><DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT><ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION><ADDRESS_1>Ismaningerstrasse 22</ADDRESS_1><CITY>München</CITY><ZIP>81675</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>